PMID- 9339686
OWN - NLM
STAT- MEDLINE
DA  - 19971114
DCOM- 19971114
LR  - 20061115
PUBM- Print
IS  - 0028-3878 (Print)
VI  - 49
IP  - 4
DP  - 1997 Oct
TI  - Higher neonatal cerebral blood flow correlates with worse childhood
      neurologic outcome.
PG  - 1035-41
AB  - Cerebral blood flow (CBF) in newborn infants is often below levels
      necessary to sustain brain viability in adults. Controversy exists
      regarding the effects of such low CBF on subsequent neurologic function.
      We determined the current childhood neurologic status and IQ in 26
      subjects who had measurements of CBF performed with PET in the neonatal
      period between 1983 and 1989 as part of a study of hypoxic-ischemic
      encephalopathy. Follow-up information at ages 4 to 12 years was obtained
      on all 26 subjects. Ten subjects had died. All 16 survivors underwent
      clinical neurologic evaluation, and 14 also underwent intelligence
      testing. Eight had abnormal clinical neurologic evaluations; eight were
      normal. The mean neonatal CBF in those with abnormal childhood neurologic
      outcome was significantly higher than in those with normal childhood
      neurologic outcome (35.64 +/- 11.80 versus 18.26 +/- 8.62 mL 100 g(-1)
      min(-1), t = 3.36, p = 0.005). A significant negative correlation between
      neonatal CBF and childhood IQ was demonstrated (Spearman rank correlation
      r = -0.675, p = 0.008). Higher CBF was associated with lower IQ. The
      higher CBF in subjects with worse neurologic and intellectual outcome may
      reflect greater loss of cerebrovascular autoregulation or other vascular
      regulatory mechanisms due to more severe brain damage.
AD  - Department of Pediatrics, Washington University School of Medicine, St.
      Louis Children's Hospital, MO 63110, USA.
FAU - Rosenbaum, J L
AU  - Rosenbaum JL
FAU - Almli, C R
AU  - Almli CR
FAU - Yundt, K D
AU  - Yundt KD
FAU - Altman, D I
AU  - Altman DI
FAU - Powers, W J
AU  - Powers WJ
LA  - eng
GR  - NS06833/NS/NINDS
GR  - NS32568/NS/NINDS
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - AIM
SB  - IM
MH  - Cerebrovascular Circulation/*physiology
MH  - *Child Development
MH  - Follow-Up Studies
MH  - Humans
MH  - Infant, Newborn
MH  - Intelligence
MH  - *Nervous System Physiology
MH  - Neurologic Examination
MH  - Tomography, Emission-Computed
EDAT- 1997/10/27
MHDA- 1997/10/27 00:01
PST - ppublish
SO  - Neurology. 1997 Oct;49(4):1035-41.
PMID- 9357896
OWN - NLM
STAT- MEDLINE
DA  - 19971120
DCOM- 19971120
LR  - 20061115
PUBM- Print
IS  - 0003-3022 (Print)
VI  - 87
IP  - 4
DP  - 1997 Oct
TI  - Bupivacaine inhibition of L-type calcium current in ventricular
      cardiomyocytes of hamster.
PG  - 926-34
AB  - BACKGROUND: The local anesthetic bupivacaine is cardiotoxic when
      accidentally injected into the circulation. Such cardiotoxicity might
      involve an inhibition of cardiac L-type Ca2+ current (ICa,L). This study
      was designed to define the mechanism of bupivacaine inhibition of ICa,L.
      METHODS: Cardiomyocytes were enzymatically dispersed from hamster
      ventricles. Certain voltage- and time-dependencies of ICa,L were recorded
      using the whole-cell patch clamp method in the presence and absence of
      different concentrations of bupivacaine. RESULTS: Bupivacaine, in a
      concentration-dependent manner (10-300 microM), tonically inhibited the
      peak amplitude of ICa,L. The inhibition was characterized by an increase
      in the time of recovery from inactivation and a negative-voltage shift of
      the steady-state inactivation curve. The inhibition was shown to be
      voltage-dependent, and the peak amplitude of ICa,L could not be restored
      to control levels by a wash from bupivacaine. CONCLUSIONS: The inhibition
      of ICa,L appears, in part, to result from bupivacaine predisposing L-type
      Ca channels to the inactivated state. Data from washout suggest that there
      may be two mechanisms of inhibition at work. Bupivacaine may bind with low
      affinity to the Ca channel and also affect an unidentified metabolic
      component that modulates Ca channel function.
AD  - Department of Anesthesiology, Winthrop-University Hospital, Mineola, New
      York, USA. krossner@epo.som.sunysb.edu
FAU - Rossner, K L
AU  - Rossner KL
FAU - Freese, K J
AU  - Freese KJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Anesthesiology
JT  - Anesthesiology
JID - 1300217
RN  - 0 (Anesthetics, Local)
RN  - 0 (Calcium Channels)
RN  - 0 (Calcium Channels, L-Type)
RN  - 2180-92-9 (Bupivacaine)
SB  - AIM
SB  - IM
MH  - Anesthetics, Local/*pharmacology
MH  - Animals
MH  - Bupivacaine/*pharmacology
MH  - Calcium Channels/*drug effects
MH  - Calcium Channels, L-Type
MH  - Cricetinae
MH  - Dose-Response Relationship, Drug
MH  - Heart/*drug effects
MH  - Male
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
PST - ppublish
SO  - Anesthesiology. 1997 Oct;87(4):926-34.
PMID- 9298188
OWN - NLM
STAT- MEDLINE
DA  - 19971117
DCOM- 19971117
LR  - 20061115
PUBM- Print
IS  - 0003-6072 (Print)
VI  - 72
IP  - 2
DP  - 1997 Aug
TI  - Formation of formate and hydrogen, and flux of reducing equivalents and
      carbon in Ruminococcus flavefaciens FD-1.
PG  - 101-9
AB  - A pathway for conversion of the metabolic intermediate phosphoenolpyruvate
      (PEP) and the formation of acetate, succinate, formate, and H2 in the
      anaerobic cellulolytic bacterium Ruminococcus flavefaciens FD-1 was
      constructed on the basis of enzyme activities detected in extracts of
      cells grown in cellulose- or cellobiose-limited continuous culture. PEP
      was converted to acetate and CO2 (via pyruvate kinase, pyruvate
      dehydrogenase, and acetate kinase) or carboxylated to form succinate (via
      PEP carboxykinase, malate dehydrogenase, fumarase, and fumarate
      reductase). Lactate was not formed even during rapid growth (batch
      culture, mu = 0.35/h). H2 was formed by a hydrogenase rather than by
      cleavage of formate, and 13C-NMR and 14C-exchange reaction data indicated
      that formate was produced by CO2 reduction, not by a cleavage of pyruvate.
      The distribution of PEP into the acetate and succinate pathways was not
      affected by changing extracellular pH and growth rates within the normal
      growth range. However, increasing growth rate from 0.017/h to 0.244/h
      resulted in a shift toward formate production, presumably at the expense
      of H2. This shift suggested that reducing equivalents could be balanced
      through formate or H2 production without affecting the yields of the major
      carbon-containing fermentation endproducts.
AD  - Department of Bacteriology, University of Wisconsin-Madison 53706, USA.
FAU - Shi, Y
AU  - Shi Y
FAU - Weimer, P J
AU  - Weimer PJ
FAU - Ralph, J
AU  - Ralph J
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - NETHERLANDS
TA  - Antonie Van Leeuwenhoek
JT  - Antonie van Leeuwenhoek
JID - 0372625
RN  - 0 (Acetates)
RN  - 0 (Bacterial Proteins)
RN  - 0 (Formates)
RN  - 110-15-6 (Succinic Acid)
RN  - 124-38-9 (Carbon Dioxide)
RN  - 127-17-3 (Pyruvic Acid)
RN  - 1333-74-0 (Hydrogen)
RN  - 16462-44-5 (Cellobiose)
RN  - 50-21-5 (Lactic Acid)
RN  - 73-89-2 (Phosphoenolpyruvate)
RN  - 9004-34-6 (Cellulose)
RN  - EC 1.18.99.1 (Hydrogenase)
SB  - IM
MH  - Acetates/*metabolism
MH  - Anaerobiosis
MH  - Bacterial Proteins/analysis/metabolism
MH  - Carbon Dioxide/metabolism
MH  - Cellobiose/metabolism
MH  - Cellulose/metabolism
MH  - Fermentation
MH  - Formates/*metabolism
MH  - Gram-Positive Cocci/enzymology/growth & development/*metabolism
MH  - Hydrogen/*metabolism
MH  - Hydrogen-Ion Concentration
MH  - Hydrogenase/metabolism
MH  - Lactic Acid/metabolism
MH  - Phosphoenolpyruvate/metabolism
MH  - Pyruvic Acid/metabolism
MH  - Succinic Acid/*metabolism
EDAT- 1997/08/01 00:00
MHDA- 1997/09/23 00:01
PST - ppublish
SO  - Antonie Van Leeuwenhoek. 1997 Aug;72(2):101-9.
PMID- 9263049
OWN - NLM
STAT- MEDLINE
DA  - 19971027
DCOM- 19971027
LR  - 20031114
PUBM- Print
IS  - 0021-8812 (Print)
VI  - 75
IP  - 8
DP  - 1997 Aug
TI  - Approximate confidence intervals for heritability from method R estimates.
PG  - 2041-6
AB  - Method R estimates of heritability (h2) and associated confidence
      intervals (CI) were obtained from simulated data using a single trait,
      direct effects, full animal model, with 50% subsampling. Five hundred data
      sets were simulated for each of five levels of h2 (.10, .20, .30, .40, and
      .50) and two types of pedigree structure (random pedigree structure [N =
      2,000] that varied over simulations, or the pedigree structure from a real
      data set [N = 2,644] that was constant for all simulations). The first 10,
      20, and all 50 h2 estimates were used to obtain 80, 90, 95, and 99% CI for
      each data set. The variance of h2 estimates within data sets approximated
      the sampling variance of the h2 estimates. The Box-Cox transformation was
      used to normalize the distribution of estimates from each data set.
      Confidence intervals were computed on the transformed scale as CI = mu +/-
      (T x sigma), where mu and sigma = the mean and SD of the N transformed h2
      estimates, respectively, and T = the critical value from the T
      distribution for a 1-alpha CI, with df = N-1. Upper and lower CI bounds
      were converted back to the original scale by reversing the transformation.
      The percentages of CI containing the true h2 value, pooled across all
      levels of h2, types of pedigree, and number of estimates used to obtain
      CI, for 80, 90, 95, and 99% CI were 81.14, 90.96, 95.27, and 98.76%,
      respectively. These results suggested that Method R h2 estimates can be
      used to obtain reliable CI.
AD  - Department of Statistics, Colorado State University, Fort Collins 80523,
      USA.
FAU - Mallinckrodt, C H
AU  - Mallinckrodt CH
FAU - Golden, B L
AU  - Golden BL
FAU - Reverter, A
AU  - Reverter A
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - J Anim Sci
JT  - Journal of animal science
JID - 8003002
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Animals, Domestic/*genetics
MH  - Confidence Intervals
MH  - Female
MH  - *Genetics/statistics & numerical data
MH  - Male
MH  - *Models, Genetic
MH  - Phenotype
MH  - Time Factors
EDAT- 1997/08/01
MHDA- 1997/08/01 00:01
PST - ppublish
SO  - J Anim Sci. 1997 Aug;75(8):2041-6.
PMID- 9308130
OWN - NLM
STAT- MEDLINE
DA  - 19971120
DCOM- 19971120
LR  - 20060504
PUBM- Print
IS  - 0277-6715 (Print)
VI  - 16
IP  - 18
DP  - 1997 Sep 30
TI  - rhDNase as an example of recurrent event analysis.
PG  - 2029-47
AB  - We consider counting process methods for analysing time-to-event data with
      multiple or recurrent outcomes, using the models developed by Anderson and
      Gill, Wei, Lin and Weissfeld and Prentice, Williams and Peterson. We
      compare the methods, and show how to implement them using popular
      statistical software programs. By analysing three data sets, we illustrate
      the strengths and pitfalls of each method. The first example is simulated
      and involves the effect of a hidden covariate. The second is based on a
      trial of gamma interferon, and behaves remarkably like the first. The
      third and most interesting example involves both multiple events and
      discontinuous intervals at risk, and the three approaches give dissimilar
      answers. We recommend the AG and marginal models for the analysis of this
      type of data.
AD  - Mayo Clinic, Rochester, MI, USA.
FAU - Therneau, T M
AU  - Therneau TM
FAU - Hamilton, S A
AU  - Hamilton SA
LA  - eng
PT  - Journal Article
PL  - ENGLAND
TA  - Stat Med
JT  - Statistics in medicine
JID - 8215016
RN  - 0 (Expectorants)
RN  - 0 (Interferon-gamma, Recombinant)
RN  - 0 (Recombinant Proteins)
RN  - EC 3.1.21.1 (DNASE1 protein, human)
RN  - EC 3.1.21.1 (Deoxyribonuclease I)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Child
MH  - Cystic Fibrosis/*drug therapy
MH  - Data Collection/statistics & numerical data
MH  - Deoxyribonuclease I/*therapeutic use
MH  - Double-Blind Method
MH  - Expectorants/*therapeutic use
MH  - Granulomatous Disease, Chronic/*therapy
MH  - Humans
MH  - Interferon-gamma, Recombinant/*therapeutic use
MH  - *Mathematical Computing
MH  - *Models, Statistical
MH  - Randomized Controlled Trials/*statistics & numerical data
MH  - Recombinant Proteins/therapeutic use
MH  - Risk
MH  - *Software
MH  - *Survival Analysis
MH  - Treatment Outcome
EDAT- 1997/10/06 17:35
MHDA- 2000/06/20 09:00
AID - 10.1002/(SICI)1097-0258(19970930)16:18<2029::AID-SIM637>3.0.CO;2-H [pii]
PST - ppublish
SO  - Stat Med. 1997 Sep 30;16(18):2029-47.
PMID- 9317033
OWN - NLM
STAT- MEDLINE
DA  - 19971030
DCOM- 19971030
LR  - 20061115
PUBM- Print
IS  - 0019-9567 (Print)
VI  - 65
IP  - 10
DP  - 1997 Oct
TI  - Involvement of p21racA, phosphoinositide 3-kinase, and vacuolar ATPase in
      phagocytosis of bacteria and erythrocytes by Entamoeba histolytica:
      suggestive evidence for coincidental evolution of amebic invasiveness.
PG  - 4243-9
AB  - Trophozoites of Entamoeba histolytica, the protozoan parasite that causes
      amebic dysentery, phagocytose bacteria in the colonic lumen and
      erythrocytes (RBC) in host tissues. Because tissue invasion is an
      evolutionary dead end, it is likely that amebic pathogenicity is
      coincidentally selected, i.e., the same methods used to kill bacteria in
      the colonic lumen are used by parasites to damage host cells and cause
      disease. In support of this idea, the amebic lectin and pore-forming
      peptide are involved in binding and killing, respectively, bacteria and
      host epithelial cells. Here amebic phagocytosis of bacteria, RBC, and
      mucin-coated beads was disrupted by overexpression of E. histolytica
      p21(racA-V12), a ras-family protein involved in selection of sites of
      actin polymerization, which had been mutated to eliminate its GTPase
      activity. p21(racA-V12) transformants were also defective in capping and
      cytokinesis, while pinocytosis of fluorescent dextrans was not affected.
      Wortmannin, a fungal inhibitor of phosphoinositide 3-kinase, markedly
      inhibited phagocytosis of bacteria, RBC, and mucin-coated beads by
      wild-type amebae. In contrast to p21(racA-V12) overexpression, wortmannin
      abolished amebic pinocytosis of dextrans but had no inhibitory effects on
      capping. Inhibition of amebic vacuolar acidification by bafilomycin also
      decreased bacterial and RBC uptake. These results, which demonstrate
      similarities between mechanisms of phagocytosis of bacteria and RBC by
      amebae and macrophages, support the idea of coincidental selection of
      amebic genes encoding proteins that mediate destruction of host cells.
AD  - Department of Tropical Public Health, Harvard School of Public Health,
      Boston, Massachusetts 02115, USA.
FAU - Ghosh, S K
AU  - Ghosh SK
FAU - Samuelson, J
AU  - Samuelson J
LA  - eng
GR  - AI-33492/AI/NIAID
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Infect Immun
JT  - Infection and immunity
JID - 0246127
RN  - 0 (Androstadienes)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Cysteine Proteinase Inhibitors)
RN  - 0 (Macrolides)
RN  - 12125-02-9 (Ammonium Chloride)
RN  - 17090-79-8 (Monensin)
RN  - 19545-26-7 (wortmannin)
RN  - 61-90-5 (Leucine)
RN  - 66701-25-5 (E 64)
RN  - EC 2.7.1.137 (1-Phosphatidylinositol 3-Kinase)
RN  - EC 3.6.1.- (GTP-Binding Proteins)
RN  - EC 3.6.5.2 (rac GTP-Binding Proteins)
SB  - IM
MH  - 1-Phosphatidylinositol 3-Kinase/genetics/*metabolism
MH  - Ammonium Chloride/pharmacology
MH  - Androstadienes/pharmacology
MH  - Animals
MH  - Anti-Bacterial Agents/pharmacology
MH  - Bacteria
MH  - Cysteine Proteinase Inhibitors/pharmacology
MH  - Entamoeba histolytica/cytology/genetics/*pathogenicity
MH  - Erythrocytes
MH  - Evolution
MH  - GTP-Binding Proteins/genetics/*metabolism
MH  - Hydrogen-Ion Concentration
MH  - Immunologic Capping
MH  - Leucine/analogs & derivatives/pharmacology
MH  - Macrolides
MH  - Macrophages/physiology
MH  - Models, Biological
MH  - Monensin/pharmacology
MH  - Mutation
MH  - Phagocytosis/*physiology
MH  - Pinocytosis
MH  - Transformation, Genetic
MH  - Vacuoles/physiology
MH  - rac GTP-Binding Proteins
EDAT- 1997/10/08
MHDA- 1997/10/08 00:01
PST - ppublish
SO  - Infect Immun. 1997 Oct;65(10):4243-9.
PMID- 9331038
OWN - NLM
STAT- MEDLINE
DA  - 19971106
DCOM- 19971106
LR  - 20041117
PUBM- Print
IS  - 0301-620X (Print)
VI  - 79
IP  - 5
DP  - 1997 Sep
TI  - Intra-articular local anaesthesia for pain after hip arthroplasty.
PG  - 796-800
AB  - We investigated 15 patients with painful hip arthroplasties using
      intra-articular injection of bupivicaine. Fourteen had pain relief and 13
      of them were subsequently found to have loosening of one or both
      components. The relief of pain after total hip arthroplasty by
      intra-articular injection of bupivicaine indicates that a satisfactory
      result is probable after revision surgery with refixation of the
      components.
AD  - Princess Elizabeth Orthopaedic Hospital, Exeter, UK.
FAU - Crawford, R W
AU  - Crawford RW
FAU - Ellis, A M
AU  - Ellis AM
FAU - Gie, G A
AU  - Gie GA
FAU - Ling, R S
AU  - Ling RS
LA  - eng
PT  - Journal Article
PL  - ENGLAND
TA  - J Bone Joint Surg Br
JT  - The Journal of bone and joint surgery.  British volume
JID - 0375355
RN  - 0 (Anesthetics, Local)
RN  - 2180-92-9 (Bupivacaine)
SB  - AIM
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anesthetics, Local/*therapeutic use
MH  - Arthrography
MH  - Bupivacaine/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Hip Prosthesis/*adverse effects
MH  - Humans
MH  - Injections, Intra-Articular
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement
MH  - Pain, Postoperative/*drug therapy/*etiology/radiography
MH  - Prosthesis Failure
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
PST - ppublish
SO  - J Bone Joint Surg Br. 1997 Sep;79(5):796-800.
PMID- 9382160
OWN - NLM
STAT- MEDLINE
DA  - 19971110
DCOM- 19971110
LR  - 20070214
PUBM- Print
IS  - 0250-8095 (Print)
VI  - 17
IP  - 5
DP  - 1997
TI  - Determinants of type of initial hemodialysis vascular access.
PG  - 425-7
AB  - Vascular access thrombosis is more common with polytetrafluoroethylene
      (PTFE) grafts than with native arteriovenous fistulae (AVF). Recent
      studies report an unexplained excess vascular access morbidity in women on
      hemodialysis. We studied 92 consecutive end-stage renal disease (ESRD)
      patients receiving their first permanent hemodialysis vascular access at
      initiation of hemodialysis to identify variables that determine assignment
      of either a PTFE graft or a native AVF. Independent variables included:
      age, gender, race, etiology of ESRD, and whether or not access surgery was
      electively planned before need for dialytic therapy. The 51 women and 41
      men included 65 blacks, 13 Hispanics, 11 whites, and 3 Orientals aged 50
      +/- (SD) 16 years. Of the 92 subjects, 54 (59%) received an AVF, while 38
      (41%) received a PTFE graft. 36 (94%) of 38 PTFE grafts were placed in the
      upper arm as compared with 9 (17%) of 54 AVF (p = 0.0001). Also, 45 (83%)
      of 54 AVF were placed in the forearm as compared with only 2 (6%) of 38
      PTFE grafts (p = 0.0001). Women were more likely to receive a PTFE graft -
      28 (55%) of 51 - than men - 10 (24%) of 41 (p = 0.003). By contrast, men
      were more likely to get an AVF - 31 (76%) of 41 - than women - 23 (45 %)
      of 51 (p = 0.003). The log linear analysis confirmed that this finding was
      significant (p = 0.0018) for the coefficient of interaction between gender
      and type of vascular access. No other independent variable had a
      significant relationship with type of vascular access. We conclude that
      women with ESRD are more likely to receive a PTFE graft for hemodialysis,
      while men are more likely to get an AVF. These findings may explain, in
      part, the reported excess vascular access morbidity in women on
      hemodialysis.
AD  - Department of Medicine, Scientific and Academic Computing Center, State
      University of New York Health Science Center, Brooklyn 11203, USA.
FAU - Ifudu, O
AU  - Ifudu O
FAU - Macey, L J
AU  - Macey LJ
FAU - Homel, P
AU  - Homel P
FAU - Hyppolite, J C
AU  - Hyppolite JC
FAU - Hong, J
AU  - Hong J
FAU - Sumrani, N
AU  - Sumrani N
FAU - Distant, D
AU  - Distant D
FAU - Sommer, B G
AU  - Sommer BG
FAU - Friedman, E A
AU  - Friedman EA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - SWITZERLAND
TA  - Am J Nephrol
JT  - American journal of nephrology
JID - 8109361
RN  - 9002-84-0 (Polytetrafluoroethylene)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Arteriovenous Shunt, Surgical/adverse effects
MH  - *Catheters, Indwelling/adverse effects
MH  - Decision Making
MH  - Female
MH  - Graft Occlusion, Vascular/etiology
MH  - Humans
MH  - Kidney Failure, Chronic/therapy
MH  - Male
MH  - Middle Aged
MH  - Polytetrafluoroethylene/adverse effects
MH  - Prospective Studies
MH  - Renal Dialysis/*methods
MH  - Sex Factors
MH  - Thrombosis/epidemiology/etiology
EDAT- 1997/01/01 00:00
MHDA- 1997/10/27 00:01
PST - ppublish
SO  - Am J Nephrol. 1997;17(5):425-7.
PMID- 9301125
OWN - NLM
STAT- MEDLINE
DA  - 19971124
DCOM- 19971124
LR  - 20061115
PUBM- Print
IS  - 0916-8451 (Print)
VI  - 61
IP  - 8
DP  - 1997 Aug
TI  - Pradimicin, a mannose-binding antibiotic, induced carbohydrate-mediated
      apoptosis in U937 cells.
PG  - 1408-10
AB  - Pradimicin (PRM), a mannose-binding antifungal antibiotic, recognizes a
      D-mannoside in the presence of calcium. We demonstrated that BMY-28864, a
      semi-synthetic analog of PRM, induced apoptosis in U937 cells which had
      been incubated with 1-deoxymannojirimycin (DMJ). Characteristic
      morphological changes such as formation of apoptotic bodies and DNA
      fragmentation were observed in apoptotic cells.
AD  - Toyama Prefectural University, Biotechnology Research Center, Japan.
      oki@pu-toyama.ac.jp
FAU - Oki, T
AU  - Oki T
FAU - Yamazaki, Y
AU  - Yamazaki Y
FAU - Furumai, T
AU  - Furumai T
FAU - Igarashi, Y
AU  - Igarashi Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - JAPAN
TA  - Biosci Biotechnol Biochem
JT  - Bioscience, biotechnology, and biochemistry
JID - 9205717
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Antigens, Surface)
RN  - 0 (Carbohydrates)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Oligosaccharides)
RN  - 19130-96-2 (1-Deoxynojirimycin)
RN  - 31103-86-3 (Mannose)
SB  - B
MH  - 1-Deoxynojirimycin/pharmacology
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Antibiotics, Antineoplastic/*pharmacology
MH  - Antigens, Surface/biosynthesis
MH  - Apoptosis/*drug effects
MH  - Carbohydrates/*physiology
MH  - Cell Line
MH  - DNA, Neoplasm/biosynthesis/chemistry
MH  - Electrophoresis, Agar Gel
MH  - Humans
MH  - Leukemia, Myeloid/metabolism
MH  - Mannose/metabolism
MH  - Oligosaccharides/biosynthesis
EDAT- 1997/08/01 00:00
MHDA- 1997/09/25 00:01
PST - ppublish
SO  - Biosci Biotechnol Biochem. 1997 Aug;61(8):1408-10.
PMID- 9378488
OWN - NLM
STAT- MEDLINE
DA  - 19971107
DCOM- 19971107
LR  - 20061115
PUBM- Print
IS  - 0019-2805 (Print)
VI  - 91
IP  - 4
DP  - 1997 Aug
TI  - TCR alpha beta+ CD4- CD8- T cells differentiate extrathymically in an
      lck-independent manner and participate in early response against Listeria
      monocytogenes infection through interferon-gamma production.
PG  - 511-9
AB  - T-cell receptor (TCR) alpha beta+ CD4- CD8- (double-negative; DN) T cells
      appear in the peritoneal cavity at an early stage of intraperitoneal
      (i.p.) infection with the intracellular pathogen Listeria monocytogenes.
      In the present report, we analysed the developmental pathway and functions
      of the TCR alpha beta+ DN T cells using the L. monocytogenes infection
      system. The TCR alpha beta+ DN T cells appeared in the peritoneal cavity
      after L. monocytogenes i.p. infection in adult-thymectomized lethally
      irradiated bone marrow chimeras and p56lck-deficient mice. The results
      demonstrated that the TCR alpha beta+ DN T cells can develop
      extrathymically in a p56lck-independent manner. Reverse
      transcription-polymerase chain reaction (RT-PCR) analysis showed that the
      TCR alpha beta+ DN T cells expressed genes for interferon-gamma
      (IFN-gamma), the macrophage chemotactic factors MCP-1 and Eta-1, and
      granulocyte-macrophage colony-stimulating factor (GM-CSF) but lacked
      expression of genes for interleukin-2 (IL-2), IL-4 and IL-10. As expected
      from the RT-PCR analysis, the TCR alpha beta+ DN T cells produced
      IFN-gamma in response to anti-TCR beta monoclonal antibody (mAb), anti-CD3
      mAb and L. monocytogenes-infected macrophages but IL-4 was undetectable
      after the stimulation. Furthermore, the intracellular cytokine staining
      analysis demonstrated that approximately half of the TCR alpha beta+ DN T
      cells detectable at the early stage of L. monocytogenes infection were
      IFN-gamma-producing cells. All of the results suggest that the TCR alpha
      beta+ DN T cells develop through a unique extrathymic p56lck-independent
      pathway and participate in early protection against bacterial infection
      through activation and accumulation of macrophages.
AD  - Department of Immunology, Kyushu University, Japan.
FAU - Kadena, T
AU  - Kadena T
FAU - Matsuzaki, G
AU  - Matsuzaki G
FAU - Fujise, S
AU  - Fujise S
FAU - Kishihara, K
AU  - Kishihara K
FAU - Takimoto, H
AU  - Takimoto H
FAU - Sasaki, M
AU  - Sasaki M
FAU - Beppu, M
AU  - Beppu M
FAU - Nakamura, S
AU  - Nakamura S
FAU - Nomoto, K
AU  - Nomoto K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - ENGLAND
TA  - Immunology
JT  - Immunology
JID - 0374672
RN  - 0 (Antigens, CD4)
RN  - 0 (Antigens, CD8)
RN  - 0 (Cytokines)
RN  - 0 (Receptors, Antigen, T-Cell, alpha-beta)
RN  - 82115-62-6 (Interferon Type II)
RN  - EC 2.7.1.37 (Lymphocyte Specific Protein Tyrosine Kinase p56(lck))
SB  - IM
MH  - Animals
MH  - Antigens, CD4/analysis
MH  - Antigens, CD8/analysis
MH  - Ascitic Fluid/immunology
MH  - Cell Culture Techniques
MH  - Cell Differentiation/immunology
MH  - Cytokines/genetics/metabolism
MH  - Female
MH  - Gene Expression
MH  - Interferon Type II/*biosynthesis
MH  - Listeria Infections/*immunology
MH  - Lymphocyte Specific Protein Tyrosine Kinase
      p56(lck)/*deficiency/immunology
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Mice, Knockout
MH  - Polymerase Chain Reaction
MH  - Receptors, Antigen, T-Cell, alpha-beta/*analysis
MH  - T-Lymphocyte Subsets/*immunology
EDAT- 1997/08/01 00:00
MHDA- 1997/10/24 00:01
PST - ppublish
SO  - Immunology. 1997 Aug;91(4):511-9.
PMID- 9298438
OWN - NLM
STAT- MEDLINE
DA  - 19971024
DCOM- 19971024
LR  - 20061115
PUBM- Print
IS  - 0160-7715 (Print)
VI  - 20
IP  - 4
DP  - 1997 Aug
TI  - Identification of Beck Depression Inventory items related to multiple
      sclerosis.
PG  - 407-14
AB  - The percentage contribution of each item on the Beck Depression Inventory
      (BDI) to the total BDI score was compared across patients with multiple
      sclerosis (MS), patients diagnosed with major depressive disorder, and
      normal college students. We considered an item to be confounded by
      MS-related symptoms if its percentage contribution to the total BDI score
      was significantly greater in the MS group than the major depression and
      control groups. Items measuring work difficulty, fatigue, and concerns
      about health met this criterion. These items accounted for 34, 17, and 19%
      of the total BDI score in the MS, major depression, and control groups,
      respectively. Using the 18-item BDI (BDI-18) which resulted from excluding
      the 3 confounded items, MS patients found to be were more depressed than
      controls but less depressed than the major depression group. The
      identification of signs of depression not confounded with MS which could
      be substituted for confounded signs was also discussed.
AD  - UCSF/Mt. Zion MS Center 94115-1642, USA.
FAU - Mohr, D C
AU  - Mohr DC
FAU - Goodkin, D E
AU  - Goodkin DE
FAU - Likosky, W
AU  - Likosky W
FAU - Beutler, L
AU  - Beutler L
FAU - Gatto, N
AU  - Gatto N
FAU - Langan, M K
AU  - Langan MK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - J Behav Med
JT  - Journal of behavioral medicine
JID - 7807105
SB  - IM
MH  - Adult
MH  - Depressive Disorder/diagnosis/*psychology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis/diagnosis/*psychology
MH  - Personality Inventory/*statistics & numerical data
MH  - Psychometrics
MH  - Reproducibility of Results
MH  - Sick Role
EDAT- 1997/08/01 00:00
MHDA- 1997/09/23 00:01
PST - ppublish
SO  - J Behav Med. 1997 Aug;20(4):407-14.
PMID- 9279722
OWN - NLM
STAT- MEDLINE
DA  - 19971028
DCOM- 19971028
LR  - 20061115
PUBM- Print
IS  - 0163-4453 (Print)
VI  - 35
IP  - 1
DP  - 1997 Jul
TI  - Early appearance of neutralizing antibodies after vaccination with an
      inactivated hepatitis A vaccine.
PG  - 37-40
AB  - Sera from 30 subjects vaccinated with the Pasteur Merieux Serums & Vaccins
      (PM) inactivated hepatitis A vaccine, and from 30 subjects vaccinated with
      the Smithkline Beecham (SB) inactivated hepatitis A vaccine, were tested
      in two laboratories in order to provide comparative data on neutralizing
      activities of vaccine-induced antibodies. Sera were also evaluated by a
      modified radioimmunoassay (mRIA) and results were compared to
      neutralization assays results. Neutralizing antibody titres provided by
      the two laboratories correlated well (coefficient or correlation 0.42, P <
      0.001). Neutralizing antibodies were detected after vaccination with both
      vaccines, and the kinetics of neutralizing antibody were the same with
      both vaccines. The titres gradually increased between the second week
      after the first dose and the post-booster dose (week 28). A strong booster
      effect of the booster vaccine dose on neutralizing titres was observed.
      Significantly higher neutralizing antibody titres with the PM vaccine were
      observed as early immune response on week 2 titres on both series of
      results. Vaccine-induced neutralizing antibody titres and vaccine-induced
      antibody mRIA titres correlated well (coefficient of correlation 0.82 and
      0.72, respectively, P < 0.0001 in both cases). These results demonstrate
      early appearance of neutralizing antibody at high titre with the PM
      vaccine.
AD  - Hygiene-Institut der Universitat Tubingen, Abteilung fur Medizinische
      Virologie und Epidemiologie der Viruskrankheiten, Germany.
FAU - Flehmig, B
AU  - Flehmig B
FAU - Staedele, H
AU  - Staedele H
FAU - Xueref, C
AU  - Xueref C
FAU - Vidor, E
AU  - Vidor E
FAU - Zuckerman, J
AU  - Zuckerman J
FAU - Zuckerman, A
AU  - Zuckerman A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - ENGLAND
TA  - J Infect
JT  - The Journal of infection
JID - 7908424
RN  - 0 (Antibodies, Viral)
RN  - 0 (Hepatitis A Vaccines)
RN  - 0 (Vaccines, Inactivated)
RN  - 0 (Viral Hepatitis Vaccines)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibodies, Viral/*analysis
MH  - Female
MH  - Hepatitis A/prevention & control
MH  - Hepatitis A Vaccines
MH  - Hepatitis A Virus, Human/*immunology
MH  - Humans
MH  - Male
MH  - Neutralization Tests
MH  - Radioimmunoassay
MH  - Vaccines, Inactivated/administration & dosage
MH  - Viral Hepatitis Vaccines/*administration & dosage
EDAT- 1997/07/01
MHDA- 1997/07/01 00:01
AID - S0163-4453(97)90929-4 [pii]
PST - ppublish
SO  - J Infect. 1997 Jul;35(1):37-40.
PMID- 9366534
OWN - NLM
STAT- MEDLINE
DA  - 19971125
DCOM- 19971125
LR  - 20041117
PUBM- Print
IS  - 0009-9260 (Print)
VI  - 52
IP  - 10
DP  - 1997 Oct
TI  - MRI and CT of metastatic hepatocellular carcinoma causing spinal cord
      compression.
PG  - 755-60
AB  - We report the imaging features in five patients with metastatic
      hepatocellular carcinoma causing spinal cord compression, three of which
      were biopsy proven and two were in patients with known diagnosis of
      hepatocellular carcinoma. The radiographic, magnetic resonance imaging
      (MRI) and computed tomography (CT) features are highlighted. Although the
      occurrence of metastatic disease in hepatocellular carcinoma is
      exceedingly rare, it may be increasingly encountered as survival of
      patients is improved with advancing methods of therapy, both surgical and
      palliative. It often accompanies local recurrence, and invariably signals
      a grave prognosis with extremely short life expectancy. Unusually, two of
      the five patients in this series presented initially with skeletal
      metastases which led to the diagnosis of hepatocellular carcinoma.
AD  - Department of Diagnostic Radiology & Organ Imaging, Chinese University of
      Hong Kong, Hong Kong.
FAU - Yang, W T
AU  - Yang WT
FAU - Yeo, W
AU  - Yeo W
FAU - Leung, S F
AU  - Leung SF
FAU - Chan, Y L
AU  - Chan YL
FAU - Johnson, P J
AU  - Johnson PJ
FAU - Metreweli, C
AU  - Metreweli C
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - ENGLAND
TA  - Clin Radiol
JT  - Clinical radiology
JID - 1306016
SB  - IM
MH  - Adult
MH  - Bone Neoplasms/radiography/*secondary
MH  - Carcinoma, Hepatocellular/complications/diagnosis/*secondary
MH  - Fatal Outcome
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/*pathology
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Spinal Cord Compression/*etiology
MH  - Spinal Neoplasms/complications/secondary
MH  - *Tomography, X-Ray Computed
EDAT- 1997/11/20
MHDA- 1997/11/20 00:01
PST - ppublish
SO  - Clin Radiol. 1997 Oct;52(10):755-60.
PMID- 9293364
OWN - NLM
STAT- MEDLINE
DA  - 19971030
DCOM- 19971030
LR  - 20041117
PUBM- Print
IS  - 0967-2109 (Print)
VI  - 5
IP  - 3
DP  - 1997 Jun
TI  - Transected thoracic aorta: age-specific differences in incidence and
      possible reasons.
PG  - 291-4
AB  - The objective of this study was to determine the incidence of aortic
      transaction in relation to age, and to examine possible reasons for the
      observed differences. Data from the North Carolina Medical Database over a
      7-year period were examined for the total number of motor vehicle accident
      victims and for the subset with aortic rupture, based on age at
      presentation. Data were then divided into 10-year intervals and the
      differences analyzed using chi-square analysis. Differences among various
      age groups were statistically significant (P = 0.0001). The highest rate
      was in the 21-30-year-old age group and average incidence for all ages was
      0.7%. High incidence of aortic transaction in the 21-30-year-old group may
      be due to an increase in high-risk behaviors in such persons, to an
      improved survival compared with other age ranges, or to an inherent
      susceptibility of the aorta at this stage of life. These data have
      important implications for the diagnosis and treatment of aortic
      transaction and should be taken into account when developing practice
      guidelines for its management.
AD  - Department of Thoracic and Cardiovascular Surgery, Carolinas Heart
      Institute, Carolinas Medical Center, North Carolina, USA.
FAU - Tripp, H F
AU  - Tripp HF
FAU - Robicsek, F
AU  - Robicsek F
FAU - Thomason, M
AU  - Thomason M
FAU - Thubrikar, M
AU  - Thubrikar M
LA  - eng
PT  - Journal Article
PL  - ENGLAND
TA  - Cardiovasc Surg
JT  - Cardiovascular surgery (London, England)
JID - 9308765
SB  - IM
MH  - Accidents, Traffic/mortality
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Aorta, Thoracic/*injuries/surgery
MH  - Aortic Rupture/etiology/mortality/*surgery
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - North Carolina/epidemiology
MH  - Registries/statistics & numerical data
MH  - Risk Factors
MH  - Sex Factors
MH  - Survival Analysis
MH  - Thoracic Injuries/etiology/mortality/*surgery
MH  - Wounds, Nonpenetrating/etiology/mortality/*surgery
EDAT- 1997/06/01 00:00
MHDA- 1997/09/18 00:01
AID - S0967-2109(97)00019-7 [pii]
PST - ppublish
SO  - Cardiovasc Surg. 1997 Jun;5(3):291-4.
PMID- 9377289
OWN - NLM
STAT- MEDLINE
DA  - 19971125
DCOM- 19971125
LR  - 20061115
PUBM- Print
IS  - 0210-0010 (Print)
VI  - 25
IP  - 145
DP  - 1997 Sep
TI  - [Clinical variability of bilateral paramedian thalamic infarcts]
PG  - 1353-62
AB  - INTRODUCTION: Thalamic infarcts in paramedian artery territory are seen
      fairly frequently owing to certain peculiarities of the vascularization of
      the thalamus. However, clinical diagnosis is usually difficult because of
      the many varieties and peculiarities of the symptomatology. MATERIAL AND
      METHODS: We present a review of twelve cases of bilateral paramedian
      infarcts of the thalamus seen in our Department of Neurology and in a
      private surgery. We analyze the symptoms and their relationship to the
      neuro-radiological findings. Finally we compare our observations with the
      descriptions published by other authors and seek and anatomo-functional
      relationship for each of the symptoms and signs observed. RESULTS: The
      usual clinical outline in our patients included disorders of
      consciousness, different types of oculomotor disorders and cerebellar
      symptoms, mainly of gait. Other less common findings were memory disorders
      and abnormal movements. In no case were there sensory changes and
      pyramidal signs were rare in the absence of significant extra-thalamic
      lesions. CONCLUSIONS: Our findings, although generally comparable to those
      described in the literature consulted, were somewhat different with regard
      to cerebellar symptoms and the absence of sensory and pyramidal signs. We
      also emphasize the marked differences seen between the individual patients
      in our series. A good knowledge of the possible clinical variants of these
      lesions is necessary for a correct initial diagnostic approach in the
      study of these patients.
AD  - Servicio de Neurologia, Hospital Ntra. Sra. de Aranzazu, San Sebastian,
      Guipuzcoa, Espana.
FAU - Martinez Perez-Balsa, A
AU  - Martinez Perez-Balsa A
FAU - Marti-Masso, J F
AU  - Marti-Masso JF
FAU - Carrera, N
AU  - Carrera N
FAU - Urtasun, M
AU  - Urtasun M
LA  - spa
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Variabilidad clinica de los infartos talamicos paramedianos bilaterales.
PL  - SPAIN
TA  - Rev Neurol
JT  - Revista de neurologia
JID - 7706841
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amnesia/etiology
MH  - Ataxia/etiology
MH  - Basal Ganglia Diseases/etiology
MH  - Cerebellum/pathology
MH  - *Cerebral Infarction/complications/pathology
MH  - Consciousness Disorders/etiology
MH  - Dysarthria/etiology
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Ocular Motility Disorders/etiology
MH  - Thalamus/*blood supply/pathology
EDAT- 1998/02/12
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Rev Neurol. 1997 Sep;25(145):1353-62.
PMID- 9379299
OWN - NLM
STAT- MEDLINE
DA  - 19971112
DCOM- 19971112
LR  - 20031114
PUBM- Print
IS  - 0022-3395 (Print)
VI  - 83
IP  - 5
DP  - 1997 Oct
TI  - Ascarophis marina n. comb. (Nematoda: cystidicolidae) from the fishes
      Parona signata (Carangidae) and Urophycis brasiliensis (Gadidae) in the
      southwestern Atlantic.
PG  - 917-21
AB  - The taxonomic position of Cystidicola marina Szidat, 1961 is revised,
      based on the re-examination of type and new specimens collected from the
      type host, Urophycis brasiliensis (Gadidae), and a new host, Parona
      signata (Carangidae), in the southwestern Atlantic. The species is
      redescribed and transferred to Ascarophis as A. marina n. comb. It is
      distinguished from other species of Ascarophis by the following
      combination of characters: body length (male: 10.2-22.5 mm, female:
      32.8-44.2 mm), number of egg filaments (2 on each pole), egg size
      (0.030-0.039 mm x 0.015-0.021 mm), and left spicule length (0.4-0.6 mm).
AD  - Centro de Estudios Parasitologicos y de Vectores (CEPAVE-CONICET), La
      Plata, Buenos Aires, Argentina.
FAU - Ivanov, V A
AU  - Ivanov VA
FAU - Navone, G T
AU  - Navone GT
FAU - Martorelli, S R
AU  - Martorelli SR
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - J Parasitol
JT  - The Journal of parasitology
JID - 7803124
SB  - IM
MH  - Animals
MH  - Female
MH  - Fish Diseases/*parasitology
MH  - Fishes
MH  - Male
MH  - Microscopy, Electron, Scanning
MH  - Nematoda/anatomy & histology/*classification/ultrastructure
MH  - Nematode Infections/parasitology/*veterinary
EDAT- 1997/10/29
MHDA- 1997/10/29 00:01
PST - ppublish
SO  - J Parasitol. 1997 Oct;83(5):917-21.
PMID- 9314714
OWN - NLM
STAT- MEDLINE
DA  - 19971030
DCOM- 19971030
LR  - 20061115
PUBM- Print
IS  - 0033-3182 (Print)
VI  - 38
IP  - 5
DP  - 1997 Sep-Oct
TI  - Use of medical services by veterans with mental disorders.
PG  - 451-8
AB  - This study examined timeliness, access, and intensity of outpatient
      medical service use in a national sample of veterans with comorbid medical
      disorders discharged from Veterans Affairs (VA) psychiatric units (N =
      44,533). The factors that predicted decreased use of medical services
      included diagnosis of schizophrenia, posttraumatic stress disorder, and
      substance abuse. The factors associated with increased use of medical
      services included proximity to a VA outpatient clinic, receipt of VA
      compensation payments, discharge from a facility with greater resources
      devoted to medical-surgical care, and prompt outpatient mental health
      follow-up. Better integration of medical and psychiatric services may help
      improve access to medical care for the severely mentally ill.
AD  - Northeast Program Evaluation Center, Department of Veterans Affairs, West
      Haven, Connecticut, USA.
FAU - Druss, B G
AU  - Druss BG
FAU - Rosenheck, R A
AU  - Rosenheck RA
LA  - eng
GR  - 15783/PHS
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Psychosomatics
JT  - Psychosomatics
JID - 0376506
SB  - IM
MH  - Adult
MH  - Aged
MH  - Ambulatory Care/utilization
MH  - Community Mental Health Services/*utilization
MH  - Comorbidity
MH  - Cross-Sectional Studies
MH  - Female
MH  - Health Services Accessibility/*statistics & numerical data
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Mental Disorders/diagnosis/*epidemiology/psychology
MH  - Middle Aged
MH  - Patient Discharge/statistics & numerical data
MH  - United States
MH  - Veterans/*psychology/statistics & numerical data
EDAT- 1997/10/07
MHDA- 1997/10/07 00:01
PST - ppublish
SO  - Psychosomatics. 1997 Sep-Oct;38(5):451-8.
PMID- 9293538
OWN - NLM
STAT- MEDLINE
DA  - 19971029
DCOM- 19971029
LR  - 20041117
PUBM- Print
IS  - 1320-5463 (Print)
VI  - 47
IP  - 8
DP  - 1997 Aug
TI  - Ameloblastic fibrosarcoma arising de novo in the maxilla.
PG  - 564-8
AB  - An ameloblastic fibrosarcoma (AFS) arising in the maxilla of a 14-year-old
      male is described. The tumor originated from the alveolar bone of the
      right maxilla with no apparent history of pre-existing lesion.
      Histologically, the lesion was composed of benign-appearing epithelial
      islands and strands scattered within an exceedingly cellular mass of
      mesenchymal tissue comprising a large number of stellate-and
      spindle-shaped fibroblast-like cells with marked pleomorphism. Occasional
      cementum-like calcification was also noted. Immunohistochemically, the
      neoplastic mesenchymal cells were positive only for vimentin, whereas the
      ameloblast-like epithelial component showed a distinctly positive reaction
      for wide-spectrum keratin and squamous cytokeratin. Clinicopathological
      features of the current case, as well as previously reported examples of
      AFS originating from the maxilla, are briefly discussed.
AD  - Department of Oral Pathology, Meikai University School of Dentistry,
      Saitama, Japan.
FAU - Tajima, Y
AU  - Tajima Y
FAU - Utsumi, N
AU  - Utsumi N
FAU - Suzuki, S
AU  - Suzuki S
FAU - Fujita, K
AU  - Fujita K
FAU - Takahashi, H
AU  - Takahashi H
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - AUSTRALIA
TA  - Pathol Int
JT  - Pathology international
JID - 9431380
SB  - IM
MH  - Adolescent
MH  - Biopsy
MH  - Fatal Outcome
MH  - Humans
MH  - Male
MH  - Maxilla/pathology
MH  - Maxillary Neoplasms/*pathology
MH  - Odontogenic Tumors/*pathology
EDAT- 1997/08/01 00:00
MHDA- 1997/09/18 00:01
PST - ppublish
SO  - Pathol Int. 1997 Aug;47(8):564-8.
PMID- 9346183
OWN - NLM
STAT- MEDLINE
DA  - 19971114
DCOM- 19971114
LR  - 20041117
PUBM- Print
IS  - 0893-3952 (Print)
VI  - 10
IP  - 10
DP  - 1997 Oct
TI  - Solitary fibrous tumor of soft tissue: a report of 15 cases, including 5
      malignant examples with light microscopic, immunohistochemical, and
      ultrastructural data.
PG  - 1028-37
AB  - We describe 15 soft tissue solitary fibrous tumors (SFTs) occurring in
      patients 24 to 78 years old (average, 50.6 yr). Ten tumors were benign and
      arose in the head and neck area (three tumors), thigh (two), vulva (two),
      upper arm (one), lower leg (one), and retroperitoneum (one). Five tumors
      were histologically malignant and arose in the thigh (two), abdominal wall
      (one), buttock (one), and retroperitoneum (one). All of the tumors were
      grossly well circumscribed. The benign tumors measured from 2 to 10 cm
      (average, 4.8 cm) and the malignant ones from 3 to 5.5 cm (average, 4.3
      cm) in greatest diameter. Microscopically, the benign tumors showed areas
      of hypercellularity with variable amounts of collagenous and myxoid
      stroma; one had amianthoid fibers. The malignant tumors were composed of
      cytologically atypical cells enmeshed in a collagenous or myxoid
      extracellular matrix. Ultrastructural study of three benign and three
      malignant tumors showed fibroblastic differentiation; one benign tumor
      showed myofibroblastic differentiation. Immunohistochemically, all of the
      tumors examined were immunoreactive for vimentin, and seven of nine were
      positive for CD34, including all of the malignant ones. There was focal
      staining for muscle actin in two benign tumors and for Leu-7 in one benign
      tumor; there was no staining for cytokeratin, desmin, S-100 protein,
      epithelial membrane antigen, or smooth muscle actin in any of the examined
      tissues. Follow-up was available for eight patients for 6 to 21 months
      (average, 12 mo). No tumor recurred locally or metastasized. The SFTs
      reported herein support the experiences of others who recently described
      these tumors in the somatic soft tissues. In addition, our series
      highlights the occurrence of malignant SFTs in the soft tissues. SFTs
      should be separated from other spindle cell sarcomas, with which they can
      be confused.
AD  - The James Homer Wright Pathology Laboratories, Massachusetts General
      Hospital, Harvard Medical School, Boston 02114, USA.
FAU - Nielsen, G P
AU  - Nielsen GP
FAU - O'Connell, J X
AU  - O'Connell JX
FAU - Dickersin, G R
AU  - Dickersin GR
FAU - Rosenberg, A E
AU  - Rosenberg AE
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - UNITED STATES
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian
      Academy of Pathology, Inc
JID - 8806605
RN  - 0 (Tumor Markers, Biological)
SB  - IM
MH  - Abdominal Muscles/pathology
MH  - Adult
MH  - Aged
MH  - Buttocks/pathology
MH  - Cell Nucleus/ultrastructure
MH  - Endoplasmic Reticulum, Rough/ultrastructure
MH  - Extremities/pathology
MH  - Female
MH  - Fibroma/chemistry/*pathology/ultrastructure
MH  - Head and Neck Neoplasms/pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - Retroperitoneal Neoplasms/pathology
MH  - Soft Tissue Neoplasms/chemistry/*pathology/ultrastructure
MH  - Tumor Markers, Biological/analysis
MH  - Vulvar Neoplasms/pathology
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Mod Pathol. 1997 Oct;10(10):1028-37.
PMID- 9325071
OWN - NLM
STAT- MEDLINE
DA  - 19971106
DCOM- 19971106
LR  - 20061115
PUBM- Print
IS  - 0090-1229 (Print)
VI  - 85
IP  - 1
DP  - 1997 Oct
TI  - Plasma effects on phagocytic activity and hydrogen peroxide production by
      polymorphonuclear leukocytes in neonates.
PG  - 67-72
AB  - To elucidate the defense mechanism in neonates against bacterial
      infections, phagocytic activity and hydrogen peroxide (H2O2) production by
      polymorphonuclear leukocytes (PMNs) in the whole blood and the effects of
      plasma on these functions were investigated on 44 healthy mature neonates
      (term 37 to 41 weeks) and 15 premature neonates (term 30 to 36 weeks)
      using two color flow cytometric analysis. The results were compared to
      those of a healthy adult control group (n = 10). PMN phagocytic activity
      was low in both mature and premature neonates. H2O2 production of PMN with
      phorbol myristate acetate (PMA) stimulation and following phagocytosis was
      augmented in both mature and premature neonates. When plasma and PMNs of
      adults and neonates were separated and combined differently, phagocytic
      activity and H2O2 production of PMNs appeared to be principally regulated
      by the plasma employed. This finding indicates that plasma has major
      effects on both phagocytosis and H2O2 production by PMNs of newborn
      neonates.
AD  - Department of Pediatrics, Kansai Medical University, Osaka, Japan.
FAU - Fujiwara, T
AU  - Fujiwara T
FAU - Kobayashi, T
AU  - Kobayashi T
FAU - Takaya, J
AU  - Takaya J
FAU - Taniuchi, S
AU  - Taniuchi S
FAU - Kobayashi, Y
AU  - Kobayashi Y
LA  - eng
PT  - In Vitro
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Clin Immunol Immunopathol
JT  - Clinical immunology and immunopathology
JID - 0356637
RN  - 16561-29-8 (Tetradecanoylphorbol Acetate)
RN  - 7722-84-1 (Hydrogen Peroxide)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - *Blood Bactericidal Activity
MH  - Fetal Blood/cytology/*immunology/*metabolism
MH  - Humans
MH  - Hydrogen Peroxide/*blood
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - Neutrophils/drug effects/*immunology/*metabolism
MH  - *Phagocytosis
MH  - Plasma/*immunology
MH  - Tetradecanoylphorbol Acetate/pharmacology
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
AID - S0090122997944032 [pii]
PST - ppublish
SO  - Clin Immunol Immunopathol. 1997 Oct;85(1):67-72.
PMID- 9379259
OWN - NLM
STAT- MEDLINE
DA  - 19971107
DCOM- 19971107
LR  - 20061115
PUBM- Print
IS  - 0736-0266 (Print)
VI  - 15
IP  - 4
DP  - 1997 Jul
TI  - Forearm muscle oxygenation decreases with low levels of voluntary
      contraction.
PG  - 507-11
AB  - The purpose of our investigation was to determine if the near infrared
      spectroscopy technique was sensitive to changes in tissue oxygenation at
      low levels of isometric contraction in the extensor carpi radialis brevis
      muscle. Nine subjects were seated with the right arm abducted to 45
      degrees, elbow flexed to 85 degrees, forearm pronated 45 degrees, and
      wrist and forearm supported on an armrest throughout the protocol. Altered
      tissue oxygenation was measured noninvasively with near infrared
      spectroscopy. The near infrared spectroscopy probe was placed over the
      extensor carpi radialis brevis of the subject's right forearm and secured
      with an elastic wrap. After 1 minute of baseline measurements taken with
      the muscle relaxed, four different loads were applied just proximal to the
      metacarpophalangeal joint such that the subjects isometrically contracted
      the extensor carpi radialis brevis at 5, 10, 15, and 50% of the maximum
      voluntary contraction for 1 minute each. A 3-minute recovery period
      followed each level of contraction. At the end of the protocol, with the
      probe still in place, a value for ischemic tissue oxygenation was obtained
      for each subject. This value was considered the physiological zero and
      hence 0% tissue oxygenation. Mean tissue oxygenation (+/-SE) decreased
      from resting baseline (100% tissue oxygenation) to 89 +/- 4, 81 +/- 8, 78
      +/- 8, and 47 +/- 8% at 5, 10, 15, and 50% of the maximum voluntary
      contraction, respectively. Tissue oxygenation levels at 10, 15, and 50% of
      the maximum voluntary contraction were significantly lower (p < 0.05) than
      the baseline value. Our results indicate that tissue oxygenation
      significantly decreases during brief, low levels of static muscle
      contraction and that near infrared spectroscopy is a sensitive technique
      for detecting deoxygenation noninvasively at low levels of forearm muscle
      contraction. Our findings have important implications in occupational
      medicine because oxygen depletion induced by low levels of muscle
      contraction may be directly linked to muscle fatigue.
AD  - Ergonomics Laboratory, University of California, Berkeley, USA.
FAU - Murthy, G
AU  - Murthy G
FAU - Kahan, N J
AU  - Kahan NJ
FAU - Hargens, A R
AU  - Hargens AR
FAU - Rempel, D M
AU  - Rempel DM
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - UNITED STATES
TA  - J Orthop Res
JT  - Journal of orthopaedic research : official publication of the Orthopaedic
      Research Society
JID - 8404726
SB  - IM
SB  - S
MH  - Adult
MH  - Exertion/physiology
MH  - Female
MH  - Forearm
MH  - Human Engineering
MH  - Humans
MH  - Male
MH  - Muscle Contraction/*physiology
MH  - Muscle Fatigue/physiology
MH  - Muscle, Skeletal/*physiology
MH  - Oxygen Consumption/*physiology
MH  - Spectroscopy, Near-Infrared
MH  - Volition/physiology
OTO - NASA
OT  - NASA Center ARC
OT  - NASA Discipline Musculoskeletal
IR  - Hargens AR
FIR - Hargens, A R
IRAD- ARC
EDAT- 1997/07/01 00:00
MHDA- 1997/10/23 00:01
AID - 10.1002/jor.1100150405 [doi]
PST - ppublish
SO  - J Orthop Res. 1997 Jul;15(4):507-11.
PMID- 9085387
OWN - NLM
STAT- MEDLINE
DA  - 19971119
DCOM- 19971119
LR  - 20041117
PUBM- Print
IS  - 0091-7435 (Print)
VI  - 26
IP  - 2
DP  - 1997 Mar-Apr
TI  - Educational and informational strategies to reduce pesticide risks.
      Council on Scientific Affairs.
PG  - 191-200
AB  - BACKGROUND: In 1993, the American Medical Association (AMA) requested its
      Council on Scientific Affairs to investigate issues and concerns related
      to (1) improving public notification of pesticide applications and (2)
      improving educational programs for commercial and farm pesticide
      applicators and increasing enforcement of licensing examination
      requirements. This report was presented at the 1994 Interim Meeting of the
      AMA House of Delegates as Report 4 of the Council on Scientific Affairs.
      METHODS: Information for the report was derived from published literature
      and from personal communications with state and federal regulatory
      officials, physicians, and representatives of pest control, lawn care, and
      farm organizations. Some information about state certification and
      training programs was obtained from telephone conversations with pesticide
      applicator training program coordinators from California, Florida,
      Illinois, Iowa, Michigan, Missouri, Nebraska, New Jersey, New York, Texas,
      Washington, and Wisconsin. These states were selected because they contain
      large agricultural or urban populations that are likely to require the
      services of trained professional pesticide applicators. RESULTS: Current
      surveillance systems are inadequate to characterize potential exposure
      problems related either to pesticide usage or to pesticide related
      illnesses. The effectiveness of applicator certification and training
      programs and public notification programs could not be determined because
      of a lack of federal and state survey data for making useful assessments.
      CONCLUSIONS: Considering current data gaps, it is prudent for homeowners,
      farmers, and workers to limit pesticide exposures to themselves and
      others.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - UNITED STATES
TA  - Prev Med
JT  - Preventive medicine
JID - 0322116
RN  - 0 (Pesticides)
SB  - IM
MH  - Certification/standards
MH  - Environmental Exposure/adverse effects/legislation &
      jurisprudence/*prevention & control
MH  - *Environmental Health/legislation & jurisprudence/standards
MH  - Government Agencies/legislation & jurisprudence/standards
MH  - Humans
MH  - Pest Control/standards
MH  - Pesticides/*adverse effects
MH  - Sentinel Surveillance
MH  - United States
RF  - 59
EDAT- 1997/03/01
MHDA- 1997/03/01 00:01
AID - S009174359690122X [pii]
PST - ppublish
SO  - Prev Med. 1997 Mar-Apr;26(2):191-200.
PMID- 9376959
OWN - NLM
STAT- MEDLINE
DA  - 19971106
DCOM- 19971106
LR  - 20051116
PUBM- Print
IS  - 1052-5157 (Print)
VI  - 7
IP  - 4
DP  - 1997 Oct
TI  - Angiographic evaluation and management of nonvariceal upper
      gastrointestinal bleeding.
PG  - 703-16
AB  - Endoscopy is the primary diagnostic and therapeutic tool used in the
      evaluation and treatment of patients with upper gastrointestinal bleeding.
      When endoscopy is unsuccessful in identifying or controlling GI
      hemorrhage, however, arteriography is useful in both the evaluation and
      treatment of upper GI hemorrhage.
AD  - Dotter Interventional Institution, Oregon Health Sciences University,
      Portland, OR 97201, USA.
FAU - Hamlin, J A
AU  - Hamlin JA
FAU - Petersen, B
AU  - Petersen B
FAU - Keller, F S
AU  - Keller FS
FAU - Rosch, J
AU  - Rosch J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - UNITED STATES
TA  - Gastrointest Endosc Clin N Am
JT  - Gastrointestinal endoscopy clinics of North America
JID - 9202792
SB  - IM
MH  - Adult
MH  - Angiography/*methods
MH  - Diagnosis, Differential
MH  - Esophageal and Gastric Varices/radiography/therapy
MH  - Gastrointestinal Hemorrhage/*radiography/therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer Hemorrhage/radiography/therapy
MH  - Postoperative Hemorrhage/radiography
MH  - Sensitivity and Specificity
RF  - 35
EDAT- 1998/02/12
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Gastrointest Endosc Clin N Am. 1997 Oct;7(4):703-16.
PMID- 9327223
OWN - NLM
STAT- MEDLINE
DA  - 19971120
DCOM- 19971120
LR  - 20051116
PUBM- Print
IS  - 1040-8746 (Print)
VI  - 9
IP  - 5
DP  - 1997 Sep
TI  - HIV-associated lymphomas.
PG  - 450-4
AB  - Intermediate and high-grade non-Hodgkin's lymphomas (NHL) with a B-cell
      phenotype are AIDS-defining illnesses. The incidence of systemic NHL
      increased greatly and primary central nervous system NHL increased even
      more in the HIV-infected population. Further increases in frequency are
      anticipated as HIV-infected individuals survive longer in an
      immunosuppressed state with improved antiretroviral treatment and
      treatment of opportunistic infections. Unusual types of NHL and
      manifestations of Hodgkin's disease are seen in HIV-infected individuals
      also. The pathologic and clinical features of the HIV-associated lymphomas
      and treatment approaches and results are the subjects of this review.
      Other articles in this issue discuss epidemiology and pathogenesis.
AD  - Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
FAU - Straus, D J
AU  - Straus DJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Review
PL  - UNITED STATES
TA  - Curr Opin Oncol
JT  - Current opinion in oncology
JID - 9007265
SB  - IM
SB  - X
MH  - Central Nervous System Neoplasms/pathology
MH  - Humans
MH  - Lymphoma, AIDS-Related/*pathology/therapy
MH  - Lymphoma, Non-Hodgkin/pathology
RF  - 46
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Curr Opin Oncol. 1997 Sep;9(5):450-4.
PMID- 9339895
OWN - NLM
STAT- MEDLINE
DA  - 19971114
DCOM- 19971114
LR  - 20061115
PUBM- Print
IS  - 1016-8478 (Print)
VI  - 7
IP  - 4
DP  - 1997 Aug 31
TI  - Hinnavin I, an antibacterial peptide from cabbage butterfly, Artogeia
      rapae.
PG  - 509-13
AB  - We have previously isolated four antibacterial peptides from the immune
      haemolymph of the fifth instar larvae of cabbage butterfly, Artogeia rapae
      [Yoe, S. M., Bang, I. S., Kang, C. S., and Kim, H. J. (1996) Mol. Cells 6,
      609-614]. They were induced by live, nonpathogenic gram negative bacteria.
      One of these novel antibacterial peptides was named hinnavin I. Hinnavin I
      is heat stable; its activity was retained after 60 min incubation at 100
      degrees C, being effective against gram negative and/or gram positive
      bacteria. Hinnavin I and lysozyme II showed a powerful synergistic effect
      on the inhibition of bacterial growth. Amino acid composition was analyzed
      and the molecular weight was determined to be 4,139.94+/-10.91 Da by the
      ESI mass spectrometer. To elucidate the primary structure of hinnavin I,
      the amino acid sequence of this peptide was determined by N-terminal
      sequencing techniques. The amino-terminal half of the molecule was rich in
      charged amino acids and was hydrophilic, whereas the carboxyl-terminal
      half was hydrophobic.
AD  - Department of Biological Sciences, Dankook University, Cheonan, Korea.
FAU - Bang, I S
AU  - Bang IS
FAU - Son, S Y
AU  - Son SY
FAU - Yoe, S M
AU  - Yoe SM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - KOREA
TA  - Mol Cells
JT  - Molecules and cells
JID - 9610936
RN  - 0 (Amino Acids)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Growth Inhibitors)
RN  - 0 (Insect Proteins)
RN  - 0 (Peptides)
RN  - 0 (hinnavin I protein, Artogeia rapae)
RN  - EC 3.2.1.17 (Muramidase)
SB  - IM
MH  - Amino Acid Sequence
MH  - Amino Acids/analysis
MH  - Animals
MH  - Anti-Bacterial Agents/*chemistry/isolation & purification/pharmacology
MH  - Butterflies/*chemistry
MH  - Drug Synergism
MH  - Escherichia coli/drug effects/growth & development
MH  - Growth Inhibitors/pharmacology
MH  - Hemolymph/chemistry
MH  - Insect Proteins/*chemistry/isolation & purification/pharmacology
MH  - Molecular Sequence Data
MH  - Molecular Weight
MH  - Muramidase/pharmacology
MH  - Peptides/*chemistry/isolation & purification/pharmacology
MH  - Sequence Analysis
EDAT- 1997/08/31 00:00
MHDA- 1997/10/27 00:01
PST - ppublish
SO  - Mol Cells. 1997 Aug 31;7(4):509-13.
PMID- 9307842
OWN - NLM
STAT- MEDLINE
DA  - 19971029
DCOM- 19971029
LR  - 20061115
PUBM- Print
IS  - 0361-090X (Print)
VI  - 21
IP  - 5
DP  - 1997
TI  - DNA adducts and the mechanism of carcinogenesis and cytotoxicity of
      methylating agents of environmental and clinical significance.
PG  - 391-405
AB  - DNA adducts are covalent complexes formed between genotoxic carcinogens
      and DNA bases, and constitute a critical early intermediate on the pathway
      of chemical carcinogenesis. Their accumulation in different tissues
      reflects the amount of activated carcinogen reaching DNA, and can
      therefore serve as an index of the biologically relevant dose reaching the
      target tissues or cells. Methylating agents are of interest in view of
      their occurrence in the environment and their use as cytotoxic drugs in
      cancer chemotherapy. Current evidence indicates that O6-methylguanine
      plays a particularly important role in the mutagenic, carcinogenic, and
      cytotoxic activities of methylating agents. O6-Methylguanine is repaired
      efficiently by the enzyme O6-alkylguanine-DNA alkyltransferase (AGT). Lack
      of this enzyme results in excessive accumulation of O6-methylguanine and
      recent evidence suggests that significant quantitative effects on adduct
      accumulation may be linked to conditions of very low AGT levels. This
      would be important from the point of view of clinical practice, since
      modulation of AGT is under investigation as a means of enhancing the
      therapeutic efficacy of clinical agents acting via the production of
      O6-methylguanine and related adducts, such as, for example, procarbazine,
      dacarbazine, and some nitrosoureas. The measurement of O6-methylguanine in
      human DNA has been employed as a tool to investigate the role of
      environmental methylating agents in human carcinogenesis. While the nature
      and origin of the methylating agents responsible for these adducts is
      currently unknown, recent studies in patas monkeys have shown that
      N-nitrosodimethylamine, a methylating carcinogen to which human exposure
      is well documented, is capable of efficiently generating O6-methylguanine
      in most tissues, including fetal tissues. Furthermore, it has been found
      that this damage is substantially enhanced by the coadministration of
      ethyl alcohol which acts by inhibiting the liver first-pass metabolism of
      the carcinogen, an observation which supports the hypothesis that alcohol
      consumption may act as a risk factor in human carcinogenesis by augmenting
      the action of nitrosamines.
AD  - National Hellenic Research Foundation, Institute of Biological Research
      and Biotechnology, Athens, Greece.
FAU - Kyrtopoulos, S A
AU  - Kyrtopoulos SA
FAU - Anderson, L M
AU  - Anderson LM
FAU - Chhabra, S K
AU  - Chhabra SK
FAU - Souliotis, V L
AU  - Souliotis VL
FAU - Pletsa, V
AU  - Pletsa V
FAU - Valavanis, C
AU  - Valavanis C
FAU - Georgiadis, P
AU  - Georgiadis P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - UNITED STATES
TA  - Cancer Detect Prev
JT  - Cancer detection and prevention
JID - 7704778
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Carcinogens)
RN  - 0 (Carcinogens, Environmental)
RN  - 0 (DNA Adducts)
RN  - 0 (Nitroso Compounds)
RN  - 138-89-6 (4-nitrosodimethylaniline)
RN  - 20535-83-5 (O-(6)-methylguanine)
RN  - 62-75-9 (Dimethylnitrosamine)
RN  - 64-17-5 (Ethanol)
RN  - 671-16-9 (Procarbazine)
RN  - 73-40-5 (Guanine)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/adverse effects/metabolism
MH  - Carcinogens/*metabolism/toxicity
MH  - Carcinogens, Environmental/metabolism/toxicity
MH  - DNA Adducts/*metabolism
MH  - DNA Damage
MH  - *DNA Methylation
MH  - Dimethylnitrosamine/metabolism/toxicity
MH  - Erythrocebus patas
MH  - Ethanol/pharmacology
MH  - Female
MH  - Guanine/analogs & derivatives/metabolism/toxicity
MH  - Humans
MH  - Leukocytes/drug effects
MH  - Liver/metabolism
MH  - Mice
MH  - Mice, Transgenic
MH  - Neoplasms/chemically induced/drug therapy
MH  - Nitroso Compounds/metabolism/toxicity
MH  - Procarbazine/metabolism/toxicity
RF  - 111
EDAT- 1997/01/01 00:00
MHDA- 1997/10/06 00:01
PST - ppublish
SO  - Cancer Detect Prev. 1997;21(5):391-405.
PMID- 9385099
OWN - NLM
STAT- MEDLINE
DA  - 19971125
DCOM- 19971125
LR  - 20041117
PUBM- Print
IS  - 1380-7870 (Print)
VI  - 1
IP  - 2
DP  - 1995
TI  - Product-limit survival functions with correlated survival times.
PG  - 171-86
AB  - A simple variance estimator for product-limit survival functions is
      demonstrated for survival times with nested errors. Such data arise
      whenever survival times are observed within clusters of related
      observations. Greenwood's formula, which assumes independent observations,
      is not appropriate in this situation. A robust variance estimator is
      developed using Taylor series linearized values and the between-cluster
      variance estimator commonly used in multi-stage sample surveys. A
      simulation study shows that the between-cluster variance estimator is
      approximately unbiased and yields confidence intervals that maintain the
      nominal level for several patterns of correlated survival times. The
      simulation study also shows that Greenwood's formula underestimates the
      variance when the survival times are positively correlated within a
      cluster and yields confidence intervals that are too narrow. Extension to
      life table methods is also discussed.
AD  - Research Triangle Institute, NC 27709-2194, USA. willy@rti.org
FAU - Williams, R L
AU  - Williams RL
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - Lifetime Data Anal
JT  - Lifetime data analysis
JID - 9516348
SB  - IM
MH  - Angina Pectoris
MH  - Animals
MH  - Avoidance Learning
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Life Tables
MH  - Linear Models
MH  - Male
MH  - Rodentia
MH  - *Survival Analysis
EDAT- 1995/01/01 00:00
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Lifetime Data Anal. 1995;1(2):171-86.
PMID- 9350074
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20061115
PUBM- Print
IS  - 0036-5513 (Print)
VI  - 57
IP  - 6
DP  - 1997 Oct
TI  - Minimal residual disease in B-lymphoproliferative disorders by PCR
      detection of immunoglobulin heavy chain gene recombination.
PG  - 541-7
AB  - We amplified and sequenced the rearranged immunoglobulin heavy chain VDJ
      genomic unit in B-leukemias and used it as a clone-specific marker for the
      molecular monitoring of the patients during and after therapeutic
      treatment. The method described is patient-specific rather than
      disorder-specific, more sensitive and less time-consuming than other
      conventional techniques for the detection of minimal residual disease. We
      propose reproducible and quick procedures, from DNA extraction to Southern
      blotting, that can be easily performed in any clinical laboratory and also
      applied to other kinds of investigation.
AD  - Dipartimento di Scienze Biomediche e Oncologia Umana, Universita di
      Torino, Ospedale San Luigi Gonzaga, Turin, Italy.
FAU - Petroni, D
AU  - Petroni D
FAU - Saglio, G
AU  - Saglio G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - NORWAY
TA  - Scand J Clin Lab Invest
JT  - Scandinavian journal of clinical and laboratory investigation
JID - 0404375
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Immunoglobulin Heavy Chains)
SB  - IM
MH  - Base Sequence
MH  - Blotting, Southern
MH  - DNA, Neoplasm/analysis
MH  - Gene Rearrangement
MH  - Humans
MH  - Immunoglobulin Heavy Chains/*genetics
MH  - Leukemia, B-Cell, Chronic/*genetics/immunology
MH  - Leukemia, Hairy Cell/*genetics/immunology
MH  - Leukemia, Lymphocytic, Acute/*genetics/immunology
MH  - Molecular Sequence Data
MH  - Neoplasm, Residual/*diagnosis/genetics/immunology
MH  - *Polymerase Chain Reaction
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
PST - ppublish
SO  - Scand J Clin Lab Invest. 1997 Oct;57(6):541-7.
PMID- 9342465
OWN - NLM
STAT- MEDLINE
DA  - 19971114
DCOM- 19971114
LR  - 20041117
PUBM- Print
IS  - 0390-6663 (Print)
VI  - 24
IP  - 2
DP  - 1997
TI  - Amniotic fluid index variations after amniocentesis, amnioinfusion and
      amnioreduction: preliminary data.
PG  - 70-3
AB  - We studied the relationship between the ultrasonographically measurable
      variations in the amniotic fluid index (AFI) and actual changes in the
      amniotic fluid volume induced by three differing invasive procedures:
      genetic amniocentesis, amnioinfusion and amnioreduction. We examined 50
      patients, all between the 15th and 34th weeks of pregnancy, subdivided
      into three groups. The first group consisted of 33 women who underwent
      genetic amniocentesis, the second was of 11 patients submitted to
      amnioinfusion for oligohydramnios (AFI < 5 cm), and the third was composed
      of 6 patients affected by hydramnios (AFI > 20 cm) and treated with
      amnioreduction. In all cases AFI was measured before and after the
      invasive procedures and their variations (delta AFI) were correlated to
      the actual quantities of liquid infused or extracted. All the procedures
      gave rise to statistically significant AFI changes. After genetic
      amniocentesis, the mean change was from 12.0 to 10.9 cm (p < 0.005), after
      amnioinfusion from 3.1 to 10.6 cm (p < 0.0001) and after amnioreduction
      from 33.1 to 22.0 cm. (p < 0.005). However, a significant linear
      correlation between delta AFI and the fluid volume variations actually
      induced was found for amnioinfusion (y = 0.236537 + 0.031465x; R2 = 44.4%;
      p < 0.05) and for amnioreduction (y = -0.0584294 + 0.012008x; R2 = 89.8%.
      p < 0.00001). Only for amnioreduction is it possible, as proved by a
      multiple regression analysis, to improve the predictability of delta AFI,
      taking into consideration together with the quantity of fluid aspirated,
      the value of the preprocedure AFI (R2 = 92%; p < 0.05).
AD  - Department of Obstetrics and Gynecology, University of Parma, Italy.
FAU - Gramellini, D
AU  - Gramellini D
FAU - Piantelli, G
AU  - Piantelli G
FAU - Di Marino, O
AU  - Di Marino O
FAU - Avanzini, A
AU  - Avanzini A
FAU - Vadora, E
AU  - Vadora E
LA  - eng
PT  - Journal Article
PL  - ITALY
TA  - Clin Exp Obstet Gynecol
JT  - Clinical and experimental obstetrics & gynecology
JID - 7802110
SB  - IM
MH  - *Amniocentesis
MH  - Amniotic Fluid/*physiology/ultrasonography
MH  - Female
MH  - Humans
MH  - Oligohydramnios/*therapy
MH  - Polyhydramnios/*therapy
MH  - Pregnancy
MH  - Reference Values
MH  - Regression Analysis
EDAT- 1997/01/01 00:00
MHDA- 1997/10/29 00:01
PST - ppublish
SO  - Clin Exp Obstet Gynecol. 1997;24(2):70-3.
PMID- 9304708
OWN - NLM
STAT- MEDLINE
DA  - 19971029
DCOM- 19971029
LR  - 20061115
PUBM- Print
IS  - 0080-0015 (Print)
VI  - 144
DP  - 1998
TI  - Applications of gene transfer in hematologic malignancy.
PG  - 60-9
AB  - Although gene transfer was originally conceived as a means to replace or
      correct defective genes in patients with inherited disorders, the process
      has shown broad potential for intervention in hematologic malignancy and
      for study of hematopoietic stem cell biology. Gene transfer strategies now
      under investigation for these applications include 1) repair of one or
      more genetic defects associated with the malignant process, 2) delivery of
      a prodrug-metabolizing enzyme that causes tumor cells to become sensitive
      to the corresponding anticancer drug, 3) modification of immune responses
      to the cancer, and 4) introduction of drug resistance genes to increase
      the therapeutic index of cytotoxic agents. Finally, by marking normal or
      malignant cells with readily detectable genes, one can monitor the
      efficacy of therapy or study the dynamics of stem cell behavior in vivo.
      At present these applications are limited by the quality of vectors, but
      as transduction efficiencies and gene regulatory mechanisms improve, gene
      transfer can be expected to evolve into a major therapeutic modality in
      its own right.
AD  - Cell and Gene Therapy Program, St. Jude Children's Research Hospital,
      Memphis, TN 38105, USA.
FAU - Brenner, M K
AU  - Brenner MK
LA  - eng
GR  - CA 20180/CA/NCI
GR  - CA 21765/CA/NCI
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - GERMANY
TA  - Recent Results Cancer Res
JT  - Recent results in cancer research. Fortschritte der Krebsforschung.
      Progres dans les recherches sur le cancer
JID - 0044671
SB  - IM
MH  - Drug Resistance, Neoplasm
MH  - *Gene Therapy
MH  - *Gene Transfer Techniques
MH  - Hematologic Neoplasms/genetics/immunology/*therapy
MH  - Hematopoietic Stem Cells
MH  - Humans
MH  - T-Lymphocytes, Cytotoxic/immunology
RF  - 37
EDAT- 1997/09/26
MHDA- 1997/09/26 00:01
PST - ppublish
SO  - Recent Results Cancer Res. 1998;144:60-9.
PMID- 9365353
OWN - NLM
STAT- MEDLINE
DA  - 19971125
DCOM- 19971125
LR  - 20061115
PUBM- Print
IS  - 0003-9993 (Print)
VI  - 78
IP  - 11
DP  - 1997 Nov
TI  - Concentric and eccentric isokinetic assessment of flexor-extensor torque
      ratios at the hip, knee, and ankle in a sample population of healthy
      subjects.
PG  - 1224-30
AB  - OBJECTIVE: To establish the relationship between the flexor/extensor
      torque ratios in the hip, knee, and ankle. DESIGN: Case series. SETTING:
      Laboratory of a university rehabilitation department. PARTICIPANTS: From a
      group of 158 healthy volunteers, 138 subjects completed all the tests in
      concentric mode, and 65 in eccentric mode. MAIN OUTCOME MEASURE: The
      flexor/extensor torque ratios of the hip, knee, and ankle were analyzed by
      means of isokinetic concentric and eccentric tests. Analysis of variance
      was carried out to compare the mean values of the ratios obtained between
      the male and female populations and between the right and left sides, and
      correlation analysis between the values of the joints. RESULTS: The
      flexor/extensor torque ratios differed significantly according to sex and
      angular velocities, but not according to side except for the ankle. No
      significant relationship was found between the flexor/extensor torque
      ratios in the hip, knee, and ankle joints. CONCLUSIONS: The
      flexor-extensor torque ratio of the knee and hip can be used as a
      reference point during rehabilitation of the contralateral side. Our
      results demonstrating the absence of correlation between the
      flexor/extensor torque ratio in each joint of the same limb, however, call
      for further longitudinal studies to be made under specific circumstances,
      such as training or immobilization of one joint, to follow the course of
      agonist/antagonist ratios and the synergistic activity between the joints.
AD  - Department of Physical Medicine and Rehabilitation, Lisfranc School of
      Medicine, Saint-Etienne University, France.
FAU - Calmels, P M
AU  - Calmels PM
FAU - Nellen, M
AU  - Nellen M
FAU - van der Borne, I
AU  - van der Borne I
FAU - Jourdin, P
AU  - Jourdin P
FAU - Minaire, P
AU  - Minaire P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Arch Phys Med Rehabil
JT  - Archives of physical medicine and rehabilitation
JID - 2985158R
SB  - AIM
SB  - IM
SB  - S
MH  - Adult
MH  - Aged
MH  - Analysis of Variance
MH  - Ankle Joint/*physiology
MH  - Biomechanics
MH  - Exercise Test
MH  - Female
MH  - Hip Joint/*physiology
MH  - Humans
MH  - Knee Joint/*physiology
MH  - Male
MH  - Middle Aged
MH  - Muscle Contraction/*physiology
MH  - Physical Medicine/methods
MH  - Posture/physiology
MH  - Range of Motion, Articular/physiology
MH  - Reference Values
MH  - Reproducibility of Results
MH  - Tensile Strength/physiology
MH  - Torque
EDAT- 1997/11/20
MHDA- 1997/11/20 00:01
AID - S0003-9993(97)90336-1 [pii]
PST - ppublish
SO  - Arch Phys Med Rehabil. 1997 Nov;78(11):1224-30.
PMID- 9327207
OWN - NLM
STAT- MEDLINE
DA  - 19971103
DCOM- 19971103
LR  - 20051116
PUBM- Print
IS  - 1062-4821 (Print)
VI  - 6
IP  - 5
DP  - 1997 Sep
TI  - The rise and fall of atrial natriuretic peptide for acute renal failure.
PG  - 474-6
AB  - Atrial natriuretic peptide can increase glomerular filtration rate and
      filtration fraction and can promote natriuresis, effects that would
      logically seem to improve renal function after acute tubular necrosis from
      ischemic or toxic injury. Early human trials suggested a beneficial effect
      of atrial natriuretic peptide on creatinine clearance, and a reduction in
      the need for dialysis in treated patients. However, randomized,
      placebo-controlled trials have failed to show a clinically relevant
      benefit on survival, dialysis-free survival, or renal function in patients
      treated with this agent.
AD  - Department of Medicine, Brigham and Women's Hospital, Harvard Medical
      School, Boston, Massachusetts 02115, USA.
FAU - Brenner, R M
AU  - Brenner RM
FAU - Chertow, G M
AU  - Chertow GM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - UNITED STATES
TA  - Curr Opin Nephrol Hypertens
JT  - Current opinion in nephrology and hypertension
JID - 9303753
RN  - 85637-73-6 (Atrial Natriuretic Factor)
SB  - IM
MH  - Atrial Natriuretic Factor/*therapeutic use
MH  - Clinical Trials
MH  - Humans
MH  - Kidney Failure, Acute/*drug therapy
MH  - Randomized Controlled Trials
RF  - 24
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Curr Opin Nephrol Hypertens. 1997 Sep;6(5):474-6.
PMID- 9324068
OWN - NLM
STAT- MEDLINE
DA  - 19971024
DCOM- 19971024
LR  - 20061115
PUBM- Print
IS  - 0024-3205 (Print)
VI  - 61
IP  - 13
DP  - 1997
TI  - Transplacental transfer of naltrexone in rats.
PG  - 1261-7
AB  - Extracts of fetal (20 days gestation) brain, heart, and liver were
      evaluated for naltrexone in rats 1 hour following maternal injection of 50
      mg/kg opioid antagonist; adult plasma from the pregnant rats was analyzed.
      Samples were prepared by ultrafiltration, lyophilized, reconstituted in
      mobile phase, and separated by reversed phase high-performance liquid
      chromatography with ultraviolet detection. This qualitative analysis
      revealed the presence of naltrexone in all fetal tissues, as well as in
      adult plasma. These results indicate naltrexone, maternally administered,
      passes through the placenta and enters the fetus. The data would suggest
      that reports concerning somatic and neurobiological acceleration in
      offspring exposed to naltrexone during gestation may be the result of a
      direct opioid antagonist action in the fetus.
AD  - Department of Neuroscience and Anatomy, The Pennsylvania State University
      College of Medicine, Hershey 17033, USA.
FAU - Zagon, I S
AU  - Zagon IS
FAU - Hurst, W J
AU  - Hurst WJ
FAU - McLaughlin, P J
AU  - McLaughlin PJ
LA  - eng
GR  - HL-53557/HL/NHLBI
GR  - NS-20500/NS/NINDS
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - ENGLAND
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Narcotic Antagonists)
RN  - 16590-41-3 (Naltrexone)
SB  - IM
MH  - Animals
MH  - Brain/embryology/metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Female
MH  - Heart/embryology
MH  - Kinetics
MH  - Liver/embryology/metabolism
MH  - Male
MH  - *Maternal-Fetal Exchange
MH  - Myocardium/metabolism
MH  - Naltrexone/*pharmacokinetics
MH  - Narcotic Antagonists/*pharmacokinetics
MH  - Placenta/*metabolism
MH  - Pregnancy
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1997/01/01 00:00
MHDA- 1997/11/04 00:01
AID - S0024320597006711 [pii]
PST - ppublish
SO  - Life Sci. 1997;61(13):1261-7.
PMID- 9322764
OWN - NLM
STAT- MEDLINE
DA  - 19971030
DCOM- 19971030
LR  - 20061115
PUBM- Print
IS  - 0378-1119 (Print)
VI  - 196
IP  - 1-2
DP  - 1997 Sep 1
TI  - Prevalence and chromosomal map location of Staphylococcus aureus adhesin
      genes.
PG  - 249-59
AB  - Using genomic DNA from 25 unrelated strains and probes specific for each
      gene, we assessed the prevalence of the Staphylococcus aureus (Sa)
      adhesion genes cna, fnbA, fnbB, fib, clfA, fbpA, ebpS and map. All 25
      strains encoded fib, clfA, ebpS, map and at least one of the fnb genes.
      fbpA and coa appeared to be allelic variants of the same gene with the
      fbpA variant being present in only four of 25 isolates. cna was present in
      10 of 25 strains. Using Southern blot analysis of SmaI-digested genomic
      DNA resolved by pulsed-field gel electrophoresis, the adhesion genes were
      mapped to SmaI fragments A (ebpS), B (fib and clfA), C (fnbA/fnbB), E
      (fbpA), F (map) and G (cna). Despite variations in SmaI restriction
      profiles, co-localization of adhesin genes with genes known to map to
      specific SmaI fragments in the Sa 8325-4 chromosome strains suggests that
      the chromosomal location of each adhesin gene is conserved.
AD  - Department of Microbiology and Immunology, University of Arkansas for
      Medical Sciences, Little Rock 72205, USA. msmeltzer@biomed.uams.edu
FAU - Smeltzer, M S
AU  - Smeltzer MS
FAU - Gillaspy, A F
AU  - Gillaspy AF
FAU - Pratt, F L Jr
AU  - Pratt FL Jr
FAU - Thames, M D
AU  - Thames MD
FAU - Iandolo, J J
AU  - Iandolo JJ
LA  - eng
GR  - AI 37729/AI/NIAID
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - NETHERLANDS
TA  - Gene
JT  - Gene
JID - 7706761
RN  - 0 (Adhesins, Bacterial)
RN  - 0 (Bacterial Proteins)
RN  - 0 (Carrier Proteins)
RN  - 0 (Fib protein, Staphylococcus aureus)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (adhesin, Staphylococcus aureus)
RN  - 0 (elastin-binding proteins)
RN  - EC 3.1.21.- (endodeoxyribonuclease XmaI)
RN  - EC 3.1.21.4 (Deoxyribonucleases, Type II Site-Specific)
SB  - IM
MH  - Adhesins, Bacterial/*genetics
MH  - Bacterial Proteins/genetics
MH  - Carrier Proteins/genetics
MH  - Chromosome Mapping
MH  - *Chromosomes, Bacterial
MH  - Deoxyribonucleases, Type II Site-Specific/genetics/metabolism
MH  - Receptors, Cell Surface/genetics
MH  - Staphylococcus aureus/*genetics
EDAT- 1997/10/10 16:17
MHDA- 2001/03/28 10:01
PST - ppublish
SO  - Gene. 1997 Sep 1;196(1-2):249-59.
PMID- 9237552
OWN - NLM
STAT- MEDLINE
DA  - 19971028
DCOM- 19971028
LR  - 20061115
PUBM- Print
IS  - 0006-8993 (Print)
VI  - 760
IP  - 1-2
DP  - 1997 Jun 20
TI  - Iron deposits in multiple sclerosis and Alzheimer's disease brains.
PG  - 298-303
AB  - Iron may contribute to the pathogenesis of neurological diseases by
      promoting oxidative damage. The localization of iron in multiple sclerosis
      (MS) and Alzheimer's disease (AD) brains was investigated to further the
      understanding of its pathogenic role in these disease states. Earlier
      studies, utilizing a standard Perls' stain, yielded conflicting reports
      regarding the distribution of iron deposits in MS brains, and a previous
      study on AD brains utilized a diaminobenzidine (DAB) enhanced version of
      this stain. In the present study, a modified version of the DAB-enhanced
      stain was used; it utilizes sodium borohydride, proteinase K, Triton X-100
      and xylenes to increase the accessibility of tissue iron to histochemical
      reagents. This modified method can reveal iron deposits that are missed by
      the Perls' or DAB-enhanced Perls' stains. In addition to its normal
      deposition in oligodendrocytes and myelin, iron was detected in reactive
      microglia, ameboid microglia and macrophages in MS brains. In AD brains,
      three types of plaques were stained: dense core, clear core and amorphous
      plaques. Punctate staining was also observed in neurons in the corticies
      of AD brains. The structure accounting for punctate labeling may be
      damaged mitochondria, lipofuscin or amyloid deposits. Dense core plaques,
      clear plaques and punctate labeling were not detected in the previous AD
      study which utilized only the DAB-enhanced Perls' stain. The labeling of
      these additional structures illustrates the benefit of the modified
      method. In summary, the localization of iron deposition in MS and AD
      brains indicates potential sites where iron could promote oxidative damage
      in these disease states.
AD  - Department of Physiology and the Smith Mental Retardation Research Center,
      University of Kansas Medical Center, Kansas City 66160, USA.
      slevine@kumc.edu
FAU - LeVine, S M
AU  - LeVine SM
LA  - eng
GR  - HD 02528/HD/NICHD
GR  - NS 33596/NS/NINDS
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - NETHERLANDS
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 7439-89-6 (Iron)
SB  - IM
MH  - Alzheimer Disease/*pathology
MH  - Brain/*pathology
MH  - Humans
MH  - Iron/*metabolism
MH  - Multiple Sclerosis/*pathology
EDAT- 1997/06/20
MHDA- 1997/06/20 00:01
AID - S0006-8993(97)00470-8 [pii]
PST - ppublish
SO  - Brain Res. 1997 Jun 20;760(1-2):298-303.
PMID- 9344613
OWN - NLM
STAT- MEDLINE
DA  - 19971125
DCOM- 19971125
LR  - 20061115
PUBM- Print
IS  - 0014-4827 (Print)
VI  - 236
IP  - 1
DP  - 1997 Oct 10
TI  - Prostaglandin H synthase expression is variable in human colorectal
      adenocarcinoma cell lines.
PG  - 321-9
AB  - The expression of prostaglandin H synthases can be induced by many stimuli
      and is likely to be important in control of the cell cycle. The analysis
      of prostaglandin H synthase-1 and -2 expression in colon adenocarcinoma
      cell lines is a useful model system for studying the function of the
      prostaglandin H synthases, especially with regard to proliferation and
      adhesion. Prostaglandin H synthase-1 protein is not found in any of eight
      human colon adenocarcinoma cell lines. Expression of prostaglandin H
      synthase-2 is variable for the eight cell lines: three constitutively
      expressed active protein, four did not express this gene at all, and one
      had mRNA but no active protein. Thus, five colorectal adenocarcinoma cell
      lines exhibit "null" expression of prostaglandin synthase-2. The three
      cell lines with constitutive expression of prostaglandin H synthase-2
      produce PGE2. Prostaglandin E2 production could be inhibited by aspirin
      and NS398 without inhibiting proliferation, while direct addition of
      prostaglandin E2 inhibits proliferation. Adhesion to collagen IV and
      fibronectin was stronger in those cell lines that expressed prostaglandin
      H synthase-2. The constitutive expression of prostaglandin H synthase-2 is
      associated with increased adhesion to extracellular matrix components and
      a potential inhibition of proliferation through the production of
      prostaglandin E2. The absence of PGH synthase-2 expression in some cell
      lines may result from the original tumor's need to inactivate these
      associated functions. Our evidence suggests that PGH synthase-2 is a
      possible candidate for a tumor suppressor gene at 1q23-qter.
AD  - Division of Hematology/Oncology, James H. Quillen College of Medicine,
      East Tennessee State University, Johnson City 37614-0622, USA.
FAU - Parker, J
AU  - Parker J
FAU - Kaplon, M K
AU  - Kaplon MK
FAU - Alvarez, C J
AU  - Alvarez CJ
FAU - Krishnaswamy, G
AU  - Krishnaswamy G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Exp Cell Res
JT  - Experimental cell research
JID - 0373226
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Extracellular Matrix Proteins)
RN  - 0 (Nitrobenzenes)
RN  - 0 (Prostaglandins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Sulfonamides)
RN  - 123653-11-2 (N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide)
RN  - 50-78-2 (Aspirin)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology
MH  - Blotting, Southern
MH  - Caco-2 Cells/cytology/*enzymology
MH  - Cell Adhesion/physiology
MH  - Cell Division/physiology
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - DNA, Neoplasm/analysis
MH  - Extracellular Matrix Proteins/metabolism
MH  - Female
MH  - Gene Expression Regulation, Enzymologic/drug effects/physiology
MH  - Gene Expression Regulation, Neoplastic/drug effects/physiology
MH  - HT29 Cells/cytology/*enzymology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nitrobenzenes/pharmacology
MH  - Prostaglandin-Endoperoxide Synthases/*genetics/metabolism
MH  - Prostaglandins/biosynthesis
MH  - RNA, Messenger/metabolism
MH  - Sulfonamides/pharmacology
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
AID - S0014-4827(97)93741-1 [pii]
AID - 10.1006/excr.1997.3741 [doi]
PST - ppublish
SO  - Exp Cell Res. 1997 Oct 10;236(1):321-9.
PMID- 9345238
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20061115
PUBM- Print
IS  - 1078-5884 (Print)
VI  - 14
IP  - 3
DP  - 1997 Sep
TI  - A paper for debate: vein versus PTFE for critical limb ischaemia--an
      unfair comparison?
PG  - 191-4
AB  - INTRODUCTION: There is a widely held view that vein grafts for
      infrainguinal arterial reconstruction perform much better than prosthetic
      conduits, the best of which seems to be PTFE. Many randomised studies have
      been conducted which confirm this opinion, but is the difference as large
      as it is thought to be? One interesting feature of published trials is
      that the results for obligatory PTFE (when no vein is available) were much
      worse than the results for randomised PTFE grafts. The only way to explain
      this is that these groups of patients were not similar, and there are
      probably other factors which contribute to the difference in results when
      vein and PTFE grafts are compared. MATERIALS AND METHODS: A consecutive
      series of 109 femoro-infrapopliteal grafts undertaken for critical limb
      ischaemia was analysed to see the difference between vein and PTFE with
      vein cuff grafts. RESULTS: Vein grafts were superior to PTFE grafts when
      the whole cohort was included (p = 0.0038); however, there was no
      significant difference when the patients were stratified for inflow and
      runoff status. CONCLUSIONS: The difference between vein and PTFE has
      probably been exaggerated in the past, due to differences in risk factors
      and in the extent of arterial disease between the two groups of patients.
      The advantage of vein becomes more significant with time.
AD  - Department of Surgery, Guy's Hospital, London, U.K.
FAU - Panayiotopoulos, Y P
AU  - Panayiotopoulos YP
FAU - Taylor, P R
AU  - Taylor PR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - ENGLAND
TA  - Eur J Vasc Endovasc Surg
JT  - European journal of vascular and endovascular surgery : the official
      journal of the European Society for Vascular Surgery
JID - 9512728
RN  - 9002-84-0 (Polytetrafluoroethylene)
SB  - IM
MH  - Blood Vessel Prosthesis
MH  - *Blood Vessel Prosthesis Implantation
MH  - Cohort Studies
MH  - Graft Occlusion, Vascular/epidemiology
MH  - Humans
MH  - Ischemia/*surgery
MH  - Leg/*blood supply
MH  - *Polytetrafluoroethylene
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Vascular Patency
MH  - Veins/*transplantation
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Eur J Vasc Endovasc Surg. 1997 Sep;14(3):191-4.
PMID- 9336588
OWN - NLM
STAT- MEDLINE
DA  - 19971113
DCOM- 19971113
LR  - 20041117
PUBM- Print
IS  - 0002-8223 (Print)
VI  - 97
IP  - 10 Suppl 2
DP  - 1997 Oct
TI  - The ketogenic diet revisited.
PG  - S192-4
AB  - The ketogenic diet is a high-fat diet that maintains the body's starvation
      mechanism, with exogenous fat provided for metabolism in lieu of stored
      fat. Mild dehydration is important to prevent dilution of the level of
      ketones in circulation at any given time. It is not known why or how
      ketosis affects seizure activity, so the principles behind the therapy
      have been developed from years of clinical experience and theoretical
      assumptions. Dietitians are essential providers of ketosis therapy, but
      the dietitian must work with a physician who understands the theories
      behind the therapy and is an active member of the ketosis therapy team.
AD  - Hermann Children's Hospital, University of Texas Medical School, Houston,
      USA.
FAU - Berryman, M S
AU  - Berryman MS
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - J Am Diet Assoc
JT  - Journal of the American Dietetic Association
JID - 7503061
SB  - AIM
SB  - IM
MH  - Diet/adverse effects/*methods
MH  - Humans
MH  - Ketosis/*etiology
MH  - Seizures/*diet therapy
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
PST - ppublish
SO  - J Am Diet Assoc. 1997 Oct;97(10 Suppl 2):S192-4.
PMID- 9336566
OWN - NLM
STAT- MEDLINE
DA  - 19971113
DCOM- 19971113
LR  - 20041117
PUBM- Print
IS  - 0002-8223 (Print)
VI  - 97
IP  - 10 Suppl 2
DP  - 1997 Oct
TI  - Research competencies in the dietetics curricula.
PG  - S102-6
AB  - Investment in dietetics research has the potential to improve general
      health; increase work performance and learning capacity; extend
      disease-free life; reduce birth defects, infections, and chronic diseases;
      and decrease health care costs. Opportunities exist for research in the
      areas of solid waste management, global environment, health care reform,
      and foodservice systems management. Research efforts can focus on
      cost-effectiveness and medical efficacy of dietary services to improve
      third-party reimbursement. Educators have a stake in creating the future
      by conducting research, teaching research to dietetic students, and
      investigating the effectiveness of education.
AD  - Veterans Affairs New Jersey Health Care Systems, East Orange 07108-1095,
      USA.
FAU - Hynak-Hankinson, M T
AU  - Hynak-Hankinson MT
FAU - Martin, S
AU  - Martin S
FAU - Wirth, J
AU  - Wirth J
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - J Am Diet Assoc
JT  - Journal of the American Dietetic Association
JID - 7503061
SB  - AIM
SB  - IM
MH  - Clinical Competence
MH  - *Curriculum
MH  - Data Collection/methods
MH  - Dietetics/*education
MH  - Humans
MH  - *Research
MH  - United States
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
PST - ppublish
SO  - J Am Diet Assoc. 1997 Oct;97(10 Suppl 2):S102-6.
PMID- 9323515
OWN - NLM
STAT- MEDLINE
DA  - 19971120
DCOM- 19971120
LR  - 20051117
PUBM- Print
IS  - 0392-0461 (Print)
VI  - 18
IP  - 4
DP  - 1997 Aug
TI  - Recurrent external ophthalmoparesis during hormonal therapy after thyroid
      ablation. Case report.
PG  - 215-6
AB  - We here report the case of a patient who had undergone total thyroid
      ablation for Graves' disease. After the beginning of oral therapy with
      1-thyroxine, she developed a left external ophthalmoparesis that remitted
      with the discontinuation of the drug and recurred whenever the replacement
      therapy (1-thyroxine or tri-iodothyronine) was reintroduced.
AD  - Divisione di Neurologia, Ospedale Civile di Belluno, Italy.
FAU - Ferracci, F
AU  - Ferracci F
FAU - Conte, F
AU  - Conte F
FAU - Marini, B
AU  - Marini B
FAU - Fassetta, G
AU  - Fassetta G
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - ITALY
TA  - Ital J Neurol Sci
JT  - Italian journal of neurological sciences
JID - 8006502
RN  - 0 (Thyroid Hormones)
SB  - IM
MH  - Aged
MH  - Combined Modality Therapy
MH  - Female
MH  - Graves Disease/drug therapy/surgery/*therapy
MH  - Humans
MH  - Recurrence
MH  - Thyroid Gland/*surgery
MH  - Thyroid Hormones/*therapeutic use
EDAT- 1997/08/01 00:00
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Ital J Neurol Sci. 1997 Aug;18(4):215-6.
PMID- 9380370
OWN - NLM
STAT- MEDLINE
DA  - 19971110
DCOM- 19971110
LR  - 20061115
PUBM- Print
IS  - 1040-5488 (Print)
VI  - 74
IP  - 9
DP  - 1997 Sep
TI  - Evaluation of Kojima-Matsubara color vision test plates: validity in young
      children.
PG  - 726-31
AB  - PURPOSE: We examined a pseudoisochromatic color plate test by Kojima and
      Matsubara for young children which uses drawings of familiar objects
      rather than letters or numbers. First, we evaluated the test's efficacy as
      a color deficiency screener and its validity in classifying the types of
      color deficiencies by comparing its results with those from the Moreland
      anomaloscope. Second, we eliminated the chromatic factor and evaluated the
      functional ability of young children to perform the task by determining
      how many correct responses were obtained using modified black/white
      replicas of the test plates. METHODS: Part 1: Twenty color-normal and 13
      color-deficient adults were diagnosed and classified with the Ishihara
      test, Panel D-15 test, and anomaloscope. Subjects were then tested with
      the Kojima-Matsubara test and result were compared with those from the
      anomaloscope. Part 2: Fifty children aged 3 to 7 years were tested with
      modified black/white test plate replicas. The number of correct responses
      for each plate was determined for five different age groups. RESULTS: Part
      1: Among the 20 color-normal subjects, 18 read all 10 plates correctly and
      2 subjects missed 1 of the 10. Only 1 of the 13 color-deficient subjects
      exhibited the expected responses for plates 2 to 6 (used for color
      deficiency screening). The color-deficient subjects' responses for plates
      7 to 10, which are used to classify red-green defects, were varied and
      only the protanomalous subjects (n = 2) followed the expected response
      pattern. Part 2: Of the 10 black/white modified plates, only 2 were
      correctly identified by all 50 children. The other plates had a
      recognition rate that ranged from 32 to 98%. CONCLUSIONS: Because the
      response patterns given by most of the color-deficient adult subjects were
      different from those in the test manual, ambiguous results would occur if
      the Kojima-Matsubara test were used for color vision screening or the
      diagnosis of color deficiency. In addition, the difficulty that many of
      the young children exhibited in identifying the objects in the black/white
      replica plates suggests that there would be a large number of false
      positive errors (classifying a color normal as color deficient) when using
      this test in young children.
AD  - Illinois College of Optometry, Chicago, USA.
FAU - Lee, D Y
AU  - Lee DY
FAU - Cotter, S A
AU  - Cotter SA
FAU - French, A L
AU  - French AL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - UNITED STATES
TA  - Optom Vis Sci
JT  - Optometry and vision science : official publication of the American
      Academy of Optometry
JID - 8904931
SB  - IM
MH  - Adult
MH  - Aging/physiology
MH  - Child
MH  - Child, Preschool
MH  - Color Perception/*physiology
MH  - Color Perception Tests/*methods
MH  - Color Vision Defects/diagnosis
MH  - Evaluation Studies
MH  - Humans
MH  - Reproducibility of Results
MH  - Vision Screening/*methods
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Optom Vis Sci. 1997 Sep;74(9):726-31.
PMID- 9333208
OWN - NLM
STAT- MEDLINE
DA  - 19971120
DCOM- 19971120
LR  - 20061115
PUBM- Print
IS  - 0031-9384 (Print)
VI  - 62
IP  - 5
DP  - 1997 Nov
TI  - Behavioral and physiological sex differences observed in an animal model
      of fulminant hepatic encephalopathy in the rat.
PG  - 1113-24
AB  - Hepatic encephalopathy is characterized by a number of neuropsychiatric
      and motor disturbances observed in patients with liver dysfunction. The
      purpose of this study is to fully characterize behavioral and
      physiological sex differences in an animal model of fulminant hepatic
      encephalopathy (FHE). Male and female rats were administered thioacetamide
      (600 mg/kg) via i.p. (intraperitoneal) injection at Hours 0 and 24 and
      allowed to progress into the four stages of FHE. Male rats reached all
      four stages of FHE significantly earlier than female rats (p < 0.05). The
      performance of the male rats deteriorated more quickly (p < 0.05) than
      that of the females in all of the sensory and motor behavioral tests. Sex
      differences were observed in the liver enzymes of the FHE rats. The levels
      of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and
      alkaline phosphatase were significantly greater (p < 0.05) in male rats in
      all four stages of FHE. Significant increases were also observed in the
      levels of direct and total bilirubin (p < 0.05). Neuronal damage was
      observed in the CA1 and CA2 regions of the hippocampus. In the CA1 region,
      male rats displayed greater pathological changes in Stages III and IV (p <
      0.05) than female rats. The damage in the CA2 region was only observed in
      Stage IV male rats. Our data indicate that observable behavioral and
      physiological sex differences occur in thioacetamide-induced FHE in the
      rat.
AD  - Department of Oral Biology, School of Dentistry, Creighton University,
      Omaha, NE 68178, USA. Nsnorton@creighton.edu
FAU - Norton, N S
AU  - Norton NS
FAU - McConnell, J R
AU  - McConnell JR
FAU - Rodriguez-Sierra, J F
AU  - Rodriguez-Sierra JF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Physiol Behav
JT  - Physiology & behavior
JID - 0151504
RN  - 62-55-5 (Thioacetamide)
SB  - IM
MH  - Animals
MH  - Behavior, Animal/drug effects/*physiology
MH  - Brain Mapping
MH  - Female
MH  - Hepatic Encephalopathy/chemically induced/pathology/*physiopathology
MH  - Hippocampus/drug effects/pathology/physiopathology
MH  - Injections, Intraperitoneal
MH  - *Liver Function Tests
MH  - Male
MH  - Neurons/drug effects/pathology/physiology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sex Factors
MH  - Thioacetamide
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
AID - S0031-9384(97)00267-9 [pii]
PST - ppublish
SO  - Physiol Behav. 1997 Nov;62(5):1113-24.
PMID- 9297630
OWN - NLM
STAT- MEDLINE
DA  - 19971124
DCOM- 19971124
LR  - 20061115
PUBM- Print
IS  - 0895-8696 (Print)
VI  - 8
IP  - 3
DP  - 1997 Jun
TI  - Corticotropin-releasing factor and glucocorticoid receptor (GR) gene
      expression in the paraventricular nucleus of immune-challenged transgenic
      mice expressing type II GR antisense ribonucleic acid.
PG  - 165-79
AB  - The purpose of this study was to investigate the effect of the immune
      activator lipopolysaccharide (LPS) on the expression of
      corticotropin-releasing factor (CRF) and glucocorticoid receptor (GR) mRNA
      in the paraventricular nucleus (PVN) of transgenic mice with impaired GR
      function caused by endogenous expression of GR antisense RNA. At 3 and 8
      wk of age, control and transgenic mice were sacrificed 4.5 h after a
      single ip administration of LPS (100 micrograms/100 g of body wt) or
      vehicle. Frozen brains were mounted on a microtome and cut in 20-microns
      sections. mRNAs encoding CRF and GR were assayed by in situ hybridization
      histochemistry using 35S-labeled riboprobes, and localization of
      Fos-immunoreactive (Fos-ir) nuclei was determined by immunocytochemistry.
      Basal expression of CRF mRNA in the PVN, central nucleus of the amygdala
      (CeA), and geniculate complex (GN) was similar in the control and
      transgenic mice. LPS induced a comparable neuronal activation in the PVN
      of control and transgenic mice as revealed by the number of Fos-ir
      neurons. Moreover, the endotoxin caused a significant increase in the CRF
      mRNA levels within the PVN and CeA, an effect observed in both animal
      models. The endotoxin did not notably modulate CRF expression in other
      regions, such as GN. Although GR mRNA was expressed in the PVN of control
      mice under basal conditions, this transcript was not detected in this
      hypothalamic structure in LPS-treated and transgenic animals. This
      indicated that endogenous Type II GR mRNA is decreased in the PVN of mice
      expressing Type II GR antisense RNA and that gene is downregulated by LPS.
      Hybridization signal for CRF and GR transcripts was not notably altered by
      the age of mice. These results provide evidence that the basal expression
      of CRF and the increase of neuroendocrine CRF transcription in response to
      immunogenic challenges are not significantly affected by impairment of the
      Type II GR function.
AD  - Laboratory of Molecular Endocrinology, Laval University, Quebec, Canada.
FAU - Laflamme, N
AU  - Laflamme N
FAU - Barden, N
AU  - Barden N
FAU - Rivest, S
AU  - Rivest S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - J Mol Neurosci
JT  - Journal of molecular neuroscience : MN
JID - 9002991
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Proto-Oncogene Proteins c-fos)
RN  - 0 (RNA, Antisense)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Glucocorticoid)
RN  - 9015-71-8 (Corticotropin-Releasing Hormone)
SB  - IM
MH  - Animals
MH  - Brain/drug effects/metabolism
MH  - Corticotropin-Releasing Hormone/*genetics
MH  - *Gene Expression
MH  - Humans
MH  - In Situ Hybridization
MH  - Lipopolysaccharides/pharmacology
MH  - Mice
MH  - Mice, Transgenic
MH  - Paraventricular Hypothalamic Nucleus/immunology/*metabolism
MH  - Proto-Oncogene Proteins c-fos/genetics/metabolism
MH  - RNA, Antisense/*biosynthesis/metabolism
MH  - RNA, Messenger/metabolism
MH  - Rats
MH  - Receptors, Glucocorticoid/*genetics
EDAT- 1997/06/01 00:00
MHDA- 1997/09/23 00:01
PST - ppublish
SO  - J Mol Neurosci. 1997 Jun;8(3):165-79.
PMID- 9378611
OWN - NLM
STAT- MEDLINE
DA  - 19971107
DCOM- 19971107
LR  - 20061115
PUBM- Print
IS  - 0074-7742 (Print)
VI  - 41
DP  - 1997
TI  - Cerebellar output channels.
PG  - 61-82
AB  - The cerebellum has long been regarded as involved in the control of
      movement, in part through its connections with the cerebral cortex. These
      connections were thought to combine inputs from widespread regions of the
      cerebral cortex and "funnel" them into the motor system at the level of
      the primary motor cortex. Retrograde transneuronal transport of herpes
      simplex virus type I has recently been used to identify areas of the
      cerebral cortex that are "directly" influenced by the output of the
      cerebellum. Results suggest that cerebellar output projects via the
      thalamus to multiple cortical areas, including premotor and prefrontal
      cortex, as well as the primary motor cortex. In addition, the projections
      to different cortical areas appear to originate from distinct regions of
      the deep cerebellar nuclei. These observations have led to the proposal
      that cerebellar output is composed of a number of separate "output
      channels." Evidence from functional imaging studies in humans and single
      neuron recording studies in monkeys suggests that individual output
      channels are concerned with different aspects of motor or cognitive
      behavior.
AD  - Veterans Administration Medical Center, Syracuse, New York, USA.
FAU - Middleton, F A
AU  - Middleton FA
FAU - Strick, P L
AU  - Strick PL
LA  - eng
GR  - MH11262/MH/NIMH
GR  - NS24328/NS/NINDS
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - UNITED STATES
TA  - Int Rev Neurobiol
JT  - International review of neurobiology
JID - 0374740
SB  - IM
MH  - Animals
MH  - Brain Mapping/*methods
MH  - Cerebellum/*physiology
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Motor Cortex/*physiology
MH  - Neural Pathways/physiology
MH  - Neurons/physiology
MH  - Prefrontal Cortex/physiology
MH  - Primates/physiology
RF  - 66
EDAT- 1997/01/01 00:00
MHDA- 1997/09/26 00:01
PST - ppublish
SO  - Int Rev Neurobiol. 1997;41:61-82.
PMID- 9348568
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20061115
PUBM- Print
IS  - 0890-9091 (Print)
VI  - 11
IP  - 9 Suppl 10
DP  - 1997 Sep
TI  - 5-FU or UFT combined with leucovorin for previously untreated metastatic
      colorectal Ca.
PG  - 48-9
AB  - This phase III study compares leucovorin plus fluorouracil (5-FU) 425
      mg/m2, days 1 through 5, 28-day cycle, with oral leucovorin plus oral UFT
      (tegafur and uracil) 300 mg/m2, days 1 through 28, 35-day cycle, in terms
      of efficacy, safety, quality of life, and pharmacoeconomics. Eligible
      patients have not been treated previously and have measurable or evaluable
      metastatic colorectal cancer, an Eastern Cooperative Oncology Group
      performance status of 2 or less, and adequate bone marrow, liver, and
      renal functions. Patients are evaluated for response clinically and by
      computed tomography. Responses are determined by World Health Organization
      criteria. The study is nearing completion, with no toxicity issues
      requiring protocol modification. The results of this study could lead to a
      change to oral therapy as the standard of care for metastatic colorectal
      cancer, providing the efficacy and toxicity of UFT/leucovorin are at least
      equivalent due to the ease of administration and patient preference for
      oral regimens.
AD  - QE II Health Sciences Centre, Halifax, Nova Scotia, Canada.
FAU - Skillings, J R
AU  - Skillings JR
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - UNITED STATES
TA  - Oncology (Williston Park)
JT  - Oncology (Williston Park, N.Y.)
JID - 8712059
RN  - 0 (Antidotes)
RN  - 0 (Drug Combinations)
RN  - 0 (UFT(R) drug)
RN  - 17902-23-7 (Tegafur)
RN  - 51-21-8 (Fluorouracil)
RN  - 58-05-9 (Leucovorin)
RN  - 66-22-8 (Uracil)
SB  - IM
MH  - Adult
MH  - Antidotes/*administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Colorectal Neoplasms/*drug therapy
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Fluorouracil/administration & dosage
MH  - Humans
MH  - Leucovorin/*administration & dosage
MH  - Tegafur/administration & dosage
MH  - Uracil/administration & dosage
EDAT- 1998/02/12
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Oncology (Williston Park). 1997 Sep;11(9 Suppl 10):48-9.
PMID- 9313184
OWN - NLM
STAT- MEDLINE
DA  - 19971029
DCOM- 19971029
LR  - 20041117
PUBM- Print
IS  - 0884-2175 (Print)
VI  - 26
IP  - 5
DP  - 1997 Sep-Oct
TI  - Women's sense of well-being before and after hysterectomy.
PG  - 540-8
AB  - OBJECTIVE: To describe women's perceived sense of well-being before and
      after hysterectomy by examining a broad array of outcomes experienced by
      women undergoing hysterectomies for benign conditions. DESIGN:
      Prospective, descriptive. SETTING: A regional tertiary care facility in
      central Texas. PARTICIPANTS: One hundred seventy-eight women presenting
      for hysterectomies for nononcologic reasons who completed all three
      periods of data collection. MAIN OUTCOME MEASURES: Subjects completed a
      questionnaire assessing information pertinent to their current gynecologic
      health and the SF-36 Health Survey before surgery and of 4 and 11 months
      after surgery. The women also completed the Zung Self-Rating Depression
      Scale preoperatively and at 4 months postoperatively. Additional
      demographic and medical information was extracted from the medical record.
      RESULTS: In the initial period after surgery, the patients experienced an
      improved health status. In addition, the women reported on improvement in
      their psychologic well-being, including less depression and improved
      sexual functioning. Relationships with others also improved after the
      surgery. CONCLUSIONS: Outcomes for these women undergoing hysterectomy for
      nononcologic reasons were generally positive. This information is vital
      for preoperative counseling by nurses of women contemplating or about to
      undergo this surgery.
AD  - Children's Health Center, Scott and White Clinic, Temple, TX 76508, USA.
FAU - Lambden, M P
AU  - Lambden MP
FAU - Bellamy, G
AU  - Bellamy G
FAU - Ogburn-Russell, L
AU  - Ogburn-Russell L
FAU - Preece, C K
AU  - Preece CK
FAU - Moore, S
AU  - Moore S
FAU - Pepin, T
AU  - Pepin T
FAU - Croop, J
AU  - Croop J
FAU - Culbert, G
AU  - Culbert G
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - J Obstet Gynecol Neonatal Nurs
JT  - Journal of obstetric, gynecologic, and neonatal nursing : JOGNN / NAACOG
JID - 8503123
SB  - IM
SB  - N
MH  - Adult
MH  - Attitude to Health
MH  - Depression
MH  - Female
MH  - *Health Status
MH  - Humans
MH  - *Hysterectomy/psychology
MH  - Middle Aged
MH  - *Patient Satisfaction
MH  - Prospective Studies
MH  - Sexuality
MH  - Treatment Outcome
MH  - Uterine Diseases/*surgery
EDAT- 1997/10/06
MHDA- 1997/10/06 00:01
PST - ppublish
SO  - J Obstet Gynecol Neonatal Nurs. 1997 Sep-Oct;26(5):540-8.
PMID- 9298185
OWN - NLM
STAT- MEDLINE
DA  - 19971117
DCOM- 19971117
LR  - 20061115
PUBM- Print
IS  - 0003-6072 (Print)
VI  - 72
IP  - 2
DP  - 1997 Aug
TI  - Seasonal occurrence of yeasts and yeast-like organisms in the river
      Danube.
PG  - 77-80
AB  - One hundred and seventy yeast strains belonging to 14 genera and 29
      species were isolated from 112 water samples of the river Danube in the
      area of Bratislava. The samples were collected through the year from April
      to March. Saccharomyces cerevisiae, Candida maltosa, Aureobasidium
      pullulans, Cystofilobasidium capitatum, Rhodotorula glutinis, Geotrichum
      candidum, and Candida krusei were the most frequent. The basidiomycetous
      yeasts and yeast-like organisms with oxidative metabolism were present in
      approximately equal numbers to those with fermentative metabolism.
      Saccharomyces cerevisiae was the dominant yeast and was isolated from 50%
      of all samples examined and represented approximately one quarter of the
      yeast community. Yeast densities ranged from 100 to 21,100 CFU per litre.
      The highest population density was observed in October. Cryptococcus
      albidus, Saccharomyces cerevisiae, Rhodotorula glutinis, and Aureobasidium
      pullulans formed the main part of the yeast population in this month.
AD  - Institute of Chemistry, Slovak Academy of Sciences, Bratislava, Slovakia.
FAU - Slavikova, E
AU  - Slavikova E
FAU - Vadkertiova, R
AU  - Vadkertiova R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - NETHERLANDS
TA  - Antonie Van Leeuwenhoek
JT  - Antonie van Leeuwenhoek
JID - 0372625
RN  - 0 (Culture Media)
SB  - IM
MH  - Aerobiosis
MH  - Ascomycota/*isolation & purification
MH  - Bacteriological Techniques
MH  - Basidiomycota/*isolation & purification
MH  - Colony Count, Microbial
MH  - Culture Media/metabolism
MH  - Ecology
MH  - Environmental Microbiology
MH  - Fermentation
MH  - Saccharomyces cerevisiae/isolation & purification
MH  - Seasons
MH  - Slovakia
MH  - *Water Microbiology
EDAT- 1997/08/01 00:00
MHDA- 1997/09/23 00:01
PST - ppublish
SO  - Antonie Van Leeuwenhoek. 1997 Aug;72(2):77-80.
PMID- 9346625
OWN - NLM
STAT- MEDLINE
DA  - 19971114
DCOM- 19971114
LR  - 20061115
PUBM- Print
IS  - 1074-3022 (Print)
VI  - 2
IP  - 1
DP  - 1996 Jan
TI  - The influence of prostaglandin E1 on platelet adherence and injury in
      preserved rat liver allografts.
PG  - 23-36
AB  - We have previously shown that part of the injury sustained by
      cold-preserved livers on reperfusion is the consequence of platelet
      adhesion to sinusoidal endothelium. The purpose of the present study was
      to determine whether prostaglandin E1 (PGE1) can reduce the injury and if
      so, how to maximize this beneficial effect. Rat livers were cold-preserved
      in University of Wisconsin solution for 30 hours then subjected to 1-hour
      warm ischemia after which they were reperfused at 37 degrees C with
      oxygenated Krebs-Henseleit solution with or without isolated platelets.
      PGE1 was used to treat the donor liver during harvesting, cold
      preservation, and reperfusion. In some studies, PGE1 was used to pretreat
      platelets before exposing them to the liver, and in other studies, both
      liver and platelets were treated. Pretreatment of platelets with
      paraformaldehyde, which inactivates them, or ADP, which activates them,
      was also studied. Treatment of livers with PGE1 significantly decreased
      preservation injury when livers were reperfused in the absence of
      platelets. However, when platelets were added to the perfusate, prior
      treatment of the liver with PGE1 had relatively minor beneficial effects.
      Pretreatment of platelets alone with PGE1 was also beneficial, but again
      the effect was small. However, when both liver and platelets were treated
      with PGE1 there was a highly significant decrease in the extent of liver
      injury and platelet adhesion. Perfusate transaminase levels were lower,
      bile flow was improved, and histologically, livers appeared less injured.
      Pretreatment of platelets with paraformaldehyde produced similar results
      to pretreatment with PGE1. When platelets were preactivated with adenosine
      diphosphate, extensive hepatic injury occurred upon reperfusion despite
      PGE1 treatment of the liver. PGE1 can lessen preservation-reperfusion
      injury impressively when administered to both liver and platelets but has
      little effect when platelets have been preactivated.
AD  - Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto,
      Ontario, Canada.
FAU - Cywes, R
AU  - Cywes R
FAU - Harvey, P R
AU  - Harvey PR
FAU - Packham, M A
AU  - Packham MA
FAU - Cameron, R
AU  - Cameron R
FAU - Strasberg, S M
AU  - Strasberg SM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Liver Transpl Surg
JT  - Liver transplantation and surgery : official publication of the American
      Association for the Study of Liver Diseases and the International Liver
      Transplantation Society
JID - 9502504
RN  - 745-65-3 (Alprostadil)
SB  - IM
MH  - Alprostadil/*pharmacology
MH  - Animals
MH  - Liver/pathology
MH  - *Liver Transplantation
MH  - Male
MH  - *Organ Preservation
MH  - Platelet Adhesiveness/*drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Reperfusion Injury/*prevention & control
MH  - Transplantation, Homologous
EDAT- 1996/01/01 00:00
MHDA- 1997/11/05 00:01
AID - S1527646596000044 [pii]
PST - ppublish
SO  - Liver Transpl Surg. 1996 Jan;2(1):23-36.
PMID- 9237858
OWN - NLM
STAT- MEDLINE
DA  - 19971124
DCOM- 19971124
LR  - 20041117
PUBM- Print
IS  - 0014-4835 (Print)
VI  - 65
IP  - 1
DP  - 1997 Jul
TI  - Description and function of the ciliary nerves--some historical remarks on
      choroidal innervation.
PG  - 1-5
AB  - The earliest accounts of the eye recognized its main function as providing
      vision, but the mechanism of how the eye functioned remained obscure for
      many centuries. The aim of the following work is to outline these changes
      in the understanding of a particular structure and function of the human
      body, namely, the ciliary nerves supplying the uveoscleral part of the
      eye. In the extensive study on the history of ophthalmology by Hirschberg
      (published between 1899 and 1918), the ciliary nerves and choroidal
      innervation are only sparsely mentioned.
AD  - Department of Anatomy II, Friedrich Alexander University
      Erlangen-Nuernberg, Erlangen, 91054, Germany.
FAU - May, C A
AU  - May CA
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - ENGLAND
TA  - Exp Eye Res
JT  - Experimental eye research
JID - 0370707
SB  - IM
MH  - Choroid/cytology/*injuries
MH  - Ciliary Body/*injuries
MH  - Ganglia
MH  - History, 16th Century
MH  - History, 17th Century
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, Ancient
MH  - History, Medieval
MH  - Humans
MH  - Nerve Fibers
EDAT- 1997/07/01
MHDA- 1997/07/01 00:01
AID - S0014-4835(97)90312-2 [pii]
AID - 10.1006/exer.1997.0312 [doi]
PST - ppublish
SO  - Exp Eye Res. 1997 Jul;65(1):1-5.
PMID- 9343384
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20061115
PUBM- Print
IS  - 0270-7306 (Print)
VI  - 17
IP  - 11
DP  - 1997 Nov
TI  - Elimination of defective alpha-factor pheromone receptors.
PG  - 6236-45
AB  - This report compares trafficking routes of a plasma membrane protein that
      was misfolded either during its synthesis or after it had reached the cell
      surface. A temperature-sensitive mutant form of the yeast alpha-factor
      pheromone receptor (ste2-3) was found to provide a model substrate for
      quality control of plasma membrane proteins. We show for the first time
      that a misfolded membrane protein is recognized at the cell surface and
      rapidly removed. When the ste2-3 mutant cells were cultured continuously
      at 34 degrees C, the mutant receptor protein (Ste2-3p) failed to
      accumulate at the plasma membrane and was degraded with a half-life of 4
      min, compared with a half-life of 33 min for wild-type receptor protein
      (Ste2p). Degradation of both Ste2-3p and Ste2p required the vacuolar
      proteolytic activities controlled by the PEP4 gene. At 34 degrees C,
      Ste2-3p comigrated with glycosylated Ste2p on sodium dodecyl
      sulfate-polyacrylamide gel electrophoresis, indicating that Ste2-3p enters
      the secretory pathway. Degradation of Ste2-3p did not require delivery to
      the plasma membrane as the sec1 mutation failed to block rapid turnover.
      Truncation of the C-terminal cytoplasmic domain of the mutant receptors
      did not permit accumulation at the plasma membrane; thus, the endocytic
      signals contained in this domain are unnecessary for intracellular
      retention. In the pep4 mutant, Ste2-3p accumulated as series of
      high-molecular-weight species, suggesting a potential role for ubiquitin
      in the elimination process. When ste2-3 mutant cells were cultured
      continuously at 22 degrees C, Ste2-3p accumulated in the plasma membrane.
      When the 22 degrees C culture was shifted to 34 degrees C, Ste2-3p was
      removed from the plasma membrane and degraded by a PEP4-dependent
      mechanism with a 24-min half-life; the wild-type Ste2p displayed a 72-min
      half-life. Thus, structural defects in Ste2-3p synthesized at 34 degrees C
      are recognized in transit to the plasma membrane, leading to rapid
      degradation, and Ste2-3p that is preassembled at the plasma membrane is
      also removed and degraded following a shift to 34 degrees C.
AD  - Department of Molecular Genetics and Microbiology, University of
      Massachusetts Medical School, Worcester 01655-0122, USA.
      jennessd@ummed.edu
FAU - Jenness, D D
AU  - Jenness DD
FAU - Li, Y
AU  - Li Y
FAU - Tipper, C
AU  - Tipper C
FAU - Spatrick, P
AU  - Spatrick P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Mol Cell Biol
JT  - Molecular and cellular biology
JID - 8109087
RN  - 0 (Fungal Proteins)
RN  - 0 (Receptors, Mating Factor)
RN  - 0 (Receptors, Peptide)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Biological Transport
MH  - Cell Compartmentation
MH  - Cell Membrane/metabolism
MH  - Cloning, Molecular
MH  - Fungal Proteins/chemistry/genetics/*metabolism
MH  - Models, Molecular
MH  - Mutation
MH  - Protein Conformation
MH  - Protein Folding
MH  - Receptors, Mating Factor
MH  - Receptors, Peptide/chemistry/genetics/*metabolism
MH  - Reproduction
MH  - Saccharomyces cerevisiae/metabolism
MH  - Sequence Analysis, DNA
MH  - *Transcription Factors
MH  - Vacuoles/metabolism
EDAT- 1997/10/29
MHDA- 1997/10/29 00:01
PST - ppublish
SO  - Mol Cell Biol. 1997 Nov;17(11):6236-45.
PMID- 9259380
OWN - NLM
STAT- MEDLINE
DA  - 19971106
DCOM- 19971106
LR  - 20061115
PUBM- Print
IS  - 0148-7299 (Print)
VI  - 74
IP  - 4
DP  - 1997 Jul 25
TI  - Obsessive compulsive symptoms in Gilles de la Tourette syndrome and
      obsessive compulsive disorder: differences by diagnosis and family
      history.
PG  - 432-8
AB  - The distribution of obsessive compulsive symptoms was compared in 16
      individuals with primary obsessive compulsive disorder (OCD) and 16
      individuals with Gilles de la Tourette syndrome (GTS) and associated
      obsessive compulsive behaviors (OCB). The two groups showed significant
      differences in the distribution of OC symptomatology. Furthermore, those
      OCD probands who shared a similar symptom profile with GTS individuals all
      had a positive family history of OCD. All of the other OCD probands were
      isolated cases. Implications of this finding on the etiology and
      pathogenesis of the two disorders are discussed.
AD  - Department of Psychiatry, University of London, United Kingdom.
FAU - Eapen, V
AU  - Eapen V
FAU - Robertson, M M
AU  - Robertson MM
FAU - Alsobrook, J P 2nd
AU  - Alsobrook JP 2nd
FAU - Pauls, D L
AU  - Pauls DL
LA  - eng
GR  - MH-00508/MH/NIMH
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Am J Med Genet
JT  - American journal of medical genetics
JID - 7708900
RN  - 50-67-9 (Serotonin)
RN  - 51-61-6 (Dopamine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Basal Ganglia/physiopathology
MH  - Child
MH  - *Compulsive Behavior
MH  - Dopamine/physiology
MH  - Female
MH  - Frontal Lobe/physiopathology
MH  - Gyrus Cinguli/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Obsessive Behavior
MH  - Obsessive-Compulsive
      Disorder/etiology/genetics/physiopathology/*psychology
MH  - Psychological Tests
MH  - Serotonin/physiology
MH  - Thalamus/physiopathology
MH  - Tourette Syndrome/etiology/genetics/physiopathology/*psychology
EDAT- 1997/07/25
MHDA- 2000/06/20 09:00
AID - 10.1002/(SICI)1096-8628(19970725)74:4<432::AID-AJMG15>3.0.CO;2-J [pii]
PST - ppublish
SO  - Am J Med Genet. 1997 Jul 25;74(4):432-8.
PMID- 9379007
OWN - NLM
STAT- MEDLINE
DA  - 19971112
DCOM- 19971112
LR  - 20061115
PUBM- Print
IS  - 0022-1767 (Print)
VI  - 159
IP  - 9
DP  - 1997 Nov 1
TI  - Regulation of C-C chemokine production by murine T cells by CD28/B7
      costimulation.
PG  - 4150-3
AB  - C-C chemokines play an important role in recruitment of T lymphocytes to
      inflammatory sites. T lymphocytes secrete chemokines, but the activation
      requirements for chemokine production by T cells are uncertain. We studied
      the regulation of C-C chemokine production by CD28 costimulatory signals
      by murine T lymphocytes. Splenocytes from BALB/c mice cultured with
      anti-CD3 mAb expressed macrophage-inflammatory protein (MIP)-1alpha mRNA
      and secreted MIP-1alpha, which was inhibited by anti-B7-1 plus anti-B7-2
      mAbs. MIP-1alpha production by Ag-stimulated T cells from DO.11.10 TCR
      transgenic mice was augmented by anti-CD28 mAb and increased compared with
      DO.11.10/CD28(-/-) cells. When T cell costimulation was provided by IL-2,
      MIP-1alpha was not enhanced. Studies with IL-2, IL-4, STAT4, and STAT6
      knock-out mice suggested that chemokine production is controlled by
      pathways different from those regulating T cell differentiation. Thus,
      CD28 costimulation may amplify an immune response by stimulating T cell
      survival, proliferation, and production of chemokines that recruit T cells
      to inflammatory sites.
AD  - Department of Medicine, The University of Illinois at Chicago, 60612, USA.
      kherold@uic.edu
FAU - Herold, K C
AU  - Herold KC
FAU - Lu, J
AU  - Lu J
FAU - Rulifson, I
AU  - Rulifson I
FAU - Vezys, V
AU  - Vezys V
FAU - Taub, D
AU  - Taub D
FAU - Grusby, M J
AU  - Grusby MJ
FAU - Bluestone, J A
AU  - Bluestone JA
LA  - eng
GR  - AI41071/AI/NIAID
GR  - DK49799/DK/NIDDK
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (Antigens, CD28)
RN  - 0 (Antigens, CD80)
RN  - 0 (Chemokines, CC)
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - AIM
SB  - IM
MH  - Animals
MH  - Antigens, CD28/*immunology
MH  - Antigens, CD80/*immunology
MH  - Cells, Cultured
MH  - Chemokines, CC/*biosynthesis/immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Transgenic
MH  - Receptors, Antigen, T-Cell/genetics/immunology
MH  - Signal Transduction/immunology
MH  - T-Lymphocytes/*immunology
EDAT- 1997/10/31
MHDA- 1997/10/31 00:01
PST - ppublish
SO  - J Immunol. 1997 Nov 1;159(9):4150-3.
PMID- 9376099
OWN - NLM
STAT- MEDLINE
DA  - 19971112
DCOM- 19971112
LR  - 20061115
PUBM- Print
IS  - 0269-9370 (Print)
VI  - 11 Suppl 1
DP  - 1997 Sep
TI  - Risk behavior and HIV seroprevalence among injecting drug users in Rio de
      Janeiro, Brazil.
PG  - S35-42
AB  - OBJECTIVE: To characterize HIV seroprevalence and risk behavior among
      injecting drug users (IDUs) in Rio de Janeiro, Brazil, between 1990 and
      1996. DESIGN: We report data from three separate cross-sectional samples
      of IDUs in Rio de Janeiro: the World Health Organization (WHO) sample (n =
      479), the Proviva sample (n = 138) and the Brasil sample (n = 110). These
      data provide the most comprehensive view available, to date, of this
      understudied population in Rio. METHODS: Demographic characteristics,
      HIV/AIDS risk behavior and HIV seroprevalence were compared across the
      three samples and combined analyses were performed to determine the
      factors associated with injecting risk behavior, sexual risk behavior and
      HIV seropositivity. RESULTS: The overall HIV seroprevalence among IDUs was
      25%. Two encouraging findings of the present analysis were the lower
      levels of needle-sharing among participants recruited in the latest years
      (1995-1996) and the lower HIV seroprevalence in the Proviva sample
      composed mainly of less educated, poorer IDUs living in deprived
      neighborhoods. No trends toward safer behavior were found for sexual risk,
      younger age being the principal factor associated with high risk.
      CONCLUSIONS: Levels of needle-sharing and sexual risk among IDUs in Rio
      remain high, demonstrating the urgent need to increase the limited
      preventive measures undertaken so far. Seroprevalence levels for HIV
      remain significantly lower in the most deprived sample, arguing for the
      fundamental importance of prompt and effective prevention strategies to
      keep infection rates from rising among the poorest and largest strata of
      Rio's IDUs.
AD  - Nucleo de Estudos e Pesquisa em Atencao ao uso de Drogas, State University
      of Rio de Janeiro, Brazil.
FAU - Telles, P R
AU  - Telles PR
FAU - Bastos, F I
AU  - Bastos FI
FAU - Guydish, J
AU  - Guydish J
FAU - Inciardi, J A
AU  - Inciardi JA
FAU - Surratt, H L
AU  - Surratt HL
FAU - Pearl, M
AU  - Pearl M
FAU - Hearst, N
AU  - Hearst N
LA  - eng
GR  - UO1DA08510/DA/NIDA
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
SB  - IM
SB  - J
SB  - X
MH  - Adolescent
MH  - Adult
MH  - Brazil/epidemiology
MH  - Female
MH  - HIV Seropositivity/*epidemiology
MH  - *HIV-1
MH  - Humans
MH  - Male
MH  - Prevalence
MH  - Substance Abuse, Intravenous
OID - PIP: 128472
OID - POP: 00269176
OTO - PIP
OT  - Americas
OT  - Behavior
OT  - Brazil
OT  - *Cross Sectional Analysis
OT  - Demographic Factors
OT  - Developing Countries
OT  - Diseases
OT  - Drug Usage
OT  - *Hiv Infections
OT  - *Iv Drug Users
OT  - Latin America
OT  - Population
OT  - Population Characteristics
OT  - Research Methodology
OT  - *Research Report
OT  - *Risk Behavior
OT  - *Sex Behavior
OT  - South America
OT  - *Urban Population
OT  - Viral Diseases
GN  - PIP: TJ: AIDS.
EDAT- 1997/10/31
MHDA- 1997/10/31 00:01
PST - ppublish
SO  - AIDS. 1997 Sep;11 Suppl 1:S35-42.
PMID- 9332329
OWN - NLM
STAT- MEDLINE
DA  - 19971119
DCOM- 19971119
LR  - 20061115
PUBM- Print
IS  - 0007-1048 (Print)
VI  - 98
IP  - 3
DP  - 1997 Sep
TI  - A randomized comparison of liposomal versus conventional amphotericin B
      for the treatment of pyrexia of unknown origin in neutropenic patients.
PG  - 711-8
AB  - One hundred and thirty-four adults and 204 children were randomized in two
      prospective, parallel comparative multicentre trials to receive either
      conventional amphotericin B 1 mg/kg/d (c-AMB), liposomal amphotericin B 1
      mg/kg/d(L-AMB1) or liposomal amphotericin B 3 mg/ kg/d (L-AMB3). Patients
      were entered if they had a pyrexia of unknown origin (PUO) defined as
      temperature of 38 degrees C or more, not responding to 96 h of systemic
      broad-spectrum antibiotic treatment, and neutropenia (< 0.5 x 10(9)/l).
      The safety and toxicity of liposomal amphotericin B was compared with that
      of conventional amphotericin B. Efficacy of treatment was assessed, with
      success defined as resolution of fever for 3 consecutive days (< 38
      degrees C) without the development of any new fungal infection. Clinical
      and laboratory parameters were collected for safety analysis. In both the
      paediatric and adult populations, L-AMB treated patients had a 2-6-fold
      decrease in the incidence (P < or = 0.01) of test-drug-related
      side-effects, compared to c-AMB. Severe trial-drug-related side-effects
      were seen in 1% of L-AMB treated patients, in contrast to 12% of patients
      on c-AMB (P < 0.01). Nephrotoxicity, in the patient subset not receiving
      concomitant nephrotoxic agents, defined as a doubling from the patients
      baseline serum creatinine level, was not observed in the L-AMB1 arm
      whereas the incidence was 3% in patients on L-AMB3 and 23% in those on
      c-AMB (P < 0.01). Moreover, time to develop nephrotoxicity was longer in
      both L-AMB arms than c-AMB (P < 0.01). Severe hypokalaemia was observed
      less frequently in both L-AMB arms (P < 0.01). Analysis was by
      intention-to-treat and included all patients randomized. Success was
      defined by a minimum of 3 consecutive days with fever (< 38 degrees C)
      continuing to study end indicated by recovery of neutrophils to 0.5 x
      10(9)/l. Addition of systemic antifungal therapy or development of
      systemic fungal infection were failures as was persistent fever to study
      end. Efficacy assessments indicated success in 49% of the total group
      treated with c-AMB, 58% of patients responded to L-AMB1 and 64% to L-AMB3.
      A statistically significant difference was found between c-AMB and L-AMB3
      (P = 0.03) but a Kaplan-Meier analysis of time to differvescence of fever
      showed there was no significant difference between the arms. It was
      concluded that liposomal amphotericin at either 1 or 3 mg/kg/d was
      significantly safer than conventional amphotericin B in children and
      adults. The main aim of this open-label study was to compare safety
      between the three trial arms. However, we provide evidence for an
      equivalent or possibly superior efficacy of liposomal amphotericin with
      regard to resolution of fever of unknown origin. Subsequent trials should
      compare amphotericin preparations in defined fungal infections.
AD  - Royal Free Hospital and School of Medicine, London.
FAU - Prentice, H G
AU  - Prentice HG
FAU - Hann, I M
AU  - Hann IM
FAU - Herbrecht, R
AU  - Herbrecht R
FAU - Aoun, M
AU  - Aoun M
FAU - Kvaloy, S
AU  - Kvaloy S
FAU - Catovsky, D
AU  - Catovsky D
FAU - Pinkerton, C R
AU  - Pinkerton CR
FAU - Schey, S A
AU  - Schey SA
FAU - Jacobs, F
AU  - Jacobs F
FAU - Oakhill, A
AU  - Oakhill A
FAU - Stevens, R F
AU  - Stevens RF
FAU - Darbyshire, P J
AU  - Darbyshire PJ
FAU - Gibson, B E
AU  - Gibson BE
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - ENGLAND
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (AmBisome)
RN  - 0 (Antibiotics, Antifungal)
RN  - 1397-89-3 (Amphotericin B)
SB  - IM
MH  - Adult
MH  - Amphotericin B/*therapeutic use
MH  - Antibiotics, Antifungal/*therapeutic use
MH  - Child
MH  - Female
MH  - Fever of Unknown Origin/complications/*drug therapy
MH  - Humans
MH  - Male
MH  - Mycoses/*drug therapy
MH  - Neutropenia/*complications
MH  - Prospective Studies
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
PST - ppublish
SO  - Br J Haematol. 1997 Sep;98(3):711-8.
PMID- 9377966
OWN - NLM
STAT- MEDLINE
DA  - 19971113
DCOM- 19971113
LR  - 20061115
PUBM- Print
IS  - 0009-479X (Print)
VI  - 62
IP  - 3
DP  - 1997
TI  - [Treatment of complex fractures within the hand with external fixation]
PG  - 205-9
AB  - External fixation with the use of bone cement was employed in treatment
      for 22 metacarpal and phalangeal fractures in 18 patients. Open fractures
      prevailed (70%). A frame or "V" construction was used. Metal implants were
      connected with balls of bone cement. The average hand function loss in
      cases of metacarpal fractures associated with nerves and tendons lesion
      was 25%.
AD  - Osrodka Replantacji Konczyn, Mikrochirurgii, Chirurgii Reki i Chirurgii
      Ogolnej w Trzebnicy.
FAU - Jablecki, J
AU  - Jablecki J
FAU - Domanasiewicz, A
AU  - Domanasiewicz A
FAU - Chelmonski, A
AU  - Chelmonski A
LA  - pol
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Leczenie skomplikowanych zlaman w obrebie reki stabilizacja zewnetrzna.
PL  - POLAND
TA  - Chir Narzadow Ruchu Ortop Pol
JT  - Chirurgia narzadow ruchu i ortopedia polska
JID - 2985137R
RN  - 0 (Bone Cements)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Bone Cements
MH  - *External Fixators
MH  - Female
MH  - Fractures, Open/*therapy
MH  - Humans
MH  - Male
MH  - Metacarpophalangeal Joint/*injuries
MH  - Middle Aged
MH  - Prosthesis Implantation
MH  - Treatment Outcome
EDAT- 1997/01/01 00:00
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Chir Narzadow Ruchu Ortop Pol. 1997;62(3):205-9.
PMID- 9303406
OWN - NLM
STAT- MEDLINE
DA  - 19971031
DCOM- 19971031
LR  - 20061115
PUBM- Print
IS  - 0066-4804 (Print)
VI  - 41
IP  - 9
DP  - 1997 Sep
TI  - Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647)
      and HMR 3004 (RU 64004).
PG  - 2019-22
AB  - HMR 3647 (RU 66647) and HMR 3004 (RU 64004), two ketolides, had MICs at
      which 50% of the strains are inhibited (MIC50s) of 0.06 to 0.125 microg/ml
      and MIC90s of 16.0 microg/ml against 352 anaerobes. MIC50s and MIC90s of
      erythromycin, azithromycin, clarithromycin, and roxithromycin were 0.5 to
      2.0 microg/ml and 32.0 to >64.0 microg/ml, respectively. HMR 3647 and HMR
      3004 were more active against non-Bacteroides fragilis-group anaerobes
      (other than Fusobacterium mortiferum, Fusobacterium varium, and
      Clostridium difficile).
AD  - Department of Pathology (Clinical Microbiology), Hershey Medical Center,
      Pennsylvania 17033, USA.
FAU - Ednie, L M
AU  - Ednie LM
FAU - Jacobs, M R
AU  - Jacobs MR
FAU - Appelbaum, P C
AU  - Appelbaum PC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Ketolides)
RN  - 0 (Macrolides)
RN  - 0 (RU 64004)
RN  - 0 (telithromycin)
RN  - 114-07-8 (Erythromycin)
RN  - 124-38-9 (Carbon Dioxide)
RN  - 80214-83-1 (Roxithromycin)
RN  - 81103-11-9 (Clarithromycin)
RN  - 83905-01-5 (Azithromycin)
SB  - IM
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Azithromycin/pharmacology
MH  - Bacteria, Anaerobic/*drug effects
MH  - Carbon Dioxide/metabolism
MH  - Clarithromycin/pharmacology
MH  - Erythromycin/pharmacology
MH  - Hydrogen-Ion Concentration
MH  - *Ketolides
MH  - *Macrolides
MH  - Microbial Sensitivity Tests
MH  - Roxithromycin/pharmacology
EDAT- 1997/09/26
MHDA- 1997/09/26 00:01
PST - ppublish
SO  - Antimicrob Agents Chemother. 1997 Sep;41(9):2019-22.
PMID- 9357967
OWN - NLM
STAT- MEDLINE
DA  - 19971120
DCOM- 19971120
LR  - 20061115
PUBM- Print
IS  - 0301-472X (Print)
VI  - 25
IP  - 12
DP  - 1997 Nov
TI  - Effect of recombinant canine stem cell factor, a c-kit ligand, on
      hematopoietic recovery after DLA-identical littermate marrow transplants
      in dogs.
PG  - 1240-5
AB  - We studied the effect of recombinant canine stem cell factor (rcSCF) on
      hematopoietic recovery, incidence of graft failure, graft-vs.-host disease
      (GVHD), and survival after marrow transplantation from dog leukocyte
      antigen (DLA)-identical canine littermates. Ten animals received 100
      microg rcSCF/kg/day b.i.d. by subcutaneous injection on days 1 through 10
      after 920 cGy total body irradiation and transplantation of a mean of
      3.7x10(8) marrow cells/kg body weight. None of the dogs received GVHD
      prophylaxis. All animals showed hematopoietic engraftment. The median
      number of days to achieve 1000 neutrophils/mm3 was 9; 100 monocytes/mm3
      were reached after 15 days, 500 lymphocytes/mm3 after 21 days, and 20,000
      platelets/mm3 after 16 days. One animal developed GVHD involving skin,
      gut, and liver and died of bacterial pneumonia 21 days after
      transplantation. The remaining nine dogs were observed for a median of 37
      days (range 29-84 days) posttransplantation until they were killed. Facial
      edema was seen in three dogs during the first 2-3 days of rcSCF
      administration. These results show that within the limits of this study it
      appears to be safe to administer SCF after DLA-identical littermate marrow
      transplants in dogs. Comparison with previously published data in the same
      model showed that neutrophil and monocyte recovery was significantly
      faster in dogs receiving SCF treatment compared with dogs without growth
      factor treatment (recovery to achieve 1000 neutrophils/mm3: median 9 days
      vs. 13 days, p = 0.002; recovery to 100 monocytes/mm3: median 15 days vs.
      105 days, p = 0.0002). Otherwise, no significant differences were seen.
      Results obtained with SCF treatment were similar to those previously
      obtained in the same model with recombinant human granulocyte
      colony-stimulating factor (rhG-CSF) treatment except that recovery of
      lymphocytes to 500/mm3 appeared to be more rapid in G-CSF-treated dogs
      (median 15 days vs. 21 days, p = 0.03).
AD  - The University of Wisconsin, Madison, USA.
FAU - Schuening, F G
AU  - Schuening FG
FAU - von Kalle, C
AU  - von Kalle C
FAU - Kiem, H P
AU  - Kiem HP
FAU - Appelbaum, F R
AU  - Appelbaum FR
FAU - Deeg, H J
AU  - Deeg HJ
FAU - Pepe, M
AU  - Pepe M
FAU - Gooley, T
AU  - Gooley T
FAU - Graham, T C
AU  - Graham TC
FAU - Hackman, R C
AU  - Hackman RC
FAU - Storb, R
AU  - Storb R
LA  - eng
GR  - CA15704/CA/NCI
GR  - CA18221/CA/NCI
GR  - DK42716/DK/NIDDK
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Exp Hematol
JT  - Experimental hematology
JID - 0402313
RN  - 0 (Recombinant Proteins)
RN  - 0 (Stem Cell Factor)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - Animals
MH  - Bone Marrow Transplantation/immunology/*veterinary
MH  - Dogs
MH  - Female
MH  - Graft Survival
MH  - Graft vs Host Disease/etiology
MH  - Granulocyte Colony-Stimulating Factor/pharmacology
MH  - Hematopoiesis/*drug effects
MH  - Histocompatibility
MH  - Male
MH  - Recombinant Proteins/pharmacology
MH  - Stem Cell Factor/*pharmacology
MH  - Time Factors
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
PST - ppublish
SO  - Exp Hematol. 1997 Nov;25(12):1240-5.
PMID- 9326217
OWN - NLM
STAT- MEDLINE
DA  - 19971106
DCOM- 19971106
LR  - 20061115
PUBM- Print
IS  - 0006-4971 (Print)
VI  - 90
IP  - 7
DP  - 1997 Oct 1
TI  - Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide
      preferentially inhibit chronic myeloid leukemia colony-forming units.
PG  - 2529-34
AB  - We previously showed that a peptide (PR1) derived from the primary granule
      enzyme proteinase 3 induced peptide specific cytotoxic T lymphocytes (CTL)
      in a normal HLA-A2.1+ individual. These CTL showed HLA-restricted
      cytotoxicity to myeloid leukemias (which overexpress proteinase 3). To
      further investigate their antileukemic potential, we studied the ability
      of PR1-specific CTL, derived from two HLA-A2.1+ normal individuals, to
      inhibit colony-forming unit granulocyte-macrophage (CFU-GM) from normal
      and leukemic individuals. CTL from 20 day PR1 peptide-pulsed lymphocyte
      cultures showed 89% to 98% HLA-A2.1-restricted colony inhibition of
      chronic myeloid leukemia targets. Colony formation in normal HLA-A2.1+
      bone marrow or HLA-A2.1- CML cells was not inhibited. Sequencing of the
      exon encoding PR1 showed that colony inhibition was not caused by
      polymorphic differences in proteinase 3 between effectors and targets.
      Analysis by flow cytometry showed that proteinase 3 was overexpressed in
      the leukemia targets compared with normal marrow targets (median channel
      fluorescence 1,399 v 298, P = .009). These results show that PR1-specific
      allogeneic T cells preferentially inhibit leukemic CFU-GM based on
      overexpression of proteinase 3, and that proteinase 3-specific CTL could
      be used for leukemia-specific adoptive immunotherapy.
AD  - Hematology Branch, National Heart, Lung and Blood Institute, National
      Institutes of Health, Bethesda, MD, USA.
FAU - Molldrem, J J
AU  - Molldrem JJ
FAU - Clave, E
AU  - Clave E
FAU - Jiang, Y Z
AU  - Jiang YZ
FAU - Mavroudis, D
AU  - Mavroudis D
FAU - Raptis, A
AU  - Raptis A
FAU - Hensel, N
AU  - Hensel N
FAU - Agarwala, V
AU  - Agarwala V
FAU - Barrett, A J
AU  - Barrett AJ
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Peptide Fragments)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - EC 3.4.21.76 (Myeloblastin)
SB  - AIM
SB  - IM
MH  - Bone Marrow/pathology
MH  - Cells, Cultured
MH  - Cytotoxicity, Immunologic
MH  - Exons/genetics
MH  - HLA-A2 Antigen/immunology
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - Leukemia, Myeloid, Chronic/*immunology/pathology
MH  - Myeloblastin
MH  - Neoplasm Proteins/chemistry/genetics/*immunology
MH  - Peptide Fragments/genetics/*immunology
MH  - Serine Endopeptidases/chemistry/genetics/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tumor Cells, Cultured
MH  - Tumor Stem Cell Assay
MH  - Tumor Stem Cells/enzymology/*immunology
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Blood. 1997 Oct 1;90(7):2529-34.
PMID- 9382507
OWN - NLM
STAT- MEDLINE
DA  - 19971107
DCOM- 19971107
LR  - 20061115
PUBM- Print
IS  - 0385-0684 (Print)
VI  - 24
IP  - 12
DP  - 1997 Sep
TI  - [Intraoperative radiotherapy in carcinoma of the body and tail of the
      pancreas]
PG  - 1687-90
AB  - The prognosis for patients with carcinoma of the body and tail of the
      pancreas is extremely poor. We analyzed the effectiveness of
      intraoperative radiotherapy (IOR) from the viewpoint of the cumulative
      survival rate and pain relief. The prognosis of patients who underwent IOR
      with/without resection was significantly longer than for patients without
      IOR (p < 0.0001). Better pain relief was obtained by IOR. Although a
      randomized prospective study is required, resection and IOR will be the
      central treatment modalities for carcinoma of the body and tail of the
      pancreas.
AD  - Dept. of Surgery I, Tohoku University School of Medicine.
FAU - Egawa, S
AU  - Egawa S
FAU - Fukuyama, S
AU  - Fukuyama S
FAU - Sunamura, M
AU  - Sunamura M
FAU - Kobari, M
AU  - Kobari M
FAU - Matsuno, S
AU  - Matsuno S
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - JAPAN
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
SB  - IM
MH  - Aged
MH  - Combined Modality Therapy
MH  - Humans
MH  - *Intraoperative Care
MH  - Middle Aged
MH  - Pain Measurement
MH  - Pain, Postoperative/physiopathology
MH  - Pancreatic Neoplasms/mortality/*radiotherapy/surgery
MH  - Radiotherapy Dosage
MH  - Radiotherapy, Adjuvant
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Gan To Kagaku Ryoho. 1997 Sep;24(12):1687-90.
PMID- 9325342
OWN - NLM
STAT- MEDLINE
DA  - 19971113
DCOM- 19971113
LR  - 20061115
PUBM- Print
IS  - 0021-9258 (Print)
VI  - 272
IP  - 41
DP  - 1997 Oct 10
TI  - Peptide mapping of the [125I]Iodoazidoketanserin and
      [125I]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine binding sites
      for the synaptic vesicle monoamine transporter.
PG  - 26049-55
AB  - The full-length cDNA for the rat recombinant synaptic vesicle monoamine
      transporter (rVMAT2) containing a COOH-terminal polyhistidine epitope was
      engineered into baculovirus DNA for expression in Spodoptera frugiperda
      (Sf9) cells. Using this recombinant baculovirus and cultured Sf9 cells,
      rVMAT2 has been expressed to high levels and purified to >95% homogeneity
      using immobilized Ni2+-affinity chromatography followed by lectin
      (concanavalin A) chromatography. Purified transporter was photolabeled
      using [125I]-7-azido-8-iodoketanserin ([125I]AZIK) and
      [125I]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine
      ([125I]TBZ-AIPP). Both [125I]AZIK and [125I]TBZ-AIPP photoaffinity
      labeling of purified rVMAT2 were protectable by 10 microM tetrabenazine
      (TBZ), 10 microM 7-aminoketanserin, and 1 mM concentrations of the
      transporter substrates dopamine, norepinephrine, and serotonin.
      Radiolabeled peptides were generated using enzymatic and chemical methods,
      purified using sodium dodecyl sulfate-polyacrylamide gel electrophoresis,
      and NH2-terminal microsequenced. Radiosequencing of [125I]AZIK-labeled
      rVMAT2 indicated derivatization of Lys-20 in the NH2 terminus, just prior
      to putative transmembrane domain 1 (TMD1). [125I]TBZ-AIPP derivatized a
      segment of rVMAT2 between Gly-408 and Cys-431 in TMD10 and 11. These data
      implicate juxtaposition of TMD1 and 10/11.
AD  - Department of Pharmacology, University of Wisconsin Medical School,
      Madison, Wisconsin 53706, USA.
FAU - Sievert, M K
AU  - Sievert MK
FAU - Ruoho, A E
AU  - Ruoho AE
LA  - eng
GR  - NS33650-02/NS/NINDS
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (2-N-((3'-iodo-4'-azidophenyl)propionyl)tetrabenazine)
RN  - 0 (Affinity Labels)
RN  - 0 (Azides)
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Membrane Transport Proteins)
RN  - 0 (Neuropeptides)
RN  - 0 (Neurotransmitter Agents)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Vesicular Biogenic Amine Transport Proteins)
RN  - 136769-36-3 (azidoiodoketanserin)
RN  - 58-46-8 (Tetrabenazine)
RN  - 74050-98-9 (Ketanserin)
SB  - IM
MH  - Affinity Labels/chemistry/*metabolism
MH  - Animals
MH  - Azides/chemistry/*metabolism
MH  - Binding Sites
MH  - Biological Transport
MH  - Iodine Radioisotopes
MH  - Ketanserin/*analogs & derivatives/chemistry/metabolism
MH  - Membrane Glycoproteins/chemistry/*metabolism
MH  - *Membrane Transport Proteins
MH  - Models, Molecular
MH  - *Neuropeptides
MH  - Neurotransmitter Agents/chemistry/*metabolism
MH  - Peptide Mapping
MH  - Protein Binding
MH  - Rats
MH  - Recombinant Proteins/metabolism
MH  - Spodoptera
MH  - Synaptic Vesicles/chemistry/*metabolism
MH  - Tetrabenazine/*analogs & derivatives/chemistry/metabolism
MH  - Vesicular Biogenic Amine Transport Proteins
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - J Biol Chem. 1997 Oct 10;272(41):26049-55.
PMID- 9301342
OWN - NLM
STAT- MEDLINE
DA  - 19971031
DCOM- 19971031
LR  - 20061115
PUBM- Print
IS  - 0003-066X (Print)
VI  - 52
IP  - 9
DP  - 1997 Sep
TI  - Politics, science, and the emergence of a new disease. The case of chronic
      fatigue syndrome.
PG  - 973-83
AB  - Chronic fatigue syndrome (CFS) emerged as a diagnostic category during the
      last decade. Initial research suggested that CFS was a relatively rare
      disorder with a high level of psychiatric comorbidity. Many physicians
      minimized the seriousness of this disorder and also interpreted the
      syndrome as being equivalent to a psychiatric disorder. These attitudes
      had negative consequences for the treatment of CFS. By the mid-1990s,
      findings from more representative epidemiological studies indicated
      considerably higher CFS prevalence rates. However, the use of the revised
      CFS case definition might have produced heterogeneous patient groups,
      possibly including some patients with pure psychiatric disorders. Social
      scientists have the expertise to more precisely define this syndrome and
      to develop appropriate and sensitive research strategies for understanding
      this disease.
AD  - Department of Psychology, DePaul University, Chicago, IL 60614, USA.
FAU - Jason, L A
AU  - Jason LA
FAU - Richman, J A
AU  - Richman JA
FAU - Friedberg, F
AU  - Friedberg F
FAU - Wagner, L
AU  - Wagner L
FAU - Taylor, R
AU  - Taylor R
FAU - Jordan, K M
AU  - Jordan KM
LA  - eng
GR  - AI36295/AI/NIAID
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Am Psychol
JT  - The American psychologist
JID - 0370521
SB  - IM
CIN - Am Psychol. 1998 Sep;53(9):1080-2. PMID: 9841580
MH  - *Attitude of Health Personnel
MH  - Comorbidity
MH  - Diagnosis, Differential
MH  - *Fatigue Syndrome,
      Chronic/classification/diagnosis/epidemiology/psychology
MH  - Humans
MH  - Mental Disorders/diagnosis/epidemiology
MH  - Prevalence
MH  - *Terminology
MH  - United States/epidemiology
EDAT- 1997/09/25
MHDA- 1997/09/25 00:01
PST - ppublish
SO  - Am Psychol. 1997 Sep;52(9):973-83.
PMID- 9353195
OWN - NLM
STAT- MEDLINE
DA  - 19971124
DCOM- 19971124
LR  - 20061115
PUBM- Print
IS  - 0036-8075 (Print)
VI  - 278
IP  - 5340
DP  - 1997 Nov 7
TI  - A low-barrier hydrogen bond in the catalytic triad of serine proteases?
      Theory versus experiment.
PG  - 1128-32
AB  - Cleland and Kreevoy recently advanced the idea that a special type of
      hydrogen bond (H-bond), termed a low-barrier hydrogen bond (LBHB), may
      account for the "missing" transition state stabilization underlying the
      catalytic power of many enzymes, and Frey et al. have proposed that the
      H-bond between aspartic acid 102 and histidine 57 in the catalytic triad
      of serine proteases is an example of a catalytically important LBHB.
      Experimental facts are here considered regarding the aspartic
      acid-histidine and cis-urocanic H-bonds that are inconsistent with
      fundamental tenets of the LBHB hypothesis. The inconsistencies between
      theory and experiment in these paradigm systems cast doubt on the
      existence of LBHBs, as currently defined, within enzyme active sites.
AD  - Department of Biochemistry, Tufts University School of Medicine, Boston,
      MA 02111, USA.
FAU - Ash, E L
AU  - Ash EL
FAU - Sudmeier, J L
AU  - Sudmeier JL
FAU - De Fabo, E C
AU  - De Fabo EC
FAU - Bachovchin, W W
AU  - Bachovchin WW
LA  - eng
GR  - GM27927/GM/NIGMS
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Science
JT  - Science
JID - 0404511
RN  - 0 (Boronic Acids)
RN  - 0 (Oligopeptides)
RN  - 0 (Protons)
RN  - 0 (Serine Proteinase Inhibitors)
RN  - 104-98-3 (Urocanic Acid)
RN  - 56-84-8 (Aspartic Acid)
RN  - 71-00-1 (Histidine)
RN  - 94242-73-6 (O-methyl-succinyl-alanyl-alanyl-prolyl-borovaline)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - EC 3.4.21.- (Subtilisins)
RN  - EC 3.4.21.12 (myxobacter alpha-lytic proteinase)
SB  - IM
MH  - Aspartic Acid/chemistry
MH  - Binding Sites
MH  - Boronic Acids/metabolism
MH  - Catalysis
MH  - Histidine/chemistry
MH  - Hydrogen Bonding
MH  - Hydrogen-Ion Concentration
MH  - Magnetic Resonance Spectroscopy
MH  - Oligopeptides/metabolism
MH  - Protons
MH  - Serine Endopeptidases/*chemistry/metabolism
MH  - Serine Proteinase Inhibitors/metabolism
MH  - Subtilisins/chemistry
MH  - Temperature
MH  - Urocanic Acid/chemistry
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
PST - ppublish
SO  - Science. 1997 Nov 7;278(5340):1128-32.
PMID- 9315221
OWN - NLM
STAT- MEDLINE
DA  - 19971114
DCOM- 19971114
LR  - 20061115
PUBM- Print
IS  - 0019-5189 (Print)
VI  - 35
IP  - 2
DP  - 1997 Feb
TI  - Enterotoxicity, haemolytic activity and antibiotic susceptibility of
      Aeromonas eucrenophila strains isolated from water and infected fish.
PG  - 144-7
AB  - Strains of A. eucrenophila isolated from fresh water (2 strains) and
      infected fish (4 strains) were tested for haemolytic activity and
      enterotoxicity and any correlation between them. Also, the resistance
      patterns of A. eucrenophila were tested especially in relation to
      ampicillin. None of the A. eucrenophila strains caused fluid accumulation
      in the initial tests, however, they did so only after one to four
      sequential passages through the gut of a susceptible host. All the strains
      of A. eucrenophila showed beta-haemolytic activities. Production of
      beta-haemolysin could be correlated with enterotoxicity. Since all the
      strains of A. eucrenophila were resistant to ampicillin, media containing
      this antibiotic may be used for their isolation from diverse sources.
AD  - Department of Microbiology, Banaras Hindu University, Varanasi, India.
FAU - Singh, D V
AU  - Singh DV
FAU - Sanyal, S C
AU  - Sanyal SC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - INDIA
TA  - Indian J Exp Biol
JT  - Indian journal of experimental biology
JID - 0233411
SB  - IM
MH  - Aeromonas/*drug effects/isolation & purification
MH  - Animals
MH  - Digestive System/microbiology
MH  - Fish Diseases/microbiology
MH  - Fishes/*microbiology
MH  - Gram-Negative Bacterial Infections/pathology/veterinary
MH  - Hemolysis
MH  - Microbial Sensitivity Tests
MH  - Rabbits
MH  - *Water Microbiology
EDAT- 1997/02/01 00:00
MHDA- 1997/10/07 00:01
PST - ppublish
SO  - Indian J Exp Biol. 1997 Feb;35(2):144-7.
PMID- 9335460
OWN - NLM
STAT- MEDLINE
DA  - 19971105
DCOM- 19971105
LR  - 20041117
PUBM- Print
IS  - 0003-276X (Print)
VI  - 249
IP  - 2
DP  - 1997 Oct
TI  - Immunohistochemical and ultrastructural investigation of the human
      vestibular dark cell area: roles of subepithelial capillaries and T
      lymphocyte-melanophage interaction in an immune surveillance system.
PG  - 153-62
AB  - BACKGROUND: The aim of the present study was to morphologically
      characterize the structure of the subepithelial blood vessels in the dark
      cell area of the human vestibular organs, and to determine whether
      immunocompetent cells such as macrophages and lymphocytes could be found
      around these small blood vessels. MATERIALS AND METHODS: All 31 surgical
      specimens (semicircular canals and utricles) were obtained from patients
      with vestibular schwannoma. Formalin fixed specimens were stained with
      hematoxylin and eosin (H&E), and with antibodies to von Willebrand Factor
      (vWF), leukocyte common antigen (LCA), and UCHL-1, and were examined with
      light microscope. Specimens fixed with glutaraldehyde were examined with a
      transmission electron microscope (TEM). OBJECTIVES: Subepithelial blood
      vessels stained positive for vWF. By TEM observation, these blood vessels
      were observed to be capillaries that consisted of non-fenestrated
      endothelium, occasional pericytes, and a basement membrane. They were
      usually accompanied by melanophages with a number of secondary lysosomes
      containing phagocytosed degraded melanosomes and lipid droplets. Moreover,
      melanocytes and their cell processes directly surrounded these
      subepithelial capillaries. The fact that cells which were positively
      stained with LCA and UCHL-1 were present both in the intra- and
      subepithelial layer of the specimens, and that by TEM the intra- and
      subepithelial mononuclear cells with a lymphoid appearance had clustered
      dense bodies in their cytoplasm, suggested that they were a population of
      T lymphocytes. CONCLUSIONS: Results suggested the possibility of a T
      lymphocyte-melanophage (macrophage) interaction, both originating from and
      harbored around subepithelial capillaries, which suggests the presence of
      an immune surveillance system in the human vestibular organs.
AD  - Department of Otorhinolaryngology, Keio University, School of Medicine,
      Tokyo, Japan.
FAU - Masuda, M
AU  - Masuda M
FAU - Yamazaki, K
AU  - Yamazaki K
FAU - Kanzaki, J
AU  - Kanzaki J
FAU - Hosoda, Y
AU  - Hosoda Y
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - Anat Rec
JT  - The Anatomical record
JID - 0370540
RN  - 0 (Antigens, CD45)
RN  - 0 (von Willebrand Factor)
SB  - IM
SB  - S
MH  - Adult
MH  - Aged
MH  - Antigens, CD45/analysis
MH  - Capillaries/immunology/ultrastructure
MH  - Ear Neoplasms/blood supply/immunology/pathology
MH  - Epithelium/blood supply/immunology/ultrastructure
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - *Immunologic Surveillance
MH  - Macrophages/*immunology
MH  - Male
MH  - Middle Aged
MH  - Neurilemmoma/blood supply/immunology/pathology
MH  - Semicircular Canals/cytology
MH  - T-Lymphocytes/*immunology
MH  - Vestibule/*blood supply/cytology/immunology
MH  - von Willebrand Factor/analysis
EDAT- 1997/10/23 22:33
MHDA- 2000/06/20 09:00
AID - 10.1002/(SICI)1097-0185(199710)249:2<153::AID-AR1>3.0.CO;2-Z [pii]
PST - ppublish
SO  - Anat Rec. 1997 Oct;249(2):153-62.
PMID- 9331078
OWN - NLM
STAT- MEDLINE
DA  - 19971028
DCOM- 19971028
LR  - 20061115
PUBM- Print
IS  - 0008-5472 (Print)
VI  - 57
IP  - 19
DP  - 1997 Oct 1
TI  - Skin autografts in epidermodysplasia verruciformis: human
      papillomavirus-associated cutaneous changes need over 20 years for
      malignant conversion.
PG  - 4214-6
AB  - Epidermodysplasia verruciformis (EV) is regarded as a model for cutaneous
      oncogenesis associated with specific human papillomaviruses (HPVs).
      Because genital HPV-associated carcinogenesis is a very long-lasting
      process requiring 20-30 years and epidemiological studies of this type for
      HPV-associated skin cancers are impossible in such a rare disease as EV,
      we observed for up to 20 years EV patients having surgery for carcinomas
      with consecutive autografts from uninvolved and non-sun-exposed skin. We
      noticed the appearance of premalignant and malignant changes around the
      grafts, whereas within the grafted skin, only benign macular lesions
      started to develop several years after transplantation. Thus, skin
      HPV-associated carcinogenesis appears to be a very slow process comparable
      to the genital carcinogenesis associated with high risk HPVs.
AD  - Department of Dermatology, Warsaw School of Medicine, Poland.
FAU - Majewski, S
AU  - Majewski S
FAU - Jablonska, S
AU  - Jablonska S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cell Transformation, Neoplastic
MH  - Cell Transformation, Viral
MH  - Epidermodysplasia Verruciformis/pathology/*surgery/virology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Papillomaviridae/*pathogenicity
MH  - Papillomavirus Infections/pathology/*surgery/virology
MH  - Precancerous Conditions/pathology/*surgery/virology
MH  - Skin Neoplasms/*etiology/pathology
MH  - Skin Transplantation/*pathology
MH  - Time Factors
MH  - Transplantation, Autologous
MH  - Tumor Virus Infections/pathology/*surgery/virology
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
PST - ppublish
SO  - Cancer Res. 1997 Oct 1;57(19):4214-6.
PMID- 9325282
OWN - NLM
STAT- MEDLINE
DA  - 19971113
DCOM- 19971113
LR  - 20061115
PUBM- Print
IS  - 0021-9258 (Print)
VI  - 272
IP  - 41
DP  - 1997 Oct 10
TI  - Covalent modification of the regulatory domain irreversibly stimulates
      cystic fibrosis transmembrane conductance regulator.
PG  - 25617-22
AB  - The cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel
      is regulated by three cytosolic domains, the regulatory domain (R domain)
      and two nucleotide binding domains. To learn more about how the cytosolic
      domains regulate channel activity, we used chemical modification to probe
      their structure. When we applied the sulfhydryl-modifying reagent
      N-ethylmaleimide (NEM) and other N-substituted maleimides to the cytosolic
      domains, we found that they rapidly and irreversibly stimulated channel
      activity. CFTR contains 14 intracellular cysteine residues that might be
      targets for NEM modification. We identified one, Cys832, that was
      essential for the response. Cys832 is located in the R domain. Single
      channel studies showed that NEM stimulated CFTR by increasing the duration
      of bursts of activity and by shortening the closed interval between
      bursts. At the single channel level, CFTR in which Cys832 was mutated to
      alanine behaved identically to wild-type CFTR, except that it failed to
      respond to NEM. Additional studies showed that NEM modification increased
      the potency of ATP-mediated stimulation. Previous work has shown that
      modification of the R domain by phosphorylation, which introduces negative
      charge, or replacement of multiple serines by negatively charged
      aspartates stimulates the channel. Our current data show that covalent
      modification of the R domain with a neutral, hydrophobic adduct at a site
      that is not phosphorylated can also stimulate CFTR. This finding suggests
      that an alteration in the conformation of the R domain may be a key
      feature that regulates channel activity.
AD  - Howard Hughes Medical Institute and the Department of Internal Medicine,
      University of Iowa College of Medicine, Iowa City, Iowa 52242, USA.
FAU - Cotten, J F
AU  - Cotten JF
FAU - Welsh, M J
AU  - Welsh MJ
LA  - eng
GR  - HL29851/HL/NHLBI
GR  - HL42385/HL/NHLBI
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (CFTR protein, human)
RN  - 126880-72-6 (Cystic Fibrosis Transmembrane Conductance Regulator)
RN  - 128-53-0 (Ethylmaleimide)
RN  - 52-90-4 (Cysteine)
RN  - 56-41-7 (Alanine)
RN  - 56-65-5 (Adenosine Triphosphate)
RN  - EC 2.7.1.37 (Cyclic AMP-Dependent Protein Kinases)
SB  - IM
MH  - Adenosine Triphosphate/metabolism
MH  - Alanine/metabolism
MH  - Binding Sites
MH  - Cyclic AMP-Dependent Protein Kinases/metabolism
MH  - Cysteine/metabolism
MH  - Cystic Fibrosis Transmembrane Conductance
      Regulator/*chemistry/genetics/metabolism
MH  - Cytoplasm/drug effects/metabolism
MH  - Ethylmaleimide/pharmacology
MH  - Humans
MH  - Models, Chemical
MH  - Mutagenesis, Site-Directed
MH  - Transfection
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - J Biol Chem. 1997 Oct 10;272(41):25617-22.
PMID- 9382073
OWN - NLM
STAT- MEDLINE
DA  - 19971112
DCOM- 19971112
LR  - 20041117
PUBM- Print
IS  - 0002-9270 (Print)
VI  - 92
IP  - 10
DP  - 1997 Oct
TI  - Multifocal hepatic lesions in AIDS: an unusual presentation of steatosis.
PG  - 1934-6
AB  - Patients infected with HIV frequently have abnormal results on liver
      tests, leading to radiographic evaluation for hepatic lesions. The
      etiology of these lesions in patients infected with HIV is most often
      secondary to infections or tumors. Occasionally, focal abnormalities in
      the liver are identified in asymptomatic patients. The etiology and
      clinical course in this subset of patients are not known. However, because
      of concerns of tumor, an evaluation is usually warranted. We report an
      unusual case of multifocal hepatic steatosis presenting as multiple liver
      lesions in an HIV-positive patient with cutaneous Kaposi's sarcoma. This
      case emphasizes the importance of obtaining a tissue diagnosis in this
      patient population.
AD  - Department of Medicine, University Hospitals of Cleveland, Ohio, USA.
FAU - Sterling, R K
AU  - Sterling RK
FAU - Herbener, T E
AU  - Herbener TE
FAU - Jacobs, G H
AU  - Jacobs GH
FAU - Post, A B
AU  - Post AB
FAU - Carey, J T
AU  - Carey JT
FAU - Haaga, J R
AU  - Haaga JR
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - UNITED STATES
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
SB  - IM
SB  - X
MH  - Acquired Immunodeficiency Syndrome/*complications
MH  - Fatty Liver/*complications/radiography
MH  - Humans
MH  - Liver/radiography
MH  - Male
MH  - Middle Aged
MH  - Sarcoma, Kaposi/complications
MH  - Skin Neoplasms/complications
MH  - Tomography, X-Ray Computed
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
PST - ppublish
SO  - Am J Gastroenterol. 1997 Oct;92(10):1934-6.
PMID- 9377881
OWN - NLM
STAT- MEDLINE
DA  - 19971110
DCOM- 19971110
LR  - 20061115
PUBM- Print
IS  - 0090-3493 (Print)
VI  - 25
IP  - 10
DP  - 1997 Oct
TI  - Patient-ventilator flow dyssynchrony: flow-limited versus pressure-limited
      breaths.
PG  - 1671-7
AB  - OBJECTIVES: Patient-ventilator flow dyssynchrony occurs when ventilator
      flow delivery is insufficient to meet patient demands. If sufficiently
      severe, flow dyssynchrony can produce significant imposed loads on
      ventilatory muscles. Flow dyssynchrony can be improved by increasing
      ventilator flow delivery. We hypothesized that the variable flow
      pressure-limited breath would be a better approach for matching patient
      flow demands than adjusting a set flow on a conventional volume-cycled
      breath. DESIGN: Clinical interventional study. SETTING: Medical intensive
      care unit. PATIENTS: Sixteen stable, mechanically ventilated patients
      receiving volume-cycled assist-control ventilation. INTERVENTIONS: Flow
      dyssynchrony was produced by reducing the set flow by 50%. Dyssynchrony
      was quantified by measuring the esophageal pressure time product during
      the assisted breath. Two strategies were then employed in an attempt to
      reduce the dyssynchrony. One strategy was to increase flow back to the
      initial set flow and then further increase flow by an additional 25% (VI
      strategy). The other strategy was to use a pressure-limited breath feature
      coupled to a volume assist breath (the P strategy). With the P strategy,
      the pressure limit was set at 75% and 100% of the static elastic recoil
      pressure at end-inspiration. MEASUREMENTS AND MAIN RESULTS: Pressure time
      product, intrinsic positive end-expiratory pressure, and the ventilatory
      pattern were measured with each strategy and were analyzed by analysis of
      variance. Induced baseline flow dyssynchrony, as measured by the pressure
      time product, was > 5 cm H2O/sec in ten of 16 patients. This dyssynchrony
      was significantly reduced by both the VI strategy and the P strategy,
      although the P strategy appeared to be more effective in those patients
      with the greatest baseline dyssynchrony. Baseline inspiratory time was
      also shortened by both the VI strategy and the P strategy; the VI strategy
      shortened baseline inspiratory time more than the P strategy. Baseline
      tidal volume, frequency, and intrinsic positive end-expiratory pressure
      were only minimally affected by either strategy. CONCLUSION: The
      pressure-limited, variable-flow approach to ventilator gas delivery
      appears to be more responsive to a vigorous patient effort than a
      fixed-flow approach.
AD  - Duke University Medical Center, Durham, NC, USA.
FAU - MacIntyre, N R
AU  - MacIntyre NR
FAU - McConnell, R
AU  - McConnell R
FAU - Cheng, K C
AU  - Cheng KC
FAU - Sane, A
AU  - Sane A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
SB  - AIM
SB  - IM
CIN - Crit Care Med. 1997 Oct;25(10):1630. PMID: 9377872
MH  - Adult
MH  - Aged
MH  - Airway Obstruction/physiopathology/therapy
MH  - Analysis of Variance
MH  - Female
MH  - Humans
MH  - Linear Models
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Physiologic/instrumentation
MH  - Positive-Pressure Respiration, Intrinsic/physiopathology/therapy
MH  - Respiration, Artificial/*methods/statistics & numerical data
MH  - Respiratory Distress Syndrome, Adult/physiopathology/therapy
MH  - *Work of Breathing
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
PST - ppublish
SO  - Crit Care Med. 1997 Oct;25(10):1671-7.
PMID- 9315229
OWN - NLM
STAT- MEDLINE
DA  - 19971114
DCOM- 19971114
LR  - 20051117
PUBM- Print
IS  - 0019-5189 (Print)
VI  - 35
IP  - 4
DP  - 1997 Apr
TI  - Ets oncogene family.
PG  - 315-22
AB  - First member of Ets gene family was discovered a decade ago by studying
      avian erythroblastosis virus, E26. This virus encodes a tripartite protein
      gag-myb-ets with a molecular weight of 135 kDa. Subsequently, a series of
      cellular Ets genes were isolated (Ets-1, Ets-2, Erg, Elk-1, Sap-1, PEA-3,
      PU.1, Fli-1, Pok/Yan, Etv-1 etc.). These genes share sequence homology to
      E26 Ets gene (v-ets or viral ets). Ets genes are highly conserved in
      phylogenetically divergent species from Drosophila to man. Mammalian Ets
      genes are located on different chromosomes. Ets gene products are
      transcriptionally active sequence-specific DNA binding proteins and are
      differentially regulated. Ets genes are involved in certain chromosomal
      translocations leading to the formation of chimeric fusion proteins that
      are associated with certain leukemias and soft tissue cancers. Ets genes
      also have a role in T-cell development and molecular and genetic analysis
      of Down Syndrome patients have implicated the human Ets-2 and Erg genes in
      the disease. Down Syndrome afflicted patients have immunologic and thymic
      disorders as well as a greater risk for leukemic disease. Thus, Ets genes
      having homology to viral oncogenes, may be instrumental in regulating
      cellular growth and differentiation, as well as organismal development.
      Alteration of these genes and their products may cause deregulation of
      normal cell growth and differentiation and result in a disease.
AD  - Department of Animal Biology, School of Veterinary Medicine, University of
      Pennsylvania, Philadelphia 19104, USA.
FAU - Dhulipal, P D
AU  - Dhulipal PD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - INDIA
TA  - Indian J Exp Biol
JT  - Indian journal of experimental biology
JID - 0233411
RN  - 0 (ETS1 protein, human)
RN  - 0 (Proto-Oncogene Protein c-ets-1)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Proto-Oncogene Proteins c-ets)
RN  - 0 (Retroviridae Proteins, Oncogenic)
RN  - 0 (Transcription Factors)
RN  - 0 (oncogene proteins v-ets)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Base Sequence
MH  - Binding Sites/genetics
MH  - DNA/genetics/metabolism
MH  - Humans
MH  - Molecular Sequence Data
MH  - Multigene Family
MH  - *Oncogenes
MH  - Proto-Oncogene Protein c-ets-1
MH  - Proto-Oncogene Proteins/*genetics/metabolism
MH  - Proto-Oncogene Proteins c-ets
MH  - Retroviridae Proteins, Oncogenic/*genetics/metabolism
MH  - Trans-Activation (Genetics)
MH  - Transcription Factors/*genetics/metabolism
RF  - 79
EDAT- 1997/04/01 00:00
MHDA- 1997/10/07 00:01
PST - ppublish
SO  - Indian J Exp Biol. 1997 Apr;35(4):315-22.
PMID- 9261855
OWN - NLM
STAT- MEDLINE
DA  - 19971105
DCOM- 19971105
LR  - 20060328
PUBM- Print
IS  - 8755-6863 (Print)
VI  - 24
IP  - 1
DP  - 1997 Jul
TI  - Massive hemoptysis as the presenting manifestation in a child with
      histoplasmosis.
PG  - 57-60
AB  - A previously healthy and asymptomatic 7-year-old white boy presented with
      a history of two episodes of hemoptysis productive of bright red blood in
      the 5 days preceding admission. After admission he developed massive
      hemoptysis that, on bronchoscopy, was noted to be emanating from the right
      lower lobe. An emergency right lower lobe resection was done. Pathological
      examination revealed hilar adenopathy and peripheral lesions with
      caseating granulomas containing yeast, morphologically consistent with
      Histoplasma capsulatum.
AD  - Department of Pediatrics, Ohio State University Medical Center, Columbus
      43210, USA.
FAU - Shaffer, J P
AU  - Shaffer JP
FAU - Barson, W
AU  - Barson W
FAU - Luquette, M
AU  - Luquette M
FAU - Groner, J I
AU  - Groner JI
FAU - Hogan, M J
AU  - Hogan MJ
FAU - Allen, E
AU  - Allen E
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - UNITED STATES
TA  - Pediatr Pulmonol
JT  - Pediatric pulmonology
JID - 8510590
RN  - 0 (Antibiotics, Antifungal)
RN  - 0 (Antifungal Agents)
RN  - 1397-89-3 (Amphotericin B)
RN  - 84625-61-6 (Itraconazole)
SB  - IM
MH  - Amphotericin B/therapeutic use
MH  - Antibiotics, Antifungal/therapeutic use
MH  - Antifungal Agents/therapeutic use
MH  - Bronchoscopy
MH  - Child
MH  - Drug Therapy, Combination
MH  - Hemoptysis/*etiology/surgery
MH  - Histoplasmosis/complications/*diagnosis/drug therapy/pathology
MH  - Humans
MH  - Itraconazole/therapeutic use
MH  - Lung/pathology
MH  - Lung Diseases, Fungal/complications/*diagnosis/drug therapy/pathology
MH  - Male
MH  - Pneumonectomy
MH  - Recurrence
EDAT- 1997/07/01
MHDA- 2000/06/22 10:00
AID - 10.1002/(SICI)1099-0496(199707)24:1<57::AID-PPUL10>3.0.CO;2-9 [pii]
PST - ppublish
SO  - Pediatr Pulmonol. 1997 Jul;24(1):57-60.
PMID- 9336559
OWN - NLM
STAT- MEDLINE
DA  - 19971031
DCOM- 19971031
LR  - 20061115
PUBM- Print
IS  - 0002-8223 (Print)
VI  - 97
IP  - 10
DP  - 1997 Oct
TI  - Review of self-efficacy and locus of control for nutrition- and
      health-related behavior.
PG  - 1122-32
AB  - This article reviews several cognitive predictors of health- and
      diet-related behaviors commonly used in theories and models of nutrition
      and health behavior change. Constructs such as self-efficacy, self-esteem,
      outcome expectancies, health value, and locus of control are examined.
      Self-efficacy has repeatedly been a good predictor of health behavior,
      sometimes explaining more than 50% of variability. Research on locus of
      control and other predictive factors has been less conclusive. The
      take-home message is threefold: (a) task specificity of self-efficacy and
      domain specificity of locus of control are crucial for unraveling their
      effects on behavior; (b) careful segmentation of different population
      groups under study may explain the inconsistencies in previous research;
      and (c) especially when studying dietary behavior, these predictors of
      behavior change should not be used alone or in place of one another but
      should be used simultaneously to explain complex food and diet-related
      behaviors. We recommend that nutritionists systematically integrate
      available theories and models and explore new areas for studying human
      behavior, such as sociology and anthropology, to form a more powerful,
      comprehensive model for behavior change.
AD  - Department of Nutrition, Pennsylvania State University, University Park
      16802, USA.
FAU - AbuSabha, R
AU  - AbuSabha R
FAU - Achterberg, C
AU  - Achterberg C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - UNITED STATES
TA  - J Am Diet Assoc
JT  - Journal of the American Dietetic Association
JID - 7503061
SB  - AIM
SB  - IM
MH  - *Feeding Behavior/psychology
MH  - *Health Behavior
MH  - Humans
MH  - *Internal-External Control
MH  - *Nutrition Physiology
MH  - *Self Concept
RF  - 95
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
AID - S0002-8223(97)00273-3 [pii]
AID - 10.1016/S0002-8223(97)00273-3 [doi]
PST - ppublish
SO  - J Am Diet Assoc. 1997 Oct;97(10):1122-32.
PMID- 9281438
OWN - NLM
STAT- MEDLINE
DA  - 19971124
DCOM- 19971124
LR  - 20061115
PUBM- Print
IS  - 0022-2828 (Print)
VI  - 29
IP  - 8
DP  - 1997 Aug
TI  - Different responses of non-ischemic and post-ischemic myocardium towards
      Ca2+ sensitization.
PG  - 2053-66
AB  - We tested whether decreased Ca2+ sensitivity is a major cause for
      dysfunctional stunned myocardium. The experiments employed a novel Ca2+
      sensitizing agent: the thiadiazinone derivative EMD 60 263. Experiments
      were done on 14 isolated, blood-perfused rabbit hearts. After control,
      seven hearts were subjected to 20 min no-flow ischemia, and then allowed
      to recover during 30 min reperfusion. Thereafter, EMD 60 263 was
      administered (3, 10 and 30 microm). For comparison, the effect of the same
      doses was investigated in seven non-ischemic hearts. At the low dose, the
      agent improved ventricular systolic function in the post-ischemic group
      significantly (LVPmax: 65+/-13 v 91+/-17 mmHg; dP/dtmax: 845+/-235 v
      1300+/-350 mmHg/s), and non-significantly in the non-ischemic group
      (LVPmax: 115+/-35 v 132+/-39 mmHg; dP/dtmax: 1415+/-545 v 1885+/-720
      mmHg/s). Early relaxation (dP/dtmin) was slightly improved in both groups
      (800+/-225 v 1050+/-220 mmHg/s post-ischemic; 1120+/-315 v 1205+/-285
      mmHg/s non-ischemic). Heart rate was increased (151+/-35 v 175+/-45
      beats/min) in the post-ischemic group and was unaffected in the
      non-ischemic group. At the higher dose, systolic ventricular function in
      the post-ischemic group was further improved (LVPmax: 109+/-17 mmHg,
      dP/dtmax: 1330+/-180 mmHg/s), but tended to decrease in the non-ischemic
      group (LVPmax: 121+/-40 mmHg, dP/dtmax: 1605+/-680 mmHg/s). This dose
      decreased heart rate in both groups (133+/-34 and 134+/-23 beats/min). 30
      microm EMD 60 263 had deleterious effects in both groups. The different
      responses towards Ca2+ sensitization suggest that a decrease in Ca2+
      sensitivity might play a role in dysfunctional stunned myocardium.
      Therefore, Ca2+ sensitizing agents of the thiadiazinone type could be
      useful to recruit a positive inotropic reserve in stunned myocardium.
AD  - Institute of Experimental Surgery, University of Dusseldorf, Dusseldorf,
      Germany.
FAU - Korbmacher, B
AU  - Korbmacher B
FAU - Sunderdiek, U
AU  - Sunderdiek U
FAU - Selcan, G
AU  - Selcan G
FAU - Arnold, G
AU  - Arnold G
FAU - Schipke, J D
AU  - Schipke JD
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - ENGLAND
TA  - J Mol Cell Cardiol
JT  - Journal of molecular and cellular cardiology
JID - 0262322
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Thiadiazines)
RN  - 158623-12-2 (EMD 60263)
RN  - 7440-70-2 (Calcium)
SB  - IM
MH  - Action Potentials/drug effects
MH  - Animals
MH  - Arrhythmia/prevention & control
MH  - Bradycardia/chemically induced
MH  - Calcium/*metabolism
MH  - Cardiotonic Agents/*pharmacology/toxicity
MH  - Drug Resistance
MH  - Heart Rate/drug effects
MH  - Male
MH  - Myocardial Contraction/*drug effects
MH  - Myocardial Ischemia/complications/*metabolism
MH  - Myocardial Reperfusion
MH  - Myocardial Reperfusion Injury/*metabolism
MH  - Myocardial Stunning/etiology/*metabolism
MH  - Oxygen Consumption/drug effects
MH  - Rabbits
MH  - Systole/drug effects
MH  - Thiadiazines/*pharmacology/toxicity
EDAT- 1997/08/01
MHDA- 1997/08/01 00:01
AID - S0022-2828(97)90440-5 [pii]
AID - 10.1006/jmcc.1997.0440 [doi]
PST - ppublish
SO  - J Mol Cell Cardiol. 1997 Aug;29(8):2053-66.
PMID- 9313157
OWN - NLM
STAT- MEDLINE
DA  - 19971119
DCOM- 19971119
LR  - 20031114
PUBM- Print
IS  - 0022-0302 (Print)
VI  - 80
IP  - 9
DP  - 1997 Sep
TI  - Effect of starch on the bioavailability of glutamine and leucine in the
      dairy cow.
PG  - 2143-8
AB  - This experiment was designed to quantify changes in utilization of Gln and
      Leu by the gut wall as a result of changes in the starch supply to the
      duodenum. Four dairy cows fitted with cannulas in the rumen and the distal
      duodenum were adapted for 3 wk to starch infusion, either into the rumen
      (600 g/d of flaked maize) or into the duodenum (300 g/d of flaked maize
      plus 300 g/d of maize meal), in a 2 x 2 crossover design. Absorption and
      elimination kinetics and the relative bioavailability of Gln and Leu were
      measured during wk 4 and 5. After infusion of 50 g of Gln or 10 g of Leu
      into the duodenum or jugular vein, blood samples were taken from the
      jugular vein at 0.5-h intervals up to 4 h after infusion. Concentrations
      of Gln and Leu in plasma fitted best to an open, one-compartment model
      (duodenal infusion) or to an open, two-compartment model (i.v. infusion).
      Both amino acids were rapidly absorbed; half-life times were less than 20
      min. The amount of Gln trapped in the splanchnic bed was higher than the
      amount of Leu trapped in the splanchnic bed. Site of starch infusion did
      not affect the relative bioavailability of amino acids.
AD  - Department of Ruminant Nutrition, Institute for Animal Science and Health,
      Lelystad, The Netherlands.
FAU - Meijer, G A
AU  - Meijer GA
FAU - Bontempo, V
AU  - Bontempo V
FAU - Van Vuuren, A M
AU  - Van Vuuren AM
FAU - Van der Meulen, J
AU  - Van der Meulen J
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - J Dairy Sci
JT  - Journal of dairy science
JID - 2985126R
RN  - 56-85-9 (Glutamine)
RN  - 61-90-5 (Leucine)
RN  - 9005-25-8 (Starch)
SB  - IM
MH  - Absorption
MH  - Animals
MH  - Biological Availability
MH  - Cattle/*physiology
MH  - Duodenum/metabolism
MH  - Female
MH  - Glutamine/*pharmacokinetics
MH  - Half-Life
MH  - Kinetics
MH  - Leucine/*pharmacokinetics
MH  - Rumen/metabolism
MH  - Starch/administration & dosage/*pharmacology
EDAT- 1997/10/06
MHDA- 1997/10/06 00:01
PST - ppublish
SO  - J Dairy Sci. 1997 Sep;80(9):2143-8.
PMID- 9344581
OWN - NLM
STAT- MEDLINE
DA  - 19971125
DCOM- 19971125
LR  - 20061115
PUBM- Print
IS  - 0014-4827 (Print)
VI  - 236
IP  - 1
DP  - 1997 Oct 10
TI  - Inhibition of retinoic acid receptor function in normal human mammary
      epithelial cells results in increased cellular proliferation and inhibits
      the formation of a polarized epithelium in vitro.
PG  - 16-28
AB  - The expression of retinoic acid receptor-beta (RAR beta) mRNA is absent or
      down-regulated in a majority of breast cancers, suggesting that loss of
      retinoic acid receptor function may be a critical event in breast cancer
      carcinogenesis. We developed an in vitro system to investigate whether the
      loss of retinoic acid receptor (RAR) function might affect the
      proliferation and structural differentiation of normal cultured human
      mammary epithelial cells (HMECs). Utilizing a truncated retinoic acid
      receptor (RAR)-alpha construct exhibiting dominant-negative activity
      against retinoic acid receptor isoforms alpha, beta, and gamma (DNRAR), we
      inhibited normal retinoic acid receptor function in HMECs. Suppression of
      RAR function in HMECs resulted in reduced growth inhibition mediated by
      all-trans-retinoic acid (ATRA). Moreover, the doubling time of HMECs
      expressing the DNRAR was significantly shortened, associated with a
      decrease in the percentage of cells in G1 and an increase in the
      percentage of cells in S-phase relative to controls. In addition, HMECs
      expressing the DNRAR cultured in prepared extracellular matrix exhibited a
      loss of extracellular matrix-induced growth arrest and formation of a
      polarized ductal epthelium. Our results suggest that ATRA and RARs may
      play an important role in regulating the proliferation of HMECs and in
      promoting differentiation.
AD  - Division of Medical Oncology, University of Washington, Seattle 98195,
      USA. vseewald@u.washington.edu
FAU - Seewaldt, V L
AU  - Seewaldt VL
FAU - Caldwell, L E
AU  - Caldwell LE
FAU - Johnson, B S
AU  - Johnson BS
FAU - Swisshelm, K
AU  - Swisshelm K
FAU - Collins, S J
AU  - Collins SJ
FAU - Tsai, S
AU  - Tsai S
LA  - eng
GR  - 2P30 DK 35816-11/DK/NIDDK
GR  - DK-48622/DK/NIDDK
GR  - KO8 CA 68210-01/CA/NCI
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Exp Cell Res
JT  - Experimental cell research
JID - 0373226
RN  - 0 (Extracellular Matrix Proteins)
RN  - 0 (Growth Substances)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (Viral Fusion Proteins)
RN  - EC 2.3.1.6 (Choline O-Acetyltransferase)
SB  - IM
MH  - Breast/*cytology
MH  - Cell Aging/physiology
MH  - Cell Division/drug effects/physiology
MH  - Cell Line
MH  - Cell Polarity/*physiology
MH  - Choline O-Acetyltransferase/genetics
MH  - Down-Regulation/physiology
MH  - Epithelial Cells/*chemistry/cytology/ultrastructure
MH  - Extracellular Matrix Proteins/pharmacology
MH  - Genes, Reporter
MH  - Growth Substances/pharmacology
MH  - Humans
MH  - Microscopy, Electron
MH  - Mutagenesis/physiology
MH  - Receptors, Retinoic Acid/*genetics/metabolism
MH  - Retroviridae/genetics
MH  - Transformation, Genetic
MH  - Viral Fusion Proteins/physiology
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
AID - S0014-4827(97)93694-6 [pii]
AID - 10.1006/excr.1997.3694 [doi]
PST - ppublish
SO  - Exp Cell Res. 1997 Oct 10;236(1):16-28.
PMID- 9380472
OWN - NLM
STAT- MEDLINE
DA  - 19971112
DCOM- 19971112
LR  - 20041117
PUBM- Print
IS  - 0891-3668 (Print)
VI  - 16
IP  - 10
DP  - 1997 Oct
TI  - Concentration of cefuroxime in middle ear effusion of children with acute
      otitis media.
PG  - 959-62
AB  - BACKGROUND: Antibiotic concentrations in serum and middle ear effusion are
      important in determining therapeutic success in acute otitis media. For
      beta-lactams the most relevant pharmacokinetic index for clinical efficacy
      is the time for which serum concentrations exceed the minimum inhibitory
      concentration (MIC) of the pathogen, which should be at least 40 to 50% of
      the dosing interval. METHODS: In this open, single center study, the
      concentration of cefuroxime achieved in the serum and middle ear effusion
      of pediatric acute otitis media patients with purulent effusion was
      assessed between 2 and 5 h after a single oral dose of 15 mg/kg cefuroxime
      axetil suspension. RESULTS: Serum concentrations of cefuroxime ranged from
      2.8 to 7.3 microg/ml and were consistent with the results of previous
      pharmacokinetic study. These results show that serum concentrations of
      cefuroxime remain above the MIC90 (2.0 microg/ml) for Streptococcus
      pneumoniae, Haemophilus influenzae and Moraxella catarrhalis for at least
      5 h (42%) of the 12-h dosing interval. Cefuroxime was detected in 14 of 17
      (82%) middle ear effusion samples and ranged from 0.2 to 3.6 microg/ml,
      indicating that cefuroxime penetrates well into the middle ear.
      CONCLUSIONS: Cefuroxime is well-absorbed and penetrates well into the
      middle ear after oral administration of cefuroxime axetil suspension.
AD  - Medical Clinic, Reykjavik, Iceland.
FAU - Thoroddsen, E
AU  - Thoroddsen E
FAU - Marr, C
AU  - Marr C
FAU - Efthymiopoulos, C
AU  - Efthymiopoulos C
FAU - Thorarinsson, H
AU  - Thorarinsson H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - UNITED STATES
TA  - Pediatr Infect Dis J
JT  - The Pediatric infectious disease journal
JID - 8701858
RN  - 0 (Cephalosporins)
RN  - 55268-75-2 (Cefuroxime)
SB  - IM
MH  - Acute Disease
MH  - Administration, Oral
MH  - Cefuroxime/metabolism/*pharmacokinetics/therapeutic use
MH  - Cephalosporins/metabolism/*pharmacokinetics/therapeutic use
MH  - Child, Preschool
MH  - Humans
MH  - Infant
MH  - Microbial Sensitivity Tests
MH  - Otitis Media with Effusion/*drug therapy/metabolism
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Pediatr Infect Dis J. 1997 Oct;16(10):959-62.
PMID- 9357761
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20061115
PUBM- Print
IS  - 0002-9513 (Print)
VI  - 273
IP  - 4 Pt 1
DP  - 1997 Oct
TI  - Cloning and functional expression of a ClC Cl- channel from the renal cell
      line A6.
PG  - C1176-85
AB  - Cl- channels are important for ion transport and cell volume regulation in
      A6 renal cells. In the present study, we used reverse transcriptase
      (RT)-polymerase chain reaction (PCR) and rapid amplification of cDNA ends
      (RACE) to identify proteins homologous to ClC Cl- channel proteins in A6
      cells. Using degenerate primers designed on consensus sequences for
      members of the ClC family, we amplified an RT-PCR product that had
      significant homology to the ClC sequences. RACE-PCR was then used to
      isolate several full-length clones that had total lengths from 2,764 to
      3,016 base pairs. Although the coding regions were identical, sequence
      differences occurred in the 5' noncoding regions. The amino acid sequences
      of the clones had high homologies to rat and human ClC-5 (85 and 84%,
      respectively, if the 5th methionine of the open reading frame represents
      the start codon). Three parts of the protein (53, 80, and 63 amino acids
      in length) were 97-100% homologous to the mammalian sequences.
      Ribonuclease protection assay analysis revealed mRNA for this protein in
      oocytes, kidney, intestine, liver, brain, and blood, with lower amounts in
      stomach, muscle, and skin. Expression of the clones in Xenopus laevis
      oocytes resulted in an outwardly rectifying Cl- current that was inhibited
      by 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid and possessed an anion
      selectivity of I- > Cl- >> gluconate.
AD  - Department of Physiology, University of Texas Medical Branch, Galveston
      77555, USA.
FAU - Lindenthal, S
AU  - Lindenthal S
FAU - Schmieder, S
AU  - Schmieder S
FAU - Ehrenfeld, J
AU  - Ehrenfeld J
FAU - Wills, N K
AU  - Wills NK
LA  - eng
SI  - GENBANK/Y09940
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - UNITED STATES
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Chloride Channels)
RN  - 0 (Chlorides)
RN  - 0 (DNA, Complementary)
RN  - 0 (Gluconates)
RN  - 0 (Iodides)
RN  - 0 (RNA Probes)
RN  - 526-95-4 (gluconic acid)
RN  - 53005-05-3 (4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid)
SB  - IM
EIN - Am J Physiol 1998 Oct;275(4 Pt 1
MH  - 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid/pharmacology
MH  - Amino Acid Sequence
MH  - Animals
MH  - Base Sequence
MH  - Cell Line
MH  - Chloride Channels/*biosynthesis/chemistry/*physiology
MH  - Chlorides/pharmacology
MH  - Cloning, Molecular
MH  - DNA, Complementary
MH  - Female
MH  - Gluconates/pharmacology
MH  - Humans
MH  - Iodides/pharmacology
MH  - Kidney/*metabolism
MH  - Membrane Potentials/drug effects
MH  - Molecular Sequence Data
MH  - Oocytes/physiology
MH  - Organ Specificity
MH  - Polymerase Chain Reaction
MH  - RNA Probes
MH  - Rats
MH  - Sequence Alignment
MH  - Sequence Homology, Amino Acid
MH  - Xenopus laevis
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
PST - ppublish
SO  - Am J Physiol. 1997 Oct;273(4 Pt 1):C1176-85.
PMID- 9285033
OWN - NLM
STAT- MEDLINE
DA  - 19971104
DCOM- 19971104
LR  - 20041117
PUBM- Print
IS  - 0304-4602 (Print)
VI  - 26
IP  - 3
DP  - 1997 May
TI  - Williams syndrome--the Singapore General Hospital experience.
PG  - 360-4
AB  - Williams syndrome first described in 1961 is generally characterised by
      mental deficiency, gregarious personality, unusual "elfin" facies,
      supravalvular aortic stenosis and idiopathic infantile hypercalcaemia.
      Patients with Williams syndrome show a hemizygous submicroscopic deletion
      of 7q11.23 detectable by fluorescent in-situ hybridisation (FISH). The
      deleted portion of the chromosome corresponds to the Elastin gene. We
      report 3 girls with characteristics of Williams syndrome in whom the
      diagnosis was confirmed by demonstration of the hemizygous deletion of
      7q11.23 in the karyotype by FISH. These patients, aged 6, 7 and 10 years,
      showed the characteristic facies and gregarious personalities. Some
      developmental delay with mild mental deficiency and dysmorphic facies were
      prominent features in the initial presentation. Cardiac lesions found in
      these patients were small patent ductus arteriosus which closed, pulmonary
      valvular stenosis and mitral valve prolapse associated with mitral
      regurgitation respectively. Hypercalcaemia was not documented in these
      patients. Learning difficulty was a major issue and all patients required
      special schooling. Chromosome analyses done on peripheral blood were found
      to be normal in all patients. FISH using the Elastin Williams Syndrome
      Chromosome Region (WSCR) probes (oncor) showed the hemizygous deletion of
      7q11.23. Diagnosis of Williams syndrome can now be confidently confirmed
      with the help of FISH.
AD  - Department of Paediatric Medicine, Singapore General Hospital, Singapore.
FAU - Teo, S H
AU  - Teo SH
FAU - Chan, D K
AU  - Chan DK
FAU - Yong, M H
AU  - Yong MH
FAU - Ng, I S
AU  - Ng IS
FAU - Wong, K Y
AU  - Wong KY
FAU - Knight, L
AU  - Knight L
FAU - Ho, L Y
AU  - Ho LY
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - SINGAPORE
TA  - Ann Acad Med Singapore
JT  - Annals of the Academy of Medicine, Singapore
JID - 7503289
SB  - IM
MH  - Child
MH  - Chromosomes, Human, Pair 7
MH  - Female
MH  - Gene Deletion
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Williams Syndrome/*diagnosis/genetics
EDAT- 1997/05/01
MHDA- 1997/05/01 00:01
PST - ppublish
SO  - Ann Acad Med Singapore. 1997 May;26(3):360-4.
PMID- 9287109
OWN - NLM
STAT- MEDLINE
DA  - 19971030
DCOM- 19971030
LR  - 20031114
PUBM- Print
IS  - 0014-5793 (Print)
VI  - 413
IP  - 1
DP  - 1997 Aug 11
TI  - Functional cloning of a cDNA encoding Mei2-like protein from Arabidopsis
      thaliana using a fission yeast pheromone receptor deficient mutant.
PG  - 16-20
AB  - To isolate Arabidopsis cDNAs that encode signal transducers and components
      involved in the regulation of meiosis, a trans-complementation analysis
      was performed using a Schizosaccharomyces pombe meiosis-defective mutant
      in which the genes for pheromone receptors were disabled. One cDNA
      obtained in this screening encodes a polypeptide, named AML1, that shows
      significant similarity to S. pombe Mei2 protein and has three putative
      RNA-recognition motifs like as Mei2. Mei2 is involved in the regulation of
      meiosis in fission yeast. Northern blot analysis showed that the AML1 gene
      is expressed in each organ. The possible functions of AML1 are discussed.
AD  - Laboratory of Plant Molecular Biology, Tsukuba Life Science Center, The
      Institute of Physical and Chemical Research (RIKEN), Ibaraki, Japan.
      takashih@sas.upenn.edu
FAU - Hirayama, T
AU  - Hirayama T
FAU - Ishida, C
AU  - Ishida C
FAU - Kuromori, T
AU  - Kuromori T
FAU - Obata, S
AU  - Obata S
FAU - Shimoda, C
AU  - Shimoda C
FAU - Yamamoto, M
AU  - Yamamoto M
FAU - Shinozaki, K
AU  - Shinozaki K
FAU - Ohto, C
AU  - Ohto C
LA  - eng
SI  - GENBANK/D86122
PT  - Journal Article
PL  - NETHERLANDS
TA  - FEBS Lett
JT  - FEBS letters
JID - 0155157
RN  - 0 (AML1 protein, Arabidopsis)
RN  - 0 (Arabidopsis Proteins)
RN  - 0 (DNA, Fungal)
RN  - 0 (Fungal Proteins)
RN  - 0 (Nucleoproteins)
RN  - 0 (Plant Proteins)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Schizosaccharomyces pombe Proteins)
RN  - 0 (mei2 protein, S pombe)
SB  - IM
MH  - Amino Acid Sequence
MH  - Arabidopsis/*genetics
MH  - *Arabidopsis Proteins
MH  - Base Sequence
MH  - Blotting, Southern
MH  - Cells, Cultured
MH  - Chemoreceptors/*metabolism
MH  - Cloning, Molecular
MH  - DNA, Fungal/*genetics
MH  - Fungal Proteins/*genetics
MH  - *Genes, Fungal
MH  - Genetic Complementation Test
MH  - Meiosis
MH  - Molecular Sequence Data
MH  - Mutation
MH  - *Nucleoproteins
MH  - Plant Proteins/*genetics
MH  - RNA-Binding Proteins/*genetics
MH  - Receptors, Cell Surface/*genetics/metabolism
MH  - Schizosaccharomyces/genetics
MH  - *Schizosaccharomyces pombe Proteins
MH  - Sequence Homology, Amino Acid
EDAT- 1997/08/11
MHDA- 1997/08/11 00:01
AID - S0014-5793(97)00871-5 [pii]
PST - ppublish
SO  - FEBS Lett. 1997 Aug 11;413(1):16-20.
PMID- 9381776
OWN - NLM
STAT- MEDLINE
DA  - 19971106
DCOM- 19971106
LR  - 20061115
PUBM- Print
IS  - 0044-3220 (Print)
VI  - 135
IP  - 4
DP  - 1997 Jul-Aug
TI  - [The Holt-Oram syndrome. Review of the literature and current orthopedic
      treatment concepts]
PG  - 368-75
AB  - PROBLEM: The clinical manifestation of the Holt-Oram-syndrome (HOS) shows
      congenital heart-disease and anomalies of the upper limb. The inheritance
      of this syndrome is autosomal dominant. The question arise, as to whether
      a contemporary orthopedic concept of treatment could developed based on
      own experiences and data from the literature. METHODS: We revised data
      from five patients with HOS treated at the Clinic for Orthopaedics of the
      University of Heidelberg. The review of the literature revealed a
      comprehensive and detailed picture of the clinical syndrome and,
      furthermore, information in respect to a comparative analysis of methods
      of treatments. RESULTS: Our patients showed characteristic cardiac
      anomalies, i.e. atrio and ventricular septal defects, and persisting
      Botall's duct (three cases). The types of malformation of the upper limb
      corresponded with those found in the literature. Furthermore the
      indication for amputation of rudimentary or hypoplastic fingers in the
      Heidelberg clinic was in accordance with the clinical treatments described
      worldwide. CONCLUSION: The type of treatment of the clubhand in cases with
      HOS depends on (1) the age and (2) the pattern and degree of accompanying
      malformations of the upper limb. For patients with aplasia of the thumb or
      amputation of a rudimental one we recommend pollicisation of the index
      finger to improve its function.
AD  - Orthopadische Universitatsklinik der RWTH Aachen.
FAU - Weber, M
AU  - Weber M
FAU - Wenz, W
AU  - Wenz W
FAU - van Riel, A
AU  - van Riel A
FAU - Kaufmann, A
AU  - Kaufmann A
FAU - Graf, J
AU  - Graf J
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Das Holt-Oram Syndrom (HOS). Literaturuberblick und aktuelle orthopadische
      Behandlungskonzepte.
PL  - GERMANY
TA  - Z Orthop Ihre Grenzgeb
JT  - Zeitschrift fur Orthopadie und ihre Grenzgebiete
JID - 1256465
SB  - IM
MH  - Child
MH  - Child, Preschool
MH  - Chromosome Aberrations/genetics
MH  - Chromosome Disorders
MH  - Ductus Arteriosus, Patent/genetics/radiography/surgery
MH  - Ectromelia/genetics/radiography/surgery
MH  - Female
MH  - Fingers/*abnormalities/radiography/surgery/transplantation
MH  - Genes, Dominant/genetics
MH  - Hand Deformities, Congenital/*genetics/radiography/surgery
MH  - Heart Defects, Congenital/*genetics/radiography/surgery
MH  - Heart Septal Defects, Atrial/genetics/radiography/surgery
MH  - Heart Septal Defects, Ventricular/genetics/radiography/surgery
MH  - Humans
MH  - Infant
MH  - Male
MH  - Retrospective Studies
MH  - Syndrome
MH  - Thumb/abnormalities/radiography/surgery
RF  - 36
EDAT- 1997/07/01 00:00
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Z Orthop Ihre Grenzgeb. 1997 Jul-Aug;135(4):368-75.
PMID- 9306153
OWN - NLM
STAT- MEDLINE
DA  - 19971104
DCOM- 19971104
LR  - 20061115
PUBM- Print
IS  - 0192-0561 (Print)
VI  - 19
IP  - 3
DP  - 1997 Mar
TI  - Ouabain effects on activated lymphocytes: augmentation of CD25 expression
      on TPA-stimulated cells and of CD69 on PHA-and TPA-stimulated cells.
PG  - 143-8
AB  - Ouabain (OUA) was capable of inhibiting peripheral blood lymphocyte (PBL)
      proliferation induced by phyothaemagglutinin (PHA) of phorbol ester (TPA),
      as measured by thymidine incorporation or cell cycle analysis. In this
      latter case it was possible to detect a block in the progression from G1
      to S phase. This inhibition could not be reversed by interleukin (IL)-2
      and was not due to an effect on CD 25 expression, as this molecule was
      only reduced in PHA cultures treated with OUA. Conversely, cultures
      activated by TPA and OUA showed an increased expression of CD25. The
      activation antigen CD69 was increased in both situation, suggesting that
      despite the absence of proliferative response the cells were being
      activated. The possibility that these cells were being deviated to the
      activation pathway leading to apoptosis is now under investigation. This
      study also suggested that CD25 induction may occur via different pathways,
      and that the selective effect of OUA for PHA-activated cells may become a
      useful tool for the understanding of the process.
AD  - Pathology Department, Hospital Antonio Pedro, Fluminense Federal
      University, Niteroi, Brazil.
FAU - Pires, V
AU  - Pires V
FAU - Harab, R C
AU  - Harab RC
FAU - Olej, B
AU  - Olej B
FAU - Rumjanek, V M
AU  - Rumjanek VM
LA  - eng
PT  - In Vitro
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - ENGLAND
TA  - Int J Immunopharmacol
JT  - International journal of immunopharmacology
JID - 7904799
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, T-Lymphocyte)
RN  - 0 (CD69 antigen)
RN  - 0 (Interleukin-2)
RN  - 0 (Phytohemagglutinins)
RN  - 0 (Receptors, Interleukin-2)
RN  - 16561-29-8 (Tetradecanoylphorbol Acetate)
RN  - 50-89-5 (Thymidine)
RN  - 630-60-4 (Ouabain)
SB  - IM
MH  - Antigens, CD/*biosynthesis
MH  - Antigens, Differentiation, T-Lymphocyte/*biosynthesis
MH  - Cell Cycle/drug effects
MH  - Flow Cytometry
MH  - Humans
MH  - Interleukin-2/pharmacology
MH  - Lymphocyte Activation/*drug effects
MH  - Lymphocytes/*drug effects/metabolism
MH  - Ouabain/*pharmacology
MH  - Phytohemagglutinins/*pharmacology
MH  - Receptors, Interleukin-2/*biosynthesis
MH  - Tetradecanoylphorbol Acetate/*pharmacology
MH  - Thymidine/blood
EDAT- 1997/03/01 00:00
MHDA- 1997/11/05 00:01
AID - S0192056196000707 [pii]
PST - ppublish
SO  - Int J Immunopharmacol. 1997 Mar;19(3):143-8.
PMID- 9337957
OWN - NLM
STAT- MEDLINE
DA  - 19971030
DCOM- 19971030
LR  - 20061115
PUBM- Print
IS  - 0007-1250 (Print)
VI  - 171
DP  - 1997 Aug
TI  - Plasma noradrenaline response to electroconvulsive therapy in depressive
      illness.
PG  - 182-6
AB  - BACKGROUND: Abnormalities of catecholaminergic function have been
      hypothesised to cause depressive illness. Plasma noradrenaline can be used
      as a marker of central noradrenergic activity. It is of interest to
      examine the change in resting plasma noradrenaline in patients with
      depressive illness over a course of electroconvulsive therapy (ECT) and
      relate this to their clinical state. METHOD: Patients referred for ECT who
      suffered from DSM-III-R major depressive disorder or dysthymia were
      recruited. Blood samples were taken before and after each treatment,
      during a course of ECT, to measure plasma noradrenaline and cortisol.
      Clinical ratings were carried out weekly during the course of ECT.
      RESULTS: Plasma noradrenaline fell significantly in those patients with
      melancholic/psychotic depressions but increased in those with
      non-melancholic depressive illness. There was a strong trend indicating
      that a fall in plasma noradrenaline was associated with improvement in
      depression ratings in the melancholic/psychotic patients only.
      CONCLUSIONS: Electroconvlusive therapy decreases plasma noradrenaline in
      melancholic/psychotic depressive illness and this shows a trend associated
      with clinical improvement.
AD  - Department of Mental Health, Queen's University of Belfast.
FAU - Kelly, C B
AU  - Kelly CB
FAU - Cooper, S J
AU  - Cooper SJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - ENGLAND
TA  - Br J Psychiatry
JT  - The British journal of psychiatry : the journal of mental science
JID - 0342367
RN  - 0 (Biological Markers)
RN  - 50-23-7 (Hydrocortisone)
RN  - 51-41-2 (Norepinephrine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biological Markers/blood
MH  - Depressive Disorder/*blood/therapy
MH  - *Electroconvulsive Therapy
MH  - Female
MH  - Humans
MH  - Hydrocortisone/blood
MH  - Male
MH  - Middle Aged
MH  - Norepinephrine/*blood
EDAT- 1997/08/01 00:00
MHDA- 1997/10/24 00:01
PST - ppublish
SO  - Br J Psychiatry. 1997 Aug;171:182-6.
PMID- 9351726
OWN - NLM
STAT- MEDLINE
DA  - 19971114
DCOM- 19971114
LR  - 20061115
PUBM- Print
IS  - 0002-8703 (Print)
VI  - 134
IP  - 4
DP  - 1997 Oct
TI  - Effect of beta-adrenergic blocking agents on mortality rate in patients
      not revascularized after myocardial infarction: data from a large HMO.
PG  - 608-13
AB  - We investigated whether patients who do not undergo coronary angiography
      and therefore any form of revascularization after a myocardial infarction
      derive greater benefit from chronic beta-blocker therapy than patients who
      undergo coronary angiography. With multivariate analyses, treatment with
      beta-blockers was a much stronger predictor of survival in patients who
      did not undergo coronary angiography (relative risk = 0.38, p = 0.005)
      than in those patients who did undergo catheterization (p < 0.05 for
      interaction). Our findings provide direct support for the recommendation
      by the American College of Cardiology/American Heart Association task
      force that beta-blocker therapy should be initiated for all infarct
      survivors who do not undergo revascularization and who have no
      contraindications.
AD  - Department of Medicine, University of California, San Francisco, USA.
      barron@ep4.ucsf.edu
FAU - Barron, H V
AU  - Barron HV
FAU - Viskin, S
AU  - Viskin S
FAU - Lundstrom, R J
AU  - Lundstrom RJ
FAU - Wong, C C
AU  - Wong CC
FAU - Swain, B E
AU  - Swain BE
FAU - Truman, A F
AU  - Truman AF
FAU - Selby, J V
AU  - Selby JV
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Adrenergic beta-Antagonists)
SB  - AIM
SB  - IM
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Aged
MH  - Female
MH  - Health Maintenance Organizations
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy/*mortality
MH  - Odds Ratio
MH  - Retrospective Studies
MH  - Risk
MH  - San Francisco
MH  - Treatment Outcome
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
AID - S0002-8703(97)70042-5 [pii]
PST - ppublish
SO  - Am Heart J. 1997 Oct;134(4):608-13.
PMID- 9302538
OWN - NLM
STAT- MEDLINE
DA  - 19971030
DCOM- 19971030
LR  - 20061115
PUBM- Print
IS  - 0278-6133 (Print)
VI  - 16
IP  - 5
DP  - 1997 Sep
TI  - Sexual assault history and health perceptions: seven general population
      studies.
PG  - 417-25
AB  - This article uses data from 7 population surveys to evaluate the
      association of sexual assault history with health perceptions. It
      estimates the extent of generalizability across gender, ethnic groups, and
      studies; the extent to which depression accounts for or mediates the
      association; and whether some circumstances of assault are more strongly
      related to poor subjective health. Data from each of 18 subsamples of the
      surveys were analyzed (pooled N = 10,001; 7,550 women and 2,451 men), and
      results were combined by using meta-analysis. Assault was associated with
      poor subjective health (odds ratio [OR] = 1.63, 95% confidence interval
      [CI] = 1.36, 1.95) and this result was consistent regardless of gender,
      ethnicity, or sample. Controlling depression did not markedly change this
      result (OR = 1.46, 95% CI = 1.21, 1.77), indicating that depression did
      not account for or mediate the assault-health perceptions association.
      Multiple assaults and assaults by strangers or spouse were most strongly
      associated with poor subjective health.
AD  - Institute for Health & Aging, University of California, San Francisco
      94143-0646, USA.
FAU - Golding, J M
AU  - Golding JM
FAU - Cooper, M L
AU  - Cooper ML
FAU - George, L K
AU  - George LK
LA  - eng
GR  - R29-MH50005/MH/NIMH
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Health Psychol
JT  - Health psychology : official journal of the Division of Health Psychology,
      American Psychological Association
JID - 8211523
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Attitude to Health
MH  - Child
MH  - Child Abuse, Sexual/*psychology/statistics & numerical data
MH  - Depression/epidemiology/psychology
MH  - Ethnic Groups/psychology/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Population Surveillance
MH  - Rape/*psychology/statistics & numerical data
MH  - United States/epidemiology
EDAT- 1997/09/26
MHDA- 1997/09/26 00:01
PST - ppublish
SO  - Health Psychol. 1997 Sep;16(5):417-25.
PMID- 9259208
OWN - NLM
STAT- MEDLINE
DA  - 19971120
DCOM- 19971120
LR  - 20031114
PUBM- Print
IS  - 0391-3988 (Print)
VI  - 20
IP  - 6
DP  - 1997 Jun
TI  - Development of intracoronary local adhesive delivery technique.
PG  - 319-26
AB  - Acute coronary occlusion may occur in weak coronary atherosclerotic
      lesions, including dissection, ulceration or thrombus. In some cases of
      occlusion "bail-out" is performed by using recently developed New Devices.
      However, these have not yet completely solved the problem to this end, we
      designed a new method of coronary revascularization, the Intracoronary
      Local Adhesive Delivery Technique, utilizing antithrombotic and absorbable
      adhesive injected locally into the fragile and morbid arterial wall using
      a drug delivery PTCA catheter more flexible than the existing New Devices.
      This adhesive strengthened and hardened the lesions. In this study, we
      examined the efficacy of making an adhesive cylinder in arteries of
      similar size to the coronary, through acute animal experiments using the
      existing clinical adhesives and drug delivery PTCA catheters and 12
      femoral arteries of adult goats. We were successful in forming firm
      tunnels along the inside of six arteries, infused with approximately 0.04
      ml Cyanoacrylate. These tunnels were observed with intravascular
      ultrasound (IVUS) imaging and evaluated microscopically. These results
      suggest the feasibility of this method as a new approach for making
      synthetic resinous stents.
AD  - Department of Medical Engineering and Cardiology, Tokoku University,
      Sendai, Japan.
FAU - Sonobe, T
AU  - Sonobe T
FAU - Naganuma, S
AU  - Naganuma S
FAU - Yambe, T
AU  - Yambe T
FAU - Kobayashi, S I
AU  - Kobayashi SI
FAU - Sizuka, K
AU  - Sizuka K
FAU - Katahira, Y
AU  - Katahira Y
FAU - Nitta, K
AU  - Nitta K
FAU - Nitta, S I
AU  - Nitta SI
LA  - eng
PT  - Journal Article
PL  - ITALY
TA  - Int J Artif Organs
JT  - The International journal of artificial organs
JID - 7802649
RN  - 0 (Cyanoacrylates)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Tissue Adhesives)
SB  - IM
MH  - Absorption
MH  - *Angioplasty, Transluminal, Percutaneous Coronary
MH  - Animals
MH  - Coronary Disease/etiology/*therapy
MH  - Cyanoacrylates/*administration & dosage/metabolism
MH  - Disease Models, Animal
MH  - Drug Delivery Systems/*standards
MH  - Feasibility Studies
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage/metabolism
MH  - Goats
MH  - Male
MH  - Myocardial Revascularization
MH  - Stents
MH  - Tissue Adhesives/standards/*therapeutic use
EDAT- 1997/06/01
MHDA- 1997/06/01 00:01
PST - ppublish
SO  - Int J Artif Organs. 1997 Jun;20(6):319-26.
PMID- 9325340
OWN - NLM
STAT- MEDLINE
DA  - 19971113
DCOM- 19971113
LR  - 20061115
PUBM- Print
IS  - 0021-9258 (Print)
VI  - 272
IP  - 41
DP  - 1997 Oct 10
TI  - Binding properties of neuroligin 1 and neurexin 1beta reveal function as
      heterophilic cell adhesion molecules.
PG  - 26032-9
AB  - beta-Neurexins and neuroligins are plasma membrane proteins that are
      displayed on the neuronal cell surface. We have now investigated the
      interaction of neurexin 1beta with neuroligin 1 to evaluate their
      potential to function as heterophilic cell adhesion molecules. Using
      detergent-solubilized neuroligins and secreted neurexin 1beta-IgG fusion
      protein, we observed binding of these proteins to each other only in the
      presence of Ca2+ and in no other divalent cation tested. Only neurexin
      1beta lacking an insert in splice site 4 bound neuroligins, whereas
      neurexin 1beta containing an insert was inactive. Half-maximal binding
      required 1-3 microM free Ca2+, which probably acts by binding to
      neuroligin 1 but not to neurexin 1beta. To determine if neurexin 1beta and
      neuroligin 1 can also interact with each other when present in a native
      membrane environment on the cell surface, we generated transfected cell
      lines expressing neuroligin 1 and neurexin 1beta. Upon mixing different
      cell populations, we found that cells aggregate only if cells expressing
      neurexin 1beta are mixed with cells expressing neuroligin 1. Aggregation
      was dependent on Ca2+ and was inhibited by the addition of soluble
      neurexin 1beta lacking an insert in splice site 4 but not by the addition
      of neurexin 1beta containing an insert in splice site 4. We conclude that
      neurexin 1beta and neuroligin 1 (and, by extension, other beta-neurexins
      and neuroligins) function as heterophilic cell adhesion molecules in a
      Ca2+-dependent reaction that is regulated by alternative splicing of
      beta-neurexins.
AD  - Department of Molecular Genetics and Howard Hughes Medical Institute,
      University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA.
FAU - Nguyen, T
AU  - Nguyen T
FAU - Sudhof, T C
AU  - Sudhof TC
LA  - eng
GR  - R01-MH52804/MH/NIMH
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Cations, Divalent)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (Membrane Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (neuroligin 1)
RN  - 156532-80-8 (neurexin Ibeta)
RN  - 7440-70-2 (Calcium)
SB  - IM
MH  - Animals
MH  - Brain/metabolism
MH  - Calcium/metabolism
MH  - Cations, Divalent/metabolism
MH  - Cell Adhesion
MH  - Cell Adhesion Molecules/*metabolism
MH  - Drosophila
MH  - Intercellular Junctions/metabolism
MH  - Membrane Proteins/genetics/*metabolism
MH  - Nerve Tissue Proteins/genetics/*metabolism
MH  - Neurons/metabolism
MH  - Protein Binding
MH  - Protein Folding
MH  - Rats
MH  - Transfection
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - J Biol Chem. 1997 Oct 10;272(41):26032-9.
PMID- 9378512
OWN - NLM
STAT- MEDLINE
DA  - 19971107
DCOM- 19971107
LR  - 20061115
PUBM- Print
IS  - 0019-5189 (Print)
VI  - 35
IP  - 5
DP  - 1997 May
TI  - Selective use of calcium chelators enhances the yield of calcium-tolerant
      myocytes from adult heart.
PG  - 451-6
AB  - Isolation of viable and functional cells from adult heart remains an
      intriguing problem for investigators who choose to use the cardiomyocyte
      model for experimental studies. With a few modifications of the existing
      procedures we have been able to improve the yield of ventricular
      myocardial cells from the adult rat heart. Sarcolemmal damage leading to
      hypercontracture due to Ca2+ loading appears to be the major hindrance to
      the successful isolation of sufficient number of viable cells. The two
      crucial steps are found to be the pre-enzymatic perfusion for
      Ca(2+)-depletion and the final step of Ca(2+)-repletion in extracellular
      medium for the isolation of Ca(2+)-tolerant myocytes. Inclusion of EGTA
      and taurine during the initial perfusion of Ca(2+)-free medium and of
      trypsin during reintroduction of Ca2+ led to a considerable increase in
      the yield of Ca(2+)-tolerant myocytes. The contraction amplitude and speed
      of shortening and relaxation of isolated cells were measured using an edge
      detection device. Selective use of calcium ion chelators appears to have a
      beneficial effect on the isolation of Ca(2+)-tolerant myocytes.
AD  - Division of Cellular & Molecular Cardiology, Sree Chitra Tirunal Institute
      for Medical Sciences & Technology, Trivandrum, India.
FAU - Nair, P
AU  - Nair P
FAU - Nair, R R
AU  - Nair RR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - INDIA
TA  - Indian J Exp Biol
JT  - Indian journal of experimental biology
JID - 0233411
RN  - 0 (Chelating Agents)
RN  - 7440-70-2 (Calcium)
SB  - IM
MH  - Animals
MH  - *Calcium
MH  - Chelating Agents/*pharmacology
MH  - Heart/*drug effects
MH  - Male
MH  - Myocardium/cytology
MH  - Rats
MH  - Rats, Wistar
EDAT- 1997/05/01 00:00
MHDA- 1997/10/07 00:01
PST - ppublish
SO  - Indian J Exp Biol. 1997 May;35(5):451-6.
PMID- 9300300
OWN - NLM
STAT- MEDLINE
DA  - 19971104
DCOM- 19971104
LR  - 20061115
PUBM- Print
IS  - 1045-3873 (Print)
VI  - 8
IP  - 9
DP  - 1997 Sep
TI  - Cultured adult rabbit myocytes: effect of adding supplements to the
      medium, and response to isoprenaline.
PG  - 1020-30
AB  - INTRODUCTION: The aims of this study were to investigate: (1) the effect
      of supplementing the culture medium on preservation of L-type calcium
      channel current (1Ca,L) in adult rabbit ventricular myocytes cultured for
      4 days; and (2) preservation of the ICa,L response in cultured myocytes to
      the beta-adrenergic agonist isoprenaline. METHODS AND RESULTS: Adult
      rabbit myocytes were cultured on laminin-pretreated glass coverslips. The
      basic, serum-free culture medium was supplemented with 2 mM L-carnitine, 5
      mM creatine, and 5 mM taurine. Myocytes were whole cell patch-clamped, and
      the L-type Ca channel current was recorded selectively as Ba flux (IBa,L)
      via the channels. IBa,L density (i.e., IBa,L amplitude normalized to
      membrane capacitance) in myocytes maintained in supplemented medium did
      not change significantly during culture (P > 0.1). By comparison, IBa,L
      density in myocytes cultured in nonsupplemented medium declined by 36%
      after 24 hours in culture (day 1) and then recovered by the fourth day
      (day 4). There was no significant difference in the response to
      isoprenaline of acutely isolated myocytes and 4-day cultured myocytes.
      Isoprenaline 100 nM increased peak IBa,L by 149% +/- 32% (mean +/- SEM) in
      acutely isolated myocytes (n = 4 cells), and by 224% +/- 60% (n = 6 cells)
      and 159% +/- 24% (n = 8 cells) in day 1 and 4 cultured myocytes,
      respectively. CONCLUSIONS: Supplemented medium improved IBa,L density in
      cultured myocytes. beta-Adrenergic receptors and intracellular messenger
      pathways appear to remain intact in adult rabbit myocytes cultured for up
      to 4 days.
AD  - Department of Physiology, University of Bristol, School of Medical
      Sciences, United Kingdom. john.s.mitcheson@bristol.ac.uk
FAU - Mitcheson, J S
AU  - Mitcheson JS
FAU - Hancox, J C
AU  - Hancox JC
FAU - Levi, A J
AU  - Levi AJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - J Cardiovasc Electrophysiol
JT  - Journal of cardiovascular electrophysiology
JID - 9010756
RN  - 0 (Adrenergic beta-Agonists)
RN  - 0 (Calcium Channels)
RN  - 0 (Culture Media, Serum-Free)
RN  - 7683-59-2 (Isoproterenol)
SB  - IM
MH  - Adrenergic beta-Agonists/pharmacology
MH  - Animals
MH  - Calcium Channels/drug effects
MH  - Cells, Cultured
MH  - Culture Media, Serum-Free/pharmacology
MH  - Heart/*drug effects/physiology
MH  - Heart Ventricles/cytology/drug effects
MH  - Isoproterenol/*pharmacology
MH  - Male
MH  - Membrane Potentials/drug effects
MH  - Myocardium/*cytology
MH  - Patch-Clamp Techniques
MH  - Rabbits
EDAT- 1997/09/23
MHDA- 1997/09/23 00:01
PST - ppublish
SO  - J Cardiovasc Electrophysiol. 1997 Sep;8(9):1020-30.
PMID- 9326653
OWN - NLM
STAT- MEDLINE
DA  - 19971124
DCOM- 19971124
LR  - 20061115
PUBM- Print
IS  - 0027-8424 (Print)
VI  - 94
IP  - 21
DP  - 1997 Oct 14
TI  - Panhandle PCR strategy to amplify MLL genomic breakpoints in
      treatment-related leukemias.
PG  - 11583-8
AB  - Panhandle PCR amplifies genomic DNA with known 5' and unknown 3' sequences
      from a template with an intrastrand loop schematically shaped like a pan
      with a handle. We used panhandle PCR to clone MLL genomic breakpoints in
      two pediatric treatment-related leukemias. The karyotype in a case of
      treatment-related acute lymphoblastic leukemia showed the
      t(4;11)(q21;q23). Panhandle PCR amplified the translocation breakpoint at
      position 2158 in intron 6 in the 5' MLL breakpoint cluster region (bcr).
      The karyotype in a case of treatment-related acute myeloid leukemia was
      normal, but Southern blot analysis showed a single MLL gene rearrangement.
      Panhandle PCR amplified the breakpoint at position 1493 in MLL intron 6.
      Screening of somatic cell hybrid and radiation hybrid DNAs by PCR and
      reverse transcriptase-PCR analysis of the leukemic cells indicated that
      panhandle PCR identified a fusion of MLL intron 6 with a previously
      uncharacterized sequence in MLL intron 1, consistent with a partial
      duplication. In both cases, the breakpoints in the MLL bcr were in Alu
      repeats, and there were Alu repeats in proximity to the breakpoints in the
      partner DNAs, suggesting that Alu sequences were relevant to these
      rearrangements. This study shows that panhandle PCR is an effective method
      for cloning MLL genomic breakpoints in treatment-related leukemias.
      Analysis of additional pediatric cases will determine whether breakpoint
      distribution deviates from the predilection for 3' distribution in the bcr
      that has been found in adult cases.
AD  - Division of Oncology, Jr. Research Institute, Department of Pediatrics,
      Children's Hospital of Philadelphia, Philadelphia, PA 19104-4318, USA.
FAU - Megonigal, M D
AU  - Megonigal MD
FAU - Rappaport, E F
AU  - Rappaport EF
FAU - Jones, D H
AU  - Jones DH
FAU - Kim, C S
AU  - Kim CS
FAU - Nowell, P C
AU  - Nowell PC
FAU - Lange, B J
AU  - Lange BJ
FAU - Felix, C A
AU  - Felix CA
LA  - eng
SI  - GENBANK/AF024540
SI  - GENBANK/AF024541
SI  - GENBANK/AF024542
SI  - GENBANK/AF024543
GR  - 1R29CA66140-02/CA/NCI
GR  - 5R25CA4009/CA/NCI
GR  - CA42232/CA/NCI
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of
      America
JID - 7505876
RN  - 0 (DNA Primers)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (MLL protein, human)
RN  - 0 (Transcription Factors)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
SB  - IM
MH  - Adult
MH  - Artificial Gene Fusion
MH  - Base Sequence
MH  - Bone Marrow/pathology
MH  - Child
MH  - Chromosome Mapping
MH  - *Chromosomes, Human, Pair 11
MH  - *Chromosomes, Human, Pair 4
MH  - DNA Primers
MH  - DNA-Binding Proteins/*genetics
MH  - Female
MH  - Gene Rearrangement
MH  - Humans
MH  - Introns
MH  - Leukemia/etiology/*genetics/pathology
MH  - Male
MH  - Molecular Sequence Data
MH  - Myeloid-Lymphoid Leukemia Protein
MH  - Neoplasms/*therapy
MH  - Neoplasms, Second Primary/*etiology/*genetics/pathology
MH  - Polymerase Chain Reaction/*methods
MH  - *Proto-Oncogenes
MH  - Repetitive Sequences, Nucleic Acid
MH  - *Transcription Factors
MH  - *Translocation, Genetic
MH  - Zinc Fingers
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11583-8.
PMID- 9322741
OWN - NLM
STAT- MEDLINE
DA  - 19971030
DCOM- 19971030
LR  - 20061115
PUBM- Print
IS  - 0378-1119 (Print)
VI  - 196
IP  - 1-2
DP  - 1997 Sep 1
TI  - Isolation and expression pattern of hahr1, a homeobox-containing cDNA from
      Helianthus annuus.
PG  - 61-8
AB  - A 2.5 kb homeobox (HB)-containing cDNA (hahr1) was isolated from a library
      prepared from rootlets of Helianthus annuus using a polymerase chain
      reaction (PCR)-based strategy. The putative protein product (77 kDa)
      contains the homeodomain (HD) and an acidic domain at the N-terminal
      region (residues 72-155). The deduced amino acid sequence of hahr1 shares
      a 53% sequence identity with GLABRA2, a HD protein associated with
      epidermal cell differentiation. Hahr1 expression was primarily found in
      dry seeds, hypocotyls and roots at stages associated with early
      developmental events. Expression was completely lacking in leaves and
      flowers. Evidence for the existence of one related gene expressed in
      sunflower stems was obtained by the presence of restriction fragment
      length polymorphism of amplified cDNA products.
AD  - Programa Multidisciplinario de Biologia Experimental (PROMUBIE), Facultad
      de Ciencias Bioquimicas y Farmaceuticas, UNR, Rosario, Argentina.
FAU - Valle, E M
AU  - Valle EM
FAU - Gonzalez, D H
AU  - Gonzalez DH
FAU - Gago, G
AU  - Gago G
FAU - Chan, R L
AU  - Chan RL
LA  - eng
SI  - GENBANK/L76588
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - NETHERLANDS
TA  - Gene
JT  - Gene
JID - 7706761
RN  - 0 (Arabidopsis Proteins)
RN  - 0 (DNA, Complementary)
RN  - 0 (GL2 protein, Arabidopsis)
RN  - 0 (HAHR1 protein, plant)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Plant Proteins)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Amino Acid Sequence
MH  - *Arabidopsis Proteins
MH  - Base Sequence
MH  - Cloning, Molecular
MH  - DNA, Complementary
MH  - *Gene Expression Regulation, Plant
MH  - Helianthus/*genetics/growth & development
MH  - Homeodomain Proteins/*genetics/*metabolism
MH  - Molecular Sequence Data
MH  - Plant Proteins/genetics/metabolism
MH  - Plant Roots/genetics/growth & development
MH  - Plant Stems/genetics
MH  - RNA, Messenger
MH  - Sequence Analysis, DNA
MH  - Sequence Homology, Amino Acid
EDAT- 1997/10/10
MHDA- 1997/10/10 00:01
AID - S0378-1119(97)00193-5 [pii]
PST - ppublish
SO  - Gene. 1997 Sep 1;196(1-2):61-8.
PMID- 9376223
OWN - NLM
STAT- MEDLINE
DA  - 19971112
DCOM- 19971112
LR  - 20061115
PUBM- Print
IS  - 0898-6568 (Print)
VI  - 9
IP  - 6
DP  - 1997 Sep
TI  - Agonist-mediated tyrosine phosphorylation of isoforms of the shc adapter
      protein by the delta opioid receptor.
PG  - 423-9
AB  - Maximally effective concentrations of the opioid agonist
      D-ala2-D-leu5-enkephalin resulted in some 2-3-fold enhancement of tyrosine
      phosphorylation of the p52 Shc adapter protein in a clone of Rat-1
      fibroblasts transfected to express stably the murine delta opioid
      receptor. More limited modifications of the tyrosine phosphorylation
      status of the p46 and p66 forms of Shc were observed in parallel.
      Epidermal growth factor caused some 10-12-fold enhancement of tyrosine
      phosphorylation of p52 Shc and marked increases in the p46 and p66 forms.
      The effect of D-ala2-D-leu5-enkephalin was prevented by pretreatment of
      the cells with pertussis toxin and was not observed in non-transfected
      parental fibroblasts whereas the effect of epidermal growth factor was
      still manifest in both these situations. Half-maximal effects of
      D-ala2-D-leu5-enkephalin on p52 Shc tyrosine phosphorylation were produced
      with sub-nanomolar concentrations, in agreement with previous results on
      the tyrosine phosphorylation of p44MAPK (Burt et al., 1996). p52 Shc
      became tyrosine phosphorylated more rapidly than p44MAPK in response to
      D-ala2-D-leu5-enkephalin and its enhanced tyrosine phosphorylation was
      maintained for at least 10 min.
AD  - Division of Biochemistry and Molecular Biology, University of Glasgow,
      Scotland, U.K.
FAU - Mullaney, I
AU  - Mullaney I
FAU - Carr, I C
AU  - Carr IC
FAU - Burt, A R
AU  - Burt AR
FAU - Wilson, M
AU  - Wilson M
FAU - Anderson, N G
AU  - Anderson NG
FAU - Milligan, G
AU  - Milligan G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - ENGLAND
TA  - Cell Signal
JT  - Cellular signalling
JID - 8904683
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Adaptor Proteins, Vesicular Transport)
RN  - 0 (Proteins)
RN  - 0 (Receptors, Opioid, delta)
RN  - 0 (Src homology 2 domain-containing, transforming protein 1)
RN  - 0 (Virulence Factors, Bordetella)
RN  - 55520-40-6 (Tyrosine)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - 63631-40-3 (Enkephalin, Leucine-2-Alanine)
RN  - EC 2.4.2.31 (Pertussis Toxin)
RN  - EC 2.7.1.112 (Receptor, Epidermal Growth Factor)
RN  - EC 2.7.1.37 (Mitogen-Activated Protein Kinase 1)
SB  - IM
MH  - *Adaptor Proteins, Signal Transducing
MH  - *Adaptor Proteins, Vesicular Transport
MH  - Animals
MH  - Clone Cells/chemistry/enzymology
MH  - Enkephalin, Leucine-2-Alanine/pharmacology
MH  - Epidermal Growth Factor/metabolism/pharmacology
MH  - Fibroblasts/chemistry/cytology/enzymology
MH  - Gene Expression/physiology
MH  - Isomerism
MH  - Mice
MH  - Mitogen-Activated Protein Kinase 1/metabolism
MH  - Pertussis Toxin
MH  - Phosphorylation
MH  - Proteins/chemistry/*metabolism
MH  - Rats
MH  - Receptor, Epidermal Growth Factor/agonists/genetics
MH  - Receptors, Opioid, delta/*agonists/genetics
MH  - Signal Transduction/drug effects/*physiology
MH  - Time Factors
MH  - Transfection
MH  - Tyrosine/*metabolism
MH  - Virulence Factors, Bordetella/pharmacology
EDAT- 1997/10/06
MHDA- 1997/10/06 00:01
AID - S0898-6568(96)00188-X [pii]
PST - ppublish
SO  - Cell Signal. 1997 Sep;9(6):423-9.
PMID- 9352845
OWN - NLM
STAT- MEDLINE
DA  - 19971113
DCOM- 19971113
LR  - 20061115
PUBM- Print
IS  - 0016-5085 (Print)
VI  - 113
IP  - 5
DP  - 1997 Nov
TI  - Physician specialty and variations in the cost of treating patients with
      acute upper gastrointestinal bleeding.
PG  - 1443-8
AB  - BACKGROUND & AIMS: Upper gastrointestinal tract bleeding is a frequent
      cause of hospitalization. The goal of this study was to assess whether the
      cost of treating patients with upper gastrointestinal bleeding varies
      among surgeons, internists, and gastroenterologists. METHODS: A
      retrospective study of 124 patients admitted with acute upper
      gastrointestinal hemorrhage was performed. Patients were stratified into
      three groups based on a validated risk score; length of stay and hospital
      costs were compared among patients primarily cared for by internists,
      surgeons, and gastroenterologists. RESULTS: The median length of stay (2
      days) for patients admitted to the gastroenterology service was
      significantly shorter than for patients admitted under the care of other
      physicians (P < 0.05). The median hospitalization cost ($2856) for
      patients admitted to the gastroenterology service was significantly lower
      than for patients admitted to the other services (P < 0.01). There were no
      significant differences in the time to endoscopy among services.
      CONCLUSIONS: Patients admitted to an urban teaching hospital directly
      under the care of a gastroenterologist had shorter hospital stays that
      were significantly less costly than patients under the primary care of
      internists or surgeons. The difference in length of stay reflects the time
      interval between endoscopy and discharge.
AD  - Massachusetts General Hospital, and Department of Medicine, Harvard
      Medical School, Boston 02114, USA.
FAU - Quirk, D M
AU  - Quirk DM
FAU - Barry, M J
AU  - Barry MJ
FAU - Aserkoff, B
AU  - Aserkoff B
FAU - Podolsky, D K
AU  - Podolsky DK
LA  - eng
GR  - T32DK07191/DK/NIDDK
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
SB  - AIM
SB  - IM
CIN - Gastroenterology. 1997 Nov;113(5):1788-90. PMID: 9352886
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Female
MH  - *Gastroenterology
MH  - Gastrointestinal Hemorrhage/*therapy
MH  - *Health Care Costs
MH  - Humans
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Regression Analysis
MH  - Retrospective Studies
MH  - Sex Factors
MH  - *Specialties, Medical
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
AID - S001650859700509X [pii]
PST - ppublish
SO  - Gastroenterology. 1997 Nov;113(5):1443-8.
PMID- 9312208
OWN - NLM
STAT- MEDLINE
DA  - 19971117
DCOM- 19971117
LR  - 20061115
PUBM- Print
IS  - 0022-2631 (Print)
VI  - 159
IP  - 3
DP  - 1997 Oct 1
TI  - Red blood cells of a transgenic mouse expressing high levels of human
      hemoglobin S exhibit deoxy-stimulated cation flux.
PG  - 187-96
AB  - Deoxy-stimulated cation fluxes have been implicated in the generation of
      the dense and irreversibly sickled red blood cells (RBCs) in patients
      homozygous for hemoglobin S (SS). We now report on the effect of short
      term deoxygenation on K+ and Na+ transport in RBCs from control mice
      (C57Bl/6J) and a transgenic (alphaHbetaS[betaMDD]) mouse line that
      expresses high levels of human alphaH and betaS-chains and has a small
      percent dense cells but does not exhibit anemia. In transgenic mouse RBCs
      (n = 5) under oxygenated conditions, K+ efflux was 0.22 +/- 0.01 mmol/L
      cell x min and Na+ influx was 0.17 +/- 0.02 mmol/L cell x min. Both fluxes
      were stimulated by 10 min deoxygenation in transgenic but not in control
      mice. The deoxy-stimulated K+ efflux from transgenic mouse RBCs was about
      55% inhibited by 5 nm charybdotoxin (CTX), a blocker of the calcium
      activated K+-channel. To compare the fluxes between human and mouse RBCs,
      we measured the area of mouse RBCs and normalized values to area per liter
      of cells. The deoxy-simulated CTX-sensitive K+ efflux was larger than the
      CTX-sensitive K+ efflux observed in RBCs from SS patients. These results
      suggest that in transgenic mice, deoxygenation increases cytosolic Ca2+ to
      levels which open Ca2+-activated K+ channels. The presence of these
      channels was confirmed in both control and transgenic mice by clamping
      intracellular Ca2+ at 10 microM with the ionophore A23187 and measuring
      Ca2+-activated K+ efflux. Both types of mouse had similar maximal rates of
      CTX-sensitive, Ca2+-activated K+ efflux that were similar to those in
      human SS cells. The capacity of the mouse red cell membrane to regulate
      cytosolic Ca2+ levels was examined by measurements of the maximal rate of
      calmodulin activated Ca2+-ATPase activity. This activity was 3-fold
      greater than that observed in human RBCs thus indicating that mouse RBC
      membranes have more capacity to regulate cytosolic Ca2+ levels.In summary,
      transgenic mouse RBCs exhibit larger values of deoxy-stimulated K+ efflux
      and Na+ influx when compared to human SS cells. They have a similar
      Ca2+-activated K+ channel activity to human SS cells while expressing a
      very high Ca2+ pump activity. These properties may contribute to the
      smaller percent of very dense cells and to the lack of adult anemia in
      this animal model.
AD  - Endocrine-Hypertension Division, Brigham and Women's Hospital, Department
      of Medicine, Harvard Medical School, 221 Longwood Avenue, Boston, MA
      02115, USA.
FAU - Romero, J R
AU  - Romero JR
FAU - Fabry, M E
AU  - Fabry ME
FAU - Suzuka, S
AU  - Suzuka S
FAU - Nagel, R L
AU  - Nagel RL
FAU - Canessa, M
AU  - Canessa M
LA  - eng
GR  - HL-35664/HL/NHLBI
GR  - HL-38655/HL/NHLBI
GR  - HL-42120/HL/NHLBI
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - J Membr Biol
JT  - The Journal of membrane biology
JID - 0211301
RN  - 0 (Hemoglobin, Sickle)
RN  - 0 (Ionophores)
RN  - 0 (Potassium Channel Blockers)
RN  - 115422-61-2 (Charybdotoxin)
RN  - 52665-69-7 (Calcimycin)
RN  - 7440-09-7 (Potassium)
RN  - 7440-23-5 (Sodium)
RN  - EC 3.6.1.8 (Calcium-Transporting ATPases)
SB  - IM
MH  - Adult
MH  - Anemia, Sickle Cell/*blood
MH  - Animals
MH  - Calcimycin/pharmacology
MH  - Calcium-Transporting ATPases/blood
MH  - Charybdotoxin/pharmacology
MH  - Erythrocytes/*metabolism
MH  - Hemoglobin, Sickle/*metabolism
MH  - Humans
MH  - Ionophores/pharmacology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Potassium/*blood
MH  - Potassium Channel Blockers
MH  - Sodium/*blood
EDAT- 1997/10/06
MHDA- 1997/10/06 00:01
PST - ppublish
SO  - J Membr Biol. 1997 Oct 1;159(3):187-96.
PMID- 9298159
OWN - NLM
STAT- MEDLINE
DA  - 19971113
DCOM- 19971113
LR  - 20041117
PUBM- Print
IS  - 0001-5660 (Print)
VI  - 46
IP  - 1
DP  - 1997
TI  - Abstraction skillfulness in monozygotic and dizygotic twin pairs.
PG  - 57-67
AB  - The computerized version of the Wisconsin Card Sorting Test (WCST) was
      administered to a sample of 96 subjects (Ss), constituted in equal parts
      by monozygotic twins (MZ), dizygotic twins (DZ), unique children and
      couples of "almost contemporary" brothers. The statistic tests (Analysis
      of principal components, ANOVA) underline, as far as the rapidity to
      define a category is concerned, a statistically significant difference
      between DZ and singletons, independently from the fact that the latter may
      be unique children. A significant difference emerged neither between MZ
      and singletons, nor between MZ and DZ.
AD  - Dipartimento di Psicologia, Universita di Roma La Sapienza.
FAU - Nicole, S
AU  - Nicole S
FAU - Del Miglio, C
AU  - Del Miglio C
LA  - eng
PT  - Journal Article
PT  - Twin Study
PL  - ITALY
TA  - Acta Genet Med Gemellol (Roma)
JT  - Acta geneticae medicae et gemellologiae
JID - 0370314
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Analysis of Variance
MH  - *Cognition
MH  - Female
MH  - Humans
MH  - Intelligence Tests
MH  - Male
MH  - Twins, Dizygotic/*psychology
MH  - Twins, Monozygotic/*psychology
EDAT- 1997/01/01 00:00
MHDA- 1997/09/23 00:01
PST - ppublish
SO  - Acta Genet Med Gemellol (Roma). 1997;46(1):57-67.
PMID- 9338089
OWN - NLM
STAT- MEDLINE
DA  - 19971114
DCOM- 19971114
LR  - 20061115
PUBM- Print
IS  - 1381-3455 (Print)
VI  - 103
IP  - 2
DP  - 1995 May
TI  - Treadmill chamber for studies of respiratory gas exchange in the rat
      during exercise.
PG  - 175-86
AB  - A treadmill for studying gas exchange in small mammals during exercise is
      presented. The system consists of a motor-driven running mat enclosed in a
      gastight chamber that receives a measured flow of air from a compressed
      air cylinder. The gas flow and temperature, pressure and instantaneous gas
      composition of the chamber (oxygen, carbon dioxide and water) are measured
      continuously and the data are computed to include the effects on chamber
      atmosphere of the rat activity, either running or at rest. The system is
      completed with a shock delivery grid that stimulates the rat to run. The
      calculations are based on the changes in the composition of the gas in the
      chamber (constantly stirred by a small electric fan) induced by the rat
      instead of relying on the alterations induced in the outflowing gas. The
      consumption of oxygen, and production of carbon dioxide and water by the
      rat are computed in real time, giving a very fast response to
      physiological change induced by exercise. The chamber is custom-made from
      an aluminium block and a plexiglass lid; all other components are
      available commercially. The system, as described, allows for a detailed
      analysis of respiratory gas (and water) exchange by rats under varying
      exercise conditions, there is practically no time lag between changes in
      respiratory gases and the detection of these changes, and the buffering
      effect of the chamber size is practically eliminated because of the
      calculation approach used.
AD  - Departament de Bioquimica i Fisiologia, Facultat de Biologia, Universitat
      de Barcelona, Spain.
FAU - Ardevol, A
AU  - Ardevol A
FAU - Adan, C
AU  - Adan C
FAU - Fernandez-Lopez, J A
AU  - Fernandez-Lopez JA
FAU - Perez, J
AU  - Perez J
FAU - Corts, J L
AU  - Corts JL
FAU - Binagui, D
AU  - Binagui D
FAU - Remesar, X
AU  - Remesar X
FAU - Alemany, M
AU  - Alemany M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - NETHERLANDS
TA  - Arch Physiol Biochem
JT  - Archives of physiology and biochemistry
JID - 9510153
RN  - 124-38-9 (Carbon Dioxide)
RN  - 7732-18-5 (Water)
RN  - 7782-44-7 (Oxygen)
SB  - IM
MH  - Animals
MH  - Carbon Dioxide/analysis
MH  - Exercise Test/*instrumentation/methods
MH  - Oxygen/analysis
MH  - Oxygen Consumption
MH  - Pressure
MH  - *Pulmonary Gas Exchange
MH  - Rats
MH  - Temperature
MH  - Water/analysis
EDAT- 1995/05/01 00:00
MHDA- 1997/10/24 00:01
PST - ppublish
SO  - Arch Physiol Biochem. 1995 May;103(2):175-86.
PMID- 9334930
OWN - NLM
STAT- MEDLINE
DA  - 19971113
DCOM- 19971113
LR  - 20061115
PUBM- Print
IS  - 0146-6615 (Print)
VI  - 53
IP  - 2
DP  - 1997 Oct
TI  - Puumala virus and two genetic variants of Tula virus are present in
      Austrian rodents.
PG  - 174-81
AB  - Puumala and Tula viruses are hantaviruses found in Europe and are
      associated with the rodents Clethrionomys glareolus and Microtus arvalis,
      respectively. Puumala virus is associated with the human disease
      nephropathia epidemica. In Austria, ten clinically diagnosed cases of
      nephropathia epidemica, presumably caused by Puumala virus infection, have
      been reported but not virologically confirmed [Leschinskaya et al., 1991;
      Aberle et al., 1996]. To identify the hantaviruses that are present in
      Austria, five species of rodents were trapped and screened for virus
      antibodies, antigen, and RNA. Hantaviruses were detected in two species,
      Cl. glareolus and M. arvalis, by reverse transcription-polymerase chain
      reaction (RT-PCR). RT-PCR products from Cl. glareolus tissues yielded a
      unique Puumala virus sequence distinct from Puumala virus sequences
      reported from other parts of Europe. RT-PCR products from M. arvalis
      tissues yielded two genetically distinct Tula virus sequences, one similar
      to sequences reported from Slovakia and the Czech Republic and another
      that appears to be a novel genetic variant of Tula virus. This is the
      first confirmed report of hantaviruses in Austria.
AD  - Division of Viral and Rickettsial Diseases, National Center for Infectious
      Diseases, Centers for Disease Control and Prevention, U.S. Department of
      Health and Human Services, Atlanta, Georgia, USA. MKB6@CDC.GOV
FAU - Bowen, M D
AU  - Bowen MD
FAU - Gelbmann, W
AU  - Gelbmann W
FAU - Ksiazek, T G
AU  - Ksiazek TG
FAU - Nichol, S T
AU  - Nichol ST
FAU - Nowotny, N
AU  - Nowotny N
LA  - eng
SI  - GENBANK/U95302
SI  - GENBANK/U95303
SI  - GENBANK/U95304
SI  - GENBANK/U95305
SI  - GENBANK/U95306
SI  - GENBANK/U95307
SI  - GENBANK/U95308
SI  - GENBANK/U95309
SI  - GENBANK/U95310
SI  - GENBANK/U95311
SI  - GENBANK/U95312
SI  - GENBANK/U95313
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (Antibodies, Viral)
RN  - 0 (Antigens, Viral)
RN  - 0 (RNA, Viral)
SB  - IM
MH  - Animals
MH  - Antibodies, Viral/blood
MH  - Antigens, Viral/analysis
MH  - Austria
MH  - Disease Reservoirs
MH  - Hantavirus/genetics/immunology/*isolation & purification
MH  - Lung/virology
MH  - Molecular Sequence Data
MH  - Muridae/*virology
MH  - *Phylogeny
MH  - RNA, Viral/analysis
MH  - Sequence Analysis, DNA
EDAT- 1997/10/23 22:31
MHDA- 2000/06/20 09:00
AID - 10.1002/(SICI)1096-9071(199710)53:2<174::AID-JMV11>3.0.CO;2-J [pii]
PST - ppublish
SO  - J Med Virol. 1997 Oct;53(2):174-81.
PMID- 9342232
OWN - NLM
STAT- MEDLINE
DA  - 19971124
DCOM- 19971124
LR  - 20061115
PUBM- Print
IS  - 0014-2956 (Print)
VI  - 248
IP  - 3
DP  - 1997 Sep 15
TI  - Molecular cloning of the gene for mouse leukotriene-C4 synthase.
PG  - 807-13
AB  - Leukotriene C4 (LTC4) synthase (LTC4S), an integral membrane protein,
      catalyzes the conjugation of leukotriene A4 with reduced glutathione to
      form LTC4, the biosynthetic parent of the additional cysteinyl leukotriene
      metabolites. An XmnI-digested fragment of a P1 clone from a 129 mouse ES
      library contained the full-length gene of 2.01 kb for mouse LTC4S. The
      mouse LTC4S gene is comprised of 5 exons of 122, 100, 71, 82 and 241
      nucleotides, with intron sizes that range from 76 nucleotides to 937
      nucleotides. The intron/exon boundaries are identical to those of the
      human genes for LTC4S and 5-lipoxygenase-activating protein (FLAP). Primer
      extension demonstrated a single transcription-initiation site 64 bp 5' of
      the ATG translation-start site. Nucleotide sequencing of 1.2 kb of the 5'
      flanking region revealed multiple putative sites for activating protein-2,
      CCAAT/enhancer-binding protein, and polyoma virus enhancer-3. Fluorescent
      in situ hybridization mapped the mouse LTC4S gene to mouse chromosome 11,
      in a region containing the genes for interleukin 13 and
      granulocyte/macrophage-colony-stimulating factor, and orthologous to the
      chromosomal location of 5q35 for the human LTC4S gene. Thus, the mouse
      LTC4S gene is similar in size, intron/exon organization and chromosomal
      localization to the human LTC4S gene. Recent mutagenic analysis of the
      conjugation function of human LTC4S has identified R51 and Y93 as critical
      for acid and base catalysis of LTA4 and reduced glutathione, respectively.
      A comparison across species for proteins that possess LTC4S activity
      reveals conservation of both of these residues, whereas R51 is absent in
      the FLAP molecules. Thus, within the glutathione S-transferase superfamily
      of genes, alignment of specific residues allows the separation of LTC4S
      family members from their most structurally similar counterparts, the FLAP
      molecules.
AD  - Division of Rheumatology, Immunology, and Allergy, Brigham and Women's
      Hospital, Boston, MA, USA. jpenrose@warren.med.harvard.edu
FAU - Penrose, J F
AU  - Penrose JF
FAU - Baldasaro, M H
AU  - Baldasaro MH
FAU - Webster, M
AU  - Webster M
FAU - Xu, K
AU  - Xu K
FAU - Austen, K F
AU  - Austen KF
FAU - Lam, B K
AU  - Lam BK
LA  - eng
GR  - AI-22531/AI/NIAID
GR  - AI-31599/AI/NIAID
GR  - AR-36308/AR/NIAMS
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - GERMANY
TA  - Eur J Biochem
JT  - European journal of biochemistry  / FEBS
JID - 0107600
RN  - EC 2.5.1.18 (Glutathione Transferase)
RN  - EC 4.4.1.20 (leukotriene-C4 synthase)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Base Sequence
MH  - Chromosome Mapping
MH  - Cloning, Molecular
MH  - Exons/genetics
MH  - Glutathione Transferase/*chemistry/*genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Introns/genetics
MH  - Mice
MH  - Microsomes/enzymology
MH  - Models, Molecular
MH  - Molecular Sequence Data
MH  - Polymerase Chain Reaction
MH  - Sequence Analysis, DNA
MH  - Sequence Homology, Amino Acid
MH  - Transcription, Genetic
EDAT- 1997/10/28
MHDA- 1997/10/28 00:01
PST - ppublish
SO  - Eur J Biochem. 1997 Sep 15;248(3):807-13.
PMID- 9357854
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20061115
PUBM- Print
IS  - 0002-9513 (Print)
VI  - 273
IP  - 4 Pt 1
DP  - 1997 Oct
TI  - Differential induction of c-fos, c-jun, and apoptosis in lung epithelial
      cells exposed to ROS or RNS.
PG  - L789-96
AB  - Reactive oxygen (ROS) or nitrogen (RNS) species can affect epithelial
      cells to cause acute damage and an array of pulmonary diseases. The goal
      of this study was to determine patterns of early response gene expression
      and functional end points of exposure to nitric oxide (NO.), H2O2, or
      peroxynitrite (ONOO-) in a line of rat lung epithelial (RLE) cells. Our
      focus was on c-fos and c-jun protooncogenes, as these genes play an
      important role in proliferation or apoptosis, possible end points of
      exposure to reactive metabolites in lung. Our data demonstrate that NO.
      generated by spermine 1,3-propanediamine
      N-14-[1-(3-aminopropyl)-2-hydroxy-2-nitrosohydrazino]-butyl] or
      S-nitroso-N-acetylpenicillamine as well as H2O2 cause increased c-fos and
      c-jun mRNA levels, nuclear proteins, and complexes binding the activator
      protein-1 recognition sequence in RLE cells. These agents also lead to
      apoptosis and increased membrane permeability. In contrast, exogenously
      administered ONOO- or 3-morpholinosydnonimine do not induce protooncogenes
      or apoptosis in RLE cells despite nitration oftyrosines. We conclude that
      ROS and RNS can elicit distinct molecular and phenotypic responses in a
      target cell of pulmonary disease.
AD  - Department of Pathology, University of Vermont, Burlington 05405, USA.
FAU - Janssen, Y M
AU  - Janssen YM
FAU - Matalon, S
AU  - Matalon S
FAU - Mossman, B T
AU  - Mossman BT
LA  - eng
GR  - ES-06499/ES/NIEHS
GR  - ES-07038/ES/NIEHS
GR  - HL-39469/HL/NHLBI
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Nitrates)
RN  - 0 (Proto-Oncogene Proteins c-fos)
RN  - 0 (Proto-Oncogene Proteins c-jun)
RN  - 0 (RNA, Messenger)
RN  - 0 (Reactive Oxygen Species)
RN  - 10102-43-9 (Nitric Oxide)
RN  - 25717-80-0 (Molsidomine)
RN  - 26404-66-0 (peroxynitric acid)
RN  - 33876-97-0 (3-morpholino-sydnonimine)
RN  - 52-67-5 (Penicillamine)
RN  - 71-44-3 (Spermine)
RN  - 7722-84-1 (Hydrogen Peroxide)
RN  - 79032-48-7 (S-Nitroso-N-Acetylpenicillamine)
SB  - IM
MH  - Animals
MH  - Apoptosis/*drug effects/physiology
MH  - Cell Line
MH  - Epithelial Cells/drug effects/physiology
MH  - Genes, fos/drug effects
MH  - Genes, jun/drug effects
MH  - Hydrogen Peroxide/*pharmacology
MH  - Lung/*drug effects
MH  - Molsidomine/analogs & derivatives/pharmacology
MH  - Nitrates/*pharmacology
MH  - Nitric Oxide/*pharmacology
MH  - Penicillamine/analogs & derivatives/pharmacology
MH  - Proto-Oncogene Proteins c-fos/*biosynthesis
MH  - Proto-Oncogene Proteins c-jun/*biosynthesis
MH  - RNA, Messenger/biosynthesis
MH  - Rats
MH  - Reactive Oxygen Species
MH  - S-Nitroso-N-Acetylpenicillamine
MH  - Spermine/pharmacology
MH  - Transcription, Genetic/drug effects
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
PST - ppublish
SO  - Am J Physiol. 1997 Oct;273(4 Pt 1):L789-96.
PMID- 9315494
OWN - NLM
STAT- MEDLINE
DA  - 19971031
DCOM- 19971031
LR  - 20060703
PUBM- Print
IS  - 0955-9930 (Print)
VI  - 9
IP  - 3
DP  - 1997 Sep
TI  - Trazodone, a double blind trial for treatment of erectile dysfunction.
PG  - 163-5
AB  - OBJECTIVE: to assess the effectiveness of oral trazodone 150 mg/d for
      treatment of erectile dysfunction. PATIENTS AND METHODS: A double-blind,
      placebo controlled, multicentre trial. A run-in period of two weeks was
      followed by four weeks of medication. Evaluation was done by patients
      diary, a questionnaire and Rigiscan nightly penile tumescence and rigidity
      (NPTR) measurements in the second and sixth week of the trial. RESULTS: 69
      patients were randomised, two patients never returned for follow-up, nine
      patients stopped the medication due to side-effects, so 58 patients are
      evaluable for effect assessment. Half of the patients suffered psychogenic
      impotence. There was no significant difference in the subjective results
      of trazodone compared to placebo. Side effects occurred more often with
      the use of trazodone, but this was not statistically significant.
      CONCLUSION: In a group of patients, that was not selected on the basis of
      the etiology of the erectile dysfunction, nor selected on the duration of
      the complaint, the efficacy of trazodone 150 mg/d, could not be shown.
AD  - Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek
      Hospital, Amsterdam, The Netherlands.
FAU - Meinhardt, W
AU  - Meinhardt W
FAU - Schmitz, P I
AU  - Schmitz PI
FAU - Kropman, R F
AU  - Kropman RF
FAU - de la Fuente, R B
AU  - de la Fuente RB
FAU - Lycklama a Nijeholt, A A
AU  - Lycklama a Nijeholt AA
FAU - Zwartendijk, J
AU  - Zwartendijk J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - ENGLAND
TA  - Int J Impot Res
JT  - International journal of impotence research
JID - 9007383
RN  - 0 (Adrenergic alpha-Antagonists)
RN  - 0 (Placebos)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 19794-93-5 (Trazodone)
SB  - IM
MH  - Adrenergic alpha-Antagonists/*therapeutic use
MH  - Double-Blind Method
MH  - Humans
MH  - Impotence/*drug therapy/psychology
MH  - Male
MH  - Placebos
MH  - Serotonin Uptake Inhibitors/*therapeutic use
MH  - Trazodone/administration & dosage/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 1997/10/07
MHDA- 1997/10/07 00:01
PST - ppublish
SO  - Int J Impot Res. 1997 Sep;9(3):163-5.
PMID- 9322229
OWN - NLM
STAT- MEDLINE
DA  - 19971113
DCOM- 19971113
LR  - 20041117
PUBM- Print
IS  - 1359-4184 (Print)
VI  - 2
IP  - 5
DP  - 1997 Sep
TI  - Imprinted X-linked genes, 'feminine intuition' and the public
      (mis)understanding of science.
PG  - 385-6
AB  - The report of an imprinted locus on the X chromosome influencing social
      behaviour was taken up with fervour by the media and reported in a way
      which neglected the reality of multifactorial complexity and the interplay
      between genetic and environmental contributors to gender differences. We
      summarize the background scientific details of the study and discuss the
      media reporting of those findings.
AD  - Department of Psychological Medicine, University of Wales College of
      Medicine, Cardiff, UK. ScourfieldJ@cardiff.ac.uk
FAU - Scourfield, J
AU  - Scourfield J
FAU - McGuffin, P
AU  - McGuffin P
LA  - eng
PT  - Journal Article
PL  - ENGLAND
TA  - Mol Psychiatry
JT  - Molecular psychiatry
JID - 9607835
SB  - IM
MH  - Humans
MH  - Intuition/*physiology
MH  - Linkage (Genetics)/*genetics
MH  - Science
MH  - *Social Behavior
MH  - X Chromosome/*genetics
EDAT- 1997/10/10
MHDA- 1997/10/10 00:01
PST - ppublish
SO  - Mol Psychiatry. 1997 Sep;2(5):385-6.
PMID- 9237795
OWN - NLM
STAT- MEDLINE
DA  - 19971124
DCOM- 19971124
LR  - 20061115
PUBM- Print
IS  - 0896-8411 (Print)
VI  - 10
IP  - 4
DP  - 1997 Aug
TI  - Treatment of NOD diabetes with a novel peptide of the hsp60 molecule
      induces Th2-type antibodies.
PG  - 323-9
AB  - A peptide from the sequence of hsp60 molecule, designated p277, has been
      shown to be functionally involved in modulating the development of
      auto-immune diabetes in the NOD mouse: administration of p277 to NOD mice
      can arrest the diabetogenic autoimmune process, even when far advanced. Is
      p277 the only hsp60 peptide able to modulate the disease? We mapped T cell
      responses to peptides spanning the mouse hsp60 molecule and identified an
      immunogenic peptide, designated p12, that is also functional in arresting
      NOD diabetes. Although no spontaneous T cell reactivity to p12 could be
      detected in NOD mice, subcutaneous administration of 100 microg of p12 in
      mineral oil to 10-week-old female NOD mice, similar to treatment with
      p277, significantly prevented progression of the disease. Administration
      of other immunogenic peptides was not effective. A peptide from the
      glutamic acid decarboxylase (GAD65) sequence, GADp35, and a peptide from
      the myco-bacterial hsp60 molecule did not influence the development of
      diabetes. The effectiveness of hsp60 peptides p12 and p277 was associated
      with the induction of antibodies to the peptides of the IgG1 and IgG2b
      isotypes, antibodies which appear to be regulated by anti-inflammatory
      cytokines. There was a negative correlation between the amounts of
      antibodies induced by the hsp60 peptides and the level of blood glucose.
      Thus, more than one peptide of the hsp60 molecule can be used to inhibit
      the development of NOD diabetes, and the effect of peptide therapy appears
      to be associated with the induction of specific antibody isotypes.
AD  - Department of Immunology, The Weizmann Institute of Science, Rehovot,
      76100, Israel.
FAU - Bockova, J
AU  - Bockova J
FAU - Elias, D
AU  - Elias D
FAU - Cohen, I R
AU  - Cohen IR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - ENGLAND
TA  - J Autoimmun
JT  - Journal of autoimmunity
JID - 8812164
RN  - 0 (Chaperonin 60)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Peptide Fragments)
SB  - IM
SB  - X
MH  - Amino Acid Sequence
MH  - Animals
MH  - Antibody Specificity
MH  - Autoimmunity
MH  - Chaperonin 60/genetics/*immunology/*therapeutic use
MH  - Diabetes Mellitus, Type 1/*immunology/prevention & control/*therapy
MH  - Female
MH  - Immunoglobulin G/biosynthesis
MH  - Lymphocyte Activation
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Molecular Sequence Data
MH  - Peptide Fragments/genetics/*immunology/*therapeutic use
MH  - Peptide Mapping
MH  - T-Lymphocytes/immunology
MH  - Th2 Cells/*immunology
EDAT- 1997/08/01
MHDA- 1997/08/01 00:01
AID - S0896-8411(97)90150-5 [pii]
AID - 10.1006/jaut.1997.0150 [doi]
PST - ppublish
SO  - J Autoimmun. 1997 Aug;10(4):323-9.
PMID- 9354327
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20061115
PUBM- Print
IS  - 0896-6273 (Print)
VI  - 19
IP  - 4
DP  - 1997 Oct
TI  - Activity regulates the synaptic localization of the NMDA receptor in
      hippocampal neurons.
PG  - 801-12
AB  - We describe here a novel effect of activity on the subcellular
      distribution of NMDA receptors in hippocampal neurons in culture. In
      spontaneously active neurons, NMDA receptors were clustered at a few
      synaptic and nonsynaptic sites. Chronic blockade of NMDA receptor activity
      induced a 380% increase in the number of NMDA receptor clusters and a
      shift to a more synaptic distribution. This effect was reversible. The
      distributions of the presynaptic marker synaptophysin, the AMPA-type
      glutamate receptor subunit GluR1, and the putative NMDA receptor
      clustering protein PSD-95 were not affected by blockade. Regulation of the
      synaptic localization of NMDA receptors by activity may define a novel
      mechanism by which input controls a neuron's ability to modify its
      synapses.
AD  - Department of Cell and Structural Biology, University of Illinois, Urbana
      61801, USA.
FAU - Rao, A
AU  - Rao A
FAU - Craig, A M
AU  - Craig AM
LA  - eng
GR  - NS33184/NS/NINDS
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Neuron
JT  - Neuron
JID - 8809320
RN  - 0 (Dlgh4 protein, rat)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Receptors, AMPA)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - 0 (Synaptophysin)
RN  - 0 (glutamate receptor ionotropic, AMPA 1)
RN  - 0 (postsynaptic density proteins)
RN  - 4368-28-9 (Tetrodotoxin)
RN  - 76726-92-6 (2-Amino-5-phosphonovalerate)
SB  - IM
MH  - 2-Amino-5-phosphonovalerate/pharmacology
MH  - Animals
MH  - Cells, Cultured
MH  - Embryo
MH  - Hippocampus/cytology/*physiology
MH  - Intracellular Signaling Peptides and Proteins
MH  - Membrane Proteins
MH  - Nerve Tissue Proteins/biosynthesis
MH  - Neurons/cytology/*physiology
MH  - Rats
MH  - Receptors, AMPA/biosynthesis
MH  - Receptors, N-Methyl-D-Aspartate/analysis/antagonists &
      inhibitors/*biosynthesis
MH  - Synapses/drug effects/*physiology/ultrastructure
MH  - Synaptophysin/analysis/biosynthesis
MH  - Tetrodotoxin/pharmacology
MH  - Up-Regulation/drug effects
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
AID - S0896-6273(00)80962-9 [pii]
PST - ppublish
SO  - Neuron. 1997 Oct;19(4):801-12.
PMID- 9297573
OWN - NLM
STAT- MEDLINE
DA  - 19971031
DCOM- 19971031
LR  - 20061115
PUBM- Print
IS  - 1023-3830 (Print)
VI  - 46
IP  - 8
DP  - 1997 Aug
TI  - Atypical association of H1 and H2 histamine receptors with signal
      transduction pathways during multistage mouse skin carcinogenesis.
PG  - 292-8
AB  - OBJECTIVE: In the present work we studied the association of histamine
      receptors with second messengers during multistage carcinogenesis in
      Sencar mice skin. METHODS: 96 Sencar female mouse, divided into six groups
      were used. Tumors appeared only in the 7,
      12-dimethylbenz[a]anthracene-initiated and
      12-O-tetradecanoylphorbol-13-acetate-promoted group. Control groups
      received only TPA, or acetone or no treatment at all. Periodically during
      the promotion period, cAMP and inositol phosphate production were measured
      after stimulation with H1 or H2 agonists in samples from all groups.
      RESULTS: In non-treated skin, H1 receptors were coupled to
      phosphatidylinositol hydrolysis and H2 receptors mediated cAMP production.
      Conversely, in tumors H2 receptors were associated with
      phosphatidylinositol hydrolysis and H1 mediated a rise in cAMP levels. The
      skin among tumors and the skin from all control groups maintained the same
      coupling as non-treated skin. An increase in mast cell number, with a
      homogeneous subepithelial distribution and marked phenotypic changes, was
      also observed in promoted skin. CONCLUSIONS: These findings indicate an
      atypical association of histamine receptors with second messengers that
      could be a critical feature for the postulated action of histamine in
      tumor growth.
AD  - Laboratorio de Radiosotopos, Facultad de Farmacia y Bioquimica,
      Universidad de Buenos Aires, Argentina.
FAU - Fitzsimons, C
AU  - Fitzsimons C
FAU - Molinari, B
AU  - Molinari B
FAU - Duran, H
AU  - Duran H
FAU - Palmieri, M
AU  - Palmieri M
FAU - Davio, C
AU  - Davio C
FAU - Cricco, G
AU  - Cricco G
FAU - Bergoc, R
AU  - Bergoc R
FAU - Rivera, E
AU  - Rivera E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - SWITZERLAND
TA  - Inflamm Res
JT  - Inflammation research : official journal of the European Histamine
      Research Society ... [et al.]
JID - 9508160
RN  - 0 (Histamine H1 Antagonists)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Phosphatidylinositols)
RN  - 0 (Receptors, Histamine H1)
RN  - 0 (Receptors, Histamine H2)
RN  - 16561-29-8 (Tetradecanoylphorbol Acetate)
RN  - 51481-61-9 (Cimetidine)
RN  - 57-97-6 (9,10-Dimethyl-1,2-benzanthracene)
RN  - 60-92-4 (Cyclic AMP)
RN  - 69014-14-8 (tiotidine)
RN  - 91-84-9 (Pyrilamine)
SB  - IM
MH  - 9,10-Dimethyl-1,2-benzanthracene
MH  - Animals
MH  - Cell Count
MH  - Cimetidine/analogs & derivatives/metabolism
MH  - Cyclic AMP/metabolism
MH  - Female
MH  - Histamine H1 Antagonists/metabolism
MH  - Histamine H2 Antagonists/metabolism
MH  - Hydrolysis
MH  - Mast Cells/pathology
MH  - Mice
MH  - Phosphatidylinositols/metabolism
MH  - Pyrilamine/metabolism
MH  - Receptors, Histamine H1/*physiology
MH  - Receptors, Histamine H2/*physiology
MH  - Second Messenger Systems
MH  - Signal Transduction/*physiology
MH  - Skin Neoplasms/chemically induced/pathology/*physiopathology
MH  - Tetradecanoylphorbol Acetate
EDAT- 1997/08/01 00:00
MHDA- 1997/09/23 00:01
PST - ppublish
SO  - Inflamm Res. 1997 Aug;46(8):292-8.
PMID- 9335237
OWN - NLM
STAT- MEDLINE
DA  - 19971113
DCOM- 19971113
LR  - 20041117
PUBM- Print
IS  - 0193-1091 (Print)
VI  - 19
IP  - 5
DP  - 1997 Oct
TI  - Atypical lymphoid infiltrates arising in cutaneous lesions of connective
      tissue disease.
PG  - 446-55
AB  - Atypical lymphoid infiltrates occurring in the setting of
      connective-tissue disease (CTD) comprise malignant neoplasms of B-cell or
      T-cell phenotypes and various reactive lymphoid hyperplasias, such as
      myoepithelial sialadenitis, lymphocytic thyroiditis, and lymphocytic
      interstitial pneumonitis. We describe 17 patients with atypical lymphoid
      infiltrates arising in cutaneous lesions of CTD, the spectrum of which
      included lupus erythematosus, dermatomyositis, relapsing polychondritis,
      and lichen sclerosus et atrophicus. There were two principal categories,
      pseudolymphoma and malignant lymphoma, the former representing 15 of the
      17 cases. The clinical and histologic features and possible pathogenetic
      mechanisms are discussed.
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard
      Medical School Pathology Services, Inc., Cambridge, Massachusetts, USA.
FAU - Magro, C M
AU  - Magro CM
FAU - Crowson, A N
AU  - Crowson AN
FAU - Harrist, T J
AU  - Harrist TJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - UNITED STATES
TA  - Am J Dermatopathol
JT  - The American Journal of dermatopathology
JID - 7911005
SB  - IM
MH  - Adult
MH  - Aged
MH  - B-Lymphocytes/pathology
MH  - Connective Tissue Diseases/*pathology
MH  - Dermatomyositis/pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lichen Sclerosus et Atrophicus/pathology
MH  - Lung Diseases, Interstitial/pathology
MH  - Lupus Erythematosus, Cutaneous/pathology
MH  - Lupus Erythematosus, Discoid/pathology
MH  - Lupus Erythematosus, Systemic/pathology
MH  - Lymphocytes/*pathology
MH  - Lymphoma/pathology
MH  - Lymphoma, T-Cell, Cutaneous/pathology
MH  - Male
MH  - Middle Aged
MH  - Phenotype
MH  - Polychondritis, Relapsing/pathology
MH  - Pseudolymphoma/pathology
MH  - Sialadenitis/pathology
MH  - Skin Diseases/*pathology
MH  - Skin Neoplasms/pathology
MH  - T-Lymphocytes/pathology
MH  - Thyroiditis, Autoimmune/pathology
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
PST - ppublish
SO  - Am J Dermatopathol. 1997 Oct;19(5):446-55.
PMID- 9321417
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20061115
PUBM- Print
IS  - 0022-2844 (Print)
VI  - 45
IP  - 4
DP  - 1997 Oct
TI  - Synonymous substitution rates in Drosophila: mitochondrial versus nuclear
      genes.
PG  - 378-91
AB  - Synonymous substitution rates in mitochondrial and nuclear genes of
      Drosophila were compared. To make accurate comparisons, we considered the
      following: (1) relative synonymous rates, which do not require divergence
      time estimates, should be used; (2) methods estimating divergence should
      take into account base composition; (3) only very closely related species
      should be used to avoid effects of saturation; (4) the heterogeneity of
      rates should be examined. We modified the methods estimating synonymous
      substitution numbers to account for base composition bias. By using these
      methods, we found that mitochondrial genes have 1.7-3.4 times higher
      synonymous substitution rates than the fastest nuclear genes or 4.5-9.0
      times higher rates than the average nuclear genes. The average rate of
      synonymous transversions was 2.7 (estimated from the melanogaster species
      subgroup) or 2.9 (estimated from the obscura group) times higher in
      mitochondrial genes than in nuclear genes. Synonymous transversions in
      mitochondrial genes occurred at an approximately equivalent rate to those
      in the fastest nuclear genes. This last result is not consistent with the
      hypothesis that the difference in turnover rates between mitochondrial and
      nuclear genomes is the major factor determining higher synonymous
      substitution rates in mtDNA. We conclude that the difference in synonymous
      substitution rates is due to a combination of two factors: a higher
      transitional mutation rate in mtDNA and constraints on nuclear genes due
      to selection for codon usage.
AD  - Department of Ecology and Evolutionary Biology, Yale University, New
      Haven, CT 06520-8106, USA.
FAU - Moriyama, E N
AU  - Moriyama EN
FAU - Powell, J R
AU  - Powell JR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - UNITED STATES
TA  - J Mol Evol
JT  - Journal of molecular evolution
JID - 0360051
RN  - 0 (DNA, Mitochondrial)
SB  - IM
MH  - Animals
MH  - Cell Nucleus/genetics
MH  - DNA, Mitochondrial/genetics
MH  - Drosophila/*genetics
MH  - Drosophila melanogaster/genetics
MH  - Evolution, Molecular
MH  - *Genes, Insect
MH  - Models, Genetic
MH  - Mutation
MH  - Time Factors
EDAT- 1997/10/08
MHDA- 1997/10/08 00:01
PST - ppublish
SO  - J Mol Evol. 1997 Oct;45(4):378-91.
PMID- 9378240
OWN - NLM
STAT- MEDLINE
DA  - 19971110
DCOM- 19971110
LR  - 20061115
PUBM- Print
IS  - 0306-3623 (Print)
VI  - 29
IP  - 3
DP  - 1997 Sep
TI  - Vasodilation profile of CD-832, a novel dihydropyridine derivative in
      rabbit aorta.
PG  - 361-6
AB  - 1. CD-832, nifedipine and nitrendipine, but not nitroglycerin and
      nicorandil, inhibited the KCl-induced contraction of rabbit aortas. 2.
      CD-832, nitroglycerin and nicorandil, but not nifedipine and nitrendipine,
      inhibited the norepinephrine-induced contraction of aortas. The inhibitory
      effects of these agents were either potentiated or inhibited by zaprinast
      or methylene blue, respectively. 3. On the KCl-induced contraction, the
      duration of CD-832-induced vasodilation was longer than that of
      nifedipine. Concerning the norepinephrine-induced contraction, the
      duration of CD-832-induced vasodilation was longer than that of
      nicorandil. 4. These results suggest that the mechanism of CD-832-induced
      vasodilation concerns both Ca(2+)-antagonistic action and a nitratelike
      action. Furthermore, the vasodilation is long lasting.
AD  - Pharmacology Laboratory, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
FAU - Noguchi, K
AU  - Noguchi K
FAU - Takahashi, K
AU  - Takahashi K
FAU - Araki, H
AU  - Araki H
FAU - Higuchi, S
AU  - Higuchi S
LA  - eng
PT  - In Vitro
PT  - Journal Article
PL  - ENGLAND
TA  - Gen Pharmacol
JT  - General pharmacology
JID - 7602417
RN  - 0 (Adrenergic alpha-Agonists)
RN  - 0 (CD 832)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Vasodilator Agents)
RN  - 21829-25-4 (Nifedipine)
RN  - 39562-70-4 (Nitrendipine)
RN  - 51-41-2 (Norepinephrine)
RN  - 55-63-0 (Nitroglycerin)
RN  - 65141-46-0 (Nicorandil)
RN  - 7447-40-7 (Potassium Chloride)
RN  - 98-92-0 (Niacinamide)
SB  - IM
MH  - Adrenergic alpha-Agonists/pharmacology
MH  - Animals
MH  - Aorta, Thoracic/*drug effects
MH  - Calcium Channel Blockers/*pharmacology
MH  - Male
MH  - Muscle Contraction/drug effects
MH  - Muscle Relaxation/drug effects
MH  - Niacinamide/*analogs & derivatives/pharmacology
MH  - Nicorandil
MH  - Nifedipine/*analogs & derivatives/pharmacology
MH  - Nitrendipine/pharmacology
MH  - Nitroglycerin/pharmacology
MH  - Norepinephrine/antagonists & inhibitors/pharmacology
MH  - Potassium Chloride/antagonists & inhibitors/pharmacology
MH  - Rabbits
MH  - Vasodilation/*drug effects
MH  - Vasodilator Agents/pharmacology
EDAT- 1997/09/01
MHDA- 1997/09/01 00:01
AID - S0306362396008130 [pii]
PST - ppublish
SO  - Gen Pharmacol. 1997 Sep;29(3):361-6.
PMID- 9356032
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20061115
PUBM- Print
IS  - 0012-1797 (Print)
VI  - 46
IP  - 11
DP  - 1997 Nov
TI  - Evidence of an increased number of type IIb muscle fibers in
      insulin-resistant first-degree relatives of patients with NIDDM.
PG  - 1822-8
AB  - Insulin resistance is a common feature in first-degree relatives of NIDDM
      patients. To explore the mechanism(s) behind this condition in more
      detail, a percutaneous muscle biopsy (vastus lateralis) was performed in
      25 first-degree relatives of NIDDM patients and 21 control subjects to
      examine muscle fiber composition and capillary density. Insulin-stimulated
      glucose disposal (Rd) was determined employing a hyperinsulinemic-(insulin
      infusion rate 0.6 mU x kg[-1] x min[-1]) euglycemic clamp. Rd (5.76 +/-
      0.35 vs. 8.06 +/- 0.36 mg x kg lean body weight [LBW]-1 x min[-], P <
      0.001) and estimated VO2max (49.3 +/- 2.8 vs. 57.2 +/- 3.5 mg x kg LBW[-1]
      x min[-1], 0.05 < P < 0.10) were decreased in the relatives. The number of
      type IIb fibers (29.5 +/- 2.5 vs. 21.0 +/- 2.8%, P < 0.05) was increased
      in the relatives, whereas no significant differences were found in other
      fiber types or capillary density between the groups. Correlations were
      observed between number of type I fibers (positive), number of type IIb
      fibers (negative), and capillary density (positive) versus Rd as well as
      estimated VO2max (P < 0.05). In a multiple linear regression analysis with
      Rd as a dependent variable, estimated VO2max, family history of NIDDM, and
      number of type IIb fibers (P < 0.001, r2 = 0.64) significantly determined
      the level of Rd, whereas capillary density did not. In conclusion,
      insulin-resistant first-degree relatives of NIDDM patients are
      characterized by an increased number of type IIb muscle fibers. Whether
      this finding reflects a reduced physical activity level and fitness in the
      relatives or is of primary genetic origin remains to be determined.
AD  - Department of Medicine (Endocrinology and Diabetes), Institute for
      Experimental Clinical Research, University of Aarhus, Denmark.
FAU - Nyholm, B
AU  - Nyholm B
FAU - Qu, Z
AU  - Qu Z
FAU - Kaal, A
AU  - Kaal A
FAU - Pedersen, S B
AU  - Pedersen SB
FAU - Gravholt, C H
AU  - Gravholt CH
FAU - Andersen, J L
AU  - Andersen JL
FAU - Saltin, B
AU  - Saltin B
FAU - Schmitz, O
AU  - Schmitz O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
SB  - S
MH  - Adult
MH  - Capillaries/anatomy & histology
MH  - Diabetes Mellitus, Type 2/*genetics
MH  - Female
MH  - Humans
MH  - Insulin Resistance/genetics/*physiology
MH  - Male
MH  - Middle Aged
MH  - Muscle Fibers, Fast-Twitch/*cytology
MH  - Muscle Fibers, Slow-Twitch/*cytology
MH  - Muscle, Skeletal/blood supply/cytology
MH  - Nuclear Family
MH  - Reference Values
MH  - Regression Analysis
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
PST - ppublish
SO  - Diabetes. 1997 Nov;46(11):1822-8.
PMID- 9379020
OWN - NLM
STAT- MEDLINE
DA  - 19971112
DCOM- 19971112
LR  - 20061115
PUBM- Print
IS  - 0022-1767 (Print)
VI  - 159
IP  - 9
DP  - 1997 Nov 1
TI  - Transgenic expression of lymphotoxin restores lymph nodes to
      lymphotoxin-alpha-deficient mice.
PG  - 4252-60
AB  - Lymphotoxin-alpha (LT alpha) has recently been demonstrated to be
      important in the development of lymph nodes (LN), Peyer's patches, and
      splenic organization, including the development of germinal centers. To
      elucidate the role of LT alpha in lymphoid organogenesis and the
      plasticity of the process, we examined LT alpha-/- mice in which an LT
      alpha transgene under the control of the rat insulin promoter (RIPLT) is
      expressed in the pancreas, kidney, and skin. The LT alpha transgene
      restored LN in LT alpha-/- mice. The reconstituted LN of RIPLT.LT alpha-/-
      mice had germinal center-like peanut agglutinin-positive regions, but
      lacked follicular dendritic cells. Although the LT alpha transgene did not
      restore Peyer's patches or splenic architecture, it restored the ability
      of the spleen to form germinal centers and follicular dendritic cell
      networks. Lymphocytes isolated from the reconstituted LN showed normal
      proliferative responses to T and B cell mitogens and were defective in
      their proliferative response to T-dependent Ag, and a decreased number of
      interdigitating dendritic cells was apparent in the RIPLT.LT alpha-/- mice
      LN. Expression of the RIPLT transgene in mice deficient in LT beta did not
      reconstitute LN, suggesting an important role for LT beta in the
      mechanisms that reconstitute LN in RIPLT.LT alpha-/- mice. These data are
      the first to demonstrate reconstitution of LN in LT alpha-/- mice and show
      that the process of LN restoration is amenable to manipulation with
      ectopic lymphotoxin.
AD  - Department of Epidemiology and Public Health, Yale University School of
      Medicine, New Haven, CT 06520, USA.
FAU - Sacca, R
AU  - Sacca R
FAU - Turley, S
AU  - Turley S
FAU - Soong, L
AU  - Soong L
FAU - Mellman, I
AU  - Mellman I
FAU - Ruddle, N H
AU  - Ruddle NH
LA  - eng
GR  - GM33904/GM/NIGMS
GR  - R01AI34404/AI/NIAID
GR  - R01CA16885/CA/NCI
GR  - etc.
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (Lymphotoxin-alpha)
SB  - AIM
SB  - IM
MH  - Animals
MH  - *Gene Expression Regulation
MH  - Lymph Nodes/*growth & development/immunology
MH  - Lymphotoxin-alpha/*genetics/immunology
MH  - Mice
MH  - *Mice, Transgenic
MH  - Peyer's Patches/growth & development/immunology
MH  - Rats
EDAT- 1997/10/31
MHDA- 1997/10/31 00:01
PST - ppublish
SO  - J Immunol. 1997 Nov 1;159(9):4252-60.
PMID- 9378367
OWN - NLM
STAT- MEDLINE
DA  - 19971112
DCOM- 19971112
LR  - 20061115
PUBM- Print
IS  - 0891-5849 (Print)
VI  - 23
IP  - 6
DP  - 1997
TI  - Tempol inhibits neutrophil and hydrogen peroxide-mediated DNA damage.
PG  - 879-84
AB  - Inflammatory conditions characterized by neutrophil activation are
      associated with a variety of chronic diseases. Reactive oxygen species are
      produced by activated neutrophils and produce DNA damage which may lead to
      tissue damage. Previous studies have shown that activated murine
      neutrophils induce DNA strand breaks in a target plasmacytoma cell, RIMPC
      2394. We studied the effect of a water soluble nitroxide anti-oxidant,
      Tempol, on murine neutrophil induction of DNA strand breaks in this
      system. Murine neutrophils were isolated from the peritoneal cavity of
      BALB/cAn mice after an i.p. injection of pristane oil. Neutrophils were
      activated by the phorbol ester PMA and co-incubated with RIMPC 2394 cells.
      Control alkaline elution studies revealed progressive DNA strand breaks in
      RIMPC cells with time. The addition of Tempol to the incubation mixture
      prevented DNA damage in a dose dependent fashion. Five mM Tempol provided
      complete protection. Tempol protection against DNA strand breaks was
      similar for both stimulated neutrophils and exogenously added hydrogen
      peroxide. Measurement of hydrogen peroxide produced by stimulated
      neutrophils demonstrated that Tempol did not decrease hydrogen peroxide
      concentration. Oxidation of reduced metals, thereby interfering with the
      production of hydroxyl radical, is the most likely mechanism of nitroxide
      protection, although superoxide dismutase (SOD) like activity and
      scavenging of carbon-based free radicals may also account for a portion of
      the observed protection. The anti-oxidant activity of Tempol inhibited DNA
      damage by activated neutrophils. The nitroxides as a class of compounds
      may have a role in the investigation and modification of inflammatory
      conditions.
AD  - Radiation Biology Branch, National Cancer Institute, Bethesda, MD 20892,
      USA.
FAU - Hahn, S M
AU  - Hahn SM
FAU - Mitchell, J B
AU  - Mitchell JB
FAU - Shacter, E
AU  - Shacter E
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - Free Radic Biol Med
JT  - Free radical biology & medicine
JID - 8709159
RN  - 0 (Antioxidants)
RN  - 0 (Cyclic N-Oxides)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Spin Labels)
RN  - 2226-96-2 (tempol)
RN  - 7722-84-1 (Hydrogen Peroxide)
SB  - IM
MH  - Animals
MH  - Antioxidants/*pharmacology
MH  - Cells, Cultured
MH  - Cyclic N-Oxides/*pharmacology
MH  - DNA Damage/*drug effects
MH  - Hydrogen Peroxide/*toxicity
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Neutrophil Activation/drug effects
MH  - Neutrophils/*drug effects/metabolism
MH  - Peritoneal Cavity/cytology
MH  - Plasmacytoma
MH  - Reactive Oxygen Species/metabolism
MH  - Respiratory Burst/drug effects
MH  - Spin Labels
MH  - Tumor Cells, Cultured
EDAT- 1997/01/01 00:00
MHDA- 1997/09/23 00:01
AID - S0891-5849(97)00079-8 [pii]
PST - ppublish
SO  - Free Radic Biol Med. 1997;23(6):879-84.
PMID- 9326899
OWN - NLM
STAT- MEDLINE
DA  - 19971031
DCOM- 19971031
LR  - 20061115
PUBM- Print
IS  - 0022-0345 (Print)
VI  - 76
IP  - 10
DP  - 1997 Oct
TI  - Association between marginal bone loss around osseointegrated mandibular
      implants and smoking habits: a 10-year follow-up study.
PG  - 1667-74
AB  - While many factors are conceivable, occlusal loading and plaque-induced
      inflammation are frequently stated as the most important ones negatively
      affecting the prognosis of oral implants. Currently, little is known about
      the relative importance of such factors. The aim of this study was to
      analyze the influence of smoking and other possibly relevant factors on
      bone loss around mandibular implants. The participants were 45 edentulous
      patients, 21 smokers and 24 non-smokers, who were followed for 10-year
      period after treatment with a fixed implant-supported prosthesis in the
      mandible. The peri-implant bone level was measured on intraoral
      radiographs, information about smoking habits was based on a careful
      interview, and oral hygiene was evaluated from clinical registration of
      plaque accumulation. Besides standard statistical methods, multiple linear
      regression models were constructed for estimation of the relative
      influence of some factors on peri-implant bone loss. The long-term results
      of the implant treatment were good, and only three implants (1%) were
      lost. The mean marginal bone loss around the mandibular implants was very
      small, about 1 mm for the entire 10-year period. It was greater in smokers
      than in non-smokers and correlated to the amount of cigarette consumption.
      Smokers with poor oral hygiene showed greater marginal bone loss around
      the mandibular implants than those with good oral hygiene. Oral hygiene
      did not significantly affect bone loss in non-smokers. Multivariate
      analyses showed that smoking was the most important factor among those
      analyzed for association with peri-implant bone loss. The separate models
      for smokers and non-smokers revealed that oral hygiene had a greater
      impact on peri-implant bone loss among smokers than among non-smokers.
      This study showed that smoking was the most important factor affecting the
      rate of peri-implant bone loss, and that oral hygiene also had an
      influence, especially in smokers, while other factors, e.g., those
      associated with occlusal loading, were of minor importance. These results
      indicate that smoking habits should be included in analyses of implant
      survival and peri-implant bone loss.
AD  - Department of Prosthetic Dentistry, Faculty of Odontology, Goteborg
      University, Sweden.
FAU - Lindquist, L W
AU  - Lindquist LW
FAU - Carlsson, G E
AU  - Carlsson GE
FAU - Jemt, T
AU  - Jemt T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - J Dent Res
JT  - Journal of dental research
JID - 0354343
SB  - D
SB  - IM
MH  - Adult
MH  - Alveolar Bone Loss/epidemiology/*etiology
MH  - Dental Prosthesis, Implant-Supported/statistics & numerical data
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Jaw, Edentulous/complications/rehabilitation
MH  - Male
MH  - Mandible
MH  - Mandibular Diseases/epidemiology/*etiology
MH  - *Mandibular Prosthesis/statistics & numerical data
MH  - Middle Aged
MH  - Oral Hygiene
MH  - *Osseointegration
MH  - Prosthesis Failure
MH  - Smoking/*adverse effects
MH  - Time Factors
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - J Dent Res. 1997 Oct;76(10):1667-74.
PMID- 9312211
OWN - NLM
STAT- MEDLINE
DA  - 19971117
DCOM- 19971117
LR  - 20061115
PUBM- Print
IS  - 0022-2631 (Print)
VI  - 159
IP  - 3
DP  - 1997 Oct 1
TI  - Characterization of a chloride-selective channel from rough endoplasmic
      reticulum membranes of rat hepatocytes: evidence for a block by phosphate.
PG  - 219-29
AB  - We have characterized the conduction and blocking properties of a chloride
      channel from rough endoplasmic reticulum membranes of rat hepatocytes
      after incorporation into a planar lipid bilayer. Our experiments revealed
      the existence of a channel with a mean conductance of 164 +/- 5 pS in
      symmetrical 200 mm KCl solutions. We determined that the channel was ten
      times more permeable for Cl- than for K+, calculated from the reversal
      potential using the Goldman-Hodgkin-Katz equation. The channel was voltage
      dependent, with an open probability value ranging from 0.9 at -20 mV to
      0.4 at +60 mV. In addition to its fully open state, the channel could also
      enter a flickering state, which appeared to involve rapid transitions to
      zero current level. Our results showed a decrease of the channel mean open
      time combined with an increase of the channel mean closed time at positive
      potentials. An analysis of the dwell time distributions for the open and
      closed intervals led to the conclusion that the observed fluctuation
      pattern was compatible with a kinetic scheme containing a single open
      state and a minimum of three closed states. The permeability sequence for
      test halides determined from reversal potentials was Br- > Cl- > I-
      approximately F-. The voltage dependence of the open probability was
      modified by the presence of halides in trans with a sequence reflecting
      the permeability sequence, suggesting that permeant anions such as Br- and
      Cl- have access to an internal site capable of controlling channel gating.
      Adding NPPB to the cis chamber inhibited the channel activity by
      increasing fast flickering and generating long silent periods, whereas
      channel activity was not affected by 50 microM DNDS in trans. The channel
      was reversibly inhibited by adding phosphate to the trans chamber. The
      inhibitory effect of phosphate was voltage-dependent and could be reversed
      by addition of Cl-. Our results suggest that channel block involves the
      interaction of HPO2-4 with a site located at 70% of the membrane span.
AD  - Department of Physiology, Membrane Transport Research Group, University of
      Montreal, C.P. 6128, Succ. Centre-ville, Montreal Canada H3C 3J7.
FAU - Eliassi, A
AU  - Eliassi A
FAU - Garneau, L
AU  - Garneau L
FAU - Roy, G
AU  - Roy G
FAU - Sauve, R
AU  - Sauve R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - J Membr Biol
JT  - The Journal of membrane biology
JID - 0211301
RN  - 0 (Chloride Channels)
RN  - 0 (Lipid Bilayers)
RN  - 0 (Nitrobenzoates)
RN  - 0 (Phosphates)
RN  - 0 (Stilbenes)
RN  - 107254-86-4 (5-nitro-2-(3-phenylpropylamino)benzoic acid)
RN  - 128-42-7 (4,4'-dinitro-2,2'-stilbenedisulfonic acid)
RN  - 1333-74-0 (Hydrogen)
RN  - 7440-09-7 (Potassium)
RN  - 7440-70-2 (Calcium)
SB  - IM
MH  - Animals
MH  - Calcium/metabolism
MH  - Chloride Channels/drug effects/*metabolism
MH  - Endoplasmic Reticulum, Rough/drug effects/*metabolism
MH  - Hydrogen/metabolism
MH  - Hydrogen-Ion Concentration
MH  - Intracellular Membranes/drug effects/metabolism
MH  - Kinetics
MH  - Lipid Bilayers/metabolism
MH  - Liver/*metabolism/ultrastructure
MH  - Nitrobenzoates/pharmacology
MH  - Phosphates/*pharmacology
MH  - Potassium/metabolism
MH  - Rats
MH  - Stilbenes/pharmacology
EDAT- 1997/10/06
MHDA- 1997/10/06 00:01
PST - ppublish
SO  - J Membr Biol. 1997 Oct 1;159(3):219-29.
PMID- 9342780
OWN - NLM
STAT- MEDLINE
DA  - 19971120
DCOM- 19971120
LR  - 20061115
PUBM- Print
IS  - 0033-3158 (Print)
VI  - 133
IP  - 2
DP  - 1997 Sep
TI  - The effects of kainic acid lesions on dopaminergic responses to
      haloperidol and clozapine.
PG  - 142-51
AB  - The antipsychotic drugs haloperidol and clozapine have the common action
      of increasing dopamine metabolism in the striatum (nucleus accumbens,
      caudate-putamen) of the rat. Intracerebroventricular administration of
      kainic acid (KA) produces neuronal loss in limbic-cortical brain regions
      which project directly or indirectly to the striatum. In the present
      study, dopamine metabolism in subregions of the striatum was examined in
      rats with KA lesions after acute and chronic haloperidol or clozapine
      administration. The main findings was that the elevating effect of acute
      haloperidol treatment on the dopamine metabolite, DOPAC, was blocked in
      the nucleus accumbens shell and diminished in medial and laterodorsal
      caudate-putamen of the KA-lesioned rats. In addition, the elevating
      effects of both acute and chronic haloperidol treatment on dopamine
      turnover were attenuated in the laterodorsal caudate-putamen of
      KA-lesioned rats. The levels of dopamine, DOPAC, and HVA after chronic
      clozapine treatment were greater in KA-lesioned than control rats. These
      results indicate that dopaminergic responses to haloperidol may be
      diminished by limbic-cortical neuropathology, while such pathology does
      not significantly alter dopaminergic responses to clozapine.
AD  - Department of Psychiatry, Washington University School of Medicine, St.
      Louis, MO 63110-1093, USA.
FAU - Bardgett, M E
AU  - Bardgett ME
FAU - Salaris, S L
AU  - Salaris SL
FAU - Jackson, J L
AU  - Jackson JL
FAU - Harding, J
AU  - Harding J
FAU - Csernansky, J G
AU  - Csernansky JG
LA  - eng
GR  - MH01109/MH/NIMH
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - GERMANY
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Dopamine Agonists)
RN  - 487-79-6 (Kainic Acid)
RN  - 51-61-6 (Dopamine)
RN  - 52-86-8 (Haloperidol)
RN  - 5786-21-0 (Clozapine)
SB  - IM
MH  - Animals
MH  - Caudate Nucleus/drug effects/metabolism
MH  - Clozapine/*pharmacology
MH  - Corpus Striatum/*drug effects/metabolism
MH  - Dopamine/*metabolism
MH  - Dopamine Agonists
MH  - Haloperidol/*pharmacology
MH  - Injections, Intraventricular
MH  - Kainic Acid/*toxicity
MH  - Male
MH  - Nucleus Accumbens/drug effects/metabolism
MH  - Putamen/drug effects/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1997/10/29
MHDA- 1997/10/29 00:01
PST - ppublish
SO  - Psychopharmacology (Berl). 1997 Sep;133(2):142-51.
PMID- 9376257
OWN - NLM
STAT- MEDLINE
DA  - 19971107
DCOM- 19971107
LR  - 20061115
PUBM- Print
IS  - 0885-8195 (Print)
VI  - 12
IP  - 3
DP  - 1997 Fall
TI  - Outcomes study of a course in breast-cancer screening.
PG  - 179-84
AB  - BACKGROUND: The Breast Cancer Screening Module is a professional training
      course within the Professional Education for Prevention and Early
      Detection (PEPED) program at the University of Texas M. D. Anderson Cancer
      Center. An outcomes study was done to determine the module's ability to
      improve screening practices crucial to breast-cancer control. METHODS: The
      five-day course combines 17 hours of class work with 20 hours of hands-on
      clinical training. Subjects were followed for one year post-training. Six
      outcome areas were evaluated: 1) knowledge about breast-cancer prevention;
      2) clinical skills; 3) changes in routine practice; 4) numbers of patients
      screened, referred, and diagnosed; 5) trainee satisfaction with the
      course; and 6) barriers to implementing screening in routine practice. The
      study population was 63 subjects (all nurse professionals). RESULTS:
      Outcomes were positive in all six evaluation areas-significant gains in
      general and clinical knowledge tests (p < or = 0.05); a significant
      increase from 54.2% pre-training to 70.5% post-training in risk counseling
      (p < or = 0.05); a sustained increase in screening practices (4.3 times
      and 2.8 times greater at 6 and 12 months post-training, respectively); 72%
      rate of high course satisfaction; and barriers to improved screening
      practices, such as time limitations among 60.4% of subjects and 57.6% of
      their employers, were identified. CONCLUSIONS: This unique training
      enhances breast-cancer prevention and screening practices and early
      detection.
AD  - Department of Clinical Cancer Prevention, University of Texas, M. D.
      Anderson Cancer Center, Houston 77030, USA.
FAU - Ford, M
AU  - Ford M
FAU - Martin, R D
AU  - Martin RD
FAU - Hilton, L W
AU  - Hilton LW
FAU - Ewert-Flannagan, T
AU  - Ewert-Flannagan T
FAU - Corrigan, G K
AU  - Corrigan GK
FAU - Johnson, G
AU  - Johnson G
FAU - Hernandez, M A
AU  - Hernandez MA
FAU - Sbach, A
AU  - Sbach A
FAU - Lippman, S M
AU  - Lippman SM
LA  - eng
GR  - CA 16413/CA/NCI
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - J Cancer Educ
JT  - Journal of cancer education : the official journal of the American
      Association for Cancer Education
JID - 8610343
SB  - IM
MH  - Breast Neoplasms/*prevention & control
MH  - Cancer Care Facilities
MH  - Clinical Competence
MH  - Counseling
MH  - Data Interpretation, Statistical
MH  - *Education, Nursing, Continuing
MH  - Evaluation Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - *Mass Screening
MH  - Outcome Assessment (Health Care)
MH  - Risk Factors
MH  - Time Factors
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - J Cancer Educ. 1997 Fall;12(3):179-84.
PMID- 9380972
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20061115
PUBM- Print
IS  - 0034-8376 (Print)
VI  - 49
IP  - 3
DP  - 1997 May-Jun
TI  - [Immunogenetic study in Mexican couples with recurrent spontaneous
      abortions]
PG  - 183-7
AB  - AIM: To study the HLA markers in Mexican couples who have suffered three
      or more spontaneous abortions. DESIGN: The study included 24 couples with
      recurrent abortions and 32 with normal fertility. METHOD: HLA class I (A,
      B, C) and class II (DR, DQ) typing was done with a standard
      microlymphocytoxity test. The intergroup differences were evaluated by
      chi-square and the Fisher exact test. RESULTS: The frequency of the MHC
      markers in the males and females of couples with abortions were not
      significantly different from those in fertile couples. However, the
      abortion couples shared class I antigens more often than expected from
      random mating as compared to fertile couples, specially in the HLA-B
      locus. We also found a significantly decreased frequency of the HLA-B7
      antigen in males belonging to the abortion group. CONCLUSION: These
      results suggest that HLA-B antigens may be markers for genes related to
      pregnancy outcome in Mexicans.
AD  - Departamento de Genetica, Hospital General de Mexico, SS, Mexico, D.F.
FAU - Silva, B
AU  - Silva B
FAU - Yamamoto-Furusho, J K
AU  - Yamamoto-Furusho JK
FAU - Grether, P
AU  - Grether P
FAU - Vargas-Alarcon, G
AU  - Vargas-Alarcon G
FAU - Kofman, S
AU  - Kofman S
FAU - Granados, J
AU  - Granados J
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Estudio inmunogenetico en parejas mexicanas con abortos espontaneos
      recurrentes.
PL  - MEXICO
TA  - Rev Invest Clin
JT  - Revista de investigacion clinica; organo del Hospital de Enfermedades de
      la Nutricion
JID - 9421552
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-B7 Antigen)
SB  - IM
MH  - Abortion, Habitual/epidemiology/genetics/*immunology
MH  - Adult
MH  - Disease Susceptibility
MH  - Female
MH  - Fertility/genetics/immunology
MH  - Gene Frequency
MH  - HLA Antigens/*analysis/genetics
MH  - HLA-B7 Antigen/analysis
MH  - Histocompatibility Testing
MH  - Humans
MH  - Male
MH  - Mexico/epidemiology
MH  - Pregnancy
MH  - Pregnancy Outcome
EDAT- 1997/05/01 00:00
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Rev Invest Clin. 1997 May-Jun;49(3):183-7.
PMID- 9354556
OWN - NLM
STAT- MEDLINE
DA  - 19971113
DCOM- 19971113
LR  - 20041117
PUBM- Print
IS  - 0003-4975 (Print)
VI  - 64
IP  - 4
DP  - 1997 Oct
TI  - Mitral valve repair in a patient with severe porcelain aorta.
PG  - 1179-81
AB  - We repaired the mitral valve in a patient with severe porcelain aorta.
      Significant mitral regurgitation developed in a 66-year-old woman with
      heavy calcification throughout the whole aorta. At operation,
      cardiopulmonary bypass was properly established by combined axillary and
      femoral arterial cannulations for sufficient systemic flow. Likewise, the
      combination of a superior mitral approach and profound hypothermic
      fibrillatory arrest in conjunction with low-flow cardiopulmonary bypass
      allowed us to repair the mitral valve successfully.
AD  - Department of Cardiovascular Surgery, Tenri Hospital, Japan.
FAU - Ogino, H
AU  - Ogino H
FAU - Ueda, Y
AU  - Ueda Y
FAU - Morioka, K
AU  - Morioka K
FAU - Matsubayashi, K
AU  - Matsubayashi K
FAU - Nomoto, T
AU  - Nomoto T
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - UNITED STATES
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
SB  - AIM
SB  - IM
MH  - Aged
MH  - Aortic Diseases/*complications
MH  - Calcinosis/*complications
MH  - Cardiopulmonary Bypass
MH  - Female
MH  - Heart Arrest, Induced
MH  - Heart Valve Prosthesis Implantation/*methods
MH  - Humans
MH  - Mitral Valve/surgery
MH  - Mitral Valve Insufficiency/complications/*surgery
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
AID - S0003-4975(97)00824-2 [pii]
PST - ppublish
SO  - Ann Thorac Surg. 1997 Oct;64(4):1179-81.
PMID- 9335178
OWN - NLM
STAT- MEDLINE
DA  - 19971106
DCOM- 19971106
LR  - 20061115
PUBM- Print
IS  - 0168-1656 (Print)
VI  - 58
IP  - 1
DP  - 1997 Oct 2
TI  - Overproduction and purification of an agarase of bacterial origin.
PG  - 59-66
AB  - The agarase gene from Streptomyces coelicolor has been cloned in the
      non-producer bacterium Streptomyces lividans under the control of its own
      set of promoters and under the control of a heterologous promoter that is
      functional only during exponential growth. The best level of
      overproduction was obtained when the strain containing the natural gene
      was cultivated in fed batch with mannitol as carbon source. The protein,
      with a relative molecular mass of 32 kDa, has been purified following an
      affinity purification method. Contaminating activities seem to be absent
      from the purified enzyme preparation that can be used to purify DNA from
      agarose gels.
AD  - Centro Nacional de Biotecnologia (CSIC), Campus de la Universidad
      Autonoma, Cantoblanco, Madrid, Spain.
FAU - Parro, V
AU  - Parro V
FAU - Vives, C
AU  - Vives C
FAU - Godia, F
AU  - Godia F
FAU - Mellado, R P
AU  - Mellado RP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - NETHERLANDS
TA  - J Biotechnol
JT  - Journal of biotechnology
JID - 8411927
RN  - 0 (Bacterial Proteins)
RN  - 9007-49-2 (DNA)
RN  - EC 3.2.1.- (Glycoside Hydrolases)
RN  - EC 3.2.1.81 (agarase)
SB  - B
MH  - Bacterial Proteins/*biosynthesis
MH  - DNA/isolation & purification
MH  - Glycoside Hydrolases/*biosynthesis/genetics/isolation & purification
MH  - Promoter Regions (Genetics)
MH  - Streptomyces/*genetics
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
AID - S0168-1656(97)00128-4 [pii]
PST - ppublish
SO  - J Biotechnol. 1997 Oct 2;58(1):59-66.
PMID- 9271786
OWN - NLM
STAT- MEDLINE
DA  - 19971028
DCOM- 19971028
LR  - 20041117
PUBM- Print
IS  - 0090-6980 (Print)
VI  - 54
IP  - 1
DP  - 1997 Jul
TI  - Oxidative stress and the mobilisation of arachidonic acid in stimulated
      human platelets: role of hydroxyl radical.
PG  - 493-509
AB  - Platelet functions, including eicosanoid biosynthesis, can be
      significantly altered by exposure to reactive oxygen species. We utilised
      the redox properties of the phenazine derivative, pyocyanin, to generate
      low micromolar levels of reactive oxygen species in order to investigate
      the metabolism of arachidonic acid by human platelets under oxidative
      stress. Eicosanoid production by platelets, pre-labelled with
      [3H]arachidonic acid (AA) and stimulated with the calcium ionophore
      A23187, was inhibited in the presence of pyocyanin. In contrast, platelets
      pre-treated with pyocyanin and concurrently exposed to A23187 and AA
      showed no evidence of inhibition. Analysis of the free label content of
      labelled, pyocyanin-treated platelets after stimulation revealed
      diminished levels of total free label and a corresponding increase in
      labelled phospholipid. Prior treatment with the antioxidants, superoxide
      dismutase, catalase or the hydroxyl radical scavenger, mannitol, before
      the addition of pyocyanin afforded protection against loss of eicosanoid
      production and restored AA release. We conclude that hydroxyl radicals
      inhibit one or more steps in the cascade leading to phospholipase A2
      activation and release of arachidonic acid from platelet phospholipid
      stores.
AD  - Centre for Infectious Diseases and Microbiology, University of Sydney,
      Westmead Hospital, NSW, Australia.
FAU - Muller, M
AU  - Muller M
FAU - Sorrell, T C
AU  - Sorrell TC
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Antioxidants)
RN  - 0 (Eicosanoids)
RN  - 0 (Phospholipids)
RN  - 0 (Reactive Oxygen Species)
RN  - 3352-57-6 (Hydroxyl Radical)
RN  - 506-32-1 (Arachidonic Acid)
RN  - 53-59-8 (NADP)
RN  - 69-65-8 (Mannitol)
RN  - 7722-84-1 (Hydrogen Peroxide)
RN  - 85-66-5 (Pyocyanine)
SB  - IM
MH  - Antioxidants/pharmacology
MH  - Arachidonic Acid/*metabolism
MH  - Blood Platelets/drug effects/*metabolism
MH  - Eicosanoids/metabolism
MH  - Humans
MH  - Hydrogen Peroxide/chemistry/metabolism
MH  - Hydroxyl Radical/*metabolism
MH  - Lipid Peroxidation
MH  - Mannitol/pharmacology
MH  - NADP/metabolism
MH  - *Oxidative Stress
MH  - Phospholipids/metabolism
MH  - Pyocyanine/metabolism/pharmacology
MH  - Reactive Oxygen Species/metabolism
EDAT- 1997/07/01
MHDA- 1997/07/01 00:01
AID - S0090698097000609 [pii]
PST - ppublish
SO  - Prostaglandins. 1997 Jul;54(1):493-509.
PMID- 9329890
OWN - NLM
STAT- MEDLINE
DA  - 19971031
DCOM- 19971031
LR  - 20061030
PUBM- Print
IS  - 0011-9059 (Print)
VI  - 36
IP  - 8
DP  - 1997 Aug
TI  - Chemotherapy-induced acral erythema in leukemic patients: a report of 15
      cases.
PG  - 593-8
AB  - BACKGROUND: Chemotherapy-induced acral erythema is a distinct localized
      cutaneous response to certain systemic chemotherapeutic agents. METHODS:
      Between January 1990 and December 1994, from a total of 76 leukemic
      patients who have received combination chemotherapy consisting of cytosine
      arabinoside and anthracycline antibiotics, 15 patients developed
      chemotherapy-induced acral erythema. Fourteen of the patients had acute
      myelocytic leukemia, and one of them had chronic myelogenous leukemia in
      blast phase. Clinical features of these 15 patients have been analysed.
      Biopsy specimens obtained from eight of the patients were also evaluated
      for histopathologic alterations. RESULTS: The overall incidence of this
      reaction was found to be 19.7% in our group of patients receiving this
      chemotherapy protocol. The onset of reaction varied from the fourth to the
      seventeenth days of the chemotherapy and resolved within 2 weeks in most
      of the patients. Lesions appeared as well-defined erythema and edema
      involving the palmar surfaces in all of the patients. In nine of the
      patients the reaction recurred with subsequent chemotherapies. Scattered
      necrotic keratinocytes, vacuolar alterations of the basal layer, and mild
      to moderate perivascular lymphocytic infiltration in the dermis were the
      histopathologic findings observed in the biopsy specimens. CONCLUSIONS:
      Chemotherapy-induced acral erythema is a frequent reaction in patients who
      are receiving high-dose chemotherapy. For patients in whom this
      self-limited condition develops, reassurance is the mainstay of therapy.
      Awareness of this reaction is also important to be able to differentiate
      it from acute graft versus host disease in patients who receive bone
      marrow transplants.
AD  - Department of Dermatology, Marmara University School of Medicine,
      Istanbul, Turkey.
FAU - Demircay, Z
AU  - Demircay Z
FAU - Gurbuz, O
AU  - Gurbuz O
FAU - Alpdogan, T B
AU  - Alpdogan TB
FAU - Yucelten, D
AU  - Yucelten D
FAU - Alpdogan, O
AU  - Alpdogan O
FAU - Kurtkaya, O
AU  - Kurtkaya O
FAU - Bayik, M
AU  - Bayik M
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - Int J Dermatol
JT  - International journal of dermatology
JID - 0243704
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Immunosuppressive Agents)
RN  - 147-94-4 (Cytarabine)
RN  - 20830-81-3 (Daunorubicin)
RN  - 23214-92-8 (Doxorubicin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibiotics, Antineoplastic/adverse effects/therapeutic use
MH  - Antimetabolites, Antineoplastic/adverse effects/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects
MH  - Cytarabine/adverse effects/therapeutic use
MH  - Daunorubicin/adverse effects/therapeutic use
MH  - Doxorubicin/adverse effects/therapeutic use
MH  - Erythema/*chemically induced/pathology
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects/therapeutic use
MH  - Leukemia, Myelocytic, Acute/complications/*drug therapy
MH  - Leukemia, Myeloid, Chronic/complications/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Recurrence
EDAT- 1997/08/01 00:00
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Int J Dermatol. 1997 Aug;36(8):593-8.
PMID- 9378393
OWN - NLM
STAT- MEDLINE
DA  - 19971110
DCOM- 19971110
LR  - 20041117
PUBM- Print
IS  - 0017-5749 (Print)
VI  - 41
IP  - 3
DP  - 1997 Sep
TI  - Intravenous immunoglobulin therapy for severe Clostridium difficile
      colitis.
PG  - 366-70
AB  - BACKGROUND: Many individuals have serum antibodies against Clostridium
      difficile toxins. Those with an impaired antitoxin response may be
      susceptible to recurrent, prolonged, or severe C difficile diarrhoea and
      colitis. AIMS: To examine whether treatment with intravenous
      immunoglobulin might be effective in patients with severe pseudomembranous
      colitis unresponsive to standard antimicrobial therapy. PATIENTS: Two
      patients with pseudomembranous colitis not responding to metronidazole and
      vancomycin were given normal pooled human immunoglobulin intravenously
      (200-300 mg/kg). METHODS: Antibodies against C difficile toxins were
      measured in nine immunoglobulin preparations by ELISA and by cytotoxin
      neutralisation assay. RESULTS: Both patients responded quickly as shown by
      resolution of diarrhoea, abdominal tenderness, and distension. All
      immunoglobulin preparations tested contained IgG against C difficile
      toxins A and B by ELISA and neutralised the cytotoxic activity of C
      difficile toxins in vitro at IgG concentrations of 0.4-1.6 mg/ml.
      CONCLUSION: Passive immunotherapy with intravenous immunoglobulin may be a
      useful addition to antibiotic therapy for severe, refractory C difficile
      colitis. IgG antitoxin is present in standard immunoglobulin preparations
      and C difficile toxin neutralising activity is evident at IgG
      concentrations which are readily achieved in the serum by intravenous
      immunoglobulin administration.
AD  - Section of Gastroenterology, Boston University School of Medicine,
      Massachusetts, USA.
FAU - Salcedo, J
AU  - Salcedo J
FAU - Keates, S
AU  - Keates S
FAU - Pothoulakis, C
AU  - Pothoulakis C
FAU - Warny, M
AU  - Warny M
FAU - Castagliuolo, I
AU  - Castagliuolo I
FAU - LaMont, J T
AU  - LaMont JT
FAU - Kelly, C P
AU  - Kelly CP
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - ENGLAND
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Antibodies)
RN  - 0 (Bacterial Proteins)
RN  - 0 (Bacterial Toxins)
RN  - 0 (Enterotoxins)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (tcdA protein, Clostridium difficile)
RN  - 0 (toxB protein, Clostridium difficile)
SB  - AIM
SB  - IM
MH  - Antibodies/analysis
MH  - *Bacterial Proteins
MH  - Bacterial Toxins/immunology
MH  - *Clostridium difficile
MH  - Enterocolitis, Pseudomembranous/*therapy
MH  - Enterotoxins/immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/analysis
MH  - *Immunoglobulins, Intravenous/chemistry
MH  - Male
MH  - Middle Aged
EDAT- 1998/02/12
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Gut. 1997 Sep;41(3):366-70.
PMID- 9380284
OWN - NLM
STAT- MEDLINE
DA  - 19971118
DCOM- 19971118
LR  - 20061115
PUBM- Print
IS  - 0375-9393 (Print)
VI  - 63
IP  - 4
DP  - 1997 Apr
TI  - [Precision of drug dilution techniques]
PG  - 115-8
AB  - OBJECT: Evaluation of accuracy of three common dilution methods for drugs.
      EXPERIMENTAL PLAN: Perspective double blind investigation from March to
      June 1995. PLACE: Anaesthesia and Resuscitation Service of Children's
      Hospital of Iglesias (CA). METHODS: Forty dopamine at 2/1000 samples,
      obtained by dilution of dopamine at 40/1000 on sale with three different
      methods by five different operators, were analysed with a chromatography
      system in liquid phase at high pressure. RESULTS: Mean concentration with
      difference not exceeding 5% from the goal, are considered acceptable. Only
      one group of samples was found to be into these limits, but it was also
      the most dangerous for the high percentage of great mistakes in dilution.
      Although there are significant differences in the accuracy and safety of
      the three dilution methods, the highest and lowest final concentrations
      obtained differ very much from those estimated. CONCLUSIONS: It is
      suggested that drugs confections with proper dilution for different
      clinical uses might be on sale.
AD  - Servizio di Anestesia e Rianimazione, Azienda USL n. 7, Ospedale
      Pediatrico F.lli Crobu, di Iglesias, (Cagliari).
FAU - Lai, A
AU  - Lai A
FAU - Silvetti, L
AU  - Silvetti L
FAU - Cossu, F
AU  - Cossu F
FAU - Di Chiara, G
AU  - Di Chiara G
FAU - Tanda, G
AU  - Tanda G
FAU - Frau, R
AU  - Frau R
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Precisione dei metodi di diluizione dei farmaci.
PL  - ITALY
TA  - Minerva Anestesiol
JT  - Minerva anestesiologica
JID - 0375272
SB  - IM
MH  - *Indicator Dilution Techniques
MH  - Reproducibility of Results
EDAT- 1997/04/01 00:00
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Minerva Anestesiol. 1997 Apr;63(4):115-8.
PMID- 9322874
OWN - NLM
STAT- MEDLINE
DA  - 19971106
DCOM- 19971106
LR  - 20060421
PUBM- Print
IS  - 1043-0342 (Print)
VI  - 8
IP  - 14
DP  - 1997 Sep 20
TI  - Retroviral mediated gene transfer of the Fanconi anemia complementation
      group C gene to hematopoietic progenitors of group C patients.
PG  - 1715-30
AB  - Fanconi Anemia (FA) is a rare genetic disorder characterized by progress
      pancytopenia, congenial abnormalities, and a predisposition to malignancy.
      Therapy is currently limited to allogeneic marrow transplantation;
      patients lacking a suitable donor usually die from aplasia or acute
      leukemia. Recently, mutation in a novel gene named FACC (Fanconi anemia
      C-complementing) has been identified as causing one type of FA. FACC
      mutations, which introduce splicing errors or stop codons, have been
      identified in approximately 15% of FA patients. We have recently been
      successful in functional complementation of four FA cell lines using
      retroviral vectors to transfer a copy of the normal FACC gene. We also
      analyzed the ability of our viral vectors to functionally correct
      hematopoietic progenitor cells from a patient bearing a splice donor
      mutation. As for the lymphoid cell lines, these CD34-enriched cells were
      extremely sensitive to MMC. After infection of these progenitor cells with
      viral vectors bearing normal FACC, the progenitors gave rise to increased
      numbers of colonies both in the absence and presence of up to 5nM MMC,
      whereas control cells were completely destroyed by 1nM MMC. In summary, we
      have demonstrated that: (1) retroviral vectors can be engineered to
      transfer a normal FACC gene to FA(C) lymphoid cell lines and primary
      hematopoietic cells; (2) introduction of a normal FACC gene into CD34+
      progenitors markedly enhances their growth in the absence and presence of
      MMC. This study is designed to determine whether hematopoietic progenitors
      transduced with the normal FACC gene can be reinfused safely into FA(C)
      patients. CD34+ cells obtained from G-CSF mobilized peripheral blood will
      be transduced ex vivo over a 72-hour period in the presence of IL-3, IL-6,
      and Stem Cell Factor with the FACC retroviral vector. These transduced
      cells will be reinfused into FA(C) patients. Patients will be monitored
      for toxicities as well as evidence of successful gene transfer and
      expression. The procedure will be repeated up to a total of 4 times with
      each treatment 2-4 months apart. Theoretically, these rescued stem cells
      should have a selective growth advantage within the hypoplastic FA marrow
      environment in vivo.
FAU - Liu, J M
AU  - Liu JM
FAU - Young, N S
AU  - Young NS
FAU - Walsh, C E
AU  - Walsh CE
FAU - Cottler-Fox, M
AU  - Cottler-Fox M
FAU - Carter, C
AU  - Carter C
FAU - Dunbar, C
AU  - Dunbar C
FAU - Barrett, A J
AU  - Barrett AJ
FAU - Emmons, R
AU  - Emmons R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - UNITED STATES
TA  - Hum Gene Ther
JT  - Human gene therapy
JID - 9008950
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (FANCC protein, human)
RN  - 0 (Fanconi Anemia Complementation Group C Protein)
RN  - 0 (Fanconi Anemia Complementation Group Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Proteins)
SB  - IM
MH  - *Cell Cycle Proteins
MH  - Cell Transplantation
MH  - Clinical Protocols
MH  - *DNA-Binding Proteins
MH  - Fanconi Anemia/*therapy
MH  - Fanconi Anemia Complementation Group C Protein
MH  - Fanconi Anemia Complementation Group Proteins
MH  - Gene Therapy/methods
MH  - *Gene Transfer Techniques
MH  - Genetic Vectors/genetics
MH  - *Hematopoietic Stem Cells
MH  - Humans
MH  - *Nuclear Proteins
MH  - Pilot Projects
MH  - Proteins/*genetics
MH  - Retroviridae/genetics
EDAT- 1997/10/10
MHDA- 1997/10/10 00:01
PST - ppublish
SO  - Hum Gene Ther. 1997 Sep 20;8(14):1715-30.
PMID- 9350014
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20041117
PUBM- Print
IS  - 0024-7758 (Print)
VI  - 42
IP  - 10
DP  - 1997 Oct
TI  - Serum CA-125 measurements > 65 U/mL. Clinical value.
PG  - 617-24
AB  - OBJECTIVE: To review the prevalence of various conditions associated with
      serum CA-125 values > 65 U/mL, to calculate the odds ratios of different
      ranges of high CA-125 in predicting cancer and to study the effect of
      menopause and the presence of a mass on the predictive value of high serum
      CA-125. STUDY DESIGN: A retrospective review of the diagnoses in 313
      consecutive women seen at the Cleveland Clinic Foundation whose serum
      CA-125 was > 65 U/mL was performed. Statistical analysis was performed
      using crosstabulation, chi 2, Fisher's exact test and the odds ratio.
      RESULTS: In patients with serum CA-125 > 65 U/mL, gynecologic cancers,
      nongynecologic cancers and non-malignant conditions constituted 74.3%,
      10.2% and 13.1% of diagnoses, respectively. In patients with serum CA-125
      > or = 1,000 U/mL, the same conditions were responsible for 89%, 7% and 3%
      of diagnoses, respectively. Endometriosis and metastatic breast cancer
      were the most common benign condition and nongynecologic cancer associated
      with serum CA-125 > 65 U/mL. The presence of an abdominopelvic mass
      significantly increased the risk of malignancy (P < .00005). Approximately
      90% of patients with CA-125 > 65 U/mL and no mass had nonmalignant
      disease. The diagnoses of serum CA-125 values > 65 U/mL varied
      significantly in premenopausal versus postmenopausal patients.
      Postmenopausal patients had a higher incidence of gynecologic (P = .002)
      and nongynecologic (P = .0008) cancers and lower incidence of benign
      conditions (P < .0005). The odds ratio that CA-125 levels were associated
      with cancer increased as the level of CA-125 increased. The odds ratio of
      malignant versus benign disease was significantly higher in
      post-menopausal patients for all intervals of CA-125 levels until the
      level of > or = 1,000 U/mL was reached. CONCLUSION: In patients seen at a
      tertiary center, serum CA-125 measurements > 65 U/mL were associated with
      nonmalignant conditions in 13% of patients. Although higher serum CA-125
      levels were more associated with gynecologic malignancies, no level of
      CA-125 occurred exclusively with gynecologic cancers. In postmenopausal
      patients with serum CA-125 values > 65 U/mL and in patients with serum
      CA-125 values > 65 U/mL and an abdominopelvic mass, subspecialty
      consultation should be considered before proceeding to surgery.
AD  - Department of Gynecology, Cleveland Clinic Foundation, Ohio, USA.
FAU - Eltabbakh, G H
AU  - Eltabbakh GH
FAU - Belinson, J L
AU  - Belinson JL
FAU - Kennedy, A W
AU  - Kennedy AW
FAU - Gupta, M
AU  - Gupta M
FAU - Webster, K
AU  - Webster K
FAU - Blumenson, L E
AU  - Blumenson LE
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - J Reprod Med
JT  - The Journal of reproductive medicine
JID - 0173343
RN  - 0 (CA-125 Antigen)
SB  - IM
CIN - J Reprod Med. 1998 Jul;43(7):635-6. PMID: 9693414
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - CA-125 Antigen/*blood
MH  - Endometriosis/blood
MH  - Female
MH  - Genital Neoplasms, Female/*blood
MH  - Heart Failure, Congestive/blood
MH  - Humans
MH  - Liver Cirrhosis/blood
MH  - Middle Aged
MH  - Ovarian Neoplasms/blood
MH  - Peritoneal Neoplasms/blood
MH  - Postmenopause
MH  - Reference Values
MH  - Retrospective Studies
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
PST - ppublish
SO  - J Reprod Med. 1997 Oct;42(10):617-24.
PMID- 9306294
OWN - NLM
STAT- MEDLINE
DA  - 19971104
DCOM- 19971104
LR  - 20041117
PUBM- Print
IS  - 0022-3956 (Print)
VI  - 31
IP  - 3
DP  - 1997 May-Jun
TI  - Physiological and behavioral responses to minor stressors in offspring of
      patients with panic disorder.
PG  - 365-76
AB  - Nineteen children born to patients with panic disorder and a comparison
      group of 16 children born to unaffected, non-psychiatric patient subjects
      exposed to novel and mildly stressful situations (visiting an unfamiliar
      place and watching a movie containing anxiogenic scenes) were assessed for
      their behaviors, heart rate, respiratory rate and salivary cortisol
      secretion. At arrival children born to patients with panic disorder had
      significantly longer latency of first spontaneous verbal comment, fewer
      prosocial behavior, and increased distress and attachment behavior. During
      the projection of the movie, children of the two groups differed for
      attachment, distress, and exploration behaviors. During the anxiogenic
      scenes children born to patients with panic disorder showed increased
      behavioral inhibition and higher heart rate. Autonomic modulation,
      respiratory rates and cortisol secretion were similar in the two groups.
      Some distinct psychophysiological patterns may constitute early
      manifestations of the transmitted liability to panic disorder.
AD  - Istituto Scientifico H S. Raffaele, Department of Neuropsychiatric
      Sciences, University of Milan School of Medicine, Italy.
FAU - Battaglia, M
AU  - Battaglia M
FAU - Bajo, S
AU  - Bajo S
FAU - Strambi, L F
AU  - Strambi LF
FAU - Brambilla, F
AU  - Brambilla F
FAU - Castronovo, C
AU  - Castronovo C
FAU - Vanni, G
AU  - Vanni G
FAU - Bellodi, L
AU  - Bellodi L
LA  - eng
PT  - Journal Article
PL  - ENGLAND
TA  - J Psychiatr Res
JT  - Journal of psychiatric research
JID - 0376331
RN  - 50-23-7 (Hydrocortisone)
SB  - IM
MH  - Adaptation, Psychological/physiology
MH  - Arousal/*genetics/physiology
MH  - Autonomic Nervous System/physiopathology
MH  - Child
MH  - Child of Impaired Parents/*psychology
MH  - Child, Preschool
MH  - Female
MH  - Heart Rate/genetics/physiology
MH  - Humans
MH  - Hydrocortisone/metabolism
MH  - Male
MH  - Panic Disorder/*genetics/physiopathology/psychology
MH  - Personality Assessment
MH  - Reference Values
MH  - Respiration/genetics/physiology
MH  - Risk Factors
MH  - Saliva/metabolism
MH  - Social Behavior
MH  - Stress, Psychological/*complications
EDAT- 1997/05/01 00:00
MHDA- 1997/11/05 00:01
AID - S0022-3956(97)00003-4 [pii]
PST - ppublish
SO  - J Psychiatr Res. 1997 May-Jun;31(3):365-76.
PMID- 9305762
OWN - NLM
STAT- MEDLINE
DA  - 19971027
DCOM- 19971027
LR  - 20061115
PUBM- Print
IS  - 0378-1119 (Print)
VI  - 195
IP  - 2
DP  - 1997 Aug 22
TI  - Rice lipid transfer protein (LTP) genes belong to a complex multigene
      family and are differentially regulated.
PG  - 177-86
AB  - Several cDNA clones encoding three different lipid transfer proteins
      (LTPs) have been isolated from rice (Oryza sativa L.) in order to analyse
      the complexity, the evolution and the expression of the LTP gene family.
      The mature proteins deduced from three clones exhibited a molecular mass
      of 9 kDa, in agreement with the molecular mass of other LTPs from plants.
      The clones were shown to be homologous in the coding region, while the 3'
      non-coding regions diverged strongly between the clones. The occurrence of
      at least three small multigene families encoding these proteins in rice
      was confirmed by Southern blot analysis. When compared with each other and
      with LTPs from other plants, the cluster including rice LTPs and other
      cereal LTPs indicated that these genes duplicated rather recently and
      independently in the different plant phyla. The expression pattern of each
      gene family was also investigated. Northern blot experiments demonstrated
      that they are differentially regulated in the different tissues analysed.
      Components such as salt, salicylic acid and abscisic acid were shown to
      modulate Ltp gene expression, depending on tissues and gene classes,
      suggesting a complex regulation of these genes.
AD  - Laboratoire de Physiologie Cellulaire et Moleculaire, URA CNRS 1180,
      Universite de Paris VI, France.
FAU - Vignols, F
AU  - Vignols F
FAU - Wigger, M
AU  - Wigger M
FAU - Garcia-Garrido, J M
AU  - Garcia-Garrido JM
FAU - Grellet, F
AU  - Grellet F
FAU - Kader, J C
AU  - Kader JC
FAU - Delseny, M
AU  - Delseny M
LA  - eng
SI  - GENBANK/X83433
SI  - GENBANK/X83434
SI  - GENBANK/X83435
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - NETHERLANDS
TA  - Gene
JT  - Gene
JID - 7706761
RN  - 0 (Antigens, Plant)
RN  - 0 (Carrier Proteins)
RN  - 0 (DNA, Plant)
RN  - 0 (Plant Proteins)
RN  - 0 (Salicylic Acids)
RN  - 0 (lipid transfer proteins, plant)
RN  - 21293-29-8 (Abscisic Acid)
RN  - 69-72-7 (Salicylic Acid)
RN  - 7647-14-5 (Sodium Chloride)
SB  - IM
MH  - Abscisic Acid/pharmacology
MH  - Amino Acid Sequence
MH  - Antigens, Plant
MH  - Base Sequence
MH  - Carrier Proteins/*genetics/metabolism
MH  - Chromosome Mapping
MH  - Cloning, Molecular
MH  - DNA, Plant/genetics
MH  - *Gene Expression Regulation, Plant
MH  - Genes, Plant
MH  - Molecular Sequence Data
MH  - Oryza sativa/*genetics/metabolism
MH  - Phylogeny
MH  - Plant Proteins
MH  - Salicylic Acid
MH  - Salicylic Acids/pharmacology
MH  - Sequence Alignment
MH  - Sequence Analysis, DNA
MH  - Sequence Homology, Amino Acid
MH  - Sodium Chloride/pharmacology
EDAT- 1997/08/22 00:00
MHDA- 1997/09/26 00:01
AID - S0378-1119(97)00137-6 [pii]
PST - ppublish
SO  - Gene. 1997 Aug 22;195(2):177-86.
PMID- 9382350
OWN - NLM
STAT- MEDLINE
DA  - 19971124
DCOM- 19971124
LR  - 20061115
PUBM- Print
IS  - 0302-4342 (Print)
VI  - 47
IP  - 2
DP  - 1997 Aug
TI  - [Risk factors in retinopathy of prematurity]
PG  - 172-6
AB  - OBJECTIVE: The objective of this study was to determine the potential risk
      factors in acute retinopathy of prematurity (ROP). PATIENTS AND METHODS: A
      retrospective study of preterm infants with birth weights less than 1,501
      g, or more if mechanical ventilation and oxygen administration were
      needed, was carried out. Indirect ophthalmoscopy (mydriasis) with
      indentation was done every 15 days from the fourth week. Fifteen factors
      were analyzed. Statistically significant differences between the groups
      with and without ROP were sought with Fisher's exact probability test,
      two-sample t-test, and the chi-square contingency-table. A logistic
      regression was done. RESULTS: Thirty-six of the 137 infants examined
      (26.2%) with birth weight < or = 1,500 g had acute ROP. Only 7.1% of the
      infants with birth weights > or = 1,501 g had retinopathy. There were
      significant differences (p < 0.05) in the following variables: birth
      weight, gestational age, blood transfusion, mechanical ventilation, FiO2
      (fraction inspired oxygen) maximum, time of FiO2 > or = 0.60 (hours) and
      time of FiO2 > or = 0.21 (days). However, the birth-weight was the only
      independent risk factor related to ROP. CONCLUSIONS: Retinopathy of the
      premature has a multifactorial etiology. The low gestational age and the
      oxygen had influence on ROP; however, low birth weight was the independent
      risk factor.
AD  - Servicio de Oftalmologia, Hospital Son Dureta, Palma de Mallorca.
FAU - Olea Vallejo, J L
AU  - Olea Vallejo JL
FAU - Corretger Ruhi, F J
AU  - Corretger Ruhi FJ
FAU - Salvat Serra, M
AU  - Salvat Serra M
FAU - Frau Rotger, E
AU  - Frau Rotger E
FAU - Galiana Ferre, C
AU  - Galiana Ferre C
FAU - Fiol Jaume, M
AU  - Fiol Jaume M
LA  - spa
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Factores de riesgo en la retinopatia del prematuro.
PL  - SPAIN
TA  - An Esp Pediatr
JT  - Anales espanoles de pediatria
JID - 0420463
SB  - IM
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Male
MH  - Oxygen Inhalation Therapy
MH  - Retinopathy of Prematurity/diagnosis/*epidemiology/therapy
MH  - Retrospective Studies
MH  - Risk Factors
EDAT- 1997/08/01 00:00
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - An Esp Pediatr. 1997 Aug;47(2):172-6.
PMID- 9376273
OWN - NLM
STAT- MEDLINE
DA  - 19971112
DCOM- 19971112
LR  - 20060424
PUBM- Print
IS  - 0007-0920 (Print)
VI  - 76
IP  - 8
DP  - 1997
TI  - Primary systemic therapy for operable breast cancer--10-year survival data
      after chemotherapy and hormone therapy.
PG  - 1099-105
AB  - Between 1984 and 1990, 94 women presenting to the Edinburgh Breast Unit
      with operable breast cancer of 4 cm or greater in diameter (T2, T3, N0,
      N1, M0) were given preoperative systemic therapy. Initially, all women
      received hormone therapy, with CHOP (cyclophosphamide 1 g m(-2),
      doxorubicin 50 mg m(-2), vincristine 1.4 mg m(-2) to a maximum of 2 mg and
      prednisolone 40 mg per day orally for 5 days) chemotherapy being
      administered to those who failed to respond by 3 months. After April 1987,
      first-line hormone therapy was only offered to women with oestrogen
      receptor (ER)-moderate/-rich (> 20 fmol mg(-1) protein) tumours, and CHOP
      was reserved for those women whose tumours failed to respond to hormone
      therapy and for those with ER-negative/-poor tumours. Response data have
      been published previously (Anderson et al, 1991). After a median follow-up
      of 7.5 years, there is no difference in survival between those women given
      initial hormone therapy and those given chemotherapy, with neither group
      having yet reached its median survival. The two key factors that predicted
      for a poor survival were the number of involved axillary nodes after
      preoperative systemic therapy (P < 0.00001) and a lack of response to
      preoperative therapy (P < 0.05). These data suggest that many women with
      ER-moderate/-rich tumours will have a good prognosis after preoperative
      hormone therapy alone. However, it is possible to identify, by their
      post-systemic therapy axillary node status, a group of women who still
      have an appalling prognosis after preoperative chemotherapy or hormone
      therapy.
AD  - ICRF Medical Oncology Unit, Western General Hospital, Edinburgh, UK.
FAU - Cameron, D A
AU  - Cameron DA
FAU - Anderson, E D
AU  - Anderson ED
FAU - Levack, P
AU  - Levack P
FAU - Hawkins, R A
AU  - Hawkins RA
FAU - Anderson, T J
AU  - Anderson TJ
FAU - Leonard, R C
AU  - Leonard RC
FAU - Forrest, A P
AU  - Forrest AP
FAU - Chetty, U
AU  - Chetty U
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - SCOTLAND
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (CHOP protocol)
RN  - 10540-29-1 (Tamoxifen)
RN  - 125-84-8 (Aminoglutethimide)
RN  - 23214-92-8 (Doxorubicin)
RN  - 50-18-0 (Cyclophosphamide)
RN  - 50-23-7 (Hydrocortisone)
RN  - 53-03-2 (Prednisone)
RN  - 566-48-3 (formestane)
RN  - 57-22-7 (Vincristine)
RN  - 63-05-8 (Androstenedione)
RN  - 65807-02-5 (Goserelin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aminoglutethimide/administration & dosage
MH  - Androstenedione/administration & dosage/analogs & derivatives
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Axilla
MH  - Breast Neoplasms/drug therapy/surgery/*therapy
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Female
MH  - Follow-Up Studies
MH  - Goserelin/administration & dosage
MH  - Humans
MH  - Hydrocortisone/administration & dosage
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Neoplasms, Hormone-Dependent/drug therapy/surgery/*therapy
MH  - Ovariectomy
MH  - Prednisone/administration & dosage
MH  - Preoperative Care
MH  - Tamoxifen/administration & dosage
MH  - Treatment Outcome
MH  - Vincristine/administration & dosage
EDAT- 1997/01/01 00:00
MHDA- 1997/11/04 00:01
PST - ppublish
SO  - Br J Cancer. 1997;76(8):1099-105.
PMID- 9376966
OWN - NLM
STAT- MEDLINE
DA  - 19971110
DCOM- 19971110
LR  - 20051116
PUBM- Print
IS  - 1052-5149 (Print)
VI  - 7
IP  - 3
DP  - 1997 Aug
TI  - Central nervous system opportunistic infections.
PG  - 513-25
AB  - The spectrum of opportunistic infections occurring in association with
      human-immunodeficiency virus, type 1, is very broad. These infections
      develop most frequently in the setting of advanced immunosuppression.
      There is no part of the neuraxis that is immune to these complications and
      the concurrence of more than one infectious illness may always be
      considered. The neuroimaging features, when coupled with the clinical and
      laboratory findings, often suggest the correct diagnosis and enable the
      physician to initiate therapy.
AD  - Department of Neurology, University of Kentucky College of Medicine,
      Lexington, USA.
FAU - Wright, D
AU  - Wright D
FAU - Schneider, A
AU  - Schneider A
FAU - Berger, J R
AU  - Berger JR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - UNITED STATES
TA  - Neuroimaging Clin N Am
JT  - Neuroimaging clinics of North America
JID - 9211377
SB  - IM
SB  - X
MH  - AIDS-Related Opportunistic Infections/*diagnosis/therapy
MH  - Brain Diseases/*diagnosis/microbiology/therapy/virology
MH  - Cytomegalovirus Infections/diagnosis
MH  - Deltaretrovirus Infections/diagnosis
MH  - *HIV-1
MH  - Herpes Simplex/diagnosis
MH  - Herpes Zoster/diagnosis
MH  - Humans
MH  - Immune Tolerance
MH  - Immunocompromised Host
MH  - Leukoencephalopathy, Progressive Multifocal/diagnosis/virology
MH  - Meningitis, Cryptococcal/diagnosis
MH  - Mycobacterium Infections/diagnosis
MH  - Mycoses/diagnosis
MH  - Neurosyphilis/diagnosis
MH  - Toxoplasmosis, Cerebral/diagnosis
RF  - 106
EDAT- 1997/08/01 00:00
MHDA- 1997/10/23 00:01
PST - ppublish
SO  - Neuroimaging Clin N Am. 1997 Aug;7(3):513-25.
PMID- 9332524
OWN - NLM
STAT- MEDLINE
DA  - 19971119
DCOM- 19971119
LR  - 20041117
PUBM- Print
IS  - 1058-4838 (Print)
VI  - 25
IP  - 2
DP  - 1997 Aug
TI  - Histoplasmosis and kidney disease in patients with AIDS.
PG  - 281-4
AB  - Renal disease in patients infected with human immunodeficiency virus (HIV)
      often presents with significant proteinuria and progressive renal failure;
      focal glomerulosclerosis is the most common renal pathology identified. To
      our knowledge, we report the first case of nephrotic-range proteinuria and
      preserved renal function in an HIV-infected patient in association with
      disseminated histoplasmosis. The initial level of proteinuria was 12.5
      g/24 h. The patient developed a concomitant lesion on his neck, which was
      biopsied and identified as Histoplasma capsulatum by fungal stains and
      culture. The serum CF titer of antibody against yeast antigens of H.
      capsulatum was 1:8. The level of serum albumin decreased to 2.0 g/dL, and
      the level of serum cholesterol increased to 284 mg/dL. Immunohistochemical
      staining of renal biopsy tissue demonstrated immune complexes within the
      mesangium; H. capsulatum antigen was also demonstrated in the mesangium.
      Therapy with oral itraconazole resulted in marked clinical improvement.
      The findings in this case emphasize the need to rule out treatable causes
      of the nephrotic syndrome in AIDS, especially in cases of immune-complex
      glomerulonephritis.
AD  - Department of Medicine, Case Western Reserve University, University
      Hospitals of Cleveland, Ohio 44106-5083, USA.
FAU - Burke, D G
AU  - Burke DG
FAU - Emancipator, S N
AU  - Emancipator SN
FAU - Smith, M C
AU  - Smith MC
FAU - Salata, R A
AU  - Salata RA
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - UNITED STATES
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious
      Diseases Society of America
JID - 9203213
RN  - 0 (Antibodies, Fungal)
RN  - 0 (Antifungal Agents)
RN  - 0 (Antigen-Antibody Complex)
RN  - 0 (Serum Albumin)
RN  - 57-88-5 (Cholesterol)
RN  - 84625-61-6 (Itraconazole)
SB  - IM
SB  - X
MH  - AIDS-Related Opportunistic Infections/*microbiology
MH  - Administration, Oral
MH  - Antibodies, Fungal/analysis/blood
MH  - Antifungal Agents/administration & dosage/therapeutic use
MH  - Antigen-Antibody Complex/analysis
MH  - Biopsy
MH  - Cholesterol/analysis/blood
MH  - Diagnosis, Differential
MH  - Glomerulonephritis, Membranoproliferative/*diagnosis/microbiology
MH  - Histoplasmosis/*complications/drug therapy/immunology
MH  - Humans
MH  - Immunohistochemistry
MH  - Itraconazole/administration & dosage/therapeutic use
MH  - Kidney/immunology/pathology
MH  - Male
MH  - Middle Aged
MH  - Proteinuria/*diagnosis/microbiology
MH  - Serum Albumin/analysis
EDAT- 1997/08/01 00:00
MHDA- 1997/10/23 00:01
PST - ppublish
SO  - Clin Infect Dis. 1997 Aug;25(2):281-4.
PMID- 9341963
OWN - NLM
STAT- MEDLINE
DA  - 19971114
DCOM- 19971114
LR  - 20051116
PUBM- Print
IS  - 0923-7534 (Print)
VI  - 8 Suppl 3
DP  - 1997
TI  - Current strategies for pain control.
PG  - S21-4
AB  - Pain is the most feared symptom for patients diagnosed with cancer.
      Although our understanding of cancer pain and its management has greatly
      improved in the past decade, an unacceptably large proportion of patients
      still do not receive adequate pain relief. Before commencing any form of
      treatment, patients must receive a thorough assessment in order to define
      the pain, causes and severity. The recommendations for progressing a
      patient from step 2 to step 3 of the WHO analgesic ladder are discussed
      here as well as the choice of strong opioid substitution. An overview of
      the benefits of considering alternative routes of administering strong
      opioids, such as the transdermal delivery of fentanyl (TTS fentanyl), and
      the use of opioid substitution in patients intolerant to the adverse
      effects of morphine are also included. Finally, newer approaches to
      relieving refractory pain, such as neuropathic and bone pain, are
      considered.
AD  - Department of Surgical and Anaesthetic Sciences, Royal Hallamshire
      Hospital, Sheffield, UK.
FAU - Ahmedzai, S
AU  - Ahmedzai S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - NETHERLANDS
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical
      Oncology / ESMO
JID - 9007735
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Analgesics, Opioid)
RN  - 437-38-7 (Fentanyl)
SB  - IM
MH  - Analgesics, Non-Narcotic/therapeutic use
MH  - Analgesics, Opioid/*therapeutic use
MH  - Bone Neoplasms/physiopathology
MH  - Fentanyl/*administration & dosage
MH  - Humans
MH  - Neoplasms/*physiopathology
MH  - Pain/*drug therapy
MH  - *Pain Measurement
RF  - 28
EDAT- 1997/01/01 00:00
MHDA- 1997/10/28 00:01
PST - ppublish
SO  - Ann Oncol. 1997;8 Suppl 3:S21-4.
PMID- 9339616
OWN - NLM
STAT- MEDLINE
DA  - 19971118
DCOM- 19971118
LR  - 20041117
PUBM- Print
IS  - 0030-9982 (Print)
VI  - 47
IP  - 8
DP  - 1997 Aug
TI  - Prevalence and severity of viral hepatitis in Pakistani pregnant women: a
      five year hospital based study.
PG  - 198-201
AB  - A hospital based observational study was carried out on pregnant women
      presenting with either acute hepatitis or fulminant hepatic failure (FHF),
      during the past years. Of 53 patients, 20 (38%) developed FHF.Non-A, Non-B
      was the commonest cause (62%) followed by hepatitis B in 17% and hepatitis
      A in 4% cases. Eight women expired (case fatality rate 15%) with a high
      maternal mortality (62%) caused by NANB hepatitis. Perinatal mortality was
      30%. Poor prognostic factors identified were lack of antenatal care,
      severity of jaundice, history of somnolence, gastrointestinal bleeding and
      a high grade of encephalopathy.
AD  - Department of Obstetrics and Gynaecology, Aga Khan University Hospital,
      Karachi.
FAU - Aziz, A B
AU  - Aziz AB
FAU - Hamid, S
AU  - Hamid S
FAU - Iqbal, S
AU  - Iqbal S
FAU - Islam, W
AU  - Islam W
FAU - Karim, S A
AU  - Karim SA
LA  - eng
PT  - Journal Article
PL  - PAKISTAN
TA  - J Pak Med Assoc
JT  - JPMA.  The Journal of the Pakistan Medical Association
JID - 7501162
SB  - IM
MH  - Adult
MH  - Female
MH  - Hepatic Encephalopathy/epidemiology/etiology
MH  - Hepatitis, Viral, Human/complications/*epidemiology
MH  - Humans
MH  - Pakistan/epidemiology
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/*epidemiology
MH  - Prevalence
EDAT- 1997/08/01 00:00
MHDA- 1997/10/27 00:01
PST - ppublish
SO  - J Pak Med Assoc. 1997 Aug;47(8):198-201.
PMID- 9323036
OWN - NLM
STAT- MEDLINE
DA  - 19971027
DCOM- 19971027
LR  - 20061115
PUBM- Print
IS  - 0014-5793 (Print)
VI  - 414
IP  - 3
DP  - 1997 Sep 15
TI  - Cloning and expression in Escherichia coli of a human gelatinase
      B-inhibitory single-chain immunoglobulin variable fragment (scFv).
PG  - 562-6
AB  - The murine monoclonal antibody REGA-3G12 selectively and specifically
      inhibits the activity of human gelatinase B. The cDNA fragments which
      encode the variable regions of the light and heavy chains were isolated by
      PCR-mediated cloning and sequenced. Single-chain Fv expression constructs
      for Escherichia coli were generated in which c-myc tag sequences were
      encoded. Inducible expression of the scFv and secretion to the periplasm
      were obtained with higher yields when the c-myc tag sequence was
      positioned at the amino-terminal side. The inhibitory activity of purified
      scFv on neutrophil gelatinase B was tested in a gelatin degradation assay
      and it was found to possess a similar specific activity as that of the
      intact monoclonal antibody and of the pepsin-clipped F(ab')2 derivative.
      This shows for the first time that inhibition of soluble enzymes with scFv
      is possible and opens new perspectives for the treatment of diseases with
      excessive and detrimental enzyme production in the host.
AD  - Laboratory of Molecular Immunology, Rega Institute for Medical Research,
      University of Leuven, Belgium.
FAU - Zhou, N
AU  - Zhou N
FAU - Paemen, L
AU  - Paemen L
FAU - Opdenakker, G
AU  - Opdenakker G
FAU - Froyen, G
AU  - Froyen G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - NETHERLANDS
TA  - FEBS Lett
JT  - FEBS letters
JID - 0155157
RN  - 0 (Immunoglobulin Fragments)
RN  - 0 (Immunoglobulin Variable Region)
RN  - 0 (Recombinant Proteins)
RN  - EC 3.4.24.- (Collagenases)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Base Sequence
MH  - Cloning, Molecular
MH  - Collagenases/*antagonists & inhibitors
MH  - Escherichia coli/*genetics
MH  - Humans
MH  - Immunoglobulin Fragments/*genetics/metabolism/*pharmacology
MH  - Immunoglobulin Variable Region/*genetics/metabolism/pharmacology
MH  - Matrix Metalloproteinase 9
MH  - Mice
MH  - Molecular Sequence Data
MH  - Recombinant Proteins/genetics/metabolism
MH  - Sequence Analysis
EDAT- 1997/10/10
MHDA- 1997/10/10 00:01
AID - S0014-5793(97)01072-7 [pii]
PST - ppublish
SO  - FEBS Lett. 1997 Sep 15;414(3):562-6.
PMID- 9337362
OWN - NLM
STAT- MEDLINE
DA  - 19971031
DCOM- 19971031
LR  - 20041117
PUBM- Print
IS  - 0735-6757 (Print)
VI  - 15
IP  - 6
DP  - 1997 Oct
TI  - Emergency extracorporeal life support for patients with near-fatal status
      asthmaticus.
PG  - 566-9
AB  - Extracorporeal life support (ECLS) was used to treat three patients with
      near-fatal status asthmaticus who did not respond to aggressive medical
      therapies and mechanical ventilation under controlled permissive
      hypercapnia. ECLS was instituted in patient 1 because PaCO2 was
      excessively high and pH was excessively low, in patient 2 because
      hypoxemia and shock were not responsive to treatment, and in patient 3
      because of sustained severe hypotension. ECLS supported adequate gas
      exchange until pulmonary function improved, diminishing the need for
      mechanical ventilation and preventing pulmonary complications. Pulmonary
      dysfunction improved markedly after only 21 to 86 hours of ECLS.
      Aggressive medical treatments were continued during ECLS. Our findings
      indicate that ECLS is a useful method for preventing death in patients
      with near-fatal status asthmaticus.
AD  - Division of Intensive and Critical Care Medicine, Kumamoto University
      School of Medicine, Japan.
FAU - Kukita, I
AU  - Kukita I
FAU - Okamoto, K
AU  - Okamoto K
FAU - Sato, T
AU  - Sato T
FAU - Shibata, Y
AU  - Shibata Y
FAU - Taki, K
AU  - Taki K
FAU - Kurose, M
AU  - Kurose M
FAU - Terasaki, H
AU  - Terasaki H
FAU - Kohrogi, H
AU  - Kohrogi H
FAU - Ando, M
AU  - Ando M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - UNITED STATES
TA  - Am J Emerg Med
JT  - The American journal of emergency medicine
JID - 8309942
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Algorithms
MH  - Blood Gas Analysis
MH  - Decision Trees
MH  - Emergencies
MH  - Extracorporeal Membrane Oxygenation/*methods
MH  - Female
MH  - Humans
MH  - Life Support Care/*methods
MH  - Lung Compliance
MH  - Middle Aged
MH  - Pulmonary Gas Exchange
MH  - Respiration, Artificial
MH  - Status Asthmaticus/physiopathology/*therapy
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
AID - S0735-6757(97)90158-3 [pii]
PST - ppublish
SO  - Am J Emerg Med. 1997 Oct;15(6):566-9.
PMID- 9323783
OWN - NLM
STAT- MEDLINE
DA  - 19971029
DCOM- 19971029
LR  - 20061115
PUBM- Print
IS  - 0281-3432 (Print)
VI  - 15
IP  - 3
DP  - 1997 Sep
TI  - The prevalence of beta-haemolytic streptococci in throat specimens from
      healthy children and adults. Implications for the clinical value of throat
      cultures.
PG  - 149-55
AB  - OBJECTIVE: To examine the influence of age and season of the year on the
      carrier rate of beta-haemolytic streptococci (BHS) in healthy individuals
      and patients with throat pain. DESIGN: The prevalence of BHS in throat
      specimens from healthy individuals was compared with that from patients
      with throat pain of the same age in a defined geographical area, collected
      during the same mid-winter and late summer periods. RESULTS: The
      prevalence of BHS in healthy individuals was low before the age of 3 years
      (1.9-7.1%) and in adults > or = 16 years (2.4-3.7%) and highest in the age
      group 3-15 years (5.0-21.2%). The difference in prevalence of BHS between
      healthy individuals and patients with throat pain was small during the
      late summer season and large during the mid-winter season. CONCLUSION:
      Prevalence of BHS varies with age and season in healthy individuals and
      patients with throat pain. During the summer, it is much more difficult to
      interpret the result of a throat culture in individuals aged < 16 years.
AD  - Department of Primary Health Care, Goteborg University, Sweden.
FAU - Gunnarsson, R K
AU  - Gunnarsson RK
FAU - Holm, S E
AU  - Holm SE
FAU - Soderstrom, M
AU  - Soderstrom M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - NORWAY
TA  - Scand J Prim Health Care
JT  - Scandinavian journal of primary health care
JID - 8510679
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Carrier State/epidemiology/*microbiology
MH  - Child
MH  - Child Day Care Centers
MH  - Child, Preschool
MH  - Humans
MH  - Infant
MH  - Pharyngitis/*microbiology
MH  - Pharynx/*microbiology
MH  - Prevalence
MH  - Prospective Studies
MH  - Seasons
MH  - Serotyping
MH  - Streptococcal Infections/*microbiology
MH  - Streptococcus pyogenes/classification/growth & development/*isolation &
      purification
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Scand J Prim Health Care. 1997 Sep;15(3):149-55.
PMID- 9344868
OWN - NLM
STAT- MEDLINE
DA  - 19971117
DCOM- 19971117
LR  - 20061115
PUBM- Print
IS  - 0006-291X (Print)
VI  - 239
IP  - 2
DP  - 1997 Oct 20
TI  - High pressure modulation of Escherichia coli DNA gyrase activity.
PG  - 552-6
AB  - Elevated pressures greater than 551 bar were found to inhibit the DNA
      supercoiling activity of Escherichia coli DNA gyrase. A large fraction of
      the inhibitory effect could be reproduced by preincubation of the enzyme
      at high pressure prior to enzymatic assay at 1 bar. It is proposed that
      elevated pressure influences gyrase structure, most likely by promoting
      the dissociation of its subunits, however, it is also possible that
      effects on enzyme activity exist.
CI  - Copyright 1997 Academic Press.
AD  - Center for Marine Biotechnology and Biomedicine, Scripps Institution of
      Oceanography, La Jolla, California 92093, USA.
FAU - Chilukuri, L N
AU  - Chilukuri LN
FAU - Fortes, P A
AU  - Fortes PA
FAU - Bartlett, D H
AU  - Bartlett DH
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - UNITED STATES
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (DNA, Superhelical)
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
SB  - IM
MH  - *Atmospheric Pressure
MH  - DNA Topoisomerases, Type II/*metabolism
MH  - DNA, Superhelical/metabolism
MH  - Electrophoresis, Agar Gel
MH  - Enzyme Activation
MH  - Escherichia coli/*enzymology
MH  - Plasmids/metabolism
MH  - Substrate Specificity
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
AID - S0006-291X(97)97503-3 [pii]
AID - 10.1006/bbrc.1997.7503 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 1997 Oct 20;239(2):552-6.
PMID- 9323782
OWN - NLM
STAT- MEDLINE
DA  - 19971029
DCOM- 19971029
LR  - 20041117
PUBM- Print
IS  - 0281-3432 (Print)
VI  - 15
IP  - 3
DP  - 1997 Sep
TI  - Enterobius vermicularis and finger sucking in young Swedish children.
PG  - 146-8
AB  - OBJECTIVE: To study the prevalence of Enterobius vermicularis and its
      association with finger sucking in young Swedish children. DESIGN:
      Cross-sectional survey with a questionnaire for symptoms of infestation
      with Enterobius vermicularis, and the children's habit of finger sucking
      (including fingernail biting). Perianal tape-test for identification of
      eggs of Enterobius vermicularis. SETTING: Primary care, day-care centres,
      and schools in a Swedish middle-sized town (approx. 80,000 inhabitants).
      PARTICIPANTS: 172 children of both sexes, 4-10 years old. MAIN OUTCOME
      MEASURES: The prevalence of Enterobius vermicularis and its association
      with finger sucking. RESULTS: 21% of the children were symptom-free
      carriers of Enterobius vermicularis, and finger sucking was strongly
      associated with a positive tape-test (p = 0.01). CONCLUSION: More children
      than previously known seemed to be symptom-free carriers of Enterobius
      vermicularis. Finger sucking should be considered when treating infested
      children and especially those with relapsing symptoms.
AD  - Primary Care Centre Hertig Knut, Central Hospital, Halmstad, Sweden.
FAU - Herrstrom, P
AU  - Herrstrom P
FAU - Fristrom, A
AU  - Fristrom A
FAU - Karlsson, A
AU  - Karlsson A
FAU - Hogstedt, B
AU  - Hogstedt B
LA  - eng
PT  - Journal Article
PL  - NORWAY
TA  - Scand J Prim Health Care
JT  - Scandinavian journal of primary health care
JID - 8510679
SB  - IM
MH  - Animals
MH  - Child
MH  - Child, Preschool
MH  - Enterobiasis/diagnosis/*epidemiology/prevention & control/*transmission
MH  - *Enterobius
MH  - Female
MH  - *Fingersucking
MH  - Humans
MH  - Male
MH  - Mass Screening
MH  - Prevalence
MH  - Sweden/epidemiology
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Scand J Prim Health Care. 1997 Sep;15(3):146-8.
PMID- 9327226
OWN - NLM
STAT- MEDLINE
DA  - 19971120
DCOM- 19971120
LR  - 20051117
PUBM- Print
IS  - 1040-8746 (Print)
VI  - 9
IP  - 5
DP  - 1997 Sep
TI  - Advances in gynecologic radiation oncology.
PG  - 471-7
AB  - Radiation therapy is an important modality in the curative and palliative
      management of patients with gynecologic malignancies. However, the
      specific roles of radiation therapy continue to evolve in terms of
      specific indications, volumes treated, techniques, and integration with
      other modalities. Retrospective assessments of outcome and prospective
      clinical trials are necessary to answer questions, generate additional
      hypotheses, and guide further refinements in the application of radiation
      therapy. This article focuses on recent literature and ongoing clinical
      trials in this disease group.
AD  - Department of Radiation Oncology, Indiana University School of Medicine,
      Indianapolis 46202, USA.
FAU - Woodburn, R
AU  - Woodburn R
FAU - Randall, M E
AU  - Randall ME
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - Curr Opin Oncol
JT  - Current opinion in oncology
JID - 9007265
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Combined Modality Therapy
MH  - Female
MH  - Genital Neoplasms, Female/*radiotherapy/surgery
MH  - Humans
MH  - Ovarian Neoplasms/radiotherapy
MH  - Uterine Cervical Neoplasms/radiotherapy
MH  - Uterine Neoplasms/radiotherapy
MH  - Vaginal Neoplasms/radiotherapy
MH  - Vulvar Neoplasms/radiotherapy
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Curr Opin Oncol. 1997 Sep;9(5):471-7.
PMID- 9344556
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20031114
PUBM- Print
IS  - 0014-4886 (Print)
VI  - 147
IP  - 2
DP  - 1997 Oct
TI  - GABA and glutamate levels in the substantia nigra reticulata following
      repetitive cerebral ischemia in gerbils.
PG  - 311-5
AB  - Repetitive cerebral ischemia produces more severe damage than a similar
      single duration insult. We have previously shown that, in gerbils, damage
      in the substantia nigra reticulata (SNr) is seen with repetitive insults
      rather than a single insult. We have also shown that there is a
      progressive decrease in the extracellular GABA in the striatum in the days
      preceding such damage, speculating that a loss of GABA may be in part
      responsible for this damage. This study evaluates the GABA levels in the
      SNr in animals exposed to repetitive ischemic insults. Each animal
      received a total of three ischemic insults of 3-min duration at hourly
      intervals. In vivo microdialysis was carried out to analyze the GABA and
      glutamate dialysate levels on Days 1, 3, 5, 7, and 14 following the
      ischemic insult. In the control and treated (ischemic) animals, there was
      a significant increase in the GABA levels with the introduction of
      nipecotic acid on Days 1, 3, 5, and 14. However, on Day 7 there was a
      significant attenuation in the GABA response to nipecotic acid in the
      treated animals in comparison to the controls. The glutamate levels in the
      treated animals were similar to the control animals on Days 1, 3, 5, and
      7. However, on Day 14 the glutamate levels were significantly lower than
      on previous days. Our experiments for the first time measure extracellular
      glutamate and GABA responses in the SNr in animals exposed to repetitive
      ischemic insults. Our experiments show that there is a significant
      decrease in the GABA concentrations at a time when ischemic damage is
      developing in this region. This confirms our hypothesis that a decrease in
      GABA may be one factor contributing to neuronal damage during the period
      following repetitive ischemic insults. Further, the rebound increase in
      GABA levels on Day 14 with a concomitant fall in glutamate levels would
      indicate that reparative processes are still active in the 2 weeks
      following the insult.
AD  - Department of Medicine, and Saskatchewan Stroke Research Centre,
      University of Saskatchewan, Saskatoon, Canada.
FAU - Shuaib, A
AU  - Shuaib A
FAU - Ijaz, M S
AU  - Ijaz MS
FAU - Miyashita, H
AU  - Miyashita H
FAU - Hussain, S
AU  - Hussain S
FAU - Kanthan, R
AU  - Kanthan R
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - Exp Neurol
JT  - Experimental neurology
JID - 0370712
RN  - 56-12-2 (gamma-Aminobutyric Acid)
RN  - 56-86-0 (Glutamic Acid)
SB  - IM
MH  - Animals
MH  - Brain Damage, Chronic/etiology/pathology
MH  - Brain Ischemia/complications/*metabolism/pathology
MH  - Chromatography, High Pressure Liquid
MH  - Convalescence
MH  - Gerbillinae
MH  - Glutamic Acid/*analysis
MH  - Male
MH  - Microdialysis
MH  - Recurrence
MH  - Substantia Nigra/*chemistry
MH  - Time Factors
MH  - gamma-Aminobutyric Acid/*analysis
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
AID - S0014-4886(97)96588-2 [pii]
AID - 10.1006/exnr.1997.6588 [doi]
PST - ppublish
SO  - Exp Neurol. 1997 Oct;147(2):311-5.
PMID- 9327635
OWN - NLM
STAT- MEDLINE
DA  - 19971029
DCOM- 19971029
LR  - 20041117
PUBM- Print
IS  - 0962-7480 (Print)
VI  - 47
IP  - 6
DP  - 1997 Aug
TI  - Occupational risk and toxicology evaluations of industrial water
      conditioning.
PG  - 337-40
AB  - This study addresses the chemical and toxicological questions due to the
      wide use of chemical treatment programmes for industrial cooling water.
      First, natural problems encountered in cooling tower systems were
      presented and grouped into three categories: (i) scaling; (ii) corrosion
      and (iii) biofouling. Chemical solutions adopted in industrial plants were
      outlined for each one in order to minimize damage and categorized as
      shut-down, production loss, heat transfer reduction, upsets, etc. Above
      all, the purpose of the work was to identify the most dangerous chemicals
      normally used, which means sources of chemical risk for safety workers and
      their environment; thus, symptoms of exposure, prevention measures and
      protection tools are also described.
AD  - Occupational Medicine Institute, University of Messina, Italy.
FAU - Broussard, G
AU  - Broussard G
FAU - Bramanti, O
AU  - Bramanti O
FAU - Marchese, F M
AU  - Marchese FM
LA  - eng
PT  - Journal Article
PL  - ENGLAND
TA  - Occup Med (Lond)
JT  - Occupational medicine (Oxford, England)
JID - 9205857
RN  - 0 (Disinfectants)
RN  - 0 (Oxidants)
RN  - 0 (Surface-Active Agents)
RN  - 7732-18-5 (Water)
SB  - IM
MH  - Corrosion
MH  - Disinfectants/*adverse effects
MH  - Humans
MH  - Occupational Diseases/chemically induced/prevention & control
MH  - Occupational Exposure/*adverse effects
MH  - Oxidants/adverse effects
MH  - Risk Factors
MH  - Safety
MH  - Surface-Active Agents/adverse effects
MH  - *Water
MH  - Water Softening/*adverse effects
EDAT- 1997/08/01 00:00
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Occup Med (Lond). 1997 Aug;47(6):337-40.
PMID- 9345269
OWN - NLM
STAT- MEDLINE
DA  - 19971124
DCOM- 19971124
LR  - 20061115
PUBM- Print
IS  - 0006-291X (Print)
VI  - 239
IP  - 1
DP  - 1997 Oct 9
TI  - Comparison of exocytotic mechanisms between acetylcholine- and
      catecholamine-containing vesicles in rat pheochromocytoma cells.
PG  - 57-62
AB  - The molecular mechanisms of exocytosis from two types of secretory
      organelles, synaptic-like microvesicles and secretory vesicles, were
      compared by measuring acetylcholine (ACh) and catecholamine (CA) release
      from a newly isolated PC12 subclone, PC12-C3 which contains a high level
      of Ach. Digitonin-permeabilized PC12-C3 cells released both transmitters
      with similar Ca(2+)-dependency. Ca(2+)-evoked Ach and CA release from
      permeabilized cells were increased in the presence of MgATP, suggesting
      the existence of a MgATP-dependent priming step prior to the
      Ca(2+)-triggered fusion step in both ACh release and CA release. The
      non-hydrolyzable analogue of GTP guanosine 5'-(gamma-thio)triphosphate
      (GTP gamma S), produced both ACh and CA release from permeabilized cells
      in the absence of Ca2+. Pretreatment with a phorbol ester which activates
      protein kinase C, potentiated depolarization-induced ACh and CA release
      from unpermeabilized cells. These results indicated that exocytosis from
      two distinct vesicle populations are mediated by the same basic molecular
      mechanisms.
AD  - Mitsubishi Kasei Institute of Life Sciences, Tokyo, Japan.
FAU - Nishiki, T
AU  - Nishiki T
FAU - Shoji-Kasai, Y
AU  - Shoji-Kasai Y
FAU - Sekiguchi, M
AU  - Sekiguchi M
FAU - Iwasaki, S
AU  - Iwasaki S
FAU - Kumakura, K
AU  - Kumakura K
FAU - Takahashi, M
AU  - Takahashi M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Catecholamines)
RN  - 37589-80-3 (Guanosine 5'-O-(3-Thiotriphosphate))
RN  - 51-84-3 (Acetylcholine)
RN  - 56-65-5 (Adenosine Triphosphate)
RN  - 7440-09-7 (Potassium)
RN  - 7440-70-2 (Calcium)
SB  - IM
MH  - Acetylcholine/*metabolism
MH  - Adenosine Triphosphate/metabolism
MH  - Animals
MH  - Calcium/metabolism
MH  - Catecholamines/*metabolism
MH  - Chromatography, High Pressure Liquid
MH  - *Exocytosis
MH  - Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology
MH  - PC12 Cells
MH  - Potassium/metabolism
MH  - Rats
MH  - Synaptic Vesicles/drug effects/*metabolism
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
AID - S0006291X97974271 [pii]
PST - ppublish
SO  - Biochem Biophys Res Commun. 1997 Oct 9;239(1):57-62.
PMID- 9297786
OWN - NLM
STAT- MEDLINE
DA  - 19971028
DCOM- 19971028
LR  - 20061115
PUBM- Print
IS  - 0045-6535 (Print)
VI  - 35
IP  - 5
DP  - 1997 Sep
TI  - Species-specific alteration of hepatic glucose 6-phosphate dehydrogenase
      activity with coplanar polychlorinated biphenyl: evidence for an
      Ah-receptor-linked mechanism.
PG  - 951-8
AB  - We examined the in vivo effect of a highly toxic coplanar polychlorinated
      biphenyl (PCB) on the hepatic activity of glucose 6-phosphate
      dehydrogenase (G6PDH) in aryl hydrocarbon (Ah)-responsive (C57/BL) and
      -less-responsive (DBA) strains of mice. The activity in the C57BL strain
      was moderately increased by 3,3',4,4',5-pentachlorobiphenyl (PCB 126) in a
      dose dependent manner. However, this was not observed in DBA mice although
      greater doses were injected. 2,2',5,5'-Tetrachlorobiphenyl (PCB 52) with a
      non-planar structure did not increase G6PDH activity. The increase in
      G6PDH activity with PCB 126 was also seen in rats, but not in guinea pigs.
      The activity in the latter species was decreased rather than increased.
      These results suggest that the induction of hepatic G6PDH by coplanar PCB
      is mediated by a mechanism involving the Ah receptor, and the response was
      highly species-specific.
AD  - Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
FAU - Hori, M
AU  - Hori M
FAU - Kondo, H
AU  - Kondo H
FAU - Ariyoshi, N
AU  - Ariyoshi N
FAU - Yamada, H
AU  - Yamada H
FAU - Oguri, K
AU  - Oguri K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - ENGLAND
TA  - Chemosphere
JT  - Chemosphere
JID - 0320657
RN  - 0 (Polychlorinated Biphenyls)
RN  - 0 (Receptors, Aryl Hydrocarbon)
RN  - EC 1.1.1.49 (Glucosephosphate Dehydrogenase)
SB  - IM
MH  - Animals
MH  - Dose-Response Relationship, Drug
MH  - Enzyme Induction
MH  - Glucosephosphate Dehydrogenase/*biosynthesis
MH  - Guinea Pigs
MH  - Liver/*drug effects/enzymology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred DBA
MH  - Polychlorinated Biphenyls/*toxicity
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Aryl Hydrocarbon/*drug effects/metabolism
MH  - Species Specificity
EDAT- 1997/09/23
MHDA- 1997/09/23 00:01
AID - S0045653597001811 [pii]
PST - ppublish
SO  - Chemosphere. 1997 Sep;35(5):951-8.
PMID- 9380946
OWN - NLM
STAT- MEDLINE
DA  - 19971120
DCOM- 19971120
LR  - 20061115
PUBM- Print
IS  - 0034-1193 (Print)
VI  - 88
IP  - 9
DP  - 1997 Sep
TI  - [The maternal-fetal immune relationship in pregnancy]
PG  - 406-14
AB  - The mother establishes with the fetus a special interaction in pregnancy
      allowing his normal survival in spite of the different HLA antigens. The
      main factors contributing to these favourable conditions for the fetus are
      an efficient local immunosuppression and the formation of a protective
      barrier between the mother and the fetus. A number of substances are
      responsible for the local immunosuppression and include cytokines,
      prostaglandins, hormones as well as various other proteins of pregnancy.
      In addition, cytokines produced by TH2 lymphocytes seem to be predominant
      with respect to those of TH1 cells. An effective protection is provided by
      the trophoblast layer, which not only forms a physical barrier between the
      mother and the fetus but evades the immune attack of the mother by
      expressing inhibitory molecules of the complement system and by down
      regulating the expression of HLA antigens. Data obtained from murine
      models and clinical observation in pathological pregnancies suggest that
      an abnormal immune response of the mother against the feto-placental unit
      may be responsible for the occurrence of recurrent spontaneous abortions.
      This is proved by the ability of the partner's lymphocytes administered to
      females in the mouse model prior to mating to reduce the incidence of
      abortions. Unfortunately, similar treatment in women with recurrent
      abortion does not appear to be very effective.
AD  - Dipartimento di Fisiologia e Patologia, Universita, Trieste.
FAU - Tedesco, F
AU  - Tedesco F
FAU - Pausa, M
AU  - Pausa M
FAU - Bulla, R
AU  - Bulla R
FAU - Melazzini, S
AU  - Melazzini S
FAU - Guaschino, S
AU  - Guaschino S
LA  - ita
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Il rapporto immune materno-fetale in gravidanza.
PL  - ITALY
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Abortion, Habitual/immunology
MH  - Animals
MH  - Decidua/immunology
MH  - Female
MH  - HLA Antigens/immunology
MH  - Humans
MH  - *Immunity, Maternally-Acquired
MH  - Pregnancy/*immunology
MH  - Pregnancy, Animal/*immunology
MH  - Trophoblasts/immunology
RF  - 61
EDAT- 1998/02/12
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Recenti Prog Med. 1997 Sep;88(9):406-14.
PMID- 9347825
OWN - NLM
STAT- MEDLINE
DA  - 19971118
DCOM- 19971118
LR  - 20041117
PUBM- Print
IS  - 0038-4348 (Print)
VI  - 90
IP  - 10
DP  - 1997 Oct
TI  - Breast metastasis from non-small cell lung cancer.
PG  - 1063-4
AB  - Breast is an unusual site for metastatic disease, particularly for
      non-small cell lung cancer. We report an unusual case of metastatic breast
      lesions from a primary anaplastic lung tumor and discuss the common and
      uncommon sites of metastasis from lung carcinomas.
AD  - Department of Respiratory Medicine, Leeds General Infirmary, England.
FAU - Sadikot, R T
AU  - Sadikot RT
FAU - Renwick, D S
AU  - Renwick DS
FAU - DaCosta, P
AU  - DaCosta P
FAU - Chalmers, A G
AU  - Chalmers AG
FAU - Pearson, S B
AU  - Pearson SB
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - UNITED STATES
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
SB  - AIM
SB  - IM
MH  - Breast Neoplasms/*secondary
MH  - Carcinoma, Non-Small-Cell Lung/*secondary
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*pathology
MH  - Middle Aged
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - South Med J. 1997 Oct;90(10):1063-4.
PMID- 9323766
OWN - NLM
STAT- MEDLINE
DA  - 19971120
DCOM- 19971120
LR  - 20051116
PUBM- Print
IS  - 0033-8397 (Print)
VI  - 69
IP  - 1
DP  - 1997 Sep-Oct
TI  - Repair of pseudoaneurysms via ultrasound-guided compression.
PG  - 55-61
AB  - Pseudoaneurysm formation is one of the potential complications of arterial
      catheterization. In the past, surgery was the usual method of treatment
      for pseudoaneurysms. Although surgical repair is still indicated in some
      cases, a noninvasive procedure called ultrasound-guided compression repair
      (UGCR) often can be used instead of surgery. During UGCR, an ultrasound
      transducer is used to apply compression to the pseudoaneurysm, causing a
      clot to form. This article describes the UGCR procedure and discusses
      results that clinicians have attained using this method of pseudoaneurysm
      repair.
AD  - Putnam County Hospital, Greencastle, Ind., USA.
FAU - Benassi, K G
AU  - Benassi KG
FAU - Cox, L A
AU  - Cox LA
FAU - Long, B W
AU  - Long BW
LA  - eng
PT  - Journal Article
PT  - Review
PL  - UNITED STATES
TA  - Radiol Technol
JT  - Radiologic technology
JID - 0401256
SB  - IM
MH  - Aneurysm, False/etiology/*therapy
MH  - Catheterization/adverse effects
MH  - Humans
MH  - Pressure
MH  - Transducers
MH  - *Ultrasonography, Doppler
RF  - 26
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Radiol Technol. 1997 Sep-Oct;69(1):55-61.
PMID- 9300992
OWN - NLM
STAT- MEDLINE
DA  - 19971027
DCOM- 19971027
LR  - 20061115
PUBM- Print
IS  - 0301-5629 (Print)
VI  - 23
IP  - 6
DP  - 1997
TI  - Comparison of B-mode, M-mode and echo-tracking methods for measurement of
      the arterial distension waveform.
PG  - 879-87
AB  - Measurements of arterial diameter throughout the cardiac cycle (i.e., the
      arterial distension waveform) are conducted increasingly to study
      mechanical properties of the arterial wall and changes associated with
      disease. The distension waveform of peripheral arteries can be measured
      noninvasively via ultrasonic echo tracking. M-mode imaging, and B-mode
      imaging. Of these, echo tracking is the most popular method because of its
      single micrometer resolution during continuous measurements under ideal
      conditions. However, high resolution within continuous measurements does
      not imply high reproducibility between measurements. Therefore, we
      compared repeated measurements of the amplitude of common carotid artery
      distension in 26 subjects, obtained sequentially in random order by: 1.
      Off-line echo tracking of digitized radiofrequency ultrasound; 2. M-mode
      imaging with automated edge detection; and 3. 30-Hz B-mode imaging with
      automated edge detection and model-based diameter estimation. In each
      case, the transducer was hand-held and was removed from the neck between
      repeated measurements. The amplitude of arterial distension was estimated
      from the serial diameter measurements by maximum likelihood (ML)
      estimation, by least-squares fit of a Fourier series model, and by
      application of a cubic smoothing spline. Within continuous measurements,
      the standard deviation of the ML distension amplitude for neighboring
      cardiac cycles was significantly smaller (p > 0.05) with echo-tracking
      (0.023 mm) than with the B-mode (0.036 mm) or M-mode (0.074 mm) methods.
      However, between discontinuous measurements on the same subject, the
      standard deviation of the ML distension amplitude was similar for the
      echo-tracking (0.076 mm) and B-mode (0.073 mm) methods. The Fourier series
      model and the cubic smoothing spline slightly reduced the standard
      deviation of the B-mode and M-mode distension amplitudes, but also reduced
      the mean amplitude estimate. On the basis of this relative comparison of
      methods, we conclude that, although echo tracking offers high resolution
      for continuous measurements, the reproducibility of discontinuous
      measurements of carotid artery distension is no better with echo tracking
      than can be obtained from 30-Hz B-mode images.
AD  - Boston Heart Foundation, Cambridge, MA 02142, USA.
FAU - Stadler, R W
AU  - Stadler RW
FAU - Taylor, J A
AU  - Taylor JA
FAU - Lees, R S
AU  - Lees RS
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - ENGLAND
TA  - Ultrasound Med Biol
JT  - Ultrasound in medicine & biology
JID - 0410553
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carotid Artery, Common/physiology/*ultrasonography
MH  - Elasticity
MH  - Female
MH  - Fourier Analysis
MH  - Humans
MH  - Image Processing, Computer-Assisted/*methods
MH  - Male
MH  - Middle Aged
MH  - Reproducibility of Results
EDAT- 1997/01/01 00:00
MHDA- 1997/09/25 00:01
AID - S0301562997000744 [pii]
PST - ppublish
SO  - Ultrasound Med Biol. 1997;23(6):879-87.
PMID- 9335407
OWN - NLM
STAT- MEDLINE
DA  - 19971105
DCOM- 19971105
LR  - 20031114
PUBM- Print
IS  - 0160-2446 (Print)
VI  - 30
IP  - 4
DP  - 1997 Oct
TI  - Hemodynamic responses to endothelin-1 and endothelin antagonists
      microinjected into the nucleus tractus solitarius in rats.
PG  - 475-80
AB  - The role of endothelin-1 (ET-1) within the nucleus tractus solitarius
      (NTS) in central cardiovascular control was investigated by local
      microinjections of ET-1 and ET-receptor antagonists. In
      urethane-anesthetized Sprague-Dawley rats, a unilateral microinjection of
      ET-1 (1.0, 3.3, and 10.0 pmol) into the NTS significantly increased
      arterial pressure, left ventricular systolic pressure, and dP/dt(max) in a
      dose-dependent manner, and slightly decreased heart rate in a
      dose-independent manner. The pressor effect lasted >90 min. In
      normotensive rats, neither PD147953, a selective ETA-receptor antagonist,
      nor PD142893, a mixed ETA- and ETB-receptor antagonist, microinjected into
      the NTS elicited any changes in arterial pressure or heart rate. The
      pressor and bradycardic effects evoked by microinjection of ET-1 into the
      NTS could be blocked by local pretreatment with PD147953 and completely
      eliminated by intravenous pretreatment with the ganglionic blocker
      hexamethonium. The arterial baroreflex sensitivity was almost totally
      suppressed by microinjection of ET-1 (3.3 pmol) in
      alpha-chloralose-anesthetized Sprague-Dawley rats. A similar pattern of
      changes in the hemodynamic variables was elicited by microinjection of
      ET-1 (3.3 pmol) into the NTS in spontaneously hypertensive rats (SHRs)
      compared with Wistar-Kyoto (WKY) rats. In SHRs, microinjection of PD142893
      did not elicit any changes in arterial pressure or heart rate. These
      results suggest that ET-1 modulates reflex control of hemodynamics by
      activation of autonomic nerve via ETA receptors in the NTS, and that the
      responsiveness of SHRs to ET-1 or PD142893 is similar to that of WKY rats.
AD  - Department of Pharmacology, Faculty of Basic Medicine, Second Military
      Medical University, Shanghai, P.R. China.
FAU - Dai, S M
AU  - Dai SM
FAU - Shan, Z Z
AU  - Shan ZZ
FAU - Miao, C Y
AU  - Miao CY
FAU - Yin, M
AU  - Yin M
FAU - Su, D F
AU  - Su DF
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Endothelin-1)
RN  - 0 (Oligopeptides)
RN  - 0 (Receptors, Endothelin)
RN  - 143037-36-9 (PD 142893)
RN  - 60-26-4 (Hexamethonium)
SB  - IM
MH  - Animals
MH  - Blood Pressure/*drug effects
MH  - Endothelin-1/*pharmacology
MH  - Heart Rate/*drug effects
MH  - Hexamethonium/pharmacology
MH  - Male
MH  - Microinjections
MH  - Oligopeptides/pharmacology
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Rats, Inbred WKY
MH  - Rats, Wistar
MH  - Receptors, Endothelin/*antagonists & inhibitors
MH  - Solitary Nucleus/*drug effects/physiology
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1997 Oct;30(4):475-80.
PMID- 9378510
OWN - NLM
STAT- MEDLINE
DA  - 19971107
DCOM- 19971107
LR  - 20061115
PUBM- Print
IS  - 0019-5189 (Print)
VI  - 35
IP  - 5
DP  - 1997 May
TI  - Effect of carbon tetrachloride on rat liver, following parathyroidectomy:
      histopathological observations.
PG  - 443-7
AB  - Absence of centrilobular necrosis, cirrhosis and giant hepatic cells with
      a large nucleus were significant observations in the liver of CCl4 treated
      rats following unilateral parathyroidectomy. Increased number of
      mitochondria and presence of binucleated cells indicated hepatic
      regeneration in unilaterally parathyroidectomized and CCl4 treated rats.
      Focal necrosis, giant cells and presence of smooth endoplasmic reticulum
      around the nucleus reflect a slight impairment in regeneration of the
      liver following bilateral parathyroidectomy and CCl4 administration. The
      results show that parathyroidectomy interferes in the pathogenesis of
      necrosis and associated lesions in the liver of CCl4 treated rats. Overall
      results indicate that unilateral parathyroidectomy afforded better
      protection than bilateral parathyroidectomy.
AD  - Department of Zoology, Ch. C.S. University, Meerut, India.
FAU - Rasgoti, S
AU  - Rasgoti S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - INDIA
TA  - Indian J Exp Biol
JT  - Indian journal of experimental biology
JID - 0233411
SB  - IM
MH  - Animals
MH  - Carbon Tetrachloride Poisoning/*pathology
MH  - Liver/*drug effects/pathology
MH  - Male
MH  - Muridae/*anatomy & histology
MH  - Parathyroid Glands/*physiology
MH  - Parathyroidectomy
EDAT- 1997/05/01 00:00
MHDA- 1997/10/07 00:01
PST - ppublish
SO  - Indian J Exp Biol. 1997 May;35(5):443-7.
PMID- 9335288
OWN - NLM
STAT- MEDLINE
DA  - 19971104
DCOM- 19971104
LR  - 20061115
PUBM- Print
IS  - 0021-9193 (Print)
VI  - 179
IP  - 20
DP  - 1997 Oct
TI  - Three genes of a motility operon and their role in flagellar rotary speed
      variation in Rhizobium meliloti.
PG  - 6391-9
AB  - The peritrichous flagella of Rhizobium meliloti rotate only clockwise and
      control directional changes of swimming cells by modulating flagellar
      rotary speed. Using Tn5 insertions, we have identified and sequenced a
      motility (mot) operon containing three genes, motB, motC, and motD, that
      are translationally coupled. The motB gene (and an unlinked motA) has been
      assigned by similarity to the Escherichia coli and Bacillus subtilis
      homologs, whereas motC and motD are new and without known precedents in
      other bacteria. In-frame deletions introduced in motB, motC, or motD each
      result in paralysis. MotD function was fully restored by complementation
      with the wild-type motD gene. By contrast, deletions in motB or motC
      required the native combination of motB and motC in trans for restoring
      normal flagellar rotation, whereas complementation with motB or motC alone
      led to uncoordinated (jiggly) swimming. Similarly, a motB-motC gene fusion
      and a Tn5 insertion intervening between motB and motC resulted in jiggly
      swimming as a consequence of large fluctuations in flagellar rotary speed.
      We conclude that MotC biosynthesis requires coordinate expression of motB
      and motC and balanced amounts of the two gene products. The MotC
      polypeptide contains an N-terminal signal sequence for export, and Western
      blots have confirmed its location in the periplasm of the R. meliloti
      cell. A working model suggests that interactions between MotB and MotC at
      the periplasmic surface of the motor control the energy flux or the energy
      coupling that drives flagellar rotation.
AD  - Lehrstuhl fur Genetik, Universitat Regensburg, Germany.
FAU - Platzer, J
AU  - Platzer J
FAU - Sterr, W
AU  - Sterr W
FAU - Hausmann, M
AU  - Hausmann M
FAU - Schmitt, R
AU  - Schmitt R
LA  - eng
SI  - GENBANK/L49337
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - J Bacteriol
JT  - Journal of bacteriology
JID - 2985120R
RN  - 0 (Bacterial Proteins)
RN  - 0 (DNA Transposable Elements)
RN  - 0 (Molecular Motor Proteins)
RN  - 0 (MotB protein, Bacteria)
RN  - 0 (MotC protein, Rhizobium meliloti)
RN  - 0 (MotD protein, Rhizobium meliloti)
RN  - 0 (Protein Sorting Signals)
SB  - IM
MH  - Amino Acid Sequence
MH  - Artificial Gene Fusion
MH  - Bacterial Proteins/chemistry/*genetics/physiology
MH  - Base Sequence
MH  - DNA Transposable Elements
MH  - Flagella/*physiology
MH  - Genetic Complementation Test
MH  - Molecular Motor Proteins
MH  - Molecular Sequence Data
MH  - Movement
MH  - Mutagenesis, Insertional
MH  - *Operon
MH  - Protein Sorting Signals
MH  - Restriction Mapping
MH  - Sequence Deletion
MH  - Sinorhizobium meliloti/*genetics/physiology
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
PST - ppublish
SO  - J Bacteriol. 1997 Oct;179(20):6391-9.
PMID- 9350135
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20061115
PUBM- Print
IS  - 0018-0661 (Print)
VI  - 126
IP  - 3
DP  - 1997
TI  - The physical location of genes cdc2 and prh1 in maize (Zea mays L.).
PG  - 211-7
AB  - A biotin-labelling in situ hybridization technique was first used to
      physically map two single copy genes, cdc2 and prh1, in maize. These two
      genes are metabolically interrelated genes. The full-length cDNA clones
      cdc2ZmA and ZmPPI of genes cdc2 and prh1 were adopted as the probes. They
      are 1.3 and 1.6 kb in size, respectively. Clone cdc2ZmA was physically
      mapped on the long arm of chromosomes 4, 8, and 9. The percent distances
      from centromere to detection site were 57.9 +/- 2.7, 28.4 +/- 1.5, and
      88.2 +/- 3.3. The detection rate was 19.2%. Clone ZmPPI was physically
      mapped on the long arm of chromosomes 4, 6, and 8. The percent distances
      were 53.6 +/- 1.2, 60.8 +/- 2.9 and 17.1 +/- 1.6. The detection ratio was
      18.5%. The technique of chromosome ISH and the relationship between the
      location and function of these two genes have been discussed.
AD  - Department of Genetics, College of Life Sciences, Wuhan University, Wuhan
      Hubei, People's Republic of China.
FAU - Ren, N
AU  - Ren N
FAU - Song, Y C
AU  - Song YC
FAU - Bi, X Z
AU  - Bi XZ
FAU - Ding, Y
AU  - Ding Y
FAU - Liu, L H
AU  - Liu LH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - SWEDEN
TA  - Hereditas
JT  - Hereditas
JID - 0374654
RN  - 0 (DNA Probes)
RN  - 0 (Genetic Markers)
RN  - EC 2.7.1.37 (CDC2 Protein Kinase)
RN  - EC 3.1.3.16 (Phosphoprotein Phosphatase)
SB  - IM
MH  - CDC2 Protein Kinase/*genetics
MH  - Centromere
MH  - *Chromosome Mapping
MH  - DNA Probes
MH  - Genetic Markers
MH  - Phosphoprotein Phosphatase/*genetics
MH  - Zea mays/*genetics
EDAT- 1997/01/01 00:00
MHDA- 1997/11/14 00:01
PST - ppublish
SO  - Hereditas. 1997;126(3):211-7.
PMID- 9306444
OWN - NLM
STAT- MEDLINE
DA  - 19971027
DCOM- 19971027
LR  - 20051116
PUBM- Print
IS  - 0740-9303 (Print)
VI  - 13
IP  - 3
DP  - 1997 Sep
TI  - Visual hallucinations after enucleation.
PG  - 221-5
AB  - Visual phenomena are frequently reported in patients after ocular trauma,
      surgery or progressive visual degeneration. In particular, hallucinations
      are often seen by patients following enucleation. Whereas these visions
      can be verbally described to the physician, they can never actually be
      seen. This article focuses on the case of a female artist who experienced
      visual hallucinations after enucleation of her dominant right eye. In
      addition to her verbal descriptions, she was able to express these
      hallucinations visually on canvas. Her case offers insight to caregivers
      about the nature of visual hallucinations in patients with similar
      experiences. A review of the general characteristics and etiologies of
      such visual phenomena is also included.
AD  - Casey Eye Institute, Oregon Health Sciences University, Portland 97201,
      USA.
FAU - Gross, N D
AU  - Gross ND
FAU - Wilson, D J
AU  - Wilson DJ
FAU - Dailey, R A
AU  - Dailey RA
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - UNITED STATES
TA  - Ophthal Plast Reconstr Surg
JT  - Ophthalmic plastic and reconstructive surgery
JID - 8508431
SB  - IM
MH  - Aged
MH  - Eye Enucleation/*adverse effects
MH  - Female
MH  - Hallucinations/*etiology/psychology
MH  - Humans
MH  - Postoperative Complications
MH  - Vision Disorders/*etiology/psychology
RF  - 18
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Ophthal Plast Reconstr Surg. 1997 Sep;13(3):221-5.
PMID- 9347706
OWN - NLM
STAT- MEDLINE
DA  - 19971119
DCOM- 19971119
LR  - 20041118
PUBM- Print
IS  - 1040-2446 (Print)
VI  - 72
IP  - 10
DP  - 1997 Oct
TI  - Reflections on death and dying.
PG  - 848-55
AB  - Americans simultaneously worry about dying and about being tethered to
      machines that keep them alive beyond a point when life has any meaning.
      People living with terminal illness often feel isolated from life around
      them and a burden on those they love; they feel uncertain that their
      deaths will be relatively free of pain and suffering and that their
      dignity will be compromised as little as possible. These failings can be
      remedied. Traditional hospice care and integrating palliative care into
      the general medical setting are important, but they cannot alone occasion
      a better dying. The medical community must re-imagine dying and reflect
      about ways to transform image into reality in practice and in training
      colleagues and successors. Physicians and others know how to provide care
      and even improve living when cure is unlikely; the harder task is to
      respect such care as profoundly as curing. The exigencies of modern
      medicine, where time is a budgetable commodity, makes caring well for
      dying patients difficult. Medicine cannot have hegemony over dying and
      cannot singularly offer people a better death, but it cannot absent itself
      either. The almost single-minded focus on decision making that has infused
      conversations about dying and death may divert attention from the
      attentiveness and loving relationships that are as vital as life's end as
      at its beginning. Medicine has "colonized" death: It has transformed it
      into a place where progress in staving it off may appear to be unlimited,
      and thus it encourages forgetting that death is part of the human
      condition. The task before medicine, and academic medicine in particular,
      is to transform death back into a human scale. With all that is available
      to delay death--but not to make it optional--the most important task is to
      recover humbleness before an awesome moment and be with the patient, one
      human being to another, knowing that dying is not always open to
      solutions.
AD  - Park Ridge Center for the Study of Health, Faith, and Ethics, Chicago,
      Illinois 60611-3215, USA. martha@prchfe.org
FAU - Holstein, M
AU  - Holstein M
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - Acad Med
JT  - Academic medicine : journal of the Association of American Medical
      Colleges
JID - 8904605
SB  - AIM
SB  - E
SB  - IM
CIN - Acad Med. 1998 Mar;73(3):221-2. PMID: 9526441
MH  - Advance Directives
MH  - *Death
MH  - Dehumanization
MH  - Ethics
MH  - Home Care Services
MH  - Humans
MH  - Narration
MH  - Physician's Role
MH  - Physician-Patient Relations
MH  - Social Change
MH  - Sociology, Medical
MH  - Stress, Psychological
MH  - Terminal Care
OID - KIE: 56617
OTO - KIE
OT  - Death and Euthanasia
GN  - KIE: KIE BoB Subject Heading: terminal care
GN  - KIE: Full author name: Holstein, Martha
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Acad Med. 1997 Oct;72(10):848-55.
PMID- 9376763
OWN - NLM
STAT- MEDLINE
DA  - 19971028
DCOM- 19971028
LR  - 20061115
PUBM- Print
IS  - 0869-2092 (Print)
VI  - 60
IP  - 4
DP  - 1997 Jul-Aug
TI  - [The pharmacokinetic interaction of cholinolytics and cholinesterase
      reactivators as a reflection of the modulation of their binding in blood
      plasma and in brain tissue]
PG  - 64-7
AB  - Radioligand assay showed that the cholinesterase (ChE) reactivators
      dipiroxime and benzyxime, but not carboxime, modulate selective absorption
      of some cholinolytics (tributam, pediphen, aprophen) in rat brain.
      Significant suppression of the specific binding of muscarine antagonists
      was recorded after chlorophos (2.LD50) intoxication. Under such
      conditions, the ChE reactivators induce increase in the number of binding
      sites and in the parameters of the constant of cholinolytic absorption on
      the brain membranes. It was also established by equilibrium dialysis that
      the binding of cholinolytics in blood plasma under the effect of ChE
      reactivators is reduced, leading to redistribution of their free and bound
      fractures, which is most favorable for tissue sorption.
FAU - Elaeva, N L
AU  - Elaeva NL
FAU - Predtechenskii, M B
AU  - Predtechenskii MB
FAU - Kul'bitskii, G N
AU  - Kul'bitskii GN
FAU - Babaina, E V
AU  - Babaina EV
FAU - Trefilov, V V
AU  - Trefilov VV
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Farmakokineticheskoe vzaimodeistvie kholinolitikov i reaktivatorov
      kholinesterazy kak otrazhenie moduliatsii ikh sviazyvaniia v plazme krovi
      i v tkani mozga.
PL  - RUSSIA
TA  - Eksp Klin Farmakol
JT  - Eksperimental'naia i klinicheskaia farmakologiia
JID - 9215981
RN  - 0 (Carbon Radioisotopes)
RN  - 0 (Cholinergic Antagonists)
RN  - 0 (Cholinesterase Reactivators)
RN  - 0 (Insecticides)
RN  - 10028-17-8 (Tritium)
RN  - 52-68-6 (Trichlorfon)
SB  - IM
MH  - Animals
MH  - Brain/*metabolism
MH  - Brain Chemistry
MH  - Carbon Radioisotopes
MH  - Cholinergic Antagonists/analysis/*pharmacokinetics/therapeutic use
MH  - Cholinesterase Reactivators/analysis/*pharmacokinetics/therapeutic use
MH  - Chromatography, High Pressure Liquid
MH  - Chromatography, Thin Layer
MH  - Drug Interactions
MH  - Insecticides/poisoning
MH  - Male
MH  - Plasma/chemistry/*metabolism
MH  - Poisoning/drug therapy/metabolism
MH  - Radioligand Assay
MH  - Rats
MH  - Time Factors
MH  - Trichlorfon/poisoning
MH  - Tritium
EDAT- 1997/07/01 00:00
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Eksp Klin Farmakol. 1997 Jul-Aug;60(4):64-7.
PMID- 9263063
OWN - NLM
STAT- MEDLINE
DA  - 19971027
DCOM- 19971027
LR  - 20061115
PUBM- Print
IS  - 0021-8812 (Print)
VI  - 75
IP  - 8
DP  - 1997 Aug
TI  - Use of a raw meat-based diet or a dry kibble diet for sand cats (Felis
      margarita).
PG  - 2154-60
AB  - Limited information is available on the utilization of different types of
      diets by captive exotic felid species. Utilization of diets by small
      exotic felids may differ depending on the diet fed. Eight sand cats (Felis
      margarita), which are small, 2- to 4-kg cats, were used to examine the
      digestibility of two types of diets: a raw meat-based diet and a dry
      kibble diet. Dry matter, crude protein and energy intakes and
      digestibilities were evaluated. Digestibilities for dry matter, energy,
      and crude protein were 83.5 +/- 4.8, 89.6 +/- 5.2, 92.4 +/- 5.3% for the
      raw meat-based diet and 72.7 +/- 12.3, 76.8 +/- 14.5, and 77.9 +/- 13.5%
      for the kibble diet. Physiological variables also were examined and
      included plasma taurine, vitamin A, retinyl palmitate, beta-carotene,
      calcium, and phosphorus. Plasma taurine means were 91.4 +/- 8.4 mumol/L in
      cats consuming the raw meat-based diet and 248.0 +/- 23.2 mumol/L in cats
      consuming the kibble diet. Plasma phosphorus was 5.2 +/- .1 and 4.5 +/- .1
      mg/dL, respectively, in cats consuming raw meat-based and kibble diets.
      beta-Carotene was 25.2 +/- 2.9 and 2.9 +/- .3 micrograms/dL, respectively,
      for cats consuming the raw meat-based and kibble diets. These results
      indicate that diets formulated for small captive exotic felid species
      should be evaluated with respect to diet type and nutrient utilization.
AD  - Daniel F. & Ada L. Rice Conservation Biology and Research Center, Chicago
      Zoological Society, Brookfield, IL 60513, USA.
FAU - Crissey, S D
AU  - Crissey SD
FAU - Swanson, J A
AU  - Swanson JA
FAU - Lintzenich, B A
AU  - Lintzenich BA
FAU - Brewer, B A
AU  - Brewer BA
FAU - Slifka, K A
AU  - Slifka KA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - J Anim Sci
JT  - Journal of animal science
JID - 8003002
RN  - 0 (Dietary Proteins)
RN  - 107-35-7 (Taurine)
RN  - 11103-57-4 (Vitamin A)
RN  - 7235-40-7 (beta Carotene)
RN  - 7440-70-2 (Calcium)
RN  - 7723-14-0 (Phosphorus)
SB  - IM
MH  - Animal Feed/standards
MH  - Animals
MH  - Body Mass Index
MH  - Calcium/blood
MH  - Carnivora/growth & development/metabolism/*physiology
MH  - Diet/*veterinary
MH  - Dietary Proteins/pharmacology
MH  - Digestion/physiology
MH  - Energy Intake/physiology
MH  - Energy Metabolism/physiology
MH  - Female
MH  - Male
MH  - *Meat/analysis
MH  - Phosphorus/blood
MH  - Taurine/blood
MH  - Vitamin A/blood
MH  - beta Carotene/analysis
EDAT- 1997/08/01
MHDA- 1997/08/01 00:01
PST - ppublish
SO  - J Anim Sci. 1997 Aug;75(8):2154-60.
PMID- 9311427
OWN - NLM
STAT- MEDLINE
DA  - 19971114
DCOM- 19971114
LR  - 20061115
PUBM- Print
IS  - 0272-9490 (Print)
VI  - 51
IP  - 9
DP  - 1997 Oct
TI  - Clinical interpretation of "In-hand manipulation in young children:
      translation movements".
PG  - 729-32
AB  - As a result of their study, Pehoski et al. (1997) have contributed to our
      knowledge of the development of in-hand manipulation skills in young
      children. Although knowledge of skill development in children who are
      typically developing must be applied with caution to children with
      disabilities, information about normal development provides us with at
      least the basis for evaluation and treatment planning. Children with
      moderate and severe problems with hand skills are very unlikely to be
      appropriate candidates for intervention for in-hand manipulation skills,
      but children with mild disabilities may be easier for the therapies to
      identify when using these data on developmental trends and descriptions of
      strategies for execution of in-hand manipulation skills. Such
      identification has the potential to lead to intervention that can
      positively influence the child's performance of a variety of functional
      tasks that rely on these skills.
AD  - Occupational Therapy Department, Towson University, Maryland 21252-7097,
      USA.
FAU - Exner, C E
AU  - Exner CE
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - UNITED STATES
TA  - Am J Occup Ther
JT  - The American journal of occupational therapy. : official publication of
      the American Occupational Therapy Association
JID - 7705978
SB  - IM
CON - Am J Occup Ther. 1997 Oct;51(9):719-28. PMID: 9311426
MH  - Adult
MH  - Child
MH  - Child Development/*physiology
MH  - Child, Preschool
MH  - Female
MH  - Functional Laterality/*physiology
MH  - Humans
MH  - Male
MH  - Motor Skills/*physiology
MH  - Occupational Therapy
MH  - Patient Care Planning
MH  - Psychomotor Disorders/physiopathology/rehabilitation
MH  - Psychomotor Performance/*physiology
MH  - Reference Values
EDAT- 1997/10/06
MHDA- 1997/10/06 00:01
PST - ppublish
SO  - Am J Occup Ther. 1997 Oct;51(9):729-32.
PMID- 9323504
OWN - NLM
STAT- MEDLINE
DA  - 19971118
DCOM- 19971118
LR  - 20061115
PUBM- Print
IS  - 0391-3988 (Print)
VI  - 20
IP  - 8
DP  - 1997 Aug
TI  - Quantitating dialysis using two dialysate samples: a simple, practical and
      accurate approach for evaluating urea kinetics.
PG  - 422-7
AB  - Urea kinetics is now widely used to determine the adequacy of dialysis.
      Several simplified formulae are currently in use but only a few have been
      accepted into clinical practice because of their simplicity and ease of
      calculation. A recent analysis of these formulae showed that for the same
      set of blood urea values the calculated Kt/V can range from 1.0 to 1.5. We
      have developed a new dialysate-based method (2DSM) to estimate the urea
      kinetic parameters using dialysate and blood samples taken at the
      beginning and at the end of dialysis. The total urea removed (TUR) was
      calculated from the geometric mean of the two dialysate samples, dialysate
      flow rate and the duration of dialysis. The Watson formula was used to
      determine the volume of distribution of urea. A comparison of the 2DSM and
      the direct dialysate quantification (DDQ) method showed the following
      results (mean +/- sd, n = 52): for total urea removal (TUR) 697 +/- 32 vs
      722 +/- 37 mmol (p = 0.6, r2 = 0.928, y = 101 + 0.83 x, mean difference 25
      +/- 76 mmol, see Bland-Altman plot), dialysate urea concentration (Durea)
      5.55 +/- 0.25 vs 5.75 +/- 0.29 mmol/l (p = 0.6, r2 = 0.928, y = 0.8 + 0.82
      x, mean difference 0.2 +/- 0.6 mmol, see Bland-Altman plot), dialyser
      clearance (K) 232 +/- 4.4 vs 235 +/- 5.6 ml/min (p = 0.54), Kt/V 1.42 +/-
      0.04 vs 1.51 +/- 0.04 (p = 0.21), volume of distribution of urea (Vd)
      40.14 +/- 1.04 vs 38.74 +/- 1.2 L, (p = 0.38), and PCR 64.6 +/- 2.6 vs
      68.1 +/- 3.1 g/day. We have developed a simple method of determining
      dialysate-based urea kinetics which requires two dialysate samples, one at
      the beginning and one at the end of dialysis and a blood sample at the
      midpoint of dialysis. TUR can be calculated using the dialysate flow rate
      and the dialysis duration and once this is known all the other kinetic
      parameters can be calculated.
AD  - Department of Medicine, Sunnybrook Health Science Centre, University of
      Toronto, Ontario.
FAU - Raj, D S
AU  - Raj DS
FAU - Tobe, S
AU  - Tobe S
FAU - Saiphoo, C
AU  - Saiphoo C
FAU - Manuel, M A
AU  - Manuel MA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - ITALY
TA  - Int J Artif Organs
JT  - The International journal of artificial organs
JID - 7802649
RN  - 0 (Dialysis Solutions)
RN  - 57-13-6 (Urea)
SB  - IM
MH  - Blood Specimen Collection
MH  - Dialysis Solutions/*analysis
MH  - Female
MH  - Humans
MH  - Kidney Failure, Chronic/blood/*therapy
MH  - Kinetics
MH  - Linear Models
MH  - Male
MH  - *Renal Dialysis
MH  - Urea/*analysis/isolation & purification
EDAT- 1997/08/01 00:00
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Int J Artif Organs. 1997 Aug;20(8):422-7.
PMID- 9344906
OWN - NLM
STAT- MEDLINE
DA  - 19971124
DCOM- 19971124
LR  - 20061115
PUBM- Print
IS  - 0042-6822 (Print)
VI  - 237
IP  - 1
DP  - 1997 Oct 13
TI  - The HIV-1 matrix domain of Gag is required for Vpu responsiveness during
      particle release.
PG  - 46-55
AB  - HIV-1 viral protein U (Vpu) facilitates virus particle release. To
      determine whether Gag is sufficient for generation of a target for
      Vpu-mediated particle release, we expressed HIV-1 Gag protein in the
      absence of the other viral genes. The resulting particles were still Vpu
      responsive. Mutational analysis of Gag indicated that the matrix domain
      (MA) is required for Vpu responsiveness. However, additional mutations in
      other domains of Gag, which affect the formation of stable virus
      particles, also abrogate Vpu responsiveness on total Gag release.
      Coexpression of the wild-type gag gene and a gag mutant lacking the MA
      domain renders the MA- mutant Vpu responsive. This indicates that Gag
      molecules lacking MA are still incorporated into particles through
      association with wild-type Gag molecules and that the resulting composite
      particles are sufficient for Vpu-mediated exit.
CI  - Copyright 1997 Academic Press.
AD  - McArdle Laboratory for Cancer Research, University of Wisconsin Medical
      School, 1400 University Avenue, Madison, Wisconsin 53706, USA.
FAU - Lee, Y H
AU  - Lee YH
FAU - Schwartz, M D
AU  - Schwartz MD
FAU - Panganiban, A T
AU  - Panganiban AT
LA  - eng
GR  - R01-AI36174/AI/NIAID
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Virology
JT  - Virology
JID - 0110674
RN  - 0 (Gene Products, gag)
RN  - 0 (Gene Products, vpu)
RN  - 0 (Viral Proteins)
SB  - IM
SB  - X
MH  - Binding Sites
MH  - Gene Deletion
MH  - Gene Products, gag/genetics/*metabolism
MH  - Gene Products, vpu/*metabolism
MH  - HIV-1/*physiology
MH  - Hela Cells
MH  - Humans
MH  - Protein Binding
MH  - Viral Proteins/metabolism
MH  - Virion/physiology
MH  - Virus Replication/*physiology
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
AID - S0042-6822(97)98711-0 [pii]
AID - 10.1006/viro.1997.8711 [doi]
PST - ppublish
SO  - Virology. 1997 Oct 13;237(1):46-55.
PMID- 9267510
OWN - NLM
STAT- MEDLINE
DA  - 19971028
DCOM- 19971028
LR  - 20061115
PUBM- Print
IS  - 0003-1488 (Print)
VI  - 211
IP  - 4
DP  - 1997 Aug 15
TI  - Effects of parenteral administration of vitamin E on health of
      periparturient dairy cows.
PG  - 466-9
AB  - OBJECTIVE: To determine the effect of administration of vitamin E
      (D-alpha-tocopherol) on the incidence of retained placenta, metritis, and
      clinical mastitis during early lactation and on tocopherol concentrations.
      DESIGN: Prospective randomized controlled study. ANIMALS: 420 Holstein
      cows. PROCEDURE: Vitamin E (3,000 mg, IM, once) was administered to 204
      cows B to 14 days before expected parturition, and 216 control cows were
      not treated. The number of cows that had retained placenta, metritis,
      clinical mastitis, displaced abomasum, and clinically apparent acetonemia
      or hypocalcemia were recorded. Serum concentrations of tocopherol, the
      tocopherol:cholesterol ratio, and glutathione-peroxidase activity were
      determined from samples obtained before administration of vitamin E, 7 and
      14 days after administration, and at 30 days after parturition from 36
      treated and 36 control cows. RESULTS: Administration of vitamin E
      significantly decreased the incidence of retained placenta and metritis
      (13/204 [6.4%] and 8/204: [3.9%], respectively, for the vitamin E-treated
      group; 27/216 [12.5%] and 19/ 216 [8.8%], respectively, for the untreated
      group) but did not affect the incidence of clinical mastitis. Serum
      vitamin E concentration was significantly higher in treated than in
      control cattle at 7 and 14 days after administration, but serum
      tocopherol: cholesterol ratio was significantly higher only at 7 days
      after administration. CLINICAL IMPLICATIONS: Parenteral administration of
      a single injection of vitamin E before parturition may decrease the
      incidence of retained placenta and metritis in dairy cows but will
      increase serum concentrations for 7 to 14 days after administration.
AD  - Department of Large Animal Clinical Sciences, College of Veterinary
      Medicine, Michigan State University, East Lansing 48824, USA.
FAU - Erskine, R J
AU  - Erskine RJ
FAU - Bartlett, P C
AU  - Bartlett PC
FAU - Herdt, T
AU  - Herdt T
FAU - Gaston, P
AU  - Gaston P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - J Am Vet Med Assoc
JT  - Journal of the American Veterinary Medical Association
JID - 7503067
RN  - 1406-18-4 (Vitamin E)
SB  - IM
CIN - J Am Vet Med Assoc. 1997 Oct 15;211(8):979-81. PMID: 9410866
MH  - Animals
MH  - Cattle
MH  - Cattle Diseases/epidemiology/*prevention & control
MH  - Endometritis/epidemiology/prevention & control/veterinary
MH  - Female
MH  - Incidence
MH  - Mastitis, Bovine/epidemiology/prevention & control
MH  - Placenta, Retained/epidemiology/prevention & control/veterinary
MH  - Pregnancy
MH  - Prospective Studies
MH  - Puerperal Disorders/epidemiology/prevention & control/*veterinary
MH  - Vitamin E/administration & dosage/blood/*therapeutic use
EDAT- 1997/08/15
MHDA- 1997/08/15 00:01
PST - ppublish
SO  - J Am Vet Med Assoc. 1997 Aug 15;211(4):466-9.
PMID- 9377678
OWN - NLM
STAT- MEDLINE
DA  - 19971105
DCOM- 19971105
LR  - 20061115
PUBM- Print
IS  - 1426-9686 (Print)
VI  - 2
IP  - 11
DP  - 1997 May
TI  - [Early and late complications after surgical gastric resection for peptic
      ulcer]
PG  - 313-4
AB  - For evaluating early and late complications after partial gastrectomy in
      gastric and duodenal ulcer, performed in 1976-92 years, was investigated
      585 patients. The surgery was carry out mutables Rydygier and Billroth-2
      methods. The smallest complications early and late found after the
      operations Finney-Haberer and Billroth-2 with Braun anastomosis and
      vagotomy.
AD  - Oddzialu Chirurgicznego Szpitala w Jasle.
FAU - Kleba, T
AU  - Kleba T
LA  - pol
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Wczesne i pozne powiklania po operacjach resekcyjnych zoladka z powodu
      choroby wrzodowej.
PL  - POLAND
TA  - Pol Merkur Lekarski
JT  - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
JID - 9705469
SB  - IM
MH  - Anastomosis, Surgical/methods
MH  - Female
MH  - Gastrectomy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*epidemiology/prevention & control
MH  - Stomach Ulcer/*surgery
MH  - Time Factors
MH  - Vagotomy
EDAT- 1997/05/01 00:00
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Pol Merkur Lekarski. 1997 May;2(11):313-4.
PMID- 9322197
OWN - NLM
STAT- MEDLINE
DA  - 19971125
DCOM- 19971125
LR  - 20051117
PUBM- Print
IS  - 1059-1052 (Print)
VI  - 6
IP  - 3
DP  - 1997 Fall
TI  - Antibiotic prophylaxis and infection resistance of massive tumor
      endoprostheses during chemotherapy.
PG  - 180-5
AB  - Fifty-five consecutively treated patients with malignant bone tumors had
      preoperative and postoperative chemotherapy by one oncologist. These same
      patients had massive bone resection and cemented endoprosthetic bone
      replacement by one orthopaedic oncologist. Despite 143 instances of
      documented fever and/or neutropenia in 45 of these 55 patients, no known
      deep periprosthetic infections developed in any patient during follow-up
      (mean, 29.4 months; median, 25 months; range, 5 months to 62 months).
      Broad spectrum antibiotics had been administered in at least 118 instances
      to these patients (intravenously in hospital, 9 times to 7 patients;
      intravenously at home, 38 times to 18 patients; and orally at home, 71
      times to 26 patients). This study confirms the low infection rate of these
      massive endoprostheses, despite neutropenic and/or febrile episodes if the
      patient is given prophylactic broad spectrum antibiotics during the
      episodes. We support the continued use of massive endoprostheses for bone
      reconstruction in patients requiring chemotherapy.
AD  - Department of Orthopaedic Surgery, Bowman Gray School of Medicine of Wake
      Forest University, Winston-Salem, NC 27157-1070, USA.
FAU - Ward, W G
AU  - Ward WG
FAU - Johnston-Jones, K
AU  - Johnston-Jones K
FAU - Lowenbraun, S
AU  - Lowenbraun S
FAU - Dorey, F
AU  - Dorey F
FAU - Rosen, G
AU  - Rosen G
FAU - Eckardt, J J
AU  - Eckardt JJ
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - J South Orthop Assoc
JT  - Journal of the Southern Orthopaedic Association
JID - 9211289
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Bacterial Agents
MH  - *Antibiotic Prophylaxis
MH  - Antineoplastic Agents/administration & dosage/*adverse effects
MH  - Bone Neoplasms/drug therapy/*surgery
MH  - Chemotherapy, Adjuvant
MH  - Child
MH  - Child, Preschool
MH  - Drug Therapy, Combination/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Fractures, Spontaneous/*surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neutropenia/chemically induced/immunology
MH  - Prospective Studies
MH  - Prosthesis-Related Infections/immunology/*prevention & control
MH  - Surgical Wound Infection/immunology/*prevention & control
EDAT- 1997/10/10
MHDA- 1997/10/10 00:01
PST - ppublish
SO  - J South Orthop Assoc. 1997 Fall;6(3):180-5.
PMID- 9299752
OWN - NLM
STAT- MEDLINE
DA  - 19971030
DCOM- 19971030
LR  - 20041117
PUBM- Print
IS  - 0301-486X (Print)
VI  - 137
IP  - 1
DP  - 1997
TI  - Disseminated dermatophytosis caused by Microsporum gypseum in two patients
      with the acquired immunodeficiency syndrome.
PG  - 9-12
AB  - Microsporum gypseum is not a common agent of human dermatophytosis. To the
      best of our knowledge, this fungus has not been described in human
      immunodeficiency virus (HIV)-infected patients. We report a tinea corporis
      infection with atypical presentation caused by M. gypseum in two patients
      with the acquired immunodeficiency syndrome (AIDS) studied at the Sao
      Paulo Hospital (Sao Paulo, Brazil).
AD  - Departamento de Dermatologia, Escola Paulista de Medicina, Univerisidade
      Federal de Sao Paulo, Brazil.
FAU - Porro, A M
AU  - Porro AM
FAU - Yoshioka, M C
AU  - Yoshioka MC
FAU - Kaminski, S K
AU  - Kaminski SK
FAU - Palmeira, M do C
AU  - Palmeira Mdo C
FAU - Fischman, O
AU  - Fischman O
FAU - Alchorne, M M
AU  - Alchorne MM
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - NETHERLANDS
TA  - Mycopathologia
JT  - Mycopathologia
JID - 7505689
RN  - 0 (Antifungal Agents)
RN  - 0 (Piperazines)
RN  - 0 (Triazoles)
SB  - IM
SB  - X
MH  - Acquired Immunodeficiency Syndrome/*complications
MH  - Adult
MH  - Antifungal Agents/therapeutic use
MH  - Dermatomycoses/*complications/drug therapy/pathology
MH  - Female
MH  - Hand Dermatoses/pathology
MH  - Humans
MH  - Male
MH  - *Microsporum
MH  - Onychomycosis/pathology
MH  - Piperazines/therapeutic use
MH  - Skin/pathology
MH  - Triazoles/therapeutic use
EDAT- 1997/01/01 00:00
MHDA- 1997/09/23 00:01
PST - ppublish
SO  - Mycopathologia. 1997;137(1):9-12.
PMID- 9377115
OWN - NLM
STAT- MEDLINE
DA  - 19971031
DCOM- 19971031
LR  - 20061115
PUBM- Print
VI  - 44
IP  - 3
DP  - 1997 May-Jun
TI  - [Serous otitis media. Comparative study of carbinoxamine- pseudoephedrine
      vs astemizole-pseudoephedrine]
PG  - 70-3
AB  - They were studied 48 children of 3 to 8 years old, of two sex (30 male and
      18 female), that attended the external service of otolaryngology of the
      Hospital of the ISSSTE of Nuevo Laredo, Tamaulipas (Mexico) and the
      private practice of the Allergy Clinic and Otolaringol in Nuevo Laredo,
      Tamaulipas, of the month of November of 1995 to April of 1996. Some of the
      side effects observed in the patients treated in the group A
      (carbinoxamine-P) were: mild sedation and in some instances
      hyperexcitability and irritability. However, it was not necessary to
      discontinue the medication or to modify the dose. In the group B
      (astemizole-P) was observed only excitement and irritability in some
      instances by hypersensitivity to the pseudoephedrine. It is very important
      to consider that the adequate and timely treatment in a patient with
      otitis serous media will permit to avoid sequels that they can cause, in
      the long run, a meaningful impact in the language and intellectual
      development of the child.
AD  - Pediatra alergologa, Hospital San Jose, Nuevo Laredo, Tamps.
FAU - Perez Carmona, N J
AU  - Perez Carmona NJ
FAU - Garcia, M A
AU  - Garcia MA
FAU - Fuentes Rejon, T
AU  - Fuentes Rejon T
LA  - spa
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Otitis media serosa. Estudio comparativo de carbinoxamina-pseudoefedrina
      vs astemizol-pseudoefedrina.
PL  - MEXICO
TA  - Rev Alerg Mex
JT  - Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
JID - 9438824
RN  - 0 (Histamine H1 Antagonists)
RN  - 0 (Nasal Decongestants)
RN  - 0 (Pyridines)
RN  - 299-42-3 (Ephedrine)
RN  - 486-16-8 (carbinoxamine)
RN  - 68844-77-9 (Astemizole)
SB  - IM
MH  - Astemizole/administration & dosage/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Drug Therapy, Combination
MH  - Ephedrine/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Histamine H1 Antagonists/administration & dosage/adverse
      effects/*therapeutic use
MH  - Humans
MH  - Hyperkinesis/chemically induced
MH  - Male
MH  - Nasal Decongestants/administration & dosage/adverse effects/*therapeutic
      use
MH  - Otitis Media with Effusion/*drug therapy
MH  - Pyridines/administration & dosage/adverse effects/*therapeutic use
MH  - Sleep Stages
MH  - Treatment Outcome
EDAT- 1997/05/01 00:00
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Rev Alerg Mex. 1997 May-Jun;44(3):70-3.
PMID- 9379424
OWN - NLM
STAT- MEDLINE
DA  - 19971110
DCOM- 19971110
LR  - 20041117
PUBM- Print
IS  - 0904-2512 (Print)
VI  - 26
IP  - 8
DP  - 1997 Sep
TI  - Immunohistochemical distribution of lymph capillaries and blood
      capillaries in the synovial membrane in cases of internal derangement of
      the temporomandibular joint.
PG  - 356-61
AB  - The distribution of lymph capillaries and blood capillaries in the
      synovial membrane was examined immunohistologically with anti-human
      collagen IV antibody and anti-human von Willebrand factor in 26 human
      temporomandibular joint (TMJ) samples comprising discs with adjoining
      synovial membrane from 10 control TMJs and from 16 TMJs with internal
      derangement. Three different distribution types were observed in the
      synovial membrane. In the control samples, the occurrence of blood
      capillaries and lymph capillaries was rare. In mildly hyperplastic
      synovitis, lymph capillaries were observed just beneath the surface of the
      synovial membrane, whereas blood capillaries occurred in a little deeper
      layer of the synovial membrane. In a severely hyperplastic synovitis, both
      lymph and blood capillaries were observed frequently. The present results
      suggest that the different distribution patterns of lymph capillaries and
      blood capillaries reflect the degree of synovitis but can not be
      attributed to specific clinical symptoms.
AD  - Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Kyoto
      University, Japan.
FAU - Yoshida, H
AU  - Yoshida H
FAU - Fujita, S
AU  - Fujita S
FAU - Nishida, M
AU  - Nishida M
FAU - Iizuka, T
AU  - Iizuka T
LA  - eng
PT  - Journal Article
PL  - DENMARK
TA  - J Oral Pathol Med
JT  - Journal of oral pathology & medicine : official publication of the
      International Association of Oral Pathologists and the American Academy of
      Oral Pathology
JID - 8911934
RN  - 0 (von Willebrand Factor)
RN  - 9007-34-5 (Collagen)
SB  - D
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Capillaries/*pathology
MH  - Collagen/analysis
MH  - Dislocations/*pathology
MH  - Female
MH  - Humans
MH  - Hyperplasia
MH  - Immunohistochemistry
MH  - Lymphatic System/*pathology
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/pathology
MH  - Synovial Membrane/blood supply/*pathology
MH  - Synovitis/pathology
MH  - Temporomandibular Joint/blood supply/pathology
MH  - Temporomandibular Joint Disk/blood supply/*pathology
MH  - Temporomandibular Joint Disorders/pathology
MH  - von Willebrand Factor/analysis
EDAT- 1997/10/06
MHDA- 1997/10/06 00:01
PST - ppublish
SO  - J Oral Pathol Med. 1997 Sep;26(8):356-61.
PMID- 9347012
OWN - NLM
STAT- MEDLINE
DA  - 19971118
DCOM- 19971118
LR  - 20061115
PUBM- Print
IS  - 0003-3898 (Print)
VI  - 55
IP  - 5
DP  - 1997 Sep-Oct
TI  - [Reference values of apolipoproteins A1 and B. Contribution of
      international standardization. Travail collaboratif entre la SFBC, l'Arcol
      et le SFRL]
PG  - 451-4
AB  - The utilization of two WHO reference materials, liquid and lyophilized,
      permitted international standardization of apolipoprotein measurements. We
      report here the results of a collaborative study between Arcol, SFBC and
      SFRL in order to establish reference ranges for apo A1 and B on nine
      standardized systems. A population of 1027 men and women supposed healthy,
      4 to 60 year old, have been selected in two Centers for Preventive
      Medicine. The serum samples were aliquoted frozen at -20 degrees C the day
      of sampling and analysed by the manufacturers with IFCC standardized
      calibrants. A specific quality control was performed using a frozen pool
      of sera. For apo A1, the centile 2.5 of the reference population varies
      from 1.04 to 1.16 g/l. The range values for the centile 97.5 varies from
      1.87 to 2.24 g/l. For apoB, the centile 2.5 varies from 0.43 to 0.57 g/l,
      and the centile 97.5 from 1.30 to 1.39 g/l. Only one system has a problem
      of dispersion with an upper limit equal to 1.20 g/l. These results improve
      that international standardization allowed actually a good comparability
      of the results, especially for apoB.
AD  - Laboratoire du Centre de medecine preventive, Vandoeuvre-les-Nancy.
FAU - Steinmetz, J
AU  - Steinmetz J
FAU - Caces, E
AU  - Caces E
FAU - Couderc, R
AU  - Couderc R
FAU - Beucler, I
AU  - Beucler I
FAU - Legrand, A
AU  - Legrand A
FAU - Henny, J
AU  - Henny J
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Valeurs de reference des apolipoproteines A1 et B. Apport de la
      standardisation internationale. Travail collaboratif entre la SFBC,
      l'Arcol et le SFRL.
PL  - FRANCE
TA  - Ann Biol Clin (Paris)
JT  - Annales de biologie clinique
JID - 2984690R
RN  - 0 (Apolipoprotein A-I)
RN  - 0 (Apolipoproteins B)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Apolipoprotein A-I/blood/*standards
MH  - Apolipoproteins B/blood/*standards
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - *International Cooperation
MH  - Male
MH  - Middle Aged
MH  - Reference Standards
MH  - Reference Values
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Ann Biol Clin (Paris). 1997 Sep-Oct;55(5):451-4.
PMID- 9315328
OWN - NLM
STAT- MEDLINE
DA  - 19971105
DCOM- 19971105
LR  - 20051117
PUBM- Print
IS  - 0895-3988 (Print)
VI  - 10
IP  - 2-3
DP  - 1997 Sep
TI  - Two new selenoproteins found in the prostatic glandular epithelium and in
      the spermatid nuclei.
PG  - 340-5
AB  - After labeling of rats in vivo with 75Se and protein separation by sodium
      dodecyl sulfate-polyacrylamide gel electrophoresis more than 25
      Se-containing bands could be distinguished. Of those proteins which were
      detected only in certain compartments and might therefore have
      tissue-specific functions, two were chosen for detailed investigation. A
      15 kDa-protein was found in the prostatic epithelium where it accounted
      for about two thirds of the protein-bound 75Se. It was mainly present in
      the cytosol but was not released into the prostatic secretion. After gel
      chromatography it was found in the fraction which contained proteins with
      molecular masses of about 300 kDa. Using two-dimensional electrophoresis a
      pI-value of about 4.5 was determined. In the testis a specific
      Se-containing 34 kDa-protein was observed which appeared after the onset
      of puberty. It was localized in the spermatid nuclei where it contained
      about 80% of the Se tracer present and was found to be bound to the DNA.
      After extraction it partly disintegrated into a 20 kDa-protein. Both
      compounds contain Se in the form of selenocysteine. The fact that their
      formation had priority over that of glutathione peroxidase during
      insufficient Se intake is an indication of their biological significance.
      Special interest in the prostatic epithelial selenoprotein derives from a
      possible inverse relationship between the Se status and the incidence of
      prostate cancer observed in epidemiological studies, whereas with the 34
      kDa-selenoprotein its appearance during the condensation phase of the
      spermatid nuclei might suggest its participation in some processes of
      sperm maturation.
AD  - Hahn-Meitner-Institut Berlin, Department Trace Elements in Health and
      Nutrition, Germany.
FAU - Behne, D
AU  - Behne D
FAU - Kyriakopoulos, A
AU  - Kyriakopoulos A
FAU - Kalcklosch, M
AU  - Kalcklosch M
FAU - Weiss-Nowak, C
AU  - Weiss-Nowak C
FAU - Pfeifer, H
AU  - Pfeifer H
FAU - Gessner, H
AU  - Gessner H
FAU - Hammel, C
AU  - Hammel C
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - Biomed Environ Sci
JT  - Biomedical and environmental sciences : BES
JID - 8909524
RN  - 0 (Proteins)
RN  - 0 (Selenoproteins)
RN  - 0 (Sep15 protein, rat)
SB  - IM
MH  - Animals
MH  - Cell Nucleus/*metabolism
MH  - Epithelial Cells/metabolism
MH  - Male
MH  - Prostate/*metabolism
MH  - Proteins/*isolation & purification/metabolism
MH  - Rats
MH  - Selenoproteins
MH  - Spermatids/*metabolism
EDAT- 1997/10/07
MHDA- 1997/10/07 00:01
PST - ppublish
SO  - Biomed Environ Sci. 1997 Sep;10(2-3):340-5.
PMID- 9341945
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20050518
PUBM- Print
IS  - 0940-9602 (Print)
VI  - 179
IP  - 5
DP  - 1997 Oct
TI  - Angioarchitectural classification of the fungiform papillae on the dorsal
      surface of the bullfrog tongue.
PG  - 393-7
AB  - In this study, the three-dimensional anatomy of the microvascular
      structure of fungiform papillae (FuP) on the dorsal surface of the
      bullfrog tongue has been investigated using scanning electron microscopy
      (SEM), and angioarchitectural classification has been carried out by means
      of the capillary loop (L. s) and intra-bridge structure (I. b). FuP from
      30 sound bullfrog tongues were used. The following research methods were
      applied: SEM observation on microvascular cast specimens (MVCS) of
      bullfrog tongue's FuP were injected with synthetic resin (Mercox).
      Observation of MVSC showed that the bullfrog tongue FuP consisted of an
      ascending branch (A. b), L. s, I. b and a descending branch (D. b). Based
      upon SEM observations of MVCS, FuP can be classified into four types: A,
      B, C, D types according to A. b, L. s, I. b and D. b. A-type (none I. b)
      formed from A. b, L. s, D. b only and with no I. b. B-type (one I. b)
      consisted of A. b, L. s, D. b and one I. b. C-type (two I. b) were
      composed of A. b, L. s, D. b and two I. b. D-type (three I. b) were
      composed of A. b, L. s, D. b and three I. b, A. b, L. s, I. b and D. b on
      each. A, B, C, D types were all same thickness.
AD  - Department of Physiology, School of Dentistry at Tokyo, Nippon Dental
      University, Japan.
FAU - Ojima, K
AU  - Ojima K
FAU - Takeda, M
AU  - Takeda M
FAU - Saiki, C
AU  - Saiki C
FAU - Takahashi, T
AU  - Takahashi T
FAU - Matsumoto, S
AU  - Matsumoto S
LA  - eng
PT  - Journal Article
PL  - GERMANY
TA  - Ann Anat
JT  - Annals of anatomy = Anatomischer Anzeiger : official organ of the
      Anatomische Gesellschaft
JID - 100963897
SB  - IM
MH  - Animals
MH  - Capillaries/ultrastructure
MH  - Female
MH  - Male
MH  - Microcirculation/*ultrasonography
MH  - Microscopy, Electron, Scanning
MH  - Models, Structural
MH  - Rana catesbeiana/*anatomy & histology
MH  - Tongue/*anatomy & histology/*blood supply
EDAT- 1997/10/28
MHDA- 1997/10/28 00:01
PST - ppublish
SO  - Ann Anat. 1997 Oct;179(5):393-7.
PMID- 9378660
OWN - NLM
STAT- MEDLINE
DA  - 19971107
DCOM- 19971107
LR  - 20001218
PUBM- Print
IS  - 0017-9078 (Print)
VI  - 73
IP  - 5
DP  - 1997 Nov
TI  - A prioritization and analysis strategy for environmental surveillance
      results.
PG  - 826-30
AB  - DOE facilities are required to conduct environmental surveillance to
      verify that facility operations are operated within the approved risk
      envelope and have not caused undue risk to the public and the environment.
      Given a reduced budget, a strategy for analyzing environmental
      surveillance data was developed to set priorities for sampling needs. The
      radiological and metal data collected at Sandia National Laboratories, New
      Mexico, were used to demonstrate the analysis strategy. Sampling locations
      were prioritized for further investigation and the needs for routine
      sampling. The process of data management, analysis, prioritization, and
      presentation has been automated through a custom-designed computer tool.
      Data collected over years can be analyzed and summarized in a short table
      format for prioritization and decision making.
AD  - Sandia National Laboratories, Albuquerque, NM 87185-0748, USA.
FAU - Shyr, L J
AU  - Shyr LJ
FAU - Herrera, H
AU  - Herrera H
FAU - Haaker, R
AU  - Haaker R
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - Health Phys
JT  - Health physics
JID - 2985093R
RN  - 0 (Cesium Radioisotopes)
RN  - 0 (Metals)
RN  - 0 (Soil Pollutants)
RN  - 0 (Soil Pollutants, Radioactive)
RN  - 10028-17-8 (Tritium)
SB  - IM
MH  - Cesium Radioisotopes/analysis
MH  - Conservation of Natural Resources/*methods
MH  - Environmental Pollution/*prevention & control
MH  - Government Agencies
MH  - Metals/analysis
MH  - New Mexico
MH  - *Radiation Protection
MH  - Soil Pollutants/analysis
MH  - Soil Pollutants, Radioactive/*analysis
MH  - Tritium/analysis
MH  - United States
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Health Phys. 1997 Nov;73(5):826-30.
PMID- 9380039
OWN - NLM
STAT- MEDLINE
DA  - 19971110
DCOM- 19971110
LR  - 20061115
PUBM- Print
IS  - 0026-895X (Print)
VI  - 52
IP  - 4
DP  - 1997 Oct
TI  - 21-Hydroxy-6,19-oxidoprogesterone: a novel synthetic steroid with specific
      antiglucocorticoid properties in the rat.
PG  - 749-53
AB  - In the rat, the conformationally highly bent steroid 21-hydroxy-6,
      19-oxidoprogesterone efficiently displaces [3H]corticosterone from
      thymus-glucocorticoid receptors and blocks type II receptors in kidney
      cytosols but competes with neither [3H]aldosterone for
      kidney-mineralocorticoid receptors nor [3H]progesterone for
      uterus-progesterone receptors. It evokes Na+ retention only at very high
      doses (approximately 100 microg/100 g of rat weight) and is unable to
      induce tyrosine aminotransferase or to increase glycogen deposits in rat
      liver. When coincubated with corticosterone or dexamethasone, 2.5 microM
      21OH-6OP inhibits 80% of tyrosine aminotransferase induction. It may
      therefore be used experimentally as an antiglucocorticoid virtually
      lacking mineralocorticoid or glucocorticoid properties as well as affinity
      for mineralocorticoid or progesterone receptors.
AD  - Departamentos de Quimica Biologica, Universidad de Buenos Aires and
      PRHOM-Consejo Nacional de Investigaciones Cientificas y Tecnicas, Ciudad
      Universitaria, (1428) Buenos Aires, Argentina.
FAU - Vicent, G P
AU  - Vicent GP
FAU - Monteserin, M C
AU  - Monteserin MC
FAU - Veleiro, A S
AU  - Veleiro AS
FAU - Burton, G
AU  - Burton G
FAU - Lantos, C P
AU  - Lantos CP
FAU - Galigniana, M D
AU  - Galigniana MD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Mol Pharmacol
JT  - Molecular pharmacology
JID - 0035623
RN  - 0 (21-hydroxy-6,19-oxidoprogesterone)
RN  - 0 (Androstanols)
RN  - 0 (Receptors, Glucocorticoid)
RN  - 0 (Receptors, Mineralocorticoid)
RN  - 10028-17-8 (Tritium)
RN  - 52-01-7 (Spironolactone)
RN  - 52-39-1 (Aldosterone)
RN  - 57-83-0 (Progesterone)
RN  - 74915-64-3
      (11,17-dihydroxy-6-methyl-17-(1-propynyl)androsta-1,4,6-triene-3-one)
RN  - 84542-26-7 (ZK 91587)
RN  - 9010-38-2 (Transcortin)
SB  - IM
MH  - Aldosterone/metabolism
MH  - Androstanols/metabolism
MH  - Animals
MH  - Kidney/metabolism
MH  - Male
MH  - Progesterone/*analogs & derivatives/chemistry/metabolism/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Glucocorticoid/*antagonists & inhibitors/metabolism
MH  - Receptors, Mineralocorticoid/metabolism
MH  - Spironolactone/analogs & derivatives/metabolism
MH  - Structure-Activity Relationship
MH  - Thymus Gland/metabolism
MH  - Transcortin/metabolism
MH  - Tritium
EDAT- 1997/10/10
MHDA- 1997/10/10 00:01
PST - ppublish
SO  - Mol Pharmacol. 1997 Oct;52(4):749-53.
PMID- 9288441
OWN - NLM
STAT- MEDLINE
DA  - 19971024
DCOM- 19971024
LR  - 20051116
PUBM- Print
IS  - 0706-7437 (Print)
VI  - 42 Suppl 2
DP  - 1997 Aug
TI  - Bipolar depression: treatment options.
PG  - 87S-91S
AB  - OBJECTIVE: To review studies on treatments for bipolar depression and make
      recommendations for practising clinicians treating patients with bipolar
      depression. METHOD: Studies that examined various treatments for bipolar
      depression were evaluated and rated for evidence of efficacy using
      Periodic Health Examination criteria. The rating for classification of
      recommendation for an intervention was made taking both the efficacy and
      the side effects into consideration. RESULTS: Mood stabilizers, cyclic
      antidepressants, monoamine oxidase inhibitors (MAOIs), and
      electroconvulsive therapy (ECT) are all effective in treating bipolar
      depression. Almost all antidepressant treatments with the exception of
      mood stabilizers have been reported to induce a manic-hypomanic switch and
      rapid cycling. CONCLUSIONS: Mood stabilizers, lithium in particular, are
      recommended as the first-line treatment. Addition of a second mood
      stabilizer or a cyclic antidepressant would be an appropriate next step.
      Newer agents such as lamotrigine offer considerable promise in treating
      bipolar depressed patients.
AD  - Department of Psychiatry, University of British Columbia, Vancouver.
      yatham@unixg.ubc.ca
FAU - Yatham, L N
AU  - Yatham LN
FAU - Kusumakar, V
AU  - Kusumakar V
FAU - Parikh, S V
AU  - Parikh SV
FAU - Haslam, D R
AU  - Haslam DR
FAU - Matte, R
AU  - Matte R
FAU - Sharma, V
AU  - Sharma V
FAU - Kennedy, S
AU  - Kennedy S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - CANADA
TA  - Can J Psychiatry
JT  - Canadian journal of psychiatry.  Revue canadienne de psychiatrie
JID - 7904187
RN  - 0 (Antidepressive Agents)
SB  - IM
MH  - Antidepressive Agents/adverse effects/*therapeutic use
MH  - Bipolar Disorder/*drug therapy/psychology
MH  - Combined Modality Therapy
MH  - Depressive Disorder/*drug therapy/psychology
MH  - Drug Therapy, Combination
MH  - Electroconvulsive Therapy
MH  - Humans
MH  - Treatment Outcome
RF  - 71
EDAT- 1997/08/01
MHDA- 1997/08/01 00:01
PST - ppublish
SO  - Can J Psychiatry. 1997 Aug;42 Suppl 2:87S-91S.
PMID- 9228551
OWN - NLM
STAT- MEDLINE
DA  - 19971120
DCOM- 19971120
LR  - 20061115
PUBM- Print
IS  - 0162-3109 (Print)
VI  - 36
IP  - 2-3
DP  - 1997 Jun
TI  - Kallikrein gene therapy: a new strategy for hypertensive diseases.
PG  - 229-36
AB  - The tissue kallikrein-kinin system has been postulated to play a role in
      blood pressure homeostasis and the pathogenesis of clinical hypertension.
      To demonstrate the potential therapeutic effects of somatic gene delivery
      in treating hypertension, we used spontaneously hypertensive rats (SHR) as
      a model. The gene encoding the human tissue kallikrein was used because of
      its powerful hypotensive action. The human kallikrein DNA constructs were
      placed under the control of the metallothionein metal response element,
      the cytomegalovirus promoter/enhancer or the Rous sarcoma virus 3'-LTR.
      The human tissue kallikrein DNA constructs were incorporated into
      adenoviral vectors via homologous recombination. The naked plasmid DNA
      constructs or adenovirus containing the kallikrein gene were first
      introduced into kidney 293 cells and the expression of human tissue
      kallikrein was identified by ELISA. The kallikrein gene was delivered into
      SHR via intramuscular, intravenous, portal vein, intraperitoneal, and
      intracerebroventricular routes. A single injection of naked human
      kallikrein DNA constructs caused a prolonged reduction of high blood
      pressure for up to 8 weeks. Adenoviral-mediated gene delivery results in
      high efficiency of human tissue kallikrein expression. Immunoreactive
      human kallikrein was detected in rat serum at the highest level at 1 day
      post gene delivery. Portal vein delivery of a reporter gene, AdCMV-LacZ,
      results in intense staining of beta-galactosidase in rat liver, suggesting
      that recombinant kallikrein is mainly produced in liver and secreted into
      the circulation. These results show that kallikrein gene delivery causes a
      sustained reduction of blood pressure in genetically hypertensive rats and
      provide important information for a potential gene therapy approach to
      human hypertension and related diseases.
AD  - Department of Biochemistry and Molecular Biology, Medical University of
      South Carolina, Charleston 29425-2211, USA.
FAU - Chao, J
AU  - Chao J
FAU - Chao, L
AU  - Chao L
LA  - eng
GR  - HL 29397/HL/NHLBI
GR  - HL 56686/HL/NHLBI
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - NETHERLANDS
TA  - Immunopharmacology
JT  - Immunopharmacology
JID - 7902474
RN  - 0 (DNA, Viral)
RN  - 9038-94-2 (Metallothionein)
RN  - EC 3.2.1.23 (beta-Galactosidase)
RN  - EC 3.4.21.- (Kallikreins)
RN  - EC 3.4.21.35 (Tissue Kallikreins)
SB  - IM
MH  - Animals
MH  - Avian Sarcoma Viruses/genetics
MH  - Blood Pressure/drug effects/genetics/physiology
MH  - Cytomegalovirus/genetics
MH  - DNA, Viral/administration & dosage/metabolism
MH  - Gene Expression Regulation, Viral/genetics
MH  - *Gene Therapy
MH  - Genes, Reporter/genetics
MH  - Genetic Vectors/genetics
MH  - Humans
MH  - Hypertension/genetics/physiopathology/*therapy
MH  - Injections, Intramuscular
MH  - Injections, Intraperitoneal
MH  - Injections, Intravenous
MH  - Injections, Intraventricular
MH  - Kallikrein-Kinin System/*genetics
MH  - Kallikreins/administration & dosage/*genetics/pharmacology/therapeutic use
MH  - Lac Operon
MH  - Metallothionein/genetics
MH  - Plasmids
MH  - Promoter Regions (Genetics)
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Time Factors
MH  - Tissue Kallikreins
MH  - beta-Galactosidase/metabolism
EDAT- 1997/06/01
MHDA- 1997/06/01 00:01
PST - ppublish
SO  - Immunopharmacology. 1997 Jun;36(2-3):229-36.
PMID- 9263235
OWN - NLM
STAT- MEDLINE
DA  - 19971030
DCOM- 19971030
LR  - 20061115
PUBM- Print
IS  - 0899-9007 (Print)
VI  - 13
IP  - 6
DP  - 1997 Jun
TI  - Effects of growth hormone and insulin-like growth factor-1 on protein
      metabolism, gut morphology, and cell-mediated immunity in burned rats.
PG  - 540-6
AB  - The effects of recombinant human growth hormone (GH) and insulin-like
      growth factor-1 (IGF-1) were investigated in burned rats. Sprague-Dawley
      rats were fed exclusively by total parenteral nutrition and were subjected
      to 20% third-degree scald burns. The rats were then divided into the
      following three groups: (1) the GH group received GH at a dose of 1
      IU.kg-1.d-1 for 2d (n = 10); (2) the IGF group received IGF-1 at a dose of
      4 mg.kg-1.d-1 for 2d (n = 19); and (3) the control group received saline
      (n = 17). Cumulative nitrogen balance increased significantly in the GH (P
      < 0.01) and IGF (P < 0.01) groups as compared with the control group.
      There were no differences in nitrogen balance between the GH and IGF
      groups. Blood glucose was decreased in the IGF group (P < 0.01) and
      increased in the GH group (P < 0.05) as compared with the control group.
      The intestinal villus height and wall thickness of the GH and IGF groups
      were significantly greater than those of the control group. Delayed-type
      hypersensitivity was enhanced in both the GH and the IGF groups as
      compared with the control group (both P < 0.01). Furthermore, the increase
      in the IGF group was significantly greater than that in the GH group (P <
      0.05). It was concluded that both GH and IGF-1 improve protein metabolism
      and immune responsiveness, as well as promote proliferation of the
      intestinal mucosa.
AD  - First Department of Surgery, School of Medicine, Chiba University, Japan.
FAU - Shimoda, N
AU  - Shimoda N
FAU - Tashiro, T
AU  - Tashiro T
FAU - Yamamori, H
AU  - Yamamori H
FAU - Takagi, K
AU  - Takagi K
FAU - Nakajima, N
AU  - Nakajima N
FAU - Ito, I
AU  - Ito I
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - UNITED STATES
TA  - Nutrition
JT  - Nutrition (Burbank, Los Angeles County, Calif.)
JID - 8802712
RN  - 0 (Blood Glucose)
RN  - 0 (Dietary Proteins)
RN  - 0 (Recombinant Proteins)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 7727-37-9 (Nitrogen)
RN  - 9002-72-6 (Growth Hormone)
SB  - IM
MH  - Animals
MH  - Blood Chemical Analysis
MH  - Blood Glucose/analysis/drug effects/metabolism
MH  - Body Weight/physiology
MH  - Burns/*immunology/*metabolism
MH  - Dietary Proteins/*drug effects/*metabolism
MH  - Growth Hormone/*pharmacology
MH  - Humans
MH  - Hypersensitivity, Delayed/physiopathology
MH  - Immunity, Cellular/*drug effects
MH  - Insulin-Like Growth Factor I/*pharmacology
MH  - Intestine, Small/*anatomy & histology/*drug effects
MH  - Kidney/anatomy & histology
MH  - Male
MH  - Nitrogen/analysis/metabolism
MH  - Organ Size
MH  - Pancreas/anatomy & histology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Recombinant Proteins/pharmacology
MH  - Stomach/anatomy & histology
MH  - Thymus Gland/anatomy & histology
EDAT- 1997/06/01
MHDA- 1997/06/01 00:01
PST - ppublish
SO  - Nutrition. 1997 Jun;13(6):540-6.
PMID- 9325098
OWN - NLM
STAT- MEDLINE
DA  - 19971028
DCOM- 19971028
LR  - 20061115
PUBM- Print
IS  - 0022-2836 (Print)
VI  - 272
IP  - 3
DP  - 1997 Sep 26
TI  - The crystal structure of the catalytic core domain of endoglucanase I from
      Trichoderma reesei at 3.6 A resolution, and a comparison with related
      enzymes.
PG  - 383-97
AB  - Cellulose is the most abundant polymer in the biosphere. Although
      generally resistant to degradation, it may be hydrolysed by cellulolytic
      organisms that have evolved a variety of structurally distinct enzymes,
      cellobiohydrolases and endoglucanases, for this purpose. Endoglucanase I
      (EG I) is the major endoglucanase produced by the cellulolytic fungus
      Trichoderma reesei, accounting for 5 to 10% of the total amount of
      cellulases produced by this organism. Together with EG I from Humicola
      insolens and T. reesei cellobiohydrolase I (CBH I), the enzyme is
      classified into family 7 of the glycosyl hydrolases, and it catalyses
      hydrolysis with a net retention of the anomeric configuration.The
      structure of the catalytic core domain (residues 1 to 371) of EG I from T.
      reesei has been determined at 3.6 A resolution by the molecular
      replacement method using the structures of T. reesei CBH I and H. insolens
      EG I as search models. By employing the 2-fold non-crystallographic
      symmetry (NCS), the structure was refined successfully, despite the
      limited resolution. The final model has an R-factor of 0.201 (Rfree
      0.258).The structure of EG I reveals an extended, open substrate-binding
      cleft, rather than a tunnel as found in the homologous cellobiohydrolase
      CBH I. This confirms the earlier proposal that the tunnel-forming loops in
      CBH I have been deleted in EG I, which has resulted in an open active site
      in EG I, enabling it to function as an endoglucanase. Comparison of the
      structure of EG I with several related enzymes reveals structural
      similarities, and differences that relate to their biological function in
      degrading particular substrates. A possible structural explanation of the
      drastically different pH profiles of T. reesei and H. insolens EG I is
      proposed.
CI  - Copyright 1997 Academic Press Limited.
AD  - Biomedical Centre, Uppsala University, Uppsala, SE-751 24, Sweden.
FAU - Kleywegt, G J
AU  - Kleywegt GJ
FAU - Zou, J Y
AU  - Zou JY
FAU - Divne, C
AU  - Divne C
FAU - Davies, G J
AU  - Davies GJ
FAU - Sinning, I
AU  - Sinning I
FAU - Stahlberg, J
AU  - Stahlberg J
FAU - Reinikainen, T
AU  - Reinikainen T
FAU - Srisodsuk, M
AU  - Srisodsuk M
FAU - Teeri, T T
AU  - Teeri TT
FAU - Jones, T A
AU  - Jones TA
LA  - eng
SI  - PDB/1EG1
SI  - PDB/R1EG1SF
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - ENGLAND
TA  - J Mol Biol
JT  - Journal of molecular biology
JID - 2985088R
RN  - 0 (Peptide Fragments)
RN  - 16462-44-5 (Cellobiose)
RN  - 9004-34-6 (Cellulose)
RN  - EC 3.2.1.4 (Cellulase)
RN  - EC 3.2.1.91 (Cellulose 1,4-beta-Cellobiosidase)
SB  - IM
MH  - Amino Acid Sequence
MH  - Bacillus/enzymology
MH  - Binding Sites
MH  - Cellobiose/metabolism
MH  - Cellulase/*chemistry
MH  - Cellulose/metabolism
MH  - Cellulose 1,4-beta-Cellobiosidase
MH  - Computer Simulation
MH  - Conserved Sequence
MH  - Crystallography, X-Ray
MH  - Mitosporic Fungi/enzymology
MH  - Models, Molecular
MH  - Molecular Sequence Data
MH  - Peptide Fragments/*chemistry
MH  - Protein Conformation
MH  - Protein Engineering
MH  - Sequence Deletion
MH  - Sequence Homology, Amino Acid
MH  - Species Specificity
MH  - Trichoderma/*enzymology
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
AID - S0022-2836(97)91243-2 [pii]
AID - 10.1006/jmbi.1997.1243 [doi]
PST - ppublish
SO  - J Mol Biol. 1997 Sep 26;272(3):383-97.
PMID- 9305568
OWN - NLM
STAT- MEDLINE
DA  - 19971030
DCOM- 19971030
LR  - 20061115
PUBM- Print
IS  - 0832-610X (Print)
VI  - 44
IP  - 9
DP  - 1997 Sep
TI  - Tacrine does not alter the potency of succinylcholine in the rat.
PG  - 1021-6
AB  - PURPOSE: Tacrine is a cholinesterase inhibitor used to manage Alzheimer's
      dementia. Given iv, it prolongs succinylcholine blockade in humans but the
      effects of chronic oral tacrine are not known. METHODS: Groups of adult
      rats were given 2.5 mg.kg-1 tacrine (chronic groups) or l ml saline
      (control) twice daily by gavage for one, two, four or eight weeks. An
      additional (acute) group received 2.5 mg.kg-1 tacrine iv. Twelve to 18 hr
      after the last gavage of tacrine or saline, and -20 min after iv tacrine,
      cumulative dose-response curves of succinylcholine were determined in the
      tibialis and soleus muscles in anaesthetized, ventilated rats during
      monitoring of evoked twitch response to indirect (nerve) train-of-four
      stimulation. RESULTS: The ED50 and ED95 of succinylcholine in control rats
      were (mean +/- SD) 204 +/- 41 and 382 +/- 96 micrograms.kg-1, respectively
      in the tibialis muscle, and 280 +/- 52 and 629 +/- 168 micrograms.kg-1 in
      the soleus muscle (P < 0.05 between muscles). In the acute and chronic
      tacrine groups, the mean ED50 and ED95 ranged from 166-197 and 277-396
      micrograms.kg-1., respectively, in the tibialis muscle, and 248-333 and
      546-667 micrograms.kg-1, in the soleus muscle. Dose responses did not
      differ among acute and chronic tacrine groups and the control group.
      CONCLUSION: Chronic oral tacrine does not alter muscle response to
      succinylcholine in the rat. This may not apply to Alzheimer patients
      receiving chronic tacrine since the interaction between acute tacrine and
      succinylcholine in the rat differs from that in humans.
AD  - Department of Anaesthesia, Royal Victoria Hospital, Montreal, Quebec,
      Canada.
FAU - Ibebunjo, C
AU  - Ibebunjo C
FAU - Eshelby, D
AU  - Eshelby D
FAU - Donati, F
AU  - Donati F
FAU - Fox, G S
AU  - Fox GS
FAU - Tchervenkov, J I
AU  - Tchervenkov JI
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - CANADA
TA  - Can J Anaesth
JT  - Canadian journal of anaesthesia = Journal canadien d'anesthesie
JID - 8701709
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Neuromuscular Depolarizing Agents)
RN  - 306-40-1 (Succinylcholine)
RN  - 321-64-2 (Tacrine)
SB  - IM
MH  - Administration, Oral
MH  - Alzheimer Disease/drug therapy
MH  - Animals
MH  - Cholinesterase Inhibitors/administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Electric Stimulation
MH  - Evoked Potentials/drug effects
MH  - Female
MH  - Hindlimb
MH  - Humans
MH  - Injections, Intravenous
MH  - Muscle Contraction/drug effects
MH  - Muscle, Skeletal/drug effects/innervation
MH  - Neuromuscular Blockade
MH  - Neuromuscular Depolarizing Agents/administration & dosage/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Succinylcholine/administration & dosage/*pharmacology
MH  - Tacrine/administration & dosage/*pharmacology
EDAT- 1997/09/26
MHDA- 1997/09/26 00:01
PST - ppublish
SO  - Can J Anaesth. 1997 Sep;44(9):1021-6.
PMID- 9334875
OWN - NLM
STAT- MEDLINE
DA  - 19971120
DCOM- 19971120
LR  - 20041117
PUBM- Print
IS  - 0091-4150 (Print)
VI  - 45
IP  - 1
DP  - 1997
TI  - Intergenerational perceptions of English speaking and Spanish speaking
      Mexican-American grandparents.
PG  - 1-21
AB  - Hispanics are facing a number of problems, such as poverty, hunger, and a
      high dropout rate at school. Health-care reform and changes in Medicaid
      and Medicare are bound to further challenge the resiliency of minority
      families. To strengthen families from within, relevant programming should
      be implemented. Information regarding the strengths and needs of
      Mexican-American grandparents was obtained in order to adapt existing
      grandparenting programs for this population. Mexican-American grandparents
      (n = 181), parents (n = 148), and grandchildren (n = 173) provided
      information on grandparent satisfaction, success, teaching, difficulty,
      frustration, and information needs. Multivariate analyses of variance
      found differences for English and Spanish speaking grandparents. Spanish
      speaking grandparents reported a greater need for information than English
      speaking grandparents, and more frustration when dealing with adolescents
      than with younger children. For the English speaking grandparents, all of
      the generations agreed that grandparents under the age of sixty-one
      experienced more frustration than their older counterparts, and those who
      spent more than five hours a month with their grandchildren were more
      effective in their role. Possible factors that account for the findings
      are discussed and recommendations for establishing a grandparent program
      are presented.
AD  - College of Education, Division of Psychology in Education, Arizona State
      University, Tempe 85287-0611, USA.
FAU - Strom, R D
AU  - Strom RD
FAU - Buki, L P
AU  - Buki LP
FAU - Strom, S K
AU  - Strom SK
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - Int J Aging Hum Dev
JT  - International journal of aging & human development
JID - 0370033
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arizona
MH  - Child
MH  - Communication
MH  - Curriculum
MH  - *Education
MH  - Female
MH  - Humans
MH  - *Intergenerational Relations
MH  - *Language
MH  - Male
MH  - Mexican Americans/*psychology
MH  - Mexico/ethnology
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Psychometrics
MH  - Questionnaires
MH  - Social Work/*organization & administration
EDAT- 1997/01/01 00:00
MHDA- 1997/10/23 00:01
PST - ppublish
SO  - Int J Aging Hum Dev. 1997;45(1):1-21.
PMID- 9350179
OWN - NLM
STAT- MEDLINE
DA  - 19971119
DCOM- 19971119
LR  - 20060424
PUBM- Print
IS  - 0955-7873 (Print)
VI  - 740
DP  - 1997
TI  - Treatment of childhood and adult acute lymphoblastic leukaemia.
PG  - 29-36
AB  - In the last 30 years the treatment of acute lymphoblastic leukaemia has
      radically changed and intensified and has resulted in improvements in the
      chances of cure in children to up to 70% but in adults only 30% will
      achieve long-term disease-free survival. Data from large therapeutic
      trials have determined good and poor prognostic risk factors which have
      been of use in planning risk-directed treatment protocols and can
      influence the chance of cure. However intensification of treatment has
      also been associated with increased toxicity and significant late effects,
      particularly in children. In the future it will be necessary for more
      international collaboration and a more uniform approach to treatment in
      order to achieve continued improvements in the survival from this disease.
      In children it will be necessary to focus efforts on improving treatment
      of relapsed patients: chemotherapy protocols in those with a first
      remission of > 36 months, or for the high-risk patients with a shorter
      first remission, new transplantation approaches directed towards enhancing
      the graft-versus-leukaemia effect are going to be of increasing
      importance. In adults, continued efforts will be directed towards
      improving first remission rates with the use of increasingly intensive
      chemotherapeutic protocols and growth factors. The use of unrelated donor
      transplantation is also likely to increase, particularly in patients with
      'poor-risk' disease.
AD  - Department of Haematology, University College London Hospitals, UK.
FAU - Liesner, R
AU  - Liesner R
FAU - Goldstone, A H
AU  - Goldstone AH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - ENGLAND
TA  - J Intern Med Suppl
JT  - Journal of internal medicine. Supplement
JID - 8912975
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bone Marrow Transplantation
MH  - Combined Modality Therapy
MH  - Humans
MH  - Leukemia, Lymphocytic, Acute, L1/genetics/immunology/*therapy
MH  - Leukemia, Lymphocytic, Acute, L2/genetics/immunology/*therapy
MH  - Remission Induction
RF  - 68
EDAT- 1997/01/01 00:00
MHDA- 1997/11/14 00:01
PST - ppublish
SO  - J Intern Med Suppl. 1997;740:29-36.
PMID- 9326222
OWN - NLM
STAT- MEDLINE
DA  - 19971106
DCOM- 19971106
LR  - 20061115
PUBM- Print
IS  - 0006-4971 (Print)
VI  - 90
IP  - 7
DP  - 1997 Oct 1
TI  - The efficacy of single-dose administration of thrombopoietin with
      coadministration of either granulocyte/macrophage or granulocyte
      colony-stimulating factor in myelosuppressed rhesus monkeys.
PG  - 2565-73
AB  - Thrombopoietin (TPO) was evaluated for efficacy in a placebo-controlled
      study in rhesus monkeys with concurrent administration of either
      granulocyte/macrophage colony-stimulating factor (GM-CSF) or granulocyte
      CSF, (G-CSF). Rhesus monkeys were subjected to 5 Gy total-body irradiation
      (TBI), resulting in 3 weeks of profound pancytopenia, and received either
      TPO 5 microg/kg intravenously (I.V.) at day 1 (n = 4), GM-CSF 25 microg/kg
      subcutaneously (S.C.) for 14 days (n = 4), TPO and GM-CSF (n = 4), G-CSF
      10 microg/kg/d S.C. for 14 days (n = 3), TPO and G-CSF (n = 4), or placebo
      (carrier, n = 4; historical controls, n = 8). Single-dose I.V. treatment
      with TPO 1 day after TBI effectively counteracted the need for thrombocyte
      transfusions (provided whenever thrombocyte levels were <40 x 10(9)/L) and
      accelerated platelet reconstitution to normal levels 2 weeks earlier than
      placebo controls. TPO/GM-CSF was more effective than single-dose TPO alone
      in stimulating thrombocyte regeneration, with a less profound nadir and a
      further accelerated recovery to normal thrombocyte counts, as well as a
      slight overshoot to supranormal levels of thrombocytes. Monkeys treated
      with TPO/GM-CSF uniformly did not require thrombocyte transfusions,
      whereas those treated with GM-CSF alone needed two to three transfusions,
      similar to the placebo-treated monkeys, which required, on average, three
      transfusions. Also, reticulocyte production was stimulated by TPO and
      further augmented in monkeys treated with TPO/GM-CSF. TPO alone did not
      stimulate neutrophil regeneration, whereas GM-CSF shortened the period of
      neutrophil counts less than 0.5 x 10(9)/L by approximately 1 week;
      TPO/GM-CSF treatment elevated the neutrophil nadir, but did not further
      accelerate recovery to normal values. TPO also augemented the neturophil
      response to G-CSF, resulting in similar patterns of reconstitution
      following TPO/G-CSF and TPO/GM-CSF treatment. TPO/GM-CSF resulted in
      significantly increased reconstitution of CD34+ bone marrow cells and
      progenitor cells such as GM-CFU and BFU-E. Adverse effects of combining
      TPO with the CSFs were not observed. It is concluded that (1) a single
      I.V. administration of TPO is sufficient to prevent severe
      thrombocytopenia following myelosuppression, (2) TPO/G-CSF and TPO/GM-CSF
      treatment result in distinct response patterns, with TPO/GM-CSF being
      superior to TPO/G-CSF in stimulating thrombocyte and erythrocyte recovery
      while being equivalent in stimulating neutrophil recovery; and (3) TPO
      significantly improves the performance of CSFs in alleviating severe
      neutropenia.
AD  - Institute of Hematology, Erasmus University Rotterdam, The Netherlands.
FAU - Neelis, K J
AU  - Neelis KJ
FAU - Hartong, S C
AU  - Hartong SC
FAU - Egeland, T
AU  - Egeland T
FAU - Thomas, G R
AU  - Thomas GR
FAU - Eaton, D L
AU  - Eaton DL
FAU - Wagemaker, G
AU  - Wagemaker G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Recombinant Proteins)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - 9014-42-0 (Thrombopoietin)
SB  - AIM
SB  - IM
MH  - Animals
MH  - Blood Cell Count/drug effects
MH  - Bone Marrow/drug effects
MH  - Bone Marrow Diseases/*drug therapy/etiology/pathology/therapy
MH  - Combined Modality Therapy
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Erythropoiesis/drug effects
MH  - Granulocyte Colony-Stimulating Factor/*administration &
      dosage/pharmacology/therapeutic use
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/*administration &
      dosage/pharmacology/therapeutic use
MH  - Hematopoiesis/*drug effects
MH  - Injections, Intravenous
MH  - Macaca mulatta
MH  - Male
MH  - Neutropenia/blood/drug therapy
MH  - Neutrophils
MH  - Platelet Transfusion
MH  - Radiation Injuries, Experimental/blood/drug therapy/pathology
MH  - Recombinant Proteins/administration & dosage/pharmacology/therapeutic use
MH  - Thrombopoietin/*administration & dosage/pharmacology/therapeutic use
MH  - Whole-Body Irradiation
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Blood. 1997 Oct 1;90(7):2565-73.
PMID- 9251867
OWN - NLM
STAT- MEDLINE
DA  - 19971106
DCOM- 19971106
LR  - 20041117
PUBM- Print
IS  - 0269-9052 (Print)
VI  - 11
IP  - 8
DP  - 1997 Aug
TI  - The relationship between sexual abuse and mild traumatic brain injury.
PG  - 587-603
AB  - It remains unclear why some individuals with mild traumatic brain injury
      (MTBI) complain of cognitive deficits many months after the injury. Given
      neuropathological changes associated with prolonged stress, such as occurs
      with repeated sexual abuse (SA), it seems possible that individuals who
      experienced SA might be predisposed to greater deficits after MTBI. Four
      groups of subjects were administered measures of cognitive and emotional
      functioning. These groups were those with MTBI (n = 10), those with a
      history of SA (n = 10), those with both MTBI and SA (n = 10), and normal
      control (NC) subjects (n = 10). Compared to the NC subjects, those with
      MTBI demonstrated deficits in working memory, those with SA demonstrated
      deficits in executive functioning, and those with both MTBI and SA
      demonstrated the greatest number of deficits which were in working memory,
      executive functioning and memory. Tests of anxiety, depression and
      post-traumatic stress disorder, while demonstrating significant symptoms
      in all clinical groups, did not correlate with the neuropsychological
      tests that differentiated the groups.
AD  - Department of Psychology, Trinity College, Hartford, CT 06106, USA.
FAU - Raskin, S A
AU  - Raskin SA
LA  - eng
PT  - Journal Article
PL  - ENGLAND
TA  - Brain Inj
JT  - Brain injury : [BI]
JID - 8710358
SB  - IM
MH  - Adult
MH  - Affect
MH  - Brain Injuries/*complications/psychology
MH  - Child
MH  - Child Abuse, Sexual/*psychology
MH  - Child, Preschool
MH  - Cognition Disorders/etiology
MH  - Female
MH  - Humans
MH  - Neuropsychological Tests
MH  - Stress Disorders, Post-Traumatic/psychology
EDAT- 1997/08/01
MHDA- 1997/08/01 00:01
PST - ppublish
SO  - Brain Inj. 1997 Aug;11(8):587-603.
PMID- 9310011
OWN - NLM
STAT- MEDLINE
DA  - 19971028
DCOM- 19971028
LR  - 20061115
PUBM- Print
IS  - 1073-449X (Print)
VI  - 156
IP  - 3 Pt 1
DP  - 1997 Sep
TI  - The early bactericidal activity of ciprofloxacin in patients with
      pulmonary tuberculosis.
PG  - 901-5
AB  - The early bactericidal activity (EBA) of ciprofloxacin (CIP) was measured
      in 80 patients with previously untreated, smear-positive pulmonary
      tuberculosis by counting viable bacilli in sputum collections during the
      first 2 d of treatment. Groups of about 10 patients were treated daily
      with graded doses of CIP or with 300 mg isoniazid or with no drug. The
      mean EBA, defined as the fall in log CFU/ ml sputum/d, increased from
      -0.011 in the no drug group to 0.046, 0.092, 0.121, and 0.205 in the
      groups receiving 250, 500, 1,000, or 1,500 mg CIP, respectively, a highly
      significant trend. These results demonstrate the antimycobacterial
      activity of CIP in high dosage, though the mean EBAs of 0.55 and 0.66 in
      two groups receiving isoniazid were much higher.
AD  - South African National Tuberculosis Research Programme, Tygerberg, South
      Africa.
FAU - Sirgel, F A
AU  - Sirgel FA
FAU - Botha, F J
AU  - Botha FJ
FAU - Parkin, D P
AU  - Parkin DP
FAU - Van de Wal, B W
AU  - Van de Wal BW
FAU - Schall, R
AU  - Schall R
FAU - Donald, P R
AU  - Donald PR
FAU - Mitchison, D A
AU  - Mitchison DA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Am J Respir Crit Care Med
JT  - American journal of respiratory and critical care medicine
JID - 9421642
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Antitubercular Agents)
RN  - 54-85-3 (Isoniazid)
RN  - 85721-33-1 (Ciprofloxacin)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Anti-Infective Agents/*administration & dosage
MH  - Antitubercular Agents/*administration & dosage
MH  - Ciprofloxacin/*administration & dosage
MH  - Colony Count, Microbial
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Isoniazid/*administration & dosage
MH  - Male
MH  - Sputum/microbiology
MH  - Time Factors
MH  - Treatment Outcome
MH  - Tuberculosis, Pulmonary/*drug therapy/microbiology
EDAT- 1997/10/06
MHDA- 1997/10/06 00:01
PST - ppublish
SO  - Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):901-5.
PMID- 9350007
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20061115
PUBM- Print
IS  - 0142-4319 (Print)
VI  - 18
IP  - 5
DP  - 1997 Oct
TI  - Coordinated fast-to-slow transitions of myosin and SERCA isoforms in
      chronically stimulated muscles of euthyroid and hyperthyroid rabbits.
PG  - 545-54
AB  - Changes in the patterns of myosin heavy chain (MHC) isoforms, isomyosins,
      and Ca(2+)-ATPase (SERCA) isoforms were studied in long-term (72 d)
      stimulated fast-twitch extensor digitorum longus (EDL) and tibialis
      anterior (TA) muscles of euthyroid and hyperthyroid rabbits. The chronic
      low-frequency stimulation-induced fast-to-slow transitions in MHC
      isoforms, isomyosins and SERCA isoforms were pronounced in muscles from
      euthyroid rabbits, but less pronounced in muscles from hyperthyroid
      rabbits. Thus, hyperthyroidism counteracted to same extent the
      stimulation-induced fast-to-slow transition. Analyses of all parameters
      were performed on the same individual muscles, providing information on
      the co-ordinated expression of SERCA and myosin isoforms. A high
      correlation (r = 0.97) was detected between relative concentrations of
      slow SERCA2a and slow MHCI isoforms. This correlation persisted under all
      experimental conditions, suggesting a co-ordinated expression of slow
      myosin and Ca(2+)-ATPase isoforms. Conversely, fast SERCA1a was correlated
      to fast myosin isoforms as a whole.
AD  - Fakultat fur Biologie, Universitat Konstanz, Germany.
FAU - Hamalainen, N
AU  - Hamalainen N
FAU - Pette, D
AU  - Pette D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - ENGLAND
TA  - J Muscle Res Cell Motil
JT  - Journal of muscle research and cell motility
JID - 8006298
RN  - 0 (Isoenzymes)
RN  - 0 (Myosin Heavy Chains)
RN  - 0 (Vanadates)
RN  - EC 3.6.1.4 (Myosins)
RN  - EC 3.6.1.8 (Calcium-Transporting ATPases)
SB  - IM
SB  - S
MH  - Animals
MH  - Calcium-Transporting ATPases/isolation & purification/*metabolism
MH  - Electric Stimulation
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Hyperthyroidism/*physiopathology
MH  - Isoenzymes/isolation & purification/metabolism
MH  - Muscle Fibers, Fast-Twitch/*physiology
MH  - Muscle, Skeletal/*physiology/physiopathology
MH  - Myosin Heavy Chains/metabolism
MH  - Myosins/isolation & purification/*metabolism
MH  - Rabbits
MH  - Reference Values
MH  - Regression Analysis
MH  - Thyroid Gland/*physiology/physiopathology
MH  - Vanadates/pharmacology
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
PST - ppublish
SO  - J Muscle Res Cell Motil. 1997 Oct;18(5):545-54.
PMID- 9283235
OWN - NLM
STAT- MEDLINE
DA  - 19971114
DCOM- 19971114
LR  - 20061115
PUBM- Print
IS  - 0033-2658 (Print)
VI  - 99
IP  - 6
DP  - 1997
TI  - [Profiles of effects of traditional oriental herbal medicines on central
      nervous systems in humans--assessment of saiboku-to and
      saiko-ka-ryukotsu-borei-to using EEG and pharmacokinetics of herbal
      medicine-derived ingredients as indices]
PG  - 355-69
AB  - To elucidate usefulness of traditional oriental herbal medicines in
      psychiatric fields, we investigated their influences on central nervous
      systems in humans by using EEG and pharmacokinetics of herbal
      medicine-derived ingredients as the indices. The subjects were 12 healthy
      male volunteers who received single oral administration and after that
      received repeated oral administrations at a daily dose of
      Saiko-ka-ryukotsu-borei-to or Saiboku-to; EEG was recorded before
      administration, 1, 3, 6 hours and 10 days after administration. On direct
      comparison of global field powers calculated from 19-lead EEG before and
      after administration, it was verified that Saiboku-to possessed effects on
      central nervous systems. For assessment of pharmacokinetics of ingredients
      derived from Saiboku-to, pre- and post-treatment serum samples were
      assayed by HPLC and two ingredients were detected, besides individual
      differences being observed in their pharmacokinetic profiles. Given that
      these pharmacokinetics could be interpreted as the phenomena associated
      with Sho (traditional physical status classifications of patients), the
      subjects were classified into groups according to individual differences
      whereby quantitative pharmaco-EEG were employed to elucidate neurotropic
      effects of Saiboku-to. As the result, following two groups were evidenced:
      (1) a group demonstrating the mood elevator type after a single
      administration despite of no changes after repeated administrations, and
      (2) a group with a shift from the mood elevator type to the nootropics
      type being observed over time, delineating overt differences in EEG
      profiles among groups. Consequently, individual differences were evidenced
      to be involved in onset of neurotropic effects of Saiboku-to, permitting
      prediction of possible responses following repeated administrations by
      using EEG profiles. It was also suggested that neurotropic effects of
      respective ingredients could be anticipated by monitoring the time-course
      changes of both EEG and plasma levels of these ingredients. In summary,
      once further studies on oriental herbal medicines might progress based on
      efficacy assessments of respective ingredients with a clue of the present
      study, it is conceivable that these findings would play an important role
      as the objective indices in clinical application of herbal medicines in
      psychiatric fields, resulting in broadening the usefulness of oriental
      herbal medicines.
AD  - Department of Neuropsychiatry, Kansai Medical University.
FAU - Fukushima, M
AU  - Fukushima M
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - JAPAN
TA  - Seishin Shinkeigaku Zasshi
JT  - Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica
JID - 9801787
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (saiboku-to)
RN  - 0 (saiko-ka-ryukotsu-borei-to)
SB  - IM
MH  - Adult
MH  - Brain/*drug effects
MH  - Chromatography, High Pressure Liquid
MH  - Drugs, Chinese Herbal/pharmacokinetics/*pharmacology
MH  - Electroencephalography/*drug effects
MH  - Humans
MH  - Male
MH  - *Medicine, Kampo
EDAT- 1997/01/01
MHDA- 1997/01/01 00:01
PST - ppublish
SO  - Seishin Shinkeigaku Zasshi. 1997;99(6):355-69.
PMID- 9335543
OWN - NLM
STAT- MEDLINE
DA  - 19971120
DCOM- 19971120
LR  - 20061115
PUBM- Print
IS  - 0006-2960 (Print)
VI  - 36
IP  - 42
DP  - 1997 Oct 21
TI  - Calmodulin-binding autoinhibitory domain controls "pH-sensing" in the
      Na+/H+ exchanger NHE1 through sequence-specific interaction.
PG  - 12854-61
AB  - The calmodulin (CaM)-binding domain reduces the affinity of the Na+/H+
      exchanger NHE1 for intracellular H+ by exerting an autoinhibitory function
      in quiescent cells. We replaced this domain (aa 637-656) with homologous
      segments from other NHE isoforms (NHE2 and 4) or functionally similar
      regions from other sources (Na+/Ca2+ exchanger, CaM-dependent protein
      kinase II, plasma membrane Ca2+-pump, or CaM-binding peptide Trp3). The
      NHE-1-, NHE2-, and NHE4-segments bound CaM with Kds of 16, 130, and 27 nM,
      respectively. These chimeric molecules were expressed in the
      exchanger-deficient cell PS120. NHE1 with incorporated NHE2-segment was
      activated in response to Ca2+-mobilizing agents ionomycin and thrombin
      resulting in an alkaline shift of the intracellular pH (pHi)-dependence of
      22Na+ uptake, as was the case with the intact rat NHE2. In contrast,
      incorporation of the NHE4-segment or other CaM-binding segments induced a
      constitutive alkaline shift of pHi-dependence with concomitant abolishment
      of Ca2+-dependent activation, indicating that these segments could not
      function as an autoinhibitory domain in NHE1. Detailed analyses revealed
      that Leu639, Lys651 and Tyr652, conserved in the NHE1- and NHE2-segments,
      but not in the NHE4-segment, are important for the autoinhibition.
      Furthermore, 125I-labeled CaM-binding peptide from NHE1 was efficiently
      crosslinked to the NHE1 protein, suggesting that the inhibitory domain
      physically interacts with part(s) of the molecule. Together, these
      findings support the notion that the reduction of H+ affinity in Na+/H+
      exchange occurs through a mechanism involving a highly sequence-specific
      interaction of the inhibitory domain with its putative acceptor in NHE1.
AD  - Department of Molecular Physiology, National Cardiovascular Center
      Research Institute, Suita, Osaka 565, Japan. wak@ri.ncvc.go.jp
FAU - Wakabayashi, S
AU  - Wakabayashi S
FAU - Ikeda, T
AU  - Ikeda T
FAU - Iwamoto, T
AU  - Iwamoto T
FAU - Pouyssegur, J
AU  - Pouyssegur J
FAU - Shigekawa, M
AU  - Shigekawa M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Biochemistry
JT  - Biochemistry
JID - 0370623
RN  - 0 (Calmodulin)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Slc9a2 protein, rat)
RN  - 0 (Sodium-Hydrogen Antiporter)
RN  - 0 (growth factor-activatable Na-H exchanger NHE-1)
RN  - 0 (sodium-hydrogen exchanger 3)
RN  - 56092-81-0 (Ionomycin)
SB  - IM
MH  - Amino Acid Sequence
MH  - Amino Acid Substitution
MH  - Animals
MH  - Base Sequence
MH  - Binding Sites
MH  - Calmodulin/*metabolism/pharmacology
MH  - Cell Line
MH  - Cross-Linking Reagents
MH  - *Hydrogen-Ion Concentration
MH  - Ionomycin/pharmacology
MH  - Kinetics
MH  - Molecular Sequence Data
MH  - Mutagenesis, Site-Directed
MH  - Peptide Fragments/chemical synthesis/*chemistry/metabolism
MH  - Rats
MH  - Recombinant Proteins/antagonists & inhibitors/chemistry/metabolism
MH  - Sequence Deletion
MH  - Sequence Homology, Amino Acid
MH  - Sodium-Hydrogen Antiporter/antagonists & inhibitors/*chemistry/*metabolism
MH  - Transfection
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
AID - 10.1021/bi9715472 [doi]
AID - bi9715472 [pii]
PST - ppublish
SO  - Biochemistry. 1997 Oct 21;36(42):12854-61.
PMID- 9356063
OWN - NLM
STAT- MEDLINE
DA  - 19971119
DCOM- 19971119
LR  - 20031114
PUBM- Print
IS  - 0022-5282 (Print)
VI  - 43
IP  - 4
DP  - 1997 Oct
TI  - Cardiopulmonary physiology of primary blast injury.
PG  - 650-5
AB  - OBJECTIVE: Bomb blast survivors are occasionally found in profound shock
      and hypoxic without external signs of injury. We investigated the
      cardiovascular and pulmonary responses of rats subjected to a blast
      pressure wave. DESIGN: Prospectively randomized, controlled animal study.
      MATERIALS AND METHODS: Rats were instrumented and subjected to a blast
      pressure wave of different intensities from a blast wave generator.
      Cardiopulmonary parameters were recorded for 3 hours or until death.
      MEASUREMENTS AND MAIN RESULTS: The cardiovascular response to a blast
      pressure wave was immediate bradycardia, hypotension, and low cardiac
      index. Three hours later, the rats developed hypotension, low cardiac
      index, and low stroke volume. Interestingly, systemic vascular resistance
      remained unchanged. The pulmonary response was a decreased PaO2 and stable
      PacO2, suggesting a ventilation-perfusion mismatch from massive pulmonary
      hemorrhage. CONCLUSIONS: Blast-induced circulatory shock resulted from
      immediate myocardial depression without a compensatory vasoconstriction.
      Hypoxia presumably resulted from a ventilation-perfusion mismatch caused
      by pulmonary hemorrhage.
AD  - Department of Surgery, University of Oklahoma Health Sciences Center, and
      Department of Veterans Affairs Medical Center, Oklahoma City 73126, USA.
FAU - Irwin, R J
AU  - Irwin RJ
FAU - Lerner, M R
AU  - Lerner MR
FAU - Bealer, J F
AU  - Bealer JF
FAU - Brackett, D J
AU  - Brackett DJ
FAU - Tuggle, D W
AU  - Tuggle DW
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
SB  - AIM
SB  - IM
MH  - Animals
MH  - Blast Injuries/*physiopathology
MH  - Evaluation Studies
MH  - Heart Injuries/*physiopathology
MH  - Hemodynamic Processes
MH  - Lung/*injuries/*physiopathology
MH  - Male
MH  - Prospective Studies
MH  - Pulmonary Circulation
MH  - Random Allocation
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
PST - ppublish
SO  - J Trauma. 1997 Oct;43(4):650-5.
PMID- 9323920
OWN - NLM
STAT- MEDLINE
DA  - 19971118
DCOM- 19971118
LR  - 20041117
PUBM- Print
IS  - 0250-636X (Print)
VI  - 18
IP  - 2
DP  - 1997 Apr-Jun
TI  - Differences in hepatitis B markers between clinical and preclinical health
      care personnel.
PG  - 69-71
AB  - Hepatitis B virus (HBV) infection is an occupational risk for health care
      personnel (HCP). Vaccination is an important preventive measure but high
      cost of vaccination limits the feasibility of giving vaccine to all HCP.
      To find an optimum approach for vaccination we conducted a study on HCP in
      Maulana Azad Medical College and associated LNJPN hospital. A total of 162
      subjects were screened. Eight were excluded because of prior vaccination
      against HBV. Two groups of subjects were selected namely preclinical and
      clinical. The preclinical group comprised first year medical students and
      the clinical group comprised of HCP who have been exposed to clinical
      departments. The subjects were screened for HBsAg, anti HBs and anti HBc
      viral markers. 86 subjects were screened in the preclinical group. Two
      (2.3%) were positive for HBsAG; 16 (18%) and 9 (10.4%) were positive for
      anti HBs and anti HBc respectively. In the clinical group a total of 68
      subjects were screened. Amongst them 1.4% were positive for HBsAg; 47
      (69%) and 38 (55%) were positive for anti HBs and anti HBc respectively.
      The study revealed that there was a significant difference in the titre of
      the viral markers in the preclinical group as compared to the clinical
      group. Seventy (82%) of preclinical subjects were at high risk for the
      infection as they moved into clinical departments. Few subjects will be
      excluded from the vaccination schedule based on anti HBs screening and
      hence screening prior to vaccination is not cost effective. However in the
      clinical group 69% will be excluded from the vaccination schedule based on
      anti HBs positivity and screening will save up to 60% of cost involved in
      vaccination.
AD  - Department of Medicine, Maulana Azad Medical College, New Delhi, India.
FAU - Khurana, V
AU  - Khurana V
FAU - Kar, P
AU  - Kar P
FAU - Mansharamani, N
AU  - Mansharamani N
FAU - Jain, V
AU  - Jain V
FAU - Kanodia, A
AU  - Kanodia A
LA  - eng
PT  - Journal Article
PL  - INDIA
TA  - Trop Gastroenterol
JT  - Tropical gastroenterology : official journal of the Digestive Diseases
      Foundation
JID - 8107122
RN  - 0 (Biological Markers)
RN  - 0 (Hepatitis B Vaccines)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Biological Markers/blood
MH  - Costs and Cost Analysis
MH  - Female
MH  - *Health Personnel
MH  - Hepatitis B/immunology/*prevention & control
MH  - *Hepatitis B Vaccines/economics
MH  - Humans
MH  - India
MH  - Male
MH  - Middle Aged
MH  - Occupational Diseases/immunology/*prevention & control
EDAT- 1997/04/01 00:00
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Trop Gastroenterol. 1997 Apr-Jun;18(2):69-71.
PMID- 9380133
OWN - NLM
STAT- MEDLINE
DA  - 19971030
DCOM- 19971030
LR  - 20061115
PUBM- Print
IS  - 0028-2162 (Print)
VI  - 141
IP  - 22
DP  - 1997 May 31
TI  - [Malignant pleural mesothelioma in general practice; complex pain
      problems]
PG  - 1081-5
AB  - In three patients, men aged 67, 57 and 69 years, malignant pleural
      mesothelioma was diagnosed. All three had worked as coal miners and were
      presented with thoracic pain. They were among seven cases of malignant
      pleural mesothelioma diagnosed in a period of five years in one suburban
      general practice (adherence: 5600 patients) in the former mining area in
      the province of Limburg. The terminal phase of the disease was
      characterized by intractable pain. High doses of opioids and adjuvants
      were necessary to achieve acceptable pain relief. It is suggested that
      step one of the 'analgesic ladder for cancer pain management' of the WHO
      (non-opioids) should be followed soon by step three (strong opioids).
      Because the incidence of pleural mesothelioma is not yet decreasing, it is
      important to know that pain management remains a serious problem.
AD  - Universiteit Maastricht, vakgroep Huisartsgeneeskunde.
FAU - Leclercq, R M
AU  - Leclercq RM
FAU - Jongmans-Liedekerken, A W
AU  - Jongmans-Liedekerken AW
LA  - dut
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Pleuramesothelioom in de huisartsenpraktijk; gecompliceerde pijnproblemen.
PL  - NETHERLANDS
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Analgesics, Opioid)
RN  - 1332-21-4 (Asbestos)
RN  - 57-27-2 (Morphine)
SB  - IM
CIN - Ned Tijdschr Geneeskd. 1997 Aug 9;141(32):1582-3. PMID: 9543758
CIN - Ned Tijdschr Geneeskd. 1997 Aug 9;141(32):1582; author reply 1583. PMID:
      9543757
MH  - Aged
MH  - Analgesics, Opioid/administration & dosage/*therapeutic use
MH  - Asbestos/adverse effects
MH  - Humans
MH  - Lung Neoplasms/*complications/etiology
MH  - Male
MH  - Mesothelioma/*complications/etiology
MH  - Middle Aged
MH  - Morphine/administration & dosage/*therapeutic use
MH  - Pain, Intractable/etiology/*prevention & control
EDAT- 1997/05/31 00:00
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 1997 May 31;141(22):1081-5.
PMID- 9303578
OWN - NLM
STAT- MEDLINE
DA  - 19971027
DCOM- 19971027
LR  - 20061115
PUBM- Print
IS  - 0028-1298 (Print)
VI  - 356
IP  - 3
DP  - 1997 Sep
TI  - The interaction of endothelin receptor responses in the isolated perfused
      rat lung.
PG  - 392-7
AB  - To gain more insight into the complex pulmonary interactions of
      endothelins (ET), we studied airway and vascular responses to endothelins
      in isolated perfused rat lungs in the presence of the novel ET(B)-receptor
      antagonist BQ788. In particular we focused on airway responses and on
      prostacyclin release. The effectiveness of BQ788 in our system was shown
      by its ability to concentration-dependently prevent vasoconstriction (IC50
      0.1 microM), bronchoconstriction (IC50 0.1 microM) and prostacyclin
      production (IC50 < 0.1 microM) induced by the ET(B)-receptor agonist
      IRL1620 (1 nmol). Airway responses to ET-1: ET-1-induced
      bronchoconstriction was aggravated by BQ123 (1 or 8 microM), while BQ788
      pretreatment (1 or 8 microM) showed no significant effect. Simultaneous
      treatment with 8 microM BQ123 and BQ788 attenuated the ET-1-induced
      bronchoconstriction. Vascular responses to ET-1: ET-1 (1 nmol)-induced
      vasoconstriction was potentiated by BQ788 (1 or 8 microM), but attenuated
      by the ET(A)-receptor antagonist BQ123 (1 microM). In the presence of
      BQ788 diminished amounts of the stable prostacyclin metabolite
      6-keto-PGF1alpha were detected in the perfusate. Simultaneous treatment
      with 8 microM BQ123 and BQ788 completely prevented the ET-1-induced
      vasoconstriction. Conclusions: Both ET(A)- and ET(B)-receptors contribute
      to ET-1-induced vasoconstriction and bronchoconstriction. The ET-1-induced
      vasoconstriction is attenuated by stimulation of ET(B)-receptors, a
      response that is partly mediated by prostacyclin. Due to the mutual
      interactions between ET(A)- and ET(B)-receptors, simultaneous inhibition
      of both receptors is required to prevent the deleterious effects of ET-1
      on lung functions.
AD  - Biochemical Pharmacology, University of Konstanz, Germany.
FAU - Uhlig, S
AU  - Uhlig S
FAU - Featherstone, R L
AU  - Featherstone RL
LA  - eng
PT  - In Vitro
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - GERMANY
TA  - Naunyn Schmiedebergs Arch Pharmacol
JT  - Naunyn-Schmiedeberg's archives of pharmacology
JID - 0326264
RN  - 0 (BQ 788)
RN  - 0 (Endothelin-1)
RN  - 0 (Endothelins)
RN  - 0 (Oligopeptides)
RN  - 0 (Peptide Fragments)
RN  - 0 (Peptides, Cyclic)
RN  - 0 (Piperidines)
RN  - 0 (Receptor, Endothelin A)
RN  - 0 (Receptor, Endothelin B)
RN  - 0 (Receptors, Endothelin)
RN  - 136553-81-6 (cyclo(Trp-Asp-Pro-Val-Leu))
RN  - 142569-99-1 (IRL 1620)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/metabolism
MH  - Animals
MH  - Bronchoconstriction/drug effects
MH  - Drug Interactions
MH  - Endothelin-1/pharmacology
MH  - Endothelins/pharmacology
MH  - Female
MH  - Lung/blood supply/drug effects/*physiology
MH  - Muscle, Smooth/drug effects/*physiology
MH  - Oligopeptides/pharmacology
MH  - Peptide Fragments/pharmacology
MH  - Peptides, Cyclic/pharmacology
MH  - Piperidines/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Receptor, Endothelin A
MH  - Receptor, Endothelin B
MH  - Receptors, Endothelin/antagonists & inhibitors/drug effects/*physiology
MH  - Vasoconstriction/drug effects
EDAT- 1997/09/26
MHDA- 1997/09/26 00:01
PST - ppublish
SO  - Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):392-7.
PMID- 9358126
OWN - NLM
STAT- MEDLINE
DA  - 19971106
DCOM- 19971106
LR  - 20061115
PUBM- Print
IS  - 0028-4793 (Print)
VI  - 337
IP  - 19
DP  - 1997 Nov 6
TI  - A comparison of recombinant hirudin with a low-molecular-weight heparin to
      prevent thromboembolic complications after total hip replacement.
PG  - 1329-35
AB  - BACKGROUND: Patients who undergo total hip replacement have a high risk of
      thromboembolic complications. Recombinant hirudin (desirudin), a specific
      inhibitor of thrombin, represents a new development in antithrombotic
      therapy. We compared the efficacy and safety of desirudin with those of a
      low-molecular-weight heparin (enoxaparin) for the prevention of
      thromboembolic complications in patients undergoing primary total hip
      replacement. METHODS: Both treatments, which were assigned in a
      randomized, double-blind manner, were started preoperatively: enoxaparin
      on the evening before surgery, and desirudin within 30 minutes before the
      start of surgery. The dose of desirudin was 15 mg subcutaneously twice
      daily, and the dose of enoxaparin was 40 mg subcutaneously once daily. The
      duration of treatment was 8 to 12 days. Deep-vein thrombosis was verified
      by bilateral venography performed at the end of the treatment period or
      earlier, if there were clinical signs of deep-vein thrombosis. RESULTS: At
      31 centers in 10 European countries, 2079 eligible patients were randomly
      assigned to receive desirudin or enoxaparin. A total of 1587 patients were
      included in the primary analysis of efficacy. In the desirudin group, as
      compared with the enoxaparin group, there was a significantly lower rate
      of proximal deep-vein thrombosis (4.5 vs. 7.5 percent, P=0.01; relative
      reduction in risk, 40.3 percent) and a lower overall rate of deep-vein
      thrombosis (18.4 vs. 25.5 percent, P=0.001; relative reduction in risk,
      28.0 percent). The safety profiles were similar in the two treatment
      groups. CONCLUSIONS: When administered 30 minutes before total hip
      replacement surgery, desirudin is more effective than enoxaparin in
      preventing deep-vein thrombosis.
AD  - Department of Orthopedics, Sahlgrenska-Ostra University Hospital,
      Goteborg, Sweden.
FAU - Eriksson, B I
AU  - Eriksson BI
FAU - Wille-Jorgensen, P
AU  - Wille-Jorgensen P
FAU - Kalebo, P
AU  - Kalebo P
FAU - Mouret, P
AU  - Mouret P
FAU - Rosencher, N
AU  - Rosencher N
FAU - Bosch, P
AU  - Bosch P
FAU - Baur, M
AU  - Baur M
FAU - Ekman, S
AU  - Ekman S
FAU - Bach, D
AU  - Bach D
FAU - Lindbratt, S
AU  - Lindbratt S
FAU - Close, P
AU  - Close P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Hirudins)
RN  - 0 (Recombinant Proteins)
RN  - 120993-53-5 (desirudin)
SB  - AIM
SB  - IM
CIN - N Engl J Med. 1997 Nov 6;337(19):1383-4. PMID: 9358134
CIN - N Engl J Med. 1998 Mar 26;338(13):920-1. PMID: 9518290
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - *Arthroplasty, Replacement, Hip
MH  - Double-Blind Method
MH  - Enoxaparin/administration & dosage/*therapeutic use
MH  - Female
MH  - Hirudin Therapy
MH  - Hirudins/administration & dosage/*analogs & derivatives
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*prevention & control
MH  - Recombinant Proteins/administration & dosage/therapeutic use
MH  - Thrombophlebitis/etiology/*prevention & control
MH  - Treatment Outcome
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
PST - ppublish
SO  - N Engl J Med. 1997 Nov 6;337(19):1329-35.
PMID- 9377034
OWN - NLM
STAT- MEDLINE
DA  - 19971028
DCOM- 19971028
LR  - 20061115
PUBM- Print
IS  - 1026-9428 (Print)
IP  - 7
DP  - 1997
TI  - [Clinical and functional aspects of adverse effects of toxic substance
      complexes in firefighters]
PG  - 14-8
AB  - The study covered influence of combined toxic chemicals on fire
      extinguishers. Acute exposure of respiratory and peripheral nervous
      systems was demonstrated. Consequences of the exposure were proved to
      include polyneuropathies, neuroses and other health disorders.
FAU - Potrokhov, O I
AU  - Potrokhov OI
FAU - Dolgikh, D V
AU  - Dolgikh DV
FAU - Kas'ianovskaia, V P
AU  - Kas'ianovskaia VP
FAU - Shevchenko, O I
AU  - Shevchenko OI
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Kliniko-funktsional'naia kharakteristika neblagopriiatnogo deistviia
      kompleksa toksicheskikh veshchestv na organizm likvidatorov pozhara.
PL  - RUSSIA
TA  - Med Tr Prom Ekol
JT  - Meditsina truda i promyshlennaia ekologiia
JID - 9434213
RN  - 0 (Hazardous Substances)
SB  - IM
MH  - Adult
MH  - *Fires
MH  - Hazardous Substances/*adverse effects
MH  - Humans
MH  - Male
MH  - Nervous System Diseases/*chemically induced/diagnosis
MH  - Neurotic Disorders/*chemically induced/diagnosis
MH  - Occupational Diseases/*chemically induced/diagnosis
MH  - *Occupations
MH  - Respiratory Tract Diseases/*chemically induced/diagnosis
MH  - Time Factors
EDAT- 1997/01/01 00:00
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Med Tr Prom Ekol. 1997;(7):14-8.
PMID- 9322672
OWN - NLM
STAT- MEDLINE
DA  - 19971030
DCOM- 19971030
LR  - 20041117
PUBM- Print
IS  - 0003-1348 (Print)
VI  - 63
IP  - 10
DP  - 1997 Oct
TI  - Vascular complications of thoracic outlet syndrome.
PG  - 913-7
AB  - Vascular complications of thoracic outlet syndrome are uncommon but may
      result in significant long-term disability. This report documents a
      retrospective review of 17 such patients. Ten patients presented with
      acute onset of upper extremity swelling and axillosubclavian vein
      thrombosis. One patient presented with chronic, intermittent arm swelling
      and subclavian vein stenosis. Three patients presented with acute symptoms
      of upper extremity emboli, and three presented with chronic arm
      claudication. Cervical ribs were discovered in four patients with arterial
      symptoms and in no patients with venous symptoms. All ten patients with
      acute venous thrombosis underwent successful thrombolysis, with venous
      stenosis uncovered in 8. Thrombolysis was also performed for two patients
      with arterial emboli. All 17 patients underwent surgical decompression of
      the thoracic outlet, 16 via a supraclavicular approach and one via a
      transaxillary approach. One subclavian arteriotomy with endarterectomy and
      one resection of a subclavian artery aneurysm were performed at the time
      of decompression. Repeat venography after decompression demonstrated
      persistent venous stenosis in one patient that was treated with balloon
      angioplasty and stenting. After a mean of 22 months' follow-up, 12
      patients had no residual symptoms, and 5 had experienced significant
      improvement of symptoms. In conclusion, a combined approach of
      thrombolysis and surgical decompression of the thoracic outlet provides a
      salutary outcome in a majority of patients.
AD  - Department of Surgery, University of Southern California School of
      Medicine, Los Angeles 90033, USA.
FAU - Hood, D B
AU  - Hood DB
FAU - Kuehne, J
AU  - Kuehne J
FAU - Yellin, A E
AU  - Yellin AE
FAU - Weaver, F A
AU  - Weaver FA
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - Am Surg
JT  - The American surgeon
JID - 0370522
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aneurysm/surgery
MH  - Angioplasty, Balloon
MH  - Arm/*blood supply
MH  - Axillary Vein/pathology
MH  - Cervical Rib Syndrome/complications
MH  - Chronic Disease
MH  - Constriction, Pathologic/etiology
MH  - Edema/etiology
MH  - Embolism/drug therapy/etiology
MH  - Endarterectomy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Intermittent Claudication/etiology
MH  - Male
MH  - Middle Aged
MH  - Peripheral Vascular Diseases/drug therapy/*etiology/radiography/surgery
MH  - Phlebography
MH  - Retrospective Studies
MH  - Stents
MH  - Subclavian Artery/pathology/surgery
MH  - Subclavian Vein/pathology
MH  - Thoracic Outlet Syndrome/*complications/surgery
MH  - Thrombolytic Therapy
MH  - Thrombosis/drug therapy/etiology
MH  - Treatment Outcome
EDAT- 1997/10/10
MHDA- 1997/10/10 00:01
PST - ppublish
SO  - Am Surg. 1997 Oct;63(10):913-7.
PMID- 9379505
OWN - NLM
STAT- MEDLINE
DA  - 19971110
DCOM- 19971110
LR  - 20061115
PUBM- Print
IS  - 0368-2811 (Print)
VI  - 27
IP  - 4
DP  - 1997 Aug
TI  - Association between p53 mutation and clinicopathological features of
      non-small cell lung cancer.
PG  - 211-5
AB  - Genetic alterations in exons 5-8 of the p53 gene, determined by
      single-strand conformation polymorphism and sequencing analyses, and the
      clinicopathological characteristics of 108 patients with non-small cell
      lung cancer were compared. Mutations in this gene were found in 37 of the
      108 patients (34%): in 30% (23/76) of those with adenocarcinomas, 46%
      (12/26) of those with squamous cell, 33% (1/3) of those with large cell
      and 33% (1/3) of those with adenosquamous carcinomas. No associations
      between the incidence of p53 mutations and the histological or cytological
      subtypes of adenocarcinomas were found. The analysis of types of
      mutations, however, showed that GC transversion was relatively common in
      papillary and clara subtypes, whereas it accounted for only 17% at most of
      p53 mutations in tubular and bronchial surface epithelial cell subtypes of
      adenocarcinomas. Univariate analyses revealed that large tumor size, high
      nodal stage and positive vascular invasion of non-small cell lung cancers,
      and high nodal stage and high-grade nuclear atypia of adenocarcinomas were
      associated significantly with p53 mutations. Multivariate analyses showed
      that the tumor sizes of non-small cell lung cancer correlated with p53
      mutations with marginal significance (P = 0.099) whereas nuclear atypia of
      adenocarcinomas correlated significantly (P = 0.028). No differences
      between the overall or relapse-free survival rates of patients with and
      without p53 mutations in non-small cell lung cancers or adenocarcinomas
      were found. These findings indicate that p53 mutations in adenocarcinomas
      of the lung are associated with the malignant phenotype of tumor cells,
      but not with patient survival.
AD  - Investigative Treatment Division, National Cancer Center Research
      Institute East, Chiba, Japan.
FAU - Guang, S G
AU  - Guang SG
FAU - Ogura, T
AU  - Ogura T
FAU - Sekine, I
AU  - Sekine I
FAU - Yokozaki, M
AU  - Yokozaki M
FAU - Esumi, H
AU  - Esumi H
FAU - Kodama, T
AU  - Kodama T
FAU - Nagai, K
AU  - Nagai K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - JAPAN
TA  - Jpn J Clin Oncol
JT  - Japanese journal of clinical oncology
JID - 0313225
RN  - 0 (DNA, Neoplasm)
RN  - 71-30-7 (Cytosine)
RN  - 73-40-5 (Guanine)
SB  - IM
MH  - Adenocarcinoma/genetics/pathology
MH  - Adenocarcinoma, Papillary/genetics/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analysis of Variance
MH  - Base Sequence
MH  - Carcinoma, Adenosquamous/genetics/pathology
MH  - Carcinoma, Large Cell/genetics/pathology
MH  - Carcinoma, Non-Small-Cell Lung/genetics/*pathology
MH  - Carcinoma, Squamous Cell/genetics/pathology
MH  - Cell Nucleus/ultrastructure
MH  - Cytosine
MH  - DNA, Neoplasm/genetics
MH  - Disease-Free Survival
MH  - Epithelium/pathology
MH  - Exons/genetics
MH  - Female
MH  - Genes, p53/*genetics
MH  - Guanine
MH  - Humans
MH  - Incidence
MH  - Lung Neoplasms/genetics/*pathology
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Mutation/*genetics
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Phenotype
MH  - Point Mutation
MH  - Polymorphism, Single-Stranded Conformational
MH  - Sequence Analysis, DNA
EDAT- 1997/08/01 00:00
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Jpn J Clin Oncol. 1997 Aug;27(4):211-5.
PMID- 9331500
OWN - NLM
STAT- MEDLINE
DA  - 19971114
DCOM- 19971114
LR  - 20060424
PUBM- Print
IS  - 0963-6897 (Print)
VI  - 6
IP  - 5
DP  - 1997 Sep-Oct
TI  - Bone marrow mononuclear cell count does not predict neutrophil and
      platelet recovery following autologous bone marrow transplant: value of
      the colony-forming unit granulocyte-macrophage (CFU-GM) assay.
PG  - 491-5
AB  - The common use of the marrow autograft mononuclear cell (MNC) count
      derives from positive correlative studies following allogeneic
      transplantation and from earlier conflicting data regarding the value of
      the bone marrow autograft colony-forming unit granulocyte-macrophage
      (CFU-GM) assay for prediction hematologic recovery after ABMT. We
      conducted a retrospective analysis at our institution to determine whether
      autograft CFU-GM levels predict engraftment of neutrophils and platelets
      after ABMT in heavily pretreated patients with hematologic malignancies.
      Between 1 January 1993 and 1 March 1995, 58 heavily pretreated patients
      received only marrow cells as the autograft product. Patients with
      Hodgkin's disease (n = 25), acute myeloid leukemia (n = 19), and
      non-Hodgkin's lymphoma (n = 14) underwent intensive therapy with etoposide
      and melphalan. Unpurged marrow containing a minimum of 1.5 x 10(8)/kg
      (range: 1.5-4.8) was infused. Median time to an absolute neutrophil count
      > or = 0.5 x 10(9)/L was 21 days (range 10-270) and median time to a
      platelet count > or = 20 x 10(9)/L independent of transfusions was 44 days
      (range 13-317). There was no correlation between autograft MNC count and
      neutrophil or platelet engraftment. However, a correlation between
      autograft CFU-GM and both platelet and neutrophil recovery was
      demonstrated with a threshold CFU-GM of 3 x 10(4)/kg; delayed neutrophil
      recovery was observed in 79% of patients below this threshold compared to
      only 9% in those with an autograft CFU-GM level of more than 3 x 10(4)/kg
      (p = 0.0001). Similarly, platelet recovery was delayed in 76% of patients
      below, and 20% of those above this threshold (p = 0.003). We conclude that
      marrow autograft CFU-GM is predictive of engraftment of both platelets and
      neutrophils in heavily pretreated patients after ABMT for hematological
      malignancies.
AD  - University of Toronto Autologous Blood and Marrow Transplant Program,
      Toronto Hospital, Ontario, Canada.
FAU - al-Fiar, F
AU  - al-Fiar F
FAU - Prince, H M
AU  - Prince HM
FAU - Imrie, K
AU  - Imrie K
FAU - Stewart, A K
AU  - Stewart AK
FAU - Crump, M
AU  - Crump M
FAU - Keating, A
AU  - Keating A
LA  - eng
PT  - Journal Article
PL  - UNITED STATES
TA  - Cell Transplant
JT  - Cell transplantation
JID - 9208854
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Blood Platelets
MH  - *Bone Marrow Transplantation
MH  - *Colony-Forming Units Assay
MH  - Combined Modality Therapy
MH  - Female
MH  - Granulocytes
MH  - Hodgkin Disease/drug therapy/therapy
MH  - Humans
MH  - Leukemia, Myeloid/drug therapy/therapy
MH  - Leukocyte Count
MH  - Leukocytes, Mononuclear/*cytology
MH  - Lymphoma, Non-Hodgkin/drug therapy/therapy
MH  - Macrophages
MH  - Male
MH  - Middle Aged
MH  - *Neutrophils
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Transplantation, Autologous
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
AID - S0963689797000535 [pii]
PST - ppublish
SO  - Cell Transplant. 1997 Sep-Oct;6(5):491-5.
PMID- 9382486
OWN - NLM
STAT- MEDLINE
DA  - 19971107
DCOM- 19971107
LR  - 20061115
PUBM- Print
IS  - 0273-2289 (Print)
VI  - 67
IP  - 1-2
DP  - 1997 Jul-Aug
TI  - Effect of different proteases on bitterness of hemoglobin hydrolysates.
PG  - 127-38
AB  - Hemoglobin was hydrolyzed by several enzymes (Proctase, Alcalase,
      Neutrase, papain). Hydrolysates were analyzed (degree of hydrolysis, gel
      permeation on Superose 12 column, tasting) and fractionated by
      ultrafiltration and 2-butanol extraction. The bitter peptides were
      isolated and identified. The results were compared with those already
      obtained with peptic hemoglobin hydrolysates. All the findings were
      confirmed. Ultrafiltration concentrated bitter compounds in the fraction
      corresponding to 500-5000 Da, and these compounds were selectively
      extracted by 2-butanol. All the bitter peptides belonged to the same
      fragment of the beta-chain of bovine hemoglobin. Finally, the use of a
      Superose 12 chromatographic column for easy detection of bitter
      hydrolysates without sensory analysis could be generalized for hemoglobin
      hydrolysates.
AD  - INSA, Centre de Bioingenierie Gilbert Durand (UMR 5504, L.A. INRA),
      Complexe Scientifique de Rangueil, Toulouse, France.
FAU - Aubes-Dufau, I
AU  - Aubes-Dufau I
FAU - Combes, D
AU  - Combes D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Appl Biochem Biotechnol
JT  - Applied biochemistry and biotechnology
JID - 8208561
RN  - 0 (Butanols)
RN  - 0 (Hemoglobins)
RN  - 0 (Peptide Fragments)
RN  - 78-92-2 (2-butanol)
RN  - EC 3.4.- (Endopeptidases)
RN  - EC 3.4.21.- (Subtilisins)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Butanols
MH  - Cattle
MH  - Chromatography, Gel
MH  - *Endopeptidases
MH  - Hemoglobins/*chemistry
MH  - Humans
MH  - Hydrolysis
MH  - Molecular Weight
MH  - Peptide Fragments/*chemistry/isolation & purification
MH  - Subtilisins
MH  - *Taste
MH  - Ultrafiltration
EDAT- 1997/07/01 00:00
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Appl Biochem Biotechnol. 1997 Jul-Aug;67(1-2):127-38.
PMID- 9335335
OWN - NLM
STAT- MEDLINE
DA  - 19971103
DCOM- 19971103
LR  - 20061115
PUBM- Print
IS  - 0092-8674 (Print)
VI  - 91
IP  - 1
DP  - 1997 Oct 3
TI  - Components and dynamics of DNA replication complexes in S. cerevisiae:
      redistribution of MCM proteins and Cdc45p during S phase.
PG  - 59-69
AB  - In S. cerevisiae, the chromatin structure of DNA replication origins
      changes as cells become competent for DNA replication, suggesting that G1
      phase-specific association of replication factors with origin DNA
      regulates entry into S phase. We demonstrate that ORC, Cdc45p, and MCM
      proteins are components of prereplication complexes (pre-RC). The
      MCM-origin association is dependent upon ORC and Cdc6p. During S phase,
      MCM proteins and Cdc45p dissociate from origin DNA and associate with
      nonorigin DNA with similar kinetics as DNA Polymerase epsilon, which is
      present at DNA replication forks. Our results identify protein components
      of the pre-RC and a novel replication complex appearing at the G1/S
      transition (the RC), and suggest that after initiation MCM proteins and
      Cdc45p move with eukaryotic replication forks.
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge
      02139, USA.
FAU - Aparicio, O M
AU  - Aparicio OM
FAU - Weinstein, D M
AU  - Weinstein DM
FAU - Bell, S P
AU  - Bell SP
LA  - eng
GR  - GM52339/GM/NIGMS
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (CDC45 protein, S cerevisiae)
RN  - 0 (CDC47 protein, S cerevisiae)
RN  - 0 (Carrier Proteins)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (DNA, Fungal)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Fungal Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Origin Recognition Complex)
RN  - 0 (Saccharomyces cerevisiae Proteins)
RN  - 122544-18-7 (CDC6 protein, S cerevisiae)
RN  - 127-07-1 (Hydroxyurea)
RN  - EC 1.17.4.- (Ribonucleotide Reductases)
SB  - IM
MH  - Carrier Proteins/*metabolism
MH  - Cell Cycle/genetics
MH  - Cell Cycle Proteins/metabolism
MH  - DNA Replication/*physiology
MH  - DNA, Fungal/biosynthesis/*metabolism
MH  - DNA-Binding Proteins/*metabolism
MH  - Enzyme Inhibitors/pharmacology
MH  - Fungal Proteins/*metabolism
MH  - Hydroxyurea/pharmacology
MH  - Models, Genetic
MH  - Nuclear Proteins/*metabolism
MH  - Origin Recognition Complex
MH  - Replication Origin/genetics
MH  - Ribonucleotide Reductases/pharmacology
MH  - S Phase/genetics
MH  - Saccharomyces cerevisiae/*genetics
MH  - *Saccharomyces cerevisiae Proteins
EDAT- 1997/10/23
MHDA- 1997/10/23 00:01
AID - S0092-8674(01)80009-X [pii]
PST - ppublish
SO  - Cell. 1997 Oct 3;91(1):59-69.
PMID- 9330258
OWN - NLM
STAT- MEDLINE
DA  - 19971114
DCOM- 19971114
LR  - 20031114
PUBM- Print
IS  - 0269-283X (Print)
VI  - 11
IP  - 3
DP  - 1997 Jul
TI  - Effects of Plasmodium yoelii nigeriensis infection on Anopheles stephensi
      egg development and resorption.
PG  - 265-9
AB  - It has been shown previously that infection with Plasmodium yoelii
      nigeriensis reduces the number of eggs produced by female Anopheles
      stephensi. Here we examine the mechanism underlying fecundity reduction.
      Ovaries from infected and uninfected (control) female mosquitoes were
      examined 12, 24 or 36 h after blood-feeding during the first gonotrophic
      cycle (replicated) or the second gonotrophic cycle (unreplicated).
      Follicular development was assessed according to Christophers' stages and
      the proportions of developing and resorbing follicles per ovary were
      determined. Resorption of some follicles commenced within 12 h of
      blood-feeding, affecting significantly more follicles in the infected
      females: 1.1% v. 3.2%. The difference was greatest 36 h after
      blood-feeding: 25% reduction (10 v. 35%) in the first cycle; 16% reduction
      (9 v. 25%) in the second gonotrophic cycle. The mean speed of oogenesis
      was also found to be significantly retarded in infected mosquitoes. During
      the second gonotrophic cycle, for example, only 92-94% of follicles
      reached stage III by 24 h and stage IV by 36 h in infected females,
      whereas all the developing follicles of uninfected females reached these
      stages more or less synchronously in the time specified.
AD  - Department of Biological Sciences, Keele University, Staffordshire, U.K.
FAU - Carwardine, S L
AU  - Carwardine SL
FAU - Hurd, H
AU  - Hurd H
LA  - eng
PT  - Journal Article
PL  - ENGLAND
TA  - Med Vet Entomol
JT  - Medical and veterinary entomology
JID - 8708682
SB  - IM
MH  - Aedes/parasitology/physiology
MH  - Analysis of Variance
MH  - Animals
MH  - Anopheles/*parasitology/physiology
MH  - Female
MH  - *Fertility
MH  - Host-Parasite Relations
MH  - Malaria/physiopathology
MH  - Male
MH  - Mice
MH  - Oocytes/physiology
MH  - Ovary/physiology
MH  - *Oviposition
MH  - Parasitemia/physiopathology
MH  - Plasmodium yoelii/pathogenicity/*physiology
EDAT- 1997/07/01 00:00
MHDA- 1997/10/23 00:01
PST - ppublish
SO  - Med Vet Entomol. 1997 Jul;11(3):265-9.
PMID- 9346280
OWN - NLM
STAT- MEDLINE
DA  - 19971121
DCOM- 19971121
LR  - 20061115
PUBM- Print
IS  - 0014-2956 (Print)
VI  - 248
IP  - 2
DP  - 1997 Sep 1
TI  - Basic residues in the 74-83 and 191-198 segments of protein kinase CK2
      catalytic subunit are implicated in negative but not in positive
      regulation by the beta-subunit.
PG  - 290-5
AB  - Protein kinase CK2 is a ubiquitous pleiotropic serine/threonine protein
      kinase whose holoenzyme is comprised of two catalytic (alpha and/or
      alpha') and two non-catalytic, beta-subunits. The beta-subunit possesses
      antagonist functions that can be physically dissected by generating
      synthetic fragments encompassing its N-terminal and C-terminal domains.
      Here we show that by mutating basic residues in the 74-77 and in the
      191-198 regions of the alpha-subunit, the negative regulation by the
      beta-subunit and by its N-terminal synthetic fragment CK2beta-(1-77),
      which is observable using calmodulin as a substrate for phosphorylation,
      is drastically reduced. In contrast, the positive regulation by a
      C-terminal, CK2beta-(155-215)-peptide is unaffected or even increased.
      Moreover, the basal activity of alpha mutants K74-77A, K79R80K83A, and
      R191R195K198A toward specific peptide substrates is stimulated by the
      beta-subunit many fold more than that of alpha wild type, while
      extrastimulation by beta mutant D55L56E57A, observable with alpha wild
      type, is abolished with these mutants. These data support the conclusion
      that down regulation by the acidic residues clustered in the N-terminal
      moiety of beta is mediated by basic residues in the 74-83 and in the
      191-198 sequences of the alpha-subunit. These are also implicated in
      substrate recognition consistent with the concept that the N-terminal
      acidic region of the beta subunit operates as a pseudosubstrate. In
      contrast, another CK2alpha mutant, V66A, is more sensitive to inhibition
      by either beta-subunit or its N-terminal, CK2beta-(1-77)-peptide, while
      its stimulation by the C-terminal peptide, CK2beta-(155-215), is
      comparable to that of alpha wild type. These observations suggest an
      indirect role of Val66 in conferring to the alpha-subunit a conformation
      less sensitive to down regulation by beta-subunit.
AD  - Dipartimento di Chimica Biologica, Universita' di Padova and Centro per lo
      Studio delle Biomembrane del Consiglio Nazionale delle Ricerche, Italy.
FAU - Sarno, S
AU  - Sarno S
FAU - Vaglio, P
AU  - Vaglio P
FAU - Marin, O
AU  - Marin O
FAU - Meggio, F
AU  - Meggio F
FAU - Issinger, O G
AU  - Issinger OG
FAU - Pinna, L A
AU  - Pinna LA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - GERMANY
TA  - Eur J Biochem
JT  - European journal of biochemistry  / FEBS
JID - 0107600
RN  - 0 (Calmodulin)
RN  - 0 (Peptide Fragments)
RN  - 9005-49-6 (Heparin)
RN  - EC 2.7.1.37 (Casein Kinase II)
RN  - EC 2.7.1.37 (Protein-Serine-Threonine Kinases)
SB  - IM
MH  - Amino Acid Sequence
MH  - Binding Sites
MH  - Calmodulin/metabolism
MH  - Casein Kinase II
MH  - Down-Regulation
MH  - Enzyme Activation
MH  - Heparin/metabolism
MH  - Molecular Sequence Data
MH  - Mutation
MH  - Peptide Fragments/genetics/*metabolism
MH  - Phosphorylation
MH  - Protein-Serine-Threonine Kinases/genetics/*metabolism
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Eur J Biochem. 1997 Sep 1;248(2):290-5.
PMID- 9378063
OWN - NLM
STAT- MEDLINE
DA  - 19971125
DCOM- 19971125
LR  - 20061115
PUBM- Print
IS  - 0012-0472 (Print)
VI  - 122
IP  - 42
DP  - 1997 Oct 17
TI  - [Refractory hydrothorax in primary biliary cirrhosis: successful treatment
      with transjugular intrahepatic portosystemic stent shunt]
PG  - 1275-80
AB  - HISTORY AND CLINICAL FINDINGS: A 55-year-old woman with known primary
      biliary cirrhosis (PBC) was hospitalized because of increasing dyspnoea. A
      year before she had for the first time experienced a right-sided pleural
      effusion which had to be drained every 4 weeks. Physical examination
      revealed dullness on percussion and greatly decreased breath sounds on
      auscultation over the entire right thorax. In addition there were signs of
      moderate ascites and leg oedema. INVESTIGATIONS: Chest radiograph showed a
      homogeneous shadowing of the right thorax without mediastinal shift.
      Diagnostic thoracocentesis produced a serous effusion, a transudate on
      chemical analysis, comparable to the composition of the ascitic fluid.
      Bacteriological and cytological tests on both fluids were unremarkable.
      TREATMENT AND COURSE: The right pleural effusion was presumed to be due to
      a hydrothorax from the ascites caused by portal hypertension associated
      with the PBC. Despite continuous diuretic treatment and thoracocentesis
      with albumin substitution every 3 days there was no improvement and
      implantation of a transjugular intrahepatic portosystemic stent shunt
      (TIPSS) was performed. This effectively lowered portal pressure and
      markedly improved the patient's condition so that further thoracocentesis
      were no longer necessary. 3 weeks after TIPSS implantation she was
      discharged in good condition. Radiography 3 weeks later demonstrated
      continued reduction in the hydrothorax. CONCLUSION: Hydrothorax is a rare
      complication of liver cirrhosis. TIPSS implantation can provide lasting
      resolution and corresponding clinical improvement of a hydrothorax,
      especially in those conditions which are refractory to diuretic treatment
      and thoracocentesis.
AD  - Abteilung Gastroenterologie und Endokrinologie, Stadtische Kliniken
      Kassel.
FAU - Nolte, W
AU  - Nolte W
FAU - Figulla, H R
AU  - Figulla HR
FAU - Ringe, B
AU  - Ringe B
FAU - Wiltfang, J
AU  - Wiltfang J
FAU - Munke, H
AU  - Munke H
FAU - Hartmann, H
AU  - Hartmann H
FAU - Pausch, J
AU  - Pausch J
FAU - Ramadori, G
AU  - Ramadori G
LA  - ger
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Refraktarer Hydrothorax bei primarer biliarer Zirrhose. Erfolgreiche
      Therapie durch einen transjugularen intrahepatischen portosystemischen
      Stent-Shunt.
PL  - GERMANY
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 0 (Diuretics)
SB  - IM
MH  - Diuretics/therapeutic use
MH  - Female
MH  - Humans
MH  - Hydrothorax/etiology/radiography/*surgery/therapy/ultrasonography
MH  - Liver Cirrhosis, Biliary/*complications
MH  - Middle Aged
MH  - *Portasystemic Shunt, Transjugular Intrahepatic
MH  - Thoracostomy
EDAT- 1998/02/12
MHDA- 1998/02/12 00:01
PST - ppublish
SO  - Dtsch Med Wochenschr. 1997 Oct 17;122(42):1275-80.
PMID- 9345446
OWN - NLM
STAT- MEDLINE
DA  - 19971118
DCOM- 19971118
LR  - 20061115
PUBM- Print
IS  - 1352-4585 (Print)
VI  - 1
IP  - 3
DP  - 1995 Nov
TI  - Cardiovascular regulation in multiple sclerosis.
PG  - 156-62
AB  - Traditional assessments of autonomic nervous system function have depended
      on invasive and complex procedures. Vagal power, which is the respiratory
      component of heart rate variability (HRV) is an alternative and
      non-invasive measure for indexing autonomic nervous control of the heart.
      In the current study, 18 multiple sclerosis (MS) and 20 healthy subjects
      matched with respect to age, education and intelligence served as
      subjects. The MS group showed significantly lower vagal power during
      natural and paced breathing than healthy subjects. Importantly, heart rate
      did not differ between the two groups. If MS patients exhibit
      abnormalities in mechanisms mediating cardiac parasympathetic control, the
      impact on quality of life and vulnerability to adverse cardiac events need
      to be further evaluated. The results of this study may have implications
      with respect to the feasibility of using HRV as both a diagnostic and
      prognostic tool for evaluating parasympathetic nervous system dysfunction
      and in providing valuable information for developing more effective
      treatment and rehabilitation strategies.
AD  - Kessler Institute for Rehabilitation, Department of Research, West Orange,
      New Jersey 07052, USA.
FAU - Diamond, B J
AU  - Diamond BJ
FAU - Kim, H
AU  - Kim H
FAU - DeLuca, J
AU  - DeLuca J
FAU - Cordero, D L
AU  - Cordero DL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - ENGLAND
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - *Cardiovascular Physiology
MH  - Female
MH  - Heart Rate/physiology
MH  - Humans
MH  - Male
MH  - Multiple Sclerosis/*physiopathology
MH  - Neuropsychological Tests
MH  - Reaction Time
MH  - Respiration/physiology
MH  - Spirometry
MH  - Vagus Nerve/physiology
EDAT- 1995/11/01 00:00
MHDA- 1997/11/04 00:01
PST - ppublish
SO  - Mult Scler. 1995 Nov;1(3):156-62.
PMID- 9316922
OWN - NLM
STAT- MEDLINE
DA  - 19971120
DCOM- 19971120
LR  - 20041117
PUBM- Print
IS  - 0095-1137 (Print)
VI  - 35
IP  - 10
DP  - 1997 Oct
TI  - Limited value of PCR for detection of Toxoplasma gondii in blood from
      human immunodeficiency virus-infected patients.
PG  - 2639-41
AB  - Cerebral toxoplasmosis is a common, opportunistic, and often
      life-threatening disease in HIV-infected patients. Diagnosis is supported
      mainly by clinical evidence and computerized tomography or magnetic
      resonance imaging scans, but brain images may share features with other
      brain diseases occurring in HIV-infected patients. To determine the
      diagnostic value of PCR for the detection of Toxoplasma gondii in blood
      from HIV-infected patients, we examined 89 blood samples from 59
      HIV-infected patients. PCR and Southern blot hybridization were done with
      DNA extracted from blood samples from 20 patients with confirmed cerebral
      toxoplasmosis and from 10 patients with suspected but not confirmed
      cerebral toxoplasmosis. The samples were taken before and 7 to 10 days
      after the beginning of antiparasitic therapy. For 9 patients who suffered
      from cerebral toxoplasmosis more than 6 months prior to the study and for
      20 patients without any evidence for toxoplasmosis only one blood sample
      per patient was examined. PCR gave positive results with 5 of the 20 blood
      samples from patients who suffered from cerebral toxoplasmosis. After 7 to
      10 days of therapy PCR results became negative in all these five cases. No
      amplification was seen with DNA from blood samples from the other 54
      patients as the target. The results presented here show that PCR testing
      of blood samples from HIV-infected patients is of limited value for the
      diagnosis of cerebral toxoplasmosis. The sensitivity was only 25%, but the
      specificity was very high (100%), so this technique may be useful for
      discriminating between cerebral toxoplasmosis and other brain diseases
      which may be mistaken for toxoplasmosis.
AD  - Department of Internal Medicine I, University of Cologne, Germany.
      Caspar.Franzen@Uni-Koeln.DE
FAU - Franzen, C
AU  - Franzen C
FAU - Altfeld, M
AU  - Altfeld M
FAU - Hegener, P
AU  - Hegener P
FAU - Hartmann, P
AU  - Hartmann P
FAU - Arendt, G
AU  - Arendt G
FAU - Jablonowski, H
AU  - Jablonowski H
FAU - Rockstroh, J
AU  - Rockstroh J
FAU - Diehl, V
AU  - Diehl V
FAU - Salzberger, B
AU  - Salzberger B
FAU - Fatkenheuer, G
AU  - Fatkenheuer G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - UNITED STATES
TA  - J Clin Microbiol
JT  - Journal of clinical microbiology
JID - 7505564
SB  - IM
SB  - X
MH  - HIV Infections/complications/*parasitology
MH  - Humans
MH  - Polymerase Chain Reaction/*methods
MH  - Predictive Value of Tests
MH  - Tomography
MH  - Toxoplasmosis, Cerebral/blood/complications/*diagnosis
EDAT- 1997/10/08
MHDA- 1997/10/08 00:01
PST - ppublish
SO  - J Clin Microbiol. 1997 Oct;35(10):2639-41.
PMID- 9296268
OWN - NLM
STAT- MEDLINE
DA  - 19971028
DCOM- 19971028
LR  - 20061115
PUBM- Print
IS  - 0003-9969 (Print)
VI  - 42
IP  - 7
DP  - 1997 Jul
TI  - Molecular cloning and characterization of the bovine tuftelin gene.
PG  - 489-96
AB  - The bovine tuftelin gene was cloned and its structure determined by DNA
      sequence analysis and comparison to that of bovine tuftelin cDNA. The
      analyses demonstrated that the cDNA contains a 1014-bp open reading frame
      encoding a protein of 338 residues with a calculated mol. wt of 38,630 and
      an isoelectric point of 5.85. These results differ from those previously
      published, (1991) which contained a different conceptual amino acid
      sequence for the carboxy terminal region and identified a different
      termination codon. The protein does not appear to share homology or domain
      motifs with any other known protein. The gene consists of 13 exons ranging
      in size from 66 to 1531 bp, the latter containing the encoded
      carboxyterminal and 3' untranslated regions. The exons are embedded in
      more than 28 kbp of genomic DNA. Codons are generally not divided at
      exon/intron borders. Several alternatively spliced transcripts were
      identified by DNA sequence analysis of the isolated products produced by
      reverse transcriptase/polymerase chain reaction.
AD  - Research Center in Oral Biology, University of Pennsylvania School of
      Dental Medicine, Philadelphia 19104, USA.
FAU - Bashir, M M
AU  - Bashir MM
FAU - Abrams, W R
AU  - Abrams WR
FAU - Rosenbloom, J
AU  - Rosenbloom J
LA  - eng
GR  - DE08239/DE/NIDCR
GR  - DE10620/DE/NIDCR
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - ENGLAND
TA  - Arch Oral Biol
JT  - Archives of oral biology
JID - 0116711
RN  - 0 (DNA, Complementary)
RN  - 0 (Dental Enamel Proteins)
RN  - 0 (tuftelin)
SB  - D
SB  - IM
MH  - Alternative Splicing
MH  - Amino Acid Sequence
MH  - Animals
MH  - Base Sequence
MH  - Blotting, Northern
MH  - Cattle
MH  - Cloning, Molecular/*methods
MH  - DNA, Complementary/genetics
MH  - Dental Enamel Proteins/*genetics
MH  - Exons/genetics
MH  - Genomic Library
MH  - Introns/genetics
MH  - Molecular Sequence Data
MH  - Sequence Analysis, DNA/methods
MH  - Transcription, Genetic
EDAT- 1997/07/01 00:00
MHDA- 1997/09/20 00:01
AID - S0003-9969(97)00039-3 [pii]
PST - ppublish
SO  - Arch Oral Biol. 1997 Jul;42(7):489-96.
PMID- 9343165
OWN - NLM
STAT- MEDLINE
DA  - 19971113
DCOM- 19971113
LR  - 20061115
PUBM- Print
IS  - 0022-538X (Print)
VI  - 71
IP  - 11
DP  - 1997 Nov
TI  - Mutation of Tp53 contributes to the malignant phenotype of Abelson
      virus-transformed lymphoid cells.
PG  - 8149-56
AB  - Abelson murine leukemia virus transforms pre-B cells in vitro and induces
      rapid-onset pre-B-cell lymphoma in vivo. Expression of an active v-Abl
      protein tyrosine kinase is required for the oncogenic functions of the
      virus. Despite the strong growth-stimulatory signal provided by v-Abl, the
      virus-induced tumors are clonal or oligoclonal, and changes in the growth
      and oncogenic potential of in vitro transformants occur during the
      derivation of the cell lines. Both of these features suggest that v-Abl
      expression must be complemented by changes in expression of one or more
      cellular genes for cells to acquire a fully malignant phenotype. Such
      genes could include other oncogenes or tumor suppressor genes. Among the
      latter is Tp53, a gene mutated in many spontaneous cancers. To determine
      if mutation of the Tp53 tumor suppressor gene plays a role in Abelson
      virus transformation, conformation-specific monoclonal antibodies were
      used to examine p53 expression in a panel of Abelson virus-transformed
      pre-B cells. Expression of mutant forms of p53 was detected in over 40% of
      the isolates. Sequence analysis revealed the presence of point mutations
      affecting the highly conserved central portion of the protein. These
      mutations interfered with the ability of p53 to activate transcription
      from a promoter containing p53-responsive elements and to induce apoptosis
      in response to DNA damage. In addition, cells expressing mutant forms of
      p53 induced a higher frequency of tumors with a more rapid course compared
      to transformants expressing wild-type p53. These data suggest that Tp53 is
      one important cellular gene involved in malignant transformation by
      Abelson virus.
AD  - Department of Pathology and Graduate Program in Immunology, Tufts
      University School of Medicine, Boston, Massachusetts 02111, USA.
FAU - Thome, K C
AU  - Thome KC
FAU - Radfar, A
AU  - Radfar A
FAU - Rosenberg, N
AU  - Rosenberg N
LA  - eng
GR  - CA 33771/CA/NCI
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - J Virol
JT  - Journal of virology
JID - 0113724
RN  - 0 (Transcription Factors)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Abelson murine leukemia virus/*genetics
MH  - Amino Acid Substitution
MH  - Apoptosis/radiation effects
MH  - B-Lymphocytes/virology
MH  - Cell Transformation, Viral/*genetics
MH  - Cells, Cultured
MH  - DNA Damage
MH  - Gamma Rays
MH  - *Genes, p53
MH  - Mutation
MH  - Transcription Factors/genetics
MH  - Tumor Suppressor Protein p53/*genetics/physiology
EDAT- 1997/10/29
MHDA- 1997/10/29 00:01
PST - ppublish
SO  - J Virol. 1997 Nov;71(11):8149-56.
PMID- 9351973
OWN - NLM
STAT- MEDLINE
DA  - 19971124
DCOM- 19971124
LR  - 20061115
PUBM- Print
IS  - 0026-895X (Print)
VI  - 52
IP  - 5
DP  - 1997 Nov
TI  - Phosphorylation of the Kv2.1 K+ channel alters voltage-dependent
      activation.
PG  - 821-8
AB  - The voltage-gated delayed-rectifier-type K+ channel Kv2.1 is expressed in
      high-density clusters on the soma and proximal dendrites of mammalian
      central neurons; thus, dynamic regulation of Kv2.1 would be predicted to
      have an impact on dendritic excitability. Rat brain Kv2.1 polypeptides are
      phosphorylated extensively, leading to a dramatically increased molecular
      mass on sodium dodecyl sulfate gels. Phosphoamino acid analysis of Kv2.1
      expressed in transfected cells and labeled in vivo with 32P shows that
      phosphorylation was restricted to serine residues and that a truncation
      mutant, DeltaC318, which lacks the last 318 amino acids in the cytoplasmic
      carboxyl terminus, was phosphorylated to a much lesser degree than was
      wild-type Kv2.1. Whole-cell patch-clamp studies showed that the
      voltage-dependence of activation of DeltaC318 was shifted to more negative
      membrane potentials than Kv2.1 without differences in macroscopic
      kinetics; however, the differences in the voltage-dependence of activation
      between Kv2.1 and DeltaC318 were eliminated by in vivo intracellular
      application of alkaline phosphatase, suggesting that these differences
      were due to differential phosphorylation. Similar analyses of other
      truncation and point mutants indicated that the phosphorylation sites
      responsible for the observed differences in voltage-dependent activation
      lie between amino acids 667 and 853 near the distal end of the Kv2.1
      carboxyl terminus. Together, these parallel biochemical and
      electrophysiological results provide direct evidence that the
      voltage-dependent activation of the delayed-rectifier K+ channel Kv2. 1
      can be modulated by direct phosphorylation of the channel protein; such
      modulation of Kv2.1 could dynamically regulate dendritic excitability.
AD  - Department of Biochemistry and Cell Biology and Institute for Cell and
      Developmental Biology, State University of New York at Stony Brook, Stony
      Brook, New York 11794-5215, USA.
FAU - Murakoshi, H
AU  - Murakoshi H
FAU - Shi, G
AU  - Shi G
FAU - Scannevin, R H
AU  - Scannevin RH
FAU - Trimmer, J S
AU  - Trimmer JS
LA  - eng
GR  - NS34375/NS/NINDS
GR  - NS34383/NS/NINDS
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Mol Pharmacol
JT  - Molecular pharmacology
JID - 0035623
RN  - 0 (Delayed Rectifier Potassium Channels)
RN  - 0 (Kcnb1 protein, rat)
RN  - 0 (Potassium Channels)
RN  - 0 (Potassium Channels, Voltage-Gated)
RN  - 0 (Shab Potassium Channels)
RN  - 56-45-1 (Serine)
SB  - IM
MH  - Animals
MH  - Brain/metabolism
MH  - COS Cells/metabolism
MH  - Delayed Rectifier Potassium Channels
MH  - Membrane Potentials
MH  - Patch-Clamp Techniques
MH  - Phosphorylation
MH  - Point Mutation
MH  - Potassium Channels/chemistry/genetics/metabolism/*physiology
MH  - *Potassium Channels, Voltage-Gated
MH  - Precipitin Tests
MH  - Rats
MH  - Serine/chemistry
MH  - Shab Potassium Channels
MH  - Transfection
EDAT- 1997/11/14
MHDA- 1997/11/14 00:01
PST - ppublish
SO  - Mol Pharmacol. 1997 Nov;52(5):821-8.
PMID- 9309626
OWN - NLM
STAT- MEDLINE
DA  - 19971030
DCOM- 19971030
LR  - 20061115
PUBM- Print
IS  - 0195-9131 (Print)
VI  - 29
IP  - 9
DP  - 1997 Sep
TI  - Effects of estradiol on substrate turnover during exercise in amenorrheic
      females.
PG  - 1160-9
AB  - The purpose of this investigation was to determine the effects of
      transdermal estradiol (E2) replacement on substrate utilization during
      exercise. Amenorrheic females (N = 6) performed three exercise trials
      following 72 h of placebo (C 72) and 72 and 144 h of medicated transdermal
      estradiol (E2) treatment (E2 72 and E2 144). Exercise involved 90 min of
      treadmill running at 65% VO2max followed by timed exercise to exhaustion
      at 85% VO2max. Resting blood samples were obtained for glucose, insulin,
      free fatty acids (FFA), and E2. Exercise blood samples were obtained for
      E2, lactate, epinephrine, and norepinephrine. Rates of appearance and
      disposal were calculated for glucose and glycerol using a primed,
      continuous infusion of [6,6-2H] glucose and [2H5] glycerol. Medicated
      transdermal placement increased E2 significantly at rest, before exercise
      (35.03 +/- 12.3, 69.5 +/- 20.1, and 73.1 +/- 31.6 pg.mL-1 for the C 72, E2
      72, and E2 144 trials, respectively, P < 0.05). Resting FFA increased
      significantly following E2 treatment (0.28 +/- 0.16, 0.41 +/- 0.27, and
      0.40 +/- 0.21 mmol.L-1 for the C 72, E2 72, and E2 144 trials,
      respectively, P < 0.05). Glucose Ra was significantly decreased during
      exercise as a result of E2 replacement (21.9 +/- 7.7, 18.9 +/- 6.2, and
      18.9 +/- 5.6 mumol.kg-1.min-1 for the C 72, E2 72, and E2 144 trials,
      respectively, P < 0.05). Average glucose Rd also decreased during exercise
      as a result of E2 replacement (21.3 +/- 7.8, 18.5 +/- 6.4, and 18.6 +/-
      5.8 mumol.kg-1.min-1 for the C 72, E2 72, and E2 144 trials, respectively,
      P < 0.05). However, the estimated relative contribution of plasma glucose
      and muscle glycogen to total carbohydrate oxidation was similar among the
      trials. Epinephrine values were significantly lower late in exercise
      during the E2 72 and E2 144 trials, compared with the C 72 trial (P <
      0.05). These results indicate that elevated E2 levels can alter glucose
      metabolism at rest and during moderate intensity exercise as a result of
      decreased gluconeogenesis, epinephrine secretion, and/or glucose
      transport.
AD  - Center for Exercise and Applied Human Physiology, University of New
      Mexico, Albuquerque 87131-1258, USA. ruby@selway.umt.edu
FAU - Ruby, B C
AU  - Ruby BC
FAU - Robergs, R A
AU  - Robergs RA
FAU - Waters, D L
AU  - Waters DL
FAU - Burge, M
AU  - Burge M
FAU - Mermier, C
AU  - Mermier C
FAU - Stolarczyk, L
AU  - Stolarczyk L
LA  - eng
GR  - 5 M01 RR00997-18/RR/NCRR
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Med Sci Sports Exerc
JT  - Medicine and science in sports and exercise
JID - 8005433
RN  - 50-28-2 (Estradiol)
RN  - 50-99-7 (Glucose)
RN  - 56-81-5 (Glycerol)
SB  - IM
SB  - S
MH  - Administration, Cutaneous
MH  - Adult
MH  - Amenorrhea/*physiopathology
MH  - Energy Metabolism
MH  - Estradiol/*pharmacology
MH  - Estrogen Replacement Therapy
MH  - Exercise/*physiology
MH  - Female
MH  - Glucose/*metabolism
MH  - Glycerol/metabolism
MH  - Humans
MH  - Sports/physiology
EDAT- 1997/10/06
MHDA- 1997/10/06 00:01
PST - ppublish
SO  - Med Sci Sports Exerc. 1997 Sep;29(9):1160-9.
PMID- 9296327
OWN - NLM
STAT- MEDLINE
DA  - 19971030
DCOM- 19971030
LR  - 20061115
PUBM- Print
IS  - 0306-5251 (Print)
VI  - 44
IP  - 3
DP  - 1997 Sep
TI  - Excretion of citalopram in breast milk.
PG  - 295-8
AB  - AIMS: The objective of this study was to measure to secretion of the
      selective serotonin uptake inhibitor citalopram in breast milk. METHODS:
      The excretion of citalopram in breast milk was studied at steady-state
      conditions in two patients with depression and in one healthy volunteer
      after ingestion of a single dose citalopram. RESULTS: Milk/serum
      concentration ratios based on single pairs of samples from the two
      patients ranged from 1.16 to 1.88. Based on milk concentration data from
      the patients, the absolute dose ingested by a suckling infant would be
      4.3-17.6 micrograms kg-1 day-1, and the relative dose 0.7-5.9% of the
      weight-adjusted maternal dose. Based on area-under-the-time-concentration
      curves from the healthy volunteer, the milk/serum ratio was 1.00, the
      absolute dose to the infant during steady-state conditions would be 11.2
      micrograms kg-1 day-1 and the relative dose 1.8% of the weight-adjusted
      maternal dose. CONCLUSION: The study shows that the relative dose to a
      suckling infant is close to that reported for fluoxetine, and higher than
      reported for fluvoxamine, paroxetine and sertraline.
AD  - Division of Clinical Pharmacology, Norrland University Hospital, Umea,
      Sweden.
FAU - Spigset, O
AU  - Spigset O
FAU - Carieborg, L
AU  - Carieborg L
FAU - Ohman, R
AU  - Ohman R
FAU - Norstrom, A
AU  - Norstrom A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - ENGLAND
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Antidepressive Agents)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 0 (Triglycerides)
RN  - 59729-33-8 (Citalopram)
SB  - IM
MH  - Adult
MH  - Antidepressive Agents/*metabolism/therapeutic use
MH  - Breast Feeding
MH  - Citalopram/*metabolism/therapeutic use
MH  - Depressive Disorder/drug therapy/metabolism
MH  - Female
MH  - Humans
MH  - Infant
MH  - Milk, Human/chemistry/*metabolism
MH  - Serotonin Uptake Inhibitors/*metabolism/therapeutic use
MH  - Triglycerides/chemistry
EDAT- 1997/09/20
MHDA- 1997/09/20 00:01
PST - ppublish
SO  - Br J Clin Pharmacol. 1997 Sep;44(3):295-8.
PMID- 9348196
OWN - NLM
STAT- MEDLINE
DA  - 19971124
DCOM- 19971124
LR  - 20061115
PUBM- Print
IS  - 0013-7227 (Print)
VI  - 138
IP  - 11
DP  - 1997 Nov
TI  - Simultaneous measurement of gonadotropin-releasing hormone in the third
      ventricular cerebrospinal fluid and hypophyseal portal blood of the ewe.
PG  - 4699-704
AB  - GnRH is present in the hypophyseal portal blood and cerebrospinal fluid
      (CSF) of several species investigated, including sheep, but the precise
      relationship between these two compartments of GnRH is unknown. In the
      present study, ovariectomized steroid-treated ewes were surgically
      prepared for the simultaneous collection of portal blood and third
      ventricular CSF. Ten-minute samples were collected for pulse analysis
      after progesterone removal and hourly for comparisons during the
      estradiol-induced LH surge. The time of onset of the portal (15.3 +/- 0.5
      h after estradiol) and CSF (15.9 +/- 0.2 h) GnRH surges was similar and
      occurred coincidentally with the LH surge (15.6 +/- 0.4 h). The period of
      the surge during which GnRH concentrations exceeded half-maximal levels
      (portal, 7.3 +/- 1.5 h; CSF, 7.3 +/- 0.3 h) was the same and outlasted the
      corresponding LH surge period (3.3 +/- 0.3 h). LH pulses started and
      peaked later than the corresponding portal GnRH pulses (onset difference,
      10 +/- 1 min; peak difference, 16 +/- 1 min; P < 0.01 for both), but the
      times of pulse onset and peak were not significantly different from those
      of concomitant CSF GnRH pulses (onset difference, 8 +/- 6 min; peak
      difference, 8 +/- 4 min). Although the times of pulse onset and peak did
      not differ between the portal and CSF GnRH compartments (onset difference,
      4 +/- 6 min; peak difference, 6 +/- 2 min), CSF GnRH pulses were longer
      than their portal counterparts (CSF, 38 +/- 3 min; portal, 15 +/- 1 min; P
      < 0.01). The amplitude of jugular LH pulses was strongly correlated (r2 =
      0.85) with portal GnRH pulse amplitude, but not with that of CSF GnRH
      pulses (r2 = 0.45); there was no correlation between portal and CSF GnRH
      pulse amplitudes (r2 = 0.25). These data show that third ventricular CSF
      GnRH reliably relates neurosecretory events occurring within the
      hypophyseal portal system at the time of the preovulatory LH surge, but is
      not as precise as portal GnRH in marking a LH pulse.
AD  - Laboratory of Neuroendocrinology, The Babraham Institute, Cambridge,
      United Kingdom. skinner@tours.inra.fr
FAU - Skinner, D C
AU  - Skinner DC
FAU - Caraty, A
AU  - Caraty A
FAU - Malpaux, B
AU  - Malpaux B
FAU - Evans, N P
AU  - Evans NP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - UNITED STATES
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
RN  - 50-28-2 (Estradiol)
RN  - 9002-67-9 (Luteinizing Hormone)
SB  - AIM
SB  - IM
MH  - Animals
MH  - Estradiol/pharmacology
MH  - Female
MH  - Gonadotropin-Releasing Hormone/*blood/*cerebrospinal fluid
MH  - Luteinizing Hormone/blood
MH  - Ovariectomy
MH  - Pituitary Gland/*blood supply
MH  - Pulsatile Flow
MH  - Sheep
MH  - Time Factors
EDAT- 1997/11/05
MHDA- 1997/11/05 00:01
PST - ppublish
SO  - Endocrinology. 1997 Nov;138(11):4699-704.